





#### **HUMAN PROTEOME ORGANIZATION**

Become A Member Of A Global Scientific Community

Define and promote proteomics.

Expand your understanding of human disease.

translating the code of life

# JOIN NOW

SAVE UP TO \$100 on membership dues!

# The Human Proteome Organization offers different membership levels and rates to best suit your needs

Membership Category	Student / Post-Doc Membership	1-Year Membership	3-Year Membership
High-Income Country	\$60	\$100	\$200
Middle-Income Country	\$45	\$75	\$150
Low-Income Country	\$30	\$50	\$100

Join or renew for 2 years and receive the 3rd year FOR FREE.

Sign up for your 2016 membership today and receive the rest of 2015 FOR FREE.

#### **AS A HUPO MEMBER YOU WILL:**

- Become part of an international scientific community of over 880 members
- Enjoy a discount on the HUPO Annual World Congress registration fees
- Vote online in the annual election of HUPO Council (Board of Directors) members
- Receive our newsletter, the HUPOST, which highlights news and activities across the proteomics community
- Be eligible to receive a HUPO award
- Enjoy special HUPO-rates for Molecular & Cellular Proteomics (MCP) online

### **CONGRESS SPONSORS**

HUPO and the 14th World Congress would like to sincerely thank the following organizations for supporting the HUPO 2015 Congress:

**DIAMOND SPONSOR** 

# Thermo

**GOLD SPONSOR** 



SILVER SPONSORS





**BRONZE SPONSORS** 







**Genome**Canada

#### SUPPORTERS











HUPO and the 14th World Congress would also like to sincerely thank the following organizations for providing awards:

#### **DISTINGUISHED ACHIEVEMENT AWARD**



#### TRANSLATIONAL PROTEOMICS AWARD



#### TRAVEL AWARDS







**EDUCATIONAL GRANT PROVIDER** 



#### **MEDIA PARTNERS**









translating the code of life

# INDUSTRIAL ADVISORY BOARD

Created in 2006, the HUPO Industrial Advisory Board (IAB) facilitates communication and input from industry partners to support the proteomics community and to recognize these partners as HUPO affiliates. HUPO supports industry allies active in the development of innovative technologies and appropriate standards that are responsive to the constant changes in the scientific proteomics environment.

#### The IAB Mission

To provide HUPO leadership (the Executive Committee) valuable input on technology and product innovation for the benefit of members and to identify industry trends that will position HUPO to meet the future challenges of its partners and organization.

#### **BENEFITS OF AN IAB MEMBERSHIP**

- Two complimentary individual HUPO memberships available for company employees (value \$200).
- Involvement in Human Proteome Project (HPP) with regular updates from project leadership.
- Direct connection with HUPO Executive Committee and Congress Organizers via monthly IAB calls.
- IAB sponsored Science and Technology Award, established in 2011, awarded to an industrial scientist, IAB representatives solicit and vet nominees. Award recipient presents a talk on the project at the annual world congress.
- Selection of abstracts for the New Technological Advances in Proteomics presentations at the annual HUPO Congress.

The Human Proteome Organization wishes to thank the following IAB members for their participation this year!















Interested in joining HUPO as an IAB member? Come and visit us in the Exhibit Hall or contact Chelsea Prangnell (HUPO Office) chelsea@hupo.org

#### **TABLE OF CONTENTS**

# SECTION 1 GENERAL CONGRESS INFORMATION

5 **Welcome Messages Congress Summary of Events** 10 **Human Proteome Organization (HUPO)** 12 **HUPO Awards** 14 **HUPO 2015 Local Organizing Committee** 24 **HUPO 2015 Scientific Organizing Committee** 25 **Convention Centre Floor Plans** 26 Registration 28 **Onsite Services** and General Information 29 **Bioinformatics Hub** 34 Information for Invited Speakers and Abstract Presenters 36 **Social Program** 38 41 **Vancouver Information** 

#### **SECTION 3**

PROGRAM SUNDAY, SEPTEMBER 27

#### **SECTION 4**

PROGRAM MONDAY, SEPTEMBER 28

#### SECTION 5

TUESDAY, SEPTEMBER 29

#### SECTION 6

PROGRAM
WEDNESDAY, SEPTEMBER 30
+ THURSDAY, OCTOBER 1

#### **SECTION 7**

**HPP SESSIONS** 

#### SECTION 8

**INDUSTRY SESSIONS** 

# SECTION 2 EXHIBIT INFORMATION

Exhibit Information 43
Exhibit Floorplan 44
Exhibitor Listing 45

#### **SECTION 9**

**POSTERS** 

# SECTION 10 AUTHOR INDEX



**Company Profiles** 

#### CONGRESS SECRETARIAT

International Conference Services Ltd. (ICS) Suite 2101 - 1177 West Hastings Street Vancouver, BC, Canada V6E 2K3

46

Phone +1 604 681 2153 Fax +1 604 681 1049

Email hupo2015@icsevents.com

www.icsevents.com





# Introducing the HUPO 2015 Meeting App!



Get 24-hour access to all Congress related information



Access to full scientific program information including abstracts



Available for iPhone, iPad, and Android

#### #HUPO2015

Join the Conversation on Facebook, LinkedIn and Twitter







@hupo\_org



/humanproteomeorg



Human Proteome Organization (HUPO)

# **SECTION 1**

# GENERAL CONGRESS INFORMATION



Dear Friends and Colleagues,

On behalf of the Human Proteome Organization (HUPO), the Canadian National Proteomics Network (CNPN) and the British Columbia Proteomics Network (BCPN), we are pleased to welcome you to the 14<sup>th</sup> Human Proteome World Congress (HUPO 2015), taking place September 27–30, 2015 at the Vancouver Convention Centre, East Building in Vancouver, Canada.



The Vancouver Congress will continue the extraordinary success of previous meetings in Boston, Yokohama and Madrid among other outstanding locations over the past years. Vancouver will hopefully provide a legacy and foundation for those to come in Taipei, Taiwan in 2016 and Dublin. Ireland in 2017. The theme of the 2015 meeting 'Translating **Proteomics and Allied -Omics** to the Clinic' will underpin the need for collaboration and cooperation of individuals from a wide range of professional backgrounds.

Vancouver is an exceptional location for the Congress. It is renowned as one of the world's outstanding convention cities, with the sparkling Pacific Ocean and towering Coast Mountains providing a unique and spectacular setting. The HUPO 2015 Congress will be held in the East Building of the Vancouver Convention Centre right under the famous sails and perched on the edge of the Pacific Ocean with wonderful space for both scientific presentations and commercial exhibition.

The social program highlighting our West Coast cuisine, unique culture and arts, combined with the breathtaking natural beauty and pre- and post congress meetings and tours will underscore the role of Vancouver as one of the world's most popular tourist destinations.



The HUPO 2015 Congress will provide a wonderful forum for you to refresh your knowledge base and explore the innovations in proteomics and genomics. The Congress has striven to offer plenty of networking events, providing you with the opportunity to meet and interact with the leading scientists and researchers, friends and colleagues as well as sponsors and exhibitors.

We hope you will join us for a symphony of outstanding science over the next four days, and take a little extra time to enjoy the spectacular and unique beauty of this region.

With best wishes,



Chry Soul Borchers

**Christoph Borchers HUPO 2015** Congress Co-Chair



Pure Kirkantt

**Pierre Thibault** HUPO 2015 Congress Co-Chair





#### A Message from Premier Christy Clark

As Premier of the Province of British Columbia, I am pleased to welcome everyone to the 14<sup>th</sup> Human Proteome Organization World Congress here in Vancouver, British Columbia.

Your meetings will be taking place in our world-class convention facilities, the Vancouver Convention Centre East Building, where experienced staff will help to ensure a successful gathering.

Thank you for coming to British Columbia and I wish you all the best in your important deliberations around new technologies, techniques and training relating to proteomics.

Sincerely,

Christy Clark Premier

Christy Old



Mayor Gregor Robertson Le maire Gregor Robertson 羅品信市長 ਗਰੈਗਰ ਰੌਬਰਟਸਨ, ਮੇਅਰ Punong-bayan Gregor Robertson

ni? ct xatəmətəf, tə tnimət, tə təməx" ?i? tə kwakkwə 1 \* We watch over the land and sea and in turn they watch over us.

September, 2015

# A Message from the Mayor

On behalf of the citizens of Vancouver, and my colleagues on City Council, I want to extend my warmest greetings to the delegates of the 14th Human Proteome Organization World Congress.

We are very proud of the reputation Vancouver enjoys as one of the world's most beautiful and unique meeting destinations. I hope that in addition to attending the conference you are able to experience the many cultural and recreational activities the City has to offer. I know everyone involved in organizing the conference will ensure your time with us is special.

Best wishes on a successful and productive conference.

Yours truly,

Gregor Robertson MAYOR

@ 604.873.7621

604.873.7685 gregor.robertson@vancouver.ca

Office of the Mayor, City of Vancouver, 453 West 12th Avenue, Vancouver, British Columbia, Canada V5Y 1V4

\* © 2012, Musqueam Indian Band. All rights reserved. Used by permission only.





ALL HUPO 2015 SESSIONS (EXCEPT FOR THE HPP WORKSHOP ON THURSDAY, OCTOBER 1) WILL TAKE PLACE AT THE VANCOUVER CONVENTION CENTRE, EAST BUILDING, 999 CANADA PLACE, VANCOUVER, BC, V6C 3C1, CANADA

# Onsite Registration Hours & Poster Pick Up

#### LOBBY, STREET/CONVENTION LEVEL

Saturday, September 26	16:00-20:00
Sunday, September 27	08:30-19:30
Monday, September 28	07:00-17:30
Tuesday, September 29	07:00-17:30

Wednesday, September 30 07:00-16:30

#### **Exhibit Hours**

#### EXHIBIT HALL (HALL B), STREET/CONVENTION LEVEL

Sunday, September 27 Welc	19:30-21:00 come Reception
Monday, September 28	10:00-17:30
Tuesday, September 29	10:00-17:30
Wednesday, September 30	10:00-16:30

#### **Speaker Ready Room Hours**

#### MEETING ROOM 7, LEVEL 1/MEETING LEVEL

Saturday, September 26	16:00-20:00	Monday, September 28	07:00-17:30
Sunday, September 27	08:30-19:30	Tuesday, September 29	07:00-17:30
		Wednesday, September 30	07:00-16:30



#### **Welcome Reception**

EXHIBIT HALL (HALL B), STREET/CONVENTION LEVEL

Sunday, September 27 19:30-21:00

#### Congress Night 'Hockey Night in Canada'

EAST BALLROOMS, STREET/CONVENTION LEVEL

Tuesday, September 29 19:30-22:30

# **Networking Breaks** and Poster Viewing

EXHIBIT HALL (HALL B), STREET/CONVENTION LEVEL

Monday, September 28 10:00-11:10 and 16:20-17:30

Tuesday, September 29 10:00-11:10 and 16:20-17:30

Wednesday, September 30 10:00-11:10

# HUMAN PROTEOME ORGANIZATION



translating the code of life

MANAGED BY INTERNATIONAL CONFERENCE SERVICES, LTD.

2101 - 1177 WEST HASTINGS STREET VANCOUVER, BC, CANADA V6E 2K3

TELEPHONE +1 604 558 5498 FAX +1 604 681 1049 EMAIL OFFICE@HUPO.ORG

The Human Proteome Organization (HUPO) is an international scientific organization representing and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques and training.

#### **HUPO's mission is:**

To define and promote proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques and training to better understand human disease.

#### **Objectives**

Foster global collaboration in major proteomics projects by gathering leading international laboratories in life sciences, bioinformatics, mass spectrometry, systems biology, pathology, and medicine;

Become the point of contact for proteomics research and commercialization activities worldwide:

# Support large-scale proteomics projects that are aimed at:

- A mechanistic understanding of fundamental biological processes (often using model organisms and non human species);
- Directly studying human disease through proteomics techniques and technologies;

Coordinate and enable the fostering of communication among funding agencies and industry partners with the proteomics community and coordinate the activities of groups and organisations interested in HUPO's Scientific Initiatives

# Coordinate the development of standard operating procedures related to:

- Sample preparation, analysis, and repetitions;
- Data collection, analysis, storage, and sharing;

#### Play a leading role in:

- Defining the location and functions of proteins in human health and disease by supporting the definition of common and specific standards for peptide and protein characterization from human and model organism specimen selection and phenotypic evaluation to data collection, storage and analysis allowing free and rapid exchange of data;
- The creation of country-based ethical and legal policy surrounding the handling, banking and use of human tissue specimens for large-scale proteomics projects.

# HUMAN PROTEOME ORGANIZATION

#### **HUPO GOVERNANCE - COUNCIL**

FXFCU		

#### **COUNCIL MEMBERS 2015**

PRESIDENT

Mark Baker

(ex-officio)

PAST PRESIDENT

Pierre Legrain

(2013-2015)

VICE-PRESIDENT

Mike Snyder

(2015-2017)

**TREASURER** 

**Bruno Domon** 

(2015-2017)

SECRETARY GENERAL

**Gyorgy Marko-Varga** 

(2015-2016)

MEMBER-AT-LARGE

Yu-Ju Chen

(2015-2016)

MEMBER-AT-LARGE

Emma Lundberg

(2015-2016)

Alexander Archakov

Mark Baker

Ana Paulina Barba

Emøke Bendixen

Jonathan Blackburn

Christoph Borchers

YuJu Chen

Fernando Corrales

Bruno Domon

Catherine Fenselau

Albert Heck

Henning Hermjakob

Peter Hoffmann

**Hubert Hondermarck** 

Ghasem Hosseini Salekdeh

Donald F. Hunt

Connie Jimenez

Ho Jeong Kwon

Martin Larsen

Bonghee Lee

Pierre Legrain

Emma Lundberg

Matthias Mann

Gyorgy Marko-Varga

Daniel Martins de Souza

Robert L. Moritz

Hisashi Narimatsu

Chris Overall

Aysel Ozpinar

Gabriel Padron

Young Mok Park

Aran Paulus

Charles Pineau

Terence C.W. Poon

Jun Qin

Paola Roncada

Solange Serrano

Richard J. Simpson

Ravi Sirdeshmukh

Richard D. Smith

Michael Snyder

Pierre Thibault

Visith Thongboonkerd

Takeshi Tomonaga

George Tsangaris

Mathias Uhlen

Marc Wilkins

Tadashi Yamamoto

Pengyuan Yang



# Distinguished Achievement in Proteomic Sciences Award

#### **Amanda Paulovich**

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

#### **HUPO AWARDS**

WINNERS WILL BE
AWARDED DURING
THE CLOSING PLENARY
SESSION ON WEDNESDAY,
SEPTEMBER 30 IN THE
PLENARY HALL (HALL A),
VANCOUVER CONVENTION
CENTRE, EAST BUILDING,
STREET/CONVENTION
LEVEL.

Wednesday, September 30 16:30-18:30 Dr. Amanda Paulovich is awarded the HUPO Achievement Award 2015 for her significant impact in advancing the accuracy/precision of clinical proteomic mass spectrometry. She has been in the forefront of developing targeted proteomic assays based on Multiple Reaction Monitoring mass spectrometry technology, which can be multiplexed, standardized, reproduced, and shared across laboratories and instrument platforms.

SPONSORED BY JOURNAL OF PROTEOME RESEARCH



# **Discovery in Proteomic Sciences Award**




**Bernhard Kuster** Technical University of Munich, Chair of Proteomics and Bioanalytics, Freising, Germany



Akhilesh Pandey
Institute of Genetic Medicine and
Department of Biological Chemistry,
Oncology and Pathology,
John Hopkins University School of Medicine,
Baltimore, Maryland, USA

Professors Bernhard Kuster and Akhilesh Pandey are jointly awarded the 2015 HUPO Discovery Award for their independent large-scale mass spectrometry-based studies of the human proteome. They investigated a wide range of tissues and cell lines with advanced instruments and made their results, published in Nature in May 2014, publicly available through ProteomeX-change for reanalysis by others throughout the proteomics community. Their data were rapidly incorporated into the ongoing Human Proteome Project of HUPO and stimulated renewed interest in confirmation and validation of protein identifications.



#### Morteza Razavi

Director of Lab Operations SISCAPA Assay Technologies Victoria, BC, Canada

#### Selena Larkin

Vice President, Marketing and Sales SISCAPA Assay Technologies Victoria, BC, Canada

#### Leigh Anderson

Chairman, CEO and Founder SISCAPA Assay Technologies, Inc., Washington, DC, USA

#### **HUPO AWARDS**

WINNERS WILL BE
AWARDED DURING
THE CLOSING PLENARY
SESSION ON WEDNESDAY,
SEPTEMBER 30 IN THE
PLENARY HALL (HALL A),
VANCOUVER CONVENTION
CENTRE, EAST BUILDING,
STREET/CONVENTION
LEVEL.

Wednesday, September 30 16:30-18:30 Leigh Anderson, Morteza Razavi and Selena Larkin are collectively awarded the HUPO Science and Technology Award 2015 for the development of the SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) technology. The SISCAPA assays enable targeted quantitation of proteins and peptides from complex biological samples. The SISCAPA process involves up-front trypsin digestion of the sample followed by immunocapture enrichment of proteotypic peptides that are surrogates for the proteins of interest. Stable isotope labeled peptides are spiked into each sample for relative quantitation of the target molecules via quantitative mass spectrometry (MS).

SPONSORED BY

THE HUPO INDUSTRIAL ADVISORY BOARD



#### **Translational Proteomics Award**

Jennifer van Eyk

Cedars Sinai Medical Center, Los Angeles, California, USA

Dr. Jennifer Van Eyk is awarded the HUPO Translational Proteomics Award 2015 for her substantial contributions in translational medicine applying proteomics technology. She was one of the first to validate the concept that disease-induced modified protein biomarkers can add specificity to disease status and discovered the disease induced modifications of cardiac troponin I that revolutionized our understanding of the complexity of heart disease and improved our ability to diagnosis heart attacks. Based on this information she developed assays for the quantification of disease induced modified forms of cardiac troponin I that revolutionized the diagnosis of heart attacks.

#### SPONSORED BY





### **Distinguished Service Award**

Catherine Costello,
Center for Biomedical Mass Spectrometry,
University School of Medicine,
Boston. USA

#### **HUPO AWARDS**

WINNERS WILL BE
AWARDED DURING
THE CLOSING PLENARY
SESSION ON WEDNESDAY,
SEPTEMBER 30 IN THE
PLENARY HALL (HALL A),
VANCOUVER CONVENTION
CENTRE, EAST BUILDING,
STREET/CONVENTION
LEVEL.

Wednesday, September 30 16:30-18:30 Prof. Catherine Costello is awarded the Distinguished HUPO Service Award for her long-term dedication to promote HUPO and HUPO activities.

Are you experiencing

# quantitation FRUSTRATION?

CIL products can help turn your frown upside down!

CIL produces internal standards with the highest chemical and isotopic purities commercially available, allowing you to focus on what really matters – getting results!



To learn more about these products, visit tinyurl.com/kyufb36

#### Products of interest:

- PeptiQuant™ MRM Assay Kits
- Heaw-labeled proteins
- SILAC reagents
- · Metabolomics reagents

For more information, please contact CIL at 1-800-ISOTOPE, email cilsales@isotope.com, or visit us at isotope.com.



Cambridge Isotope Laboratories, Inc. isotope.com Visit us in Booth #212!

Enriching Scientific Discovery

#### Anuli Uzozie, Switzerland

P06.02 - Quantitative Mass Spectrometry Reveals Markers for Colorectal Tumors

#### Victor Llombart, Spain

CS04.07 - Protein Profiling of Brain Ischemia by MALDI-Imaging-Mass-Spectrometry

#### Manja Wölter, Germany

CS28.06 - Risk Assessment of Development Impairment in Preterm Babies by Cord Blood Proteome Profiling

#### Yelena Yefremova, Germany

CS26.10 - Ion Mobility and Surface Topology Mapping Reveals the Cause of the Protein G-IgG Affinity Switch

#### Kondethimmanahalli Chandramouli, Saudi Arabia

P11.03 - Proteomic Changes Associated with Reproductive Periods in Male Polychaetous Neanthes Arenaceodentata

#### Martin Freino, United Kingdom

CS22.03 - Kinome, Total Proteome and Phosphoproteome Analysis of the CRC64 Cell Line Panel

#### Sandra Goetze, Switzerland

P06.06 - Development of a Risk Stratification Test to Discern Aggressive and Non-Aggressive Prostate Cancer

#### Maria Yakovleva, Sweden

P06.07 - Large-Scale Analysis of Melanoma Tissue Samples

#### Linda Switzar, Netherlands

P04.09 - Development of LC-Electrochemistry-MS for Disulfide Mapping: Application to Notch3 Protein Fragments

#### Asfa Alli Shaik, Singapore

P15.06 - Quantitative Proteomics Analysis Unravels Functional Roles of Englerin A in Renal Cancer

#### Honggiang Qin, China

CS20.05 - Development of Methods for Site-Specific Analysis of N-Linked Protein Glycosylation

#### Aman Makaju, USA

CS10.04 - Identification of Cofactors Influencing Smyd1's Histone Methyltransferase Activity via ChIP-MS

#### Sarah Haves. Australia

P06.15 - SWATH-MS Profiling of NSCLC Cell Lines: Defining Mechanisms of Erlotinib Resistance

#### Mathieu Lavallée-Adam, USA

CS25.06 - MS3ID: A Novel MS3-Based Method Coupled to a Supervised Learning Algorithm for Top-Down Proteomics

#### Vincent Puard, United Kingdom

CS16.06 - Detection of Biomarkers of Sepsis Using Affimer Microarrays

#### Evelyne Maes, Belgium

P06.20 - Proteomic Analysis of Tumor-Associated Macrophages in an In Vivo Tumor Microenvironment

#### Barbara Cardinali, Italy

P07.05 - Evaluation of New Biomarkers of Resistance to Trastuzumab in the Treatment of HER2+ Breast Cancer

#### Vincent Geoghegan, United Kingdom

CS20.07 - Analysis of Arginine Methylation in Primary T Cells Reveals Roles in Cell Signalling and Fate

#### Christoph Krisp, Australia

P06.26 - SWATH Quantitation Using Ion Libraries from Multiple Cancer Cell-Types Identifies Drug Resistance

#### David Greening, Australia

P06.28 - YBX1 Induces Oncogenicity via Release of Angiogenic Factors into the Tumour Microenvironment

#### Ya-Ju Hsieh, Taiwan

PO4.16 - Systematic Exploration of Subcellular Redox Status by Methionine-Containing Peptide Enrichment

#### Verena Tinnefeld, Germany

CS26.09 - Enrichment of Cross-Links from Complex Samples by Charge-Based Fractional Diagonal Chromatography

#### Elena Ponomarenko, Russia

P13.06 - Gene-centric Knowledgebase as a Tool for Estimating Protein Species Number

#### Frank Fleurbaaij, Netherlands

P09.12 - CE-MS for the Detection of Carbapenemases in (Multi-)Drug-Resistant Gram-Negative Bacteria

#### Michael Götze, Germany

P01.09 - Efficient Identification of Cross-Linked Peptides with StavroX and MeroX in Structural Proteomics

#### Zon Lai, Germany

CS01.04 - Proteolytic Processing in the Progression of Low-Grade Astrocytomas to Glioblastoma Multiforme

#### Teresa García-Berrocoso, Spain

CS07.04 - Plasmatic RBP4 and GFAP as Biomarkers to Differentiate Ischemic from Hemorrhagic Stroke

#### Linnea Lagerstedt, Switzerland

P07.13 - A Biomarker Panel to Rule-Out CT-Scan Lesions in Mild Traumatic Brain Injury

#### Maria Pavlou, Switzerland

CS21.07 - The Listeria Monocytogenes Proteotype

#### Anna Häggmark, Sweden

P16.09 - Neuroproteomic Profiling of 277 Brain-Enriched Proteins in CSF and Plasma

#### Latifa Latrous. Tunisia

P11.12 - Gas Phase Interactions of Nucleosides with Organomercuric Compounds

#### Jennifer Abelin, USA

CS08.08 - Insights into Immune Responses to Commensal Bacteria through MHC Class II Antigen Quantification

#### Claudia Corbo, Italy

CS14.06 - Membrane Proteins of Leukocyte-Inspired Nanoparticles Improve Their Therapeutic Efficacy

#### Sandra Anjo, Portugal

P01.14 - Oxidative Stress Dependent Regulation of DJ-1: An Interatomic Point of View

#### Shamim Mushtaq, Pakistan

P14.01 - Expression & Association of CDK10 with ETS2 during Human Corneal Wound Healing

#### Can Cenik, USA

CS23.03 - Integrative Analysis of RNA, Translation and Protein Level Variation across Humans

#### Cristian Piras, Italy

P09.19 - Label Free Study for Control of Listeria Monocytogenes to Enhance Food Safety

#### Pia Jensen, Denmark

P15.20 - Identifying Novel Signaling Mechanisms Underlying Insulin Release from Glucose Stimulated Beta Cells

#### Viviana Greco. Italy

P09.23 - Proteomics Investigation of Pseudomonas Fluorescens Chromogenic Strains: Insight in Blue-Mozzarella

#### Marina Rodchenkova, Russia

P16.17 - Implementation of Mass Spectrometry for Detection Amyloid-? Peptides in Plasma

#### Ruth Huttenhain, USA

P09.24 - Investigating HIV-Mediated Dynamics of Cullin RING E3 Ligases by AP-MS and Proximity Biotinylation

#### Andrea Matlock, USA

CS13.05 - Pathological Variability of Motor Neuron Disorders in Patent-Derived iPSC Using SWATH-MS

#### **BCPN Travel Award Winners**



#### **BCProteomics**Network

#### Nicholas Brodie, Canada

P10.01 - A Structural Proteomics Study of Native Alpha-Synuclein in Solution

#### Patrick Chan, Canada

P11.10 - Proteomic Profiling of the [PSI+] Yeast Prion Strain by Quantitative Mass Spectrometry

#### Gillian Dornan, Canada

CS22.10 - The Molecular Mechanism of PI3K Mutations Implicated in Immunodeficiencies

#### Nikolaus Fortelny, Canada

P19.01 - Truncated Protein Isoforms and Their Genesis in the Human Proteome

#### Karen Lithgow, Canada

PO9.31 - Proteomic Characterization of Vascular Adhesins from the Syphilis Spirochete, Treponema Pallidum

#### Steven McArthur, Canada

P09.01 - Detecting and Quantifying Dengue Viral Proteins and Virus Maturation by MRM-MS

#### Robert Popp, Canada

P06.14 - Immuno-MALDI for Quantifying Akt1 and Akt2 Phosphorylation in Colorectal Cancer

#### Amrit Singh, Canada

P28.13 - Multi-Omic Blood Biomarker Signatures of the Late Phase Asthmatic Response

#### **Nestor Solis. Canada**

CS08.09 - Multi-Omics to Examine Proteolytic Cleavage, Expression and Abundances in Macrophage Differentiation

#### ChenXi Yang, Canada

P07.35 - Differential Expression of C3a and C5a in Allergic Asthma

#### Yuzi Zheng, Canada

CS02.05 - Investigating TDP-43-Mediated Neurodegeneration by Mass Spectrometry

#### Mang Zhu, Canada

P10.03 - A Feature Analysis of Lower Solubility Proteins in Unstressed and Heat-Shocked Yeast Cells

#### Giada Marino, Canada

P11.27 - Pulmonary Fibrosis: TAILS N-Terminomics Unravels the Role of MMP12

#### Claudia Gaither, Canada

CS21.10 - Proteomic Investigation of a Potential Type I Secretion System in the Syphilis Spirochete, Treponema Pallidum

#### Theo Klein, Canada

HPP03.04 - TMT10-TAILS Analysis of Lymphocytes to Unravel the Role of Proteolysis in B Cell Activation

#### Nichollas Scott, Canada

P13.01 - Characterization of the Protein Complex Landscape of Murine Tissues

#### Ameva Ranade, Canada

P02.14 - Methodology Development for Quantification of Tightly Adsorbed Proteins

#### **CNPN Travel Award Winners**



#### Carolyn Kachuk, Canada

CS24.05 - Comparison of Acetone Precipitation and FASP II for Protein Identification through Bottom up MS

#### James Knight, Canada

P13.10 - ProHits 2.0: A Bioinformatics Management and Analysis System Optimized for Interaction Studies

#### Dimitrios Korbakis, Canada

P04.27 - Immunoaffinity-MS Platform for Antibody Screening and Native Protein Analysis in **Biological Fluids** 

#### Nikunj Gevariya, Canada

P06.56 - Omega-3 Fatty Acid-Enriched Diet Favors a Reduction of Murine TRAMP-C2 Prostate Tumor Growth Compared to Omega-6 Fatty Acid-Enriched Diet

#### Theano D. Karakosta, Canada

P17.15 - Multiplexed SRM Assay for Measurement of Tissue Kallikrein-Related Peptidases in **Biological Fluids** 

#### Antoine Méant, Canada

P06.35 - Characterization of the Interactome of RSK Isoforms to Decipher Their Roles in Cancer Cells

#### Mario Navarrete, Canada

CS09.09 - Serine Hydrolase Activities in Urine from Patients Undergoing Cardiac Bypass Surgery



Process Variability - it's the challenge you face in traditional immunohistochemistry (IHC) experiments.

Experience controlled removal of solutions in seconds.

Experience minimal slide handling.

The SNAP i.d.® 2.0 system has been delighting Western blot users for years. Now we've applied its power to IHC.



Enhance your research with the SNAP i.d.® 2.0 system. www.emdmillipore.com/IHC

EMD Millipore Corp. is a subsidiary of Merck KGaA, Darmstadt, Germany



EMD Millipore, the M logo, and SNAP i.d. are registered trademarks of Merck KGaA, Darmstadt, Germany. LAm-15-11687 07/2015 e2015 EMD Millipore Corporation, Billerica, MA USA, All rights reserved.



#### **HUPO 2015 COMMITTEES**

### HUPO 2015 LOCAL ORGANIZING COMMITTEE

#### **CONGRESS CHAIR**

#### **Christoph Borchers**

University of Victoria Victoria, Canada

#### **CONGRESS CO-CHAIR**

#### **Pierre Thibault**

University of Montreal Monreal, Canada

#### COMMITTEE

#### **George Agnes**

Simon Fraser University Vancouver, Canada

#### Yossef Av-gay

University of British Columbia Vancouver, Canada

#### Mari DeMarco

University of British Columbia Vancouver, Canada

#### Suzanne Gill

Genome BC Vancouver, Canada

#### Natalie Glavas

BC Proteomics Network Vancouver, Canada

#### Juergen Kast

University of British Columbia Vancouver, Canada

#### Paul Keown

University of British Columbia Vancouver, Canada

#### **Thibault Mayor**

University of British Columbia Vancouver, Canada

#### **Bruce McManus**

University of British Columbia Vancouver, Canada

#### **Rob McMaster**

University of British Columbia Vancouver, Canada

#### Susan Murch

University of British Columbia Okanagan Kelowna, Canada

#### **Chris Overall**

University of British Columbia Vancouver, Canada

#### **Bingyun Sun**

Simon Fraser University Vancouver, Canada

#### Scott Tebbutt

University of British Columbia Vancouver, Canada

### **HUPO 2015 COMMITTEES**

#### HUPO 2015 SCIENTIFIC ORGANIZING COMMITTEE

#### **Mark Baker**

Australian School of Advanced Medicine, Macquarie University Sydney, Australia

#### **Christoph Borchers** University of Victoria

University of Victoria Victoria, Canada

#### Maxey C.M. Chung

National University of Singapore Singapore, Singapore

#### **Eric Deutsch**

Institute for Systems Biology Seattle, USA

#### Oliver Fiehn

UC Davis Davis, USA

#### **David Goodlett**

University of Maryland Baltimore, USA

#### Sam Hanash

University of Texas MD Anderson Cancer Center Houston, USA

#### Fuchu He

Beijing Proteome Research Center Beijing, China

#### Gil Omenn

University of Michigan Ann Arbor, USA

#### Young-Ki Paik

Yonsei Proteome Research Center, Yonsei University Seoul, South Korea

#### Peipei Ping

UCLA Los Angeles, USA

#### K. W. Michael Siu

University of Windsor Windsor, Canada

#### **Richard Smith**

Pacific Northwest National Laboratory Richland, USA

#### Mike Snyder

Stanford University Palo Alto, USA

#### **Pierre Thibault**

University of Montreal Montreal, Canada

#### Takeshi Tomonaga

National Institute of Biomedical Innovation Osaka, Japan

#### Jennifer Van Eyk

Cedars-Sinai Medical Center Los Angeles, USA

#### **David Wishart**

University of Alberta Edmonton, Canada


#### Tadashi Yamamoto

Niigata University Niigata, Japan


#### John Yates

The Scripps Research Institute LaJolla, USA

# **CONVENTION CENTRE, EAST BUILDING**



# CONVENTION CENTRE, EAST BUILDING



#### REGISTRATION

Registration for all attendees (delegates, exhibitors) is located at the Vancouver Convention Centre, East Building Lobby, Street/Convention Level.

#### **Hours of Operation**

Wednesday, September 30

Saturday, September 26	16:00-20:00
Sunday, September 27	08:30-19:30
Monday, September 28	07:00-17:30
Tuesday, September 29	07:00-17:30

07:00-16:30

#### **REGISTRATION MATERIALS**

# Registration Fees for full Congress includes:

Access to all scientific session except for the Clinical, Educational and Mentoring Day as well as the HPP Workshop on Thursday, October 1 (additional fees apply)

Access to Welcome Reception on Sunday, September 27

Access to Exhibit and Poster Hall

Access to all Networking Breaks and Poster Viewing Sessions

Delegate Bag with Congress materials

# Registration Fees for Single Day Registration includes:

Access to all scientific session on the day of attendance

Access to Exhibit and Poster Hall on day of attendance

Access to Networking Breaks and Poster Viewing Sessions on day of attendance

Delegate Bag with Congress materials

#### NAME BADGES

Delegates and guests are requested to wear their name badge at all times in order to participate in the Scientific Sessions, Networking Events and Exhibition.

#### LOST BADGE/NAME CHANGES

A 50 CAD fee applies for any reprints due to onsite name changes or lost badges.

#### **HUPO 2015 Official Mobile App**

Download the free HUPO 2015 mobile app for a convenient way to stay up-to-date via your phone or tablet. View the full scientific schedule, abstracts, exhibit information including floor plan and exhibitor biographies, and general Congress and venue information on our easy to use app!

The app is compatible with all iOS devices (iPhone, iTouch and iPad) and all Android mobile devices. Timely updates on program or room changes will be distributed through the mobile app via notification alerts.

#### Join the Conversation

**HUPO 2015 OFFICIAL SOCIAL MEDIA ACCOUNTS** 

Share your experience and images from HUPO 2015 with colleagues and friends via Facebook, LinkedIn and Twitter, Our official social media feeds throughout the Congress can be followed @hupo org. We encourage you to tag your posts with #HUPO2015.



@hupo\_org



/humanproteomeorg



Linked in Human Proteome Organization (HUPO)

#### **Delegate Services Information Desk**

LOCATED IN THE ENTRANCE LOBBY OF THE VANCOUVER CONVENTION CENTRE EAST BUILDING, STREET/CONVENTION LEVEL

Sunday, September 27 08:00-16:00

Monday, September 28 08:00-16:00

Tuesday, September 29 08:00-16:00

Wednesday, September 30 08:00-16:00

Knowledgeable local staff will provide local information and assist with:

- Ground Transportation
- Airport Transfers
- Sightseeing Tours
- · Pre- and Post Tours
- Restaurant recommendations and booking

#### **ABSTRACTS**

Abstracts selected for HUPO are presented in Oral, Mini Oral and Poster Sessions. All accepted and confirmed abstracts are available in the mobile app and are also collected in an online abstract book available on the Congress website at www.hupo2015.com.

#### **AIRPORT TRANSFERS**

For individual airport transfer bookings please see the Delegate Services Information Desk located in the entrance lobby of the Vancouver Convention Centre East Building, Street/Convention Level.

#### **ATTIRE**

Business casual is appropriate. Room temperature can vary in session rooms. We encourage attendees to dress in layers for their personal comfort. Attire for the Congress Night on Tuesday, September 29 is casual.

#### **ATM**

Two ATMs are located in the Lobby of the East Building behind the information desk.

#### **BAGGAGE CHECK**

See Coat Check

#### **BUSINESS CENTRE**

There is no business centre inside the Vancouver Convention Centre, East Building. Delegates may visit the FedEx Office Print & Ship Centre located at 779 W Pender St., Vancouver, BC, C6C 1H2, two blocks away from the Vancouver Convention Centre, East Building.

#### **CAMERAS AND CELL PHONES**

No cameras or video cameras are allowed in any event during HUPO. As a courtesy to fellow attendees, please turn off cell phones during scientific sessions.

#### CERTIFICATE OF ATTENDANCE

International attendees can request a 'Certificate of Attendance' by completing the Congress Evaluation Form available on the Congress website on Thursday, October 1, 2015. After completing the evaluation form you will be able to download your Certificate of Attendance.

#### **CHARGING STATIONS**

A Charging Station area is located in the Exhibit Hall (Hall B) allowing delegates to power up their cell phones, iPads, laptops and other electronic devices for free. This station will be in high demand; therefore sessions are limited to 15 minutes.

CHARGING STATION SUPPORTED BY



# CME ACCREDITATION AND CME CERTIFICATE

The Congress is not CME accredited.

#### **COAT CHECK**

With all official Congress hotels being in walking distance to the Convention Centre, there will be no coat check.

#### **COFFEE BREAKS**

See Networking Breaks

#### **DELEGATE BAG RETURN**

If you do not want to take home your Delegate Bag, please return it to the Registration Desk.

# EMERGENCY SERVICES AND FIRST AID

#### EMERGENCY NUMBER

In the event of a health, safety, or criminal emergency, dial 9-1-1.

You may also dial 7500 from any of the house phones or +1 604 647 7500 from your mobile phone.

The First Aid Office is located in the East Lobby next to the washrooms. Kindly note that the First Aid Office is not staffed. For access please call the above mentioned emergency numbers.

#### **EVALUATIONS**

A Congress evaluation survey will be e-mailed to all delegates after the Congress. Please help us to improve the Congress by completing your survey.

#### **EXHIBITS**

The exhibits are an integral part of the experience at HUPO and will feature the latest in technology and research. The exhibits are located in the Exhibit Hall (Hall B), Street/Convention Level at the Vancouver Convention Centre, East Building.

#### HIGHLIGHT OF THE DAY EBLAST

Watch out for daily morning emails (Sunday-Wednesday) providing you with an update highlighting the best sessions and presentations as well as exciting things to do in Vancouver. The eNews will also include any speaker or room updates.

#### **HUPO**



translating the code of life

Please visit the HUPO Booth (#401) for updates on membership, and general information.

#### **LANGUAGE**

The official language of the HUPO 2015 Congress is English.

#### LOST AND FOUND

Lost and Found items should be returned/claimed at the Registration Desk.

#### **NETWORKING BREAKS**

Networking Breaks will take place in the Exhibit Hall (Hall B), Street/Convention Level at the following times. Refreshments will be provided.

#### **Networking Break and Poster Viewing**

#### EXHIBIT HALL (HALL B), STREET/CONVENTION LEVEL

Monday, September 28 10:00 - 11:10 and 16:20 - 17:30

Tuesday, September 29 10:00 - 11:10 and 16:20 - 17:30

Wednesday, September 30 10:00 - 11:10 and 16:20 - 16:30

#### **PARKING**

Parking is available in the Vancouver Convention Centre West and East Building.

# VANCOUVER CONVENTION CENTRE EAST 999 CANADA PLACE

#### VINCI PARK

Enter at the foot of Howe Street, obtain ticket from dispenser and proceed to P1 or P2.

Use Convention Centre/Hotel elevators (not World Trade Centre elevators).

For Convention Level: press "G" for Registration, Ballrooms and Exhibits.

For Meeting Rooms: press "M".

#### **PUBLIC TRANSPORTATION**

Vancouver is a walkable city and all Congress hotels are within a maximum of 15 minute walking distance.

#### RESTAURANTS

There are plenty of restaurants choices in Vancouver. You may also want to try out one of the many food trucks around the Convention Centre and the downtown area. A food court is located right underneath the Fairmont Waterfront Hotel across from the Vancouver Convention Centre, East Building.

The staff at the Delegate Services Information Desk will be happy to assist with recommendations and bookings. Delegates may also seek assistance within Vancouver from the Vancouver Downtown Ambassadors. Staff are easily located by their blue uniforms outside the Convention Centre.

#### **SMOKING**

It is against the law to smoke in any indoor public place or worksite, including pubs, bars, restaurants, and shopping centres. Designated smoking rooms are non-existent, and public transit, transit shelters, taxis and work vehicles are also smoke-free

In addition, there is a 3 metre nonsmoking "buffer zone" around public and work place doorways, opening windows and air intakes including apartments and condominiums.

#### SPEAKER READY ROOM

Meeting Room 7 located on Level 1/ Meeting Level is the designated Speaker Ready Room. All Presenters are required to submit and/or preview their slides at least 24 hours prior to their scheduled presentation to ensure compatibility with the Congress AV Equipment.

#### HOURS OF OPERATION

Saturday, September 26	16:00-20:00
Sunday, September 27	08:30-19:30
Monday, September 28	07:00-17:30
Tuesday, September 29	07:00-17:30

Wednesday, September 30 07:00-16:30

#### WIRELESS INTERNET

HUPO is providing free Wi-Fi throughout the Vancouver Convention Centre. To ensure a positive Wi-Fi experience for all users please do not use your own wireless Hotspot device. These additional Wi-Fi devices create significant RF interference which can interfere with all Wi-Fi networks. Please turn these devices off and connect to the Wi-Fi network HUPO 2015 and open your web browser to connect to the Internet.

**NETWORK: HUPO 2015** 

NO PASSWORD IS REQUIRED, BUT YOU WILL NEED TO OPEN YOUR BROWSER TO CONNECT.

#### STAFF AND VOLUNTEERS


Volunteers are working throughout the Convention Centre and are happy to assist with any questions delegates may have regarding the Congress or the Convention Centre. Delegates can easily locate them by their staff/ volunteer shirts.

#### SUPPORTED BY



#### DISCLAIMER

THE ORGANIZERS HAVE MADE EVERY ATTEMPT TO ENSURE THAT ALL INFORMATION IN THIS PUBLICATION IS CORRECT. THE ORGANIZERS TAKE NO RESPONSIBILITY FOR CHANGES TO THE PROGRAM OR ANY LOSS THAT MAY OCCUR AS A RESULT OF CHANGES TO THE PROGRAM. SOME OF THE INFORMATION PROVIDED IN THIS PUBLICATION HAS BEEN PROVIDED BY EXTERNAL SOURCES. ALTHOUGH EVERY EFFORT HAS BEEN MADE TO ENSURE THE ACCURACY, CURRENCY AND RELIABILITY OF THE CONTENT, THE ORGANIZERS ACCEPT NO RESPONSIBILITY IN THAT REGARD.



The Bioinformatics Hub at HUPO 2015 in Vancouver is organized by the Computational Mass Spectrometry initiative, a joint initiative of HUPO, ISCB and the Metabolomics Society.

The objective of this hands-on meeting is to develop and execute original bioinformatics analyses on the publicly available human proteomics data during the Congress, facilitated by several leading proteomics informatics groups, and completely open for participation by any and all interested Congress attendees.

Moreover, the intent is to maximize constructive interactions between wet-lab researchers, mass spectrometry practitioners and bioinformaticians by organizing dedicated 'problem-busting' Ask-The-Experts sessions, where proteomics bioinformatics experts and the audience together provide and answer any hot topic questions in proteomics bioinformatics.

The Bioinformatics Hub will start on September 27, the day preceding the main Congress, and continue the work, the brainstorming, the problembusting and interaction during the remainder of the Congress.

the public human proteomics data;

- 2 to come up with novel approaches and ideas to perform integrative proteomics data analysis and interpretation:
- 3 to discuss with participants about the possibilities and limitations of existing tools and data processing algorithms, fostering collaborative interactions between wet-lab researchers and bioinformaticians; and
- 4 to identify gaps in the existing proteomics bioinformatics tools, inspiring future work to fill these gaps.

#### **BIOINFORMATICS HUB**

#### Ask-The-Experts sessions will be held every day between 10:00 and 11:00.

#### Just a few examples of highly interesting topics that can be explored include:

- The search for missing proteins
- The identification of splice isoforms and splice junction peptides, calculations of protein-level FDR based on across-experiment data
- The mapping of post-translational modifications on peptides and proteins.

#### CONTRIBUTORS:

#### Nuno Bandeira.

UCSD. USA

#### Ron Beavis.

UNIVERSITY OF MANITOBA, CANADA

#### Eric Deutsch.

INSTITUTE FOR SYSTEMS BIOLOGY, USA

#### Henning Hermjakob,

EMBL-EUROPEAN BIOINFORMATICS INSTITUTE,

#### Oliver Kohlbacher.

UNIVERSITY OF TUEBINGEN, GERMANY

#### Lennart Martens.

GHENT UNIVERSITY AND VIB. BELGIUM

#### Yassene Mohammed.

UNIVERSITY OF VICTORIA, CANADA AND LUMC, NETHERLANDS

#### Andrew Su.

THE SCRIPPS RESEARCH INSTITUTE, USA

#### Yves Vandenbrouck.

CEA GRENOBLE, FRANCE

#### Marc Vaudel.

UNIVERSITY OF BERGEN, NORWAY

#### Juan Antonio Vizcaíno,

EMBL-EUROPEAN BIOINFORMATICS INSTITUTE, UNITED KINGDOM

#### **ORGANIZERS:**

#### Henning Hermjakob,

EMBL-EUROPEAN BIOINFORMATICS INSTITUTE, UNITED KINGDOM

#### Lennart Martens.

GHENT UNIVERSITY AND VIB, BELGIUM

#### Yassene Mohammed,

UNIVERSITY OF VICTORIA, CANADA AND LUMC, NETHERLANDS

#### Yves Vandenbrouck.

CEA GRENOBLE, FRANCE

THE BIOINFORMATICS HUB AT HUPO 2015 IS SPONSORED BY





# INFORMATION FOR INVITED FACULTY AND ABSTRACT PRESENTERS

#### **Speaker Ready Room**

All Invited Speakers as well as Oral and Mini Oral Abstract Presenters are required to report to the Speaker Ready Room at least 4 hours prior to their scheduled presentation in order to upload their presentation slides or to check their previously uploaded slides.

## NO FILE SUBMISSIONS WILL BE ACCEPTED IN THE SESSION ROOMS.

Computers are available to preview and upload presentations. Presenters should make sure all fonts appear as expected and all sound/video clips are working properly. The final version must be submitted to the Speaker Ready Room, no presentation submissions will be accepted in the Session Rooms.

#### SPEAKER READY ROOM IS LOCATED IN MEETING ROOM 7. LEVEL 1/MEETING LEVEL

Saturday, September 26	16:00-20:00
Sunday, September 27	08:30-19:30
Monday, September 28	07:00-17:30
Tuesday, September 29	07:00-17:30

Wednesday, September 30 07:00-16:30

#### Oral Presentation with Poster Presentation

You will have a total of **15 minutes**; 12 minutes of presentation, followed by 3 minutes time for questions from the audience. Time limits will be strictly enforced.

Please be in room for your session 10 minutes before the start time of the session. The Session Chairs will start and end strictly on time.

You are asked to prepare a PPT Presentation with **max. 10 slides** (not including title and author slide).

You are required to submit your presentation slides to the Speaker Ready Room (onsite) at least 4 hours prior to your scheduled presentation.

In addition to your talk you will be given the opportunity to prepare a poster and have it displayed in the Exhibit Hall for the entire duration of the Congress. Please see Poster Presentation information below for further instructions.

#### Mini Oral with Poster Presentation

You will have a total of **5 minutes** (no Q&A). Time Limits will be strictly enforced.

Please be in room for your session 10 minutes before the start time of

# INFORMATION FOR INVITED FACULTY AND ABSTRACT PRESENTERS

the session. The Session Chairs will start and end strictly on time.

You are asked to prepare a PPT Presentation with **max. 5 slides** (not including title and author slide).

You are required to submit your presentation slides to the Speaker Ready Room (onsite) at least 4 hours prior to your scheduled presentation.

In addition to your 5 minute oral talk you will be asked to prepare a poster. Please see Poster Presentation below for further instructions.

#### **Poster Presentation**

#### The maximum poster size is:

**4' x 4'.** Poster Boards will be Velcro and Push Pin compatible.

All Posters will be displayed in the Exhibit Hall (Hall B) at the Vancouver Convention Centre, East Building.

All Posters will be on display for the entire duration of the Congress. However, poster presenters are asked to stand by their poster during the morning and afternoon networking breaks on the day of their Poster Session to informally answer questions from Congress Delegates.

#### **Author Stand By Times**

#### **ODD POSTER NUMBERS**

Monday, September 28 10:00–11:10 and 16:20–17:30

#### **EVEN POSTER NUMBERS**

Tuesday, September 29 10:00-11:10 and 16:20-17:30

#### SETUP HOURS

Sunday, September 27 19:30-21:00 OR 07:30-10:00

#### TAKE DOWN HOURS

Wednesday, September 30 16:30

#### **Poster Pick Up Counter**

#### REGISTRATION DESK, STREET/CONVENTION LEVEL

 Saturday, September 26
 16:00-20:00

 Sunday, September 27
 08:30-19:30

 Monday, September 28
 07:00-17:30

 Tuesday, September 29
 07:00-17:30

 Wednesday, September 30
 07:00-16:30



#### **Welcome Reception**

Sunday, September 27, 2015

19:30-21:00

VANCOUVER CONVENTION CENTRE, EAST BUILDING, EXHIBIT HALL (HALL B)

The Welcome Reception is included in full registration. Additional tickets for guests can be purchased at the time of registration or onsite.

Additional tickets for friends and guests: 75 CAD

Following the Opening Ceremony, delegates are invited to the Exhibition Hall for the Welcome Reception and the chance to mix and mingle with exhibitors, friends and colleagues while enjoying local wines and exquisite canapés.

#### **SOCIAL PROGRAM**

#### Congress Night — Hockey Night in Canada



Experience a Congress Night like no other with a truly Canadian Hockey Night in Canada!

"HELLO OUT THERE, WE'RE ON THE AIR, IT'S 'HOCKEY NIGHT' TONIGHT.

TENSION GROWS, THE WHISTLE BLOWS, AND THE PUCK GOES DOWN THE ICE

THE GOALIE JUMPS, AND THE PLAYERS BUMP, AND THE FANS ALL GO INSANE

SOMEONE ROARS, "BOBBY SCORES!", AT THE GOOD OL' HOCKEY GAME.

OH! THE GOOD OL' HOCKEY GAME, IS THE BEST GAME YOU CAN NAME

AND THE BEST GAME YOU CAN NAME, IS THE GOOD OL' HOCKEY GAME"

- Stompin' Tom Connors, The Good Old Hockey Game

#### Congress Night — Hockey Night In Canada

Tuesday, September 29, 2015

19:30-22:30

VANCOUVER CONVENTION CENTRE, EAST BUILDING, BALLROOMS A+B+C

Tickets are only 100 CAD, and includes skate rentals and commemorative photos with various hockey players.

Don't miss out and join us at the HUPO 2015 Congress Night, "Hockey Night in Canada" on September 29, 2015! Hockey is an incredibly important pastime that began in Canada in the 1880's and all Canadians, young and old, grew up watching hockey.

To pass on this important tradition to our guests and international delegates, we invite you, your family and friends to experience a once in a lifetime experience at the HUPO 2015 Congress Night, "Hockey Night in Canada," on Tuesday, September 29, 2015, from 19:30 to 22:30

As the Vancouver Convention Centre East Ballroom is magically transformed into a hockey ice rink, delegates will have the chance to skate and play hockey on the large synthetic ice rink, or dance along with our amazing cover band on the dance floor, or alternatively to sit back and relax while enjoying a casual Vancouver West Coast Style buffet dinner in the lounge area. There will be fun & exciting activities for everyone!

This will be a Congress Night like no other, and we encourage you to bring your families and friends to enjoy this special night with us.

#### **SOCIAL PROGRAM**

#### LOCAL SIGHTSEEING TOURS

#### Local Sightseeing Tours

"VANCOUVER IS A CITY UNLIKE ANY OTHER. WHEREVER I LOOK, I SEE WATER OR MOUNTAINS — OR BOTH. AND EVERYONE LOOKS SO HEALTHY."

THE DAILY TELEGRAPH (UK)

Nestled between the Pacific Ocean and Coast Mountains, Vancouver is consistently ranked as one of the most livable cities.

Bring a camera to capture the breathtaking panoramic views while walking along the Seawall, relax in Stanley Park, take a boat ride to Granville Island, enjoy world-class shopping and our famous West Coast cuisine and join a guided sightseeing adventure.

#### HERE ARE THE MOST POPULAR TOURS:



#### **Vancouver City Tour**




#### Whistler and Shannon Falls



**Enchanting Victoria** 

#### FOR FURTHER INFORMATION AND RESERVATIONS

Please contact our partner Westcoast Sightseeing Tours at 1.887.451.1777 or 1.604.451.1600 or visit www.vancouversightseeing.com



QUICK FACTS

The Vancouver Metropolitan Area has a population of 2.4 million as of 2010, which is approximately half of the entire population of British Columbia; the city of Vancouver proper has over 600,000 people (census data from 2011)

Vancouver was ranked as the third most livable city by the EIU in 2013 and fifth most livable city by the Mercer Quality of Life Survey

Vancouver boasts one of the most diverse multicultural populations in Canada—alongside English and Chinese, you may also hear Punjabi, German, Italian, French, Tagalog, Japanese, Korean, and Spanish as you walk around the city

Through various initiatives, Vancouver is on track to its goal of being the greenest city in the world by 2020—currently 93% of the electricity used in Vancouver is generated from sustainable sources such as hydroelectricity


Stanley Park, just northwest of downtown Vancouver, is one of the largest urban parks in North America

The City of Vancouver is a highly diverse and multicultural city with people from all around the world. As such, it is a popular tourist destination and has been regarded as one of the most outstanding convention cities in the world.

Vancouver has been ranked one of the most livable cities in the world for the past decade and was ranked as having the 4th highest quality of living in the world as of 2010, on par with cities such as Melbourne, Vienna, and Toronto. The city offers plenty of fine dining and shopping, but it is also an excellent place for more outdoor pursuits such as hiking, golfing, boating, and surfing.

Learn more about Vancouver's diverse marine life at the **Vancouver Aquarium**, or see unique artwork at numerous art galleries (including the **Vancouver Art Gallery**).

There is something to do for everybody!



# Join the conversation!





#HUPO2015





# SECTION 2 EXHIBIT INFORMATION



#### Location

#### **EXHIBIT HALL (HALL B), STREET LEVEL**

Sunday, September 27 19:30-21:00 Monday, September 28 10:00-17:30 10:00-17:30 Tuesday, September 29

Wednesday, September 30 10:00-16:30

**NETWORKING BREAKS** 


Monday and Tuesday 10:00-11:10 and 16:20-17:30

Wednesday 10:00-11:10 and 16:20-16:30

#### POSTER SESSIONS

Presenter Attendance during morning and afternoon **Networking Breaks** 

**FLOOR PLAN** 



#### **ENTRANCE**

#### **EXHIBITOR LISTING**

#### ALPHABETICAL BY EXHIBITOR

ALPHABETICAL BY EXHIBITOR	
COMPANY	воотн#
Abcam	112
Agilent Technologies	302
Atlas Antibodies	204
BC Proteomics Network	102
BIOCRATES Life Sciences AG	407
Biotech Support Group LLC	107
Bruker Daltonics	213
Cambridge Isotope Laboratories, Inc.	212
Canadian National Proteomics Network	102
Cell Signaling Technology	202
Denator	208
Elsevier	408
EMD Millipore Corporation	100
Fluidigm Corporation	406
GE Healthcare	113
Genome BC	210
Genome Canada	210
HUPO 2016, Taipei	403
HUPO 2017, Dublin	403B
HUPO, Human Proteome Organization	401
IMSC 2016	402
INTAVIS Bioanalytical Instruments	400
JPT Peptide Technologies, GmbH	307
Matrix Science	103
Molecular & Cellular Proteomics (ASBMB Journal)	413
Optys Tech Corporation	105
PEAKS Software (Bioinformatics Solutions Inc.)	206
Pressure BioSciences, Inc.	311
PROOF Centre of Excellence	416TT
Protein Metrics Inc.	404
ProteinSimple	415
Proteintech Group, Inc.	111
Proteome Software	305
Rapid Novor Inc	108
SCIEX SENGENICS	300 110
Sigma-Aldrich Life Sciences	205
Silantes GmbH The Metabolomics Innovation Centre	409 405
Thermo Scientific	301
UVic Genome BC Proteomics Centre	309 410
Veritomyx VICI Valco Instruments	109
Wako Laboratory Chemicals	114
Waters Corporation	201
vvaters Corporation	201

#### BY BOOTH#

BOOTH#	COMPANY
100	EMD Millipore Corporation
102	BC Proteomics Network / Canadian National Proteomics Network
103	Matrix Science
105	Optys Tech Corporation
107	Biotech Support Group LLC
108	Rapid Novor Inc
109	VICI Valco Instruments
110	SENGENICS
111	Proteintech Group, Inc.
112	Abcam
113	GE Healthcare
114	Wako Laboratory Chemicals
201	Waters Corporation
202	Cell Signaling Technology
204	Atlas Antibodies
205	Sigma-Aldrich Life Sciences
206	PEAKS Software (Bioinformatics Solutions Inc.)
208	Denator
210	Genome Canada
210	Genome BC
212	Cambridge Isotope Laboratories, Inc.
213	Bruker Daltonics
300	SCIEX
301	Thermo Scientific
302	Agilent Technologies
305	Proteome Software
307	JPT Peptide Technologies, GmbH
309	UVic Genome BC Proteomics Centre
311	Pressure BioSciences, Inc.
400	INTAVIS Bioanalytical Instruments
401	HUPO, Human Proteome Organization
402	IMSC 2016
403	HUPO 2016, Taipei
403B	HUPO 2017, Dublin
404	Protein Metrics Inc.
405	The Metabolomics Innovation Centre
406	Fluidigm Corporation
407	BIOCRATES Life Sciences AG
408	Elsevier
409	Silantes GmbH
410	Veritomyx
413	Molecular & Cellular Proteomics (ASBMB Journal)
415	ProteinSimple
416TT	PROOF Centre of Excellence

#### **COMPANY PROFILES**



#### Abcam

Abcam plc is a provider of protein research tools and services, with an unrivaled range of products and expert technical support, enabling scientists to analyze living cells at the molecular level and improving the understanding of health and disease. To find out more, please visit www.abcam.com



#### **Agilent Technologies**

Agilent manufactures and distributes a complete line of instrumentation serving the clinical, analytical, biotech, environmental, pharmaceutical, forensic science, food and flavor, academia, and all other laboratory markets that have needs for the best in quality, performance, and serviceability in the instruments they purchase.



#### **Atlas Antibodies**

Based in Sweden, Atlas Antibodies manufactures and distributes advanced research reagents targeting all human proteins, among those the antibodies developed and validated in the prestigious Human Protein Atlas project. In 2014 the company launched a new product family of isotope labeled multipeptide Mass Spectrometry standards for absolute quantification, called QPrEST.



#### **BC Proteomics Network**

The BC Proteomics Network is a network of research professionals from universities, research institutions and industry throughout British Columbia. The network's mandate is to leverage proteomics resources, promote awareness of proteomics, educate current and future researchers in proteomics, and harness the proficiency of BC scientists to perform cross-disciplinary research.



#### **BIOCRATES Life Sciences AG**

Biocrates Life Sciences, developer of targeted metabolic phenotyping solutions, supports the discovery and validation of biomarkers for complex multifactorial diseases in pre-clinical and clinical research. Biocrates kits and services analyze more than 630 endogenous metabolites under quality-controlled conditions and can be used with a wide range of species and matrices.



#### **Biotech Support Group LLC**

Biotech Support Group serves the explosive growth in proteomic sample prep, with unique and proprietary surface chemistries. We are dedicated to create new methods and applications to drive efficient workflows and better data quality for all downstream proteomic and biomarker analyses.

#### **COMPANY PROFILES**



#### **Bruker Daltonics**

Bruker is a leading provider of Chromatography and Mass Spectrometry instruments and solutions for the Analytical Sciences. Our innovative and easy-to-use product families (ESI-QTOF, Ion Trap, FTMS, MALDI-TOF, LC-Triple Quads and GC-Triple Quads) provide the highest performance, ruggedness and value for a wide range of applications in the food, environmental, forensic, industrial, pharmaceutical and life science research markets.



#### Cambridge Isotope Laboratories, Inc.

Cambridge Isotope Laboratories, Inc. (CIL) is the world leader in the manufacture of stable isotope-labeled (13C, D, 15N, 17O, 18O) compounds used for quantitative MS-based applications. CIL has many products to meet the needs of the proteomic community: MRM Proteomics kits, MouseExpress\* mouse feed and tissue, SILAC reagents, and others.



#### **Canadian National Proteomics Network**

CNPN is a not-for-profit, federally incorporated organization created to provide a co-operative mechanism for building the proteomics research infrastructure in Canada and to further a better understanding of proteomics in the Canadian life-sciences community. CNPN sponsors scientific conferences, seminars and forums to create a national focus for scientific collaboration and education



#### **Cell Signaling Technology**

Founded by research scientists, Cell Signaling Technology (CST) is a family-owned company focused on proteomic discovery especially in the cancer field. Our products and services support your proteomics research and because we believe you have the right to expect more reliable results, our scientists produce, validate and support all our antibodies in-house.



#### Denator

Denator offers a superior sample preservation technology that eliminates molecular changes and degradation of biological samples. It enables accurate analysis and quantification of unstable protein biomarkers such as phosphorylations and endogenous peptides. It ensures quality and standardization of sample collection, ensuring more precise, reliable data from your clinical proteomics research.



#### Elsevier

Discover Elsevier's leading scholarly publications and online solutions for proteomics. Our proteomics journals include Journal of Proteomics, BBA Proteins and Proteomics and the fully Open Access journals Translational Proteomics, EuPA Open Proteomics.

#### **COMPANY PROFILES**



#### **EMD Millipore Corporation**

EMD Millipore is the Life Science division of Merck KGaA of Germany, supporting research, development and production of biotech and pharmaceutical drug therapies. We support our customers in physiologically predictive cellular analysis, multianalyte network elucidation and functional genomics with innovative platforms for protein detection, complemented by protein preparation technologies that enable fast, effective purification without sample loss.



#### **Fluidigm Corporation**

Fluidigm partners with life science researchers and enterprises to provide simplified workflows for genomics and proteomics applications. Whether your quest is to understand the profiles and functions of single cells or to meet high-throughput data demands of a production-scale laboratory, you'll find a solution at fluidigm.com.



#### **GE Healthcare**

GE Healthcare Life Sciences provides expertise and tools for a wide range of applications, including basic research of cells and proteins, drug discovery research, and tools to support large-scale manufacturing of biopharmaceuticals. By combining our knowledge, talent, and resources, we deliver innovative products and solutions that help our customers achieve their goals.



#### **Genome BC**

Genome BC is a catalyst for the life sciences cluster on Canada's West Coast and manages a cumulative portfolio of over \$660M in research projects and science and technology platforms. Working with governments, academia and industry, the organization's goal is to generate social and economic benefits for BC and Canada.



**Genome**Canada

#### **Genome Canada**

Genome Canada is a not-for-profit organization that acts as a catalyst for developing and applying genomics and genomic-based technologies across multiple sectors to create economic and social benefits for Canadians. For more information, visit www.genomecanada.ca.



#### HUPO 2016, Taipei

HUPO 2016 will be held in Taipei, September 18-22, 2016. It is our intention to make the scientific program of HUPO 2016 a most vibrant and forward looking one by capturing the essence of current technical advances and future possibilities in all emerging fields of proteomic applications, from basic to translational sciences.

#### **COMPANY PROFILES**



#### HUPO 2017, Dublin

BSPR and EuPA are delighted to welcome you to the 16th Annual World Congress of HUPO to be held in Dublin 17-20th September 2017.

Please come & visit us at our stand to find out more about HUPO 2017 & to enter our competition to win a free registration.



#### **HUPO, Human Proteome Organization**

The Human Proteome Organization (HUPO) is an international scientific organization representing and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques, and training to better understand human disease. HUPO fosters international initiatives and encourages the formation of national and regional human proteome-related societies.



#### **IMSC 2016**

The Canadian Society for Mass Spectrometry (CSMS) will host the 21st International Mass Spectrometry Conference (IMSC 2016) in Toronto, Canada. This is the first time the IMSC is being held in North America. The IMSC 2016 provides an excellent forum for scientists to discuss research related to mass spectrometry.



#### **INTAVIS Bioanalytical Instruments**

INTAVIS Bioanalytical Instruments focuses on automation of complex scientific protocols. We concentrate on applications in proteomics, and functional genomics. The DigestPro MSi, is a dedicated platform for protein digestion and sample preparation in proteome research. It automates both in-gel and solution digest procedures for protein analysis by mass spectrometry.



#### JPT Peptide Technologies, GmbH

JPT is an ISO certified provider of innovative peptide products and services focused on proteomics, developing immune therapeutics & diagnostics and enyzme profiling. JPT has a large portfolio of proprietary products such as SpikeMixTM Peptide Pools & SpikeTidesTM that provide access to low cost stable isotope labeled and/or quantified peptides.



#### **Matrix Science**

Matrix Science develops and markets Mascot software, the benchmark for identification, characterization and quantitation of proteins using mass spectrometry data.

#### **COMPANY PROFILES**



#### Molecular & Cellular Proteomics (ASBMB Journal)

Molecular & Cellular Proteomics (MCP) showcases contributions that describe the structural and functional properties of proteins and their expression. Emphasis is placed on determining how the presence or absence of proteins affect biological responses, and how the interaction of proteins with germane cellular partners allows them to function.



#### **Optys Tech Corporation**

Pinnacle is Optys' revolutionary flagship software for proteomics and glycoproteomics. Available in a single software is: comprehensive quantitation of 10,000s of proteins across of 100s of samples using DIA, DDA, PRM or SRM with fully integrated statistics and biological interpretation; complete N-linked glycoprotein identification routine; in-depth analysis in protein characterization.



#### PEAKS Software (Bioinformatics Solutions Inc.)

Bioinformatics Solutions Inc. is the creator of PEAKS Software: A Complete Proteomics Analysis Package. PEAKS provides a simple workflow for in-depth analysis of raw LC-MS/MS proteomic data. From de novo sequencing, database search, homology search to peptide feature extraction and LC-MS alignment, PEAKS provides tools for complete data analysis qualitatively and quantitatively at both the protein and peptide levels.



#### Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development and sale of proprietary laboratory instrumentation and consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented enabling technology platform that uses cycles of hydrostatic pressure between ambient and ultrahigh levels to control bio-molecular interactions for biomarker discovery, enhanced protein digestion, and other research applications.



#### **PROOF Centre of Excellence**

PROOF Centre is a not-for-profit biomarker development engine focused on producing omics-derived laboratory tests to better predict, diagnose and prognose vital organ failure. We embrace a cross-disciplinary team representing academia, health care, government, industry, patients and the public, convened to improve health and reduce the burden of organ disease. www.proofcentre.ca

#### **COMPANY PROFILES**



#### Protein Metrics Inc.

Protein Metrics is a software company serving biopharmaceutical development and proteomics research. The company focuses on the analysis of mass spectrometry and LC-UV data and offers a software products that address peptide identification, rapid peptide mapping, quantitative comparisons, and sensitive analysis and reporting of variants and post-translational modifications.



#### **ProteinSimple**

Our goal is to make protein analysis simpler, more quantitative and affordable. Our comprehensive portfolio of tools includes Simple Western systems that quantify protein expression and Biologics systems that probe the structure and purity of protein-based therapeutics.



#### Proteintech Group, Inc.

Proteintech is the original manufacturer of over 11,000 antibodies validated in WB and IHC on primary tissues and cell lysates. Whole protein antigens produce antibodies w/unparalleled high quality working in more species and applications. Locations (US, Europe, China, Japan), all antibodies in stock, next-day delivery.



#### **Proteome Software**

Proteome Software builds user-friendly bioinformatics tools for intuitive visualization and management of experimental results. Our Scaffold Suite validates, organizes, compares, and interprets mass spectrometry data, and has become the industry standard in sharing MS/MS proteomics data. Elements for Metabolomics brings many of these valued features to MS/MS based metabolomics analysis.



#### **Rapid Novor Inc**

Rapid Novor offers Novor software for real-time peptide sequencing and variation (PTM and mutation) detection, FREE for academic research.



#### **SCIEX**

SCIEX delivers advanced analytical technologies and software that contribute to the understanding and research of human disease. Innovative LC/MS, LC/MS/MS and CE solutions enable deeper analysis of complex biological systems by providing comprehensive quantitation and characterization required across proteomics, lipidomics and metabolomics — leading to advances in systems biology and biomarker discovery. sciex.com

#### **COMPANY PROFILES**



#### SENGENICS

Sengenics core technology is the patented Immunome™ autoantibody profiling platform. It is the only protein array platform in the world where EVERY protein is full-length, correctly folded and functionally validated. Applications include monitoring differential immune response to drugs or vaccines, modelling microbial infections and biomarker discovery for any disease where immune system dysfunction plays a role.



#### Sigma-Aldrich Life Sciences

SIGMA' Life Science offers a wide portfolio of innovative technologies, products and services spanning cell biology, proteomics, protein biochemistry, genomics, functional genomics, biomolecules and epigenetics. Through continued investment in innovation and quality we are the leading destination for life science researchers to access deep biological information and market leading products that improve the quality of life.



#### Silantes GmbH

Silantes activities are focused on the production and marketing of compounds labelled with stable isotopes (SI: 2H, 13C, 15N) used in NMR structural analysis and quantitative mass spectrometry. Silantes is specialized on SILAC/SILAM-products. NMR(SI): growth media & nucleotides; Proteomics(SI): amino acids; cell culture-kits & in vivo-13C-lys-labelling of SILA(C/M)-model organism



#### The Metabolomics Innovation Centre

The Metabolomics Innovation Centre (TMIC) is Canada's national metabolomics laboratory. TMIC uses real-world proven technologies, in-house innovations, and years of analytical experience to provide cutting-edge metabolomic services and technologies. Our mission is to provide quantitative metabolomic analysis to a wide range of clients at the most reasonable prices.



#### **Thermo Scientific**

Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. For more information, visit www.thermoscientific.com.

#### **COMPANY PROFILES**






#### UVic Genome BC Proteomics Centre

The Proteomics Centre (www.proteincentre.com) is a Genome Canada-funded hub for proteomics research. We develop cutting-edge technologies that are translated into an expansive range of high-quality proteomics services. Services provided through UVic and UBC include specialized techniques for quantitative/clinical proteomics (in collaboration with McGill), structural and functional proteomics, and custom projects.



#### Veritomyx

Veritomyx' advanced signal processing algorithms in PeakInvestigator™ mass-spectral analysis software reveal information hidden in overlapped peaks, increasing effective mass-analyzer resolution by 3-4x. This improves metabolomic and proteomic discovery and identification rates. Also, Veritomyx' next-generation PeptideSequencer™ software (alpha) outperforms current market leaders in de novo peptide identifications. See what you're missing!



#### **VICI Valco Instruments**

A designer and manufacturer of standard and custom valves and fittings for precision analytical, bio-medical, and bio-compatible instrumentation. Products also include a variety of related products including pneumatic and electric actuators, tubing and sampling loops, heated enclosures, valve sequence and temperature controllers, gas purifiers, GC detectors, and digital interfaces.



#### **Wako Laboratory Chemicals**

Wako Laboratory Chemicals, strives to supply unique laboratory reagents to scientists in all fields of research. Following nine decades of tradition, we supply high quality, high purity reagents for your life's research. Product lines consist of antibodies, enzymes, biochemicals, organic chemicals, analytical standards, HPLC columns and much more.




#### **Waters Corporation**

Waters Corporation creates business advantages for laboratory-dependent organizations by delivering scientific innovation to enable customers to make significant advancements. Waters helps customers make profound discoveries, optimize laboratory operations, deliver product performance, and ensure regulatory compliance with a connected portfolio of separations and analytical science, laboratory informatics, mass spectrometry, as well as thermal analysis.

Visit us in Booth 301

### Clarity in the Chaos



#### EASY-nLC 1200 System

Enhanced pressure capabilities and improved system usability results in a unique customer experience

- 1200 bar backpressure
- · Proprietary switching valves for maintenance free handling
- Fingertight nanoViper™ fittings of all high-pressure connections for easy, tool-free maintenance
- Well proven features, such as Intelligent Flow Control for fast column equilibration and sample loading

#### **Acclaim PepMap Columns**

Experience higher analytical depth by exploiting the enhanced pressure capability of the EASY-nLC 1200 with a 75 cm column

- 1200 bar pressure rating
- Available with Acclaim PepMap 2 µm 100 Å C18 stationary phase
- · Complete with nanoViper fitting for ease-of-use

Come and see us during our Lunchtime Seminar
Tuesday, September 29 from 1:15-2:15 p.m.
Vancouver Convention Centre, East Building, Meeting Room 1
Pushing the Boundaries of Comprehensive Proteome Profiling

"How to Boost your nanoLC-MS Performance and Throughput in Proteomics"

Dr. Paul Taylor, Senior Proteomics Specialist, SPARC BioCentre, Hospital for Sick Children, Toronto



# SECTION 3 PROGRAM SUNDAY, SEPTEMBER 27

#### **PROGRAM**

#### SATURDAY, SEPTEMBER 26 & SUNDAY, SEPTEMBER 27, 2015

#### **SATURDAY, SEPTEMBER 26, 2015**

Registration Open	16:00 - 20:00
Speaker Ready Room Open	16:00 - 20:00

#### **SUNDAY, SEPTEMBER 27, 2015**

Bioinformatics Hub	08:00 - 17:00
Registration Open	08:30 - 19:30
Speaker Ready Room Open	08:30 - 19:30
Exhibit Hall Open (Welc	19:30 – 21:00 come Reception)

08:30 - 17:00 HPP General Investigators Meeting

CHAIR: GIL OMENN, USA ROOM 11



FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 91 IN THIS PROGRAM BOOK.

#### 09:00 - 15:30 Mentoring Day (Ticketed Session)

CHAIR: JENNIFER VAN EYK, USA ROOM 8+15



REFRESHMENTS AND LUNCH PROVIDED

09:00 The HUPO Expedition

Mark S. Baker, Macquarie University, Australia

09:15 Value of proteOMICS for Science and Life

Fred E. Regnier, Purdue University, USA

09:35 Proteomics, Present and Future

Ruedi Aebersold, ETH Zurich, Institute for Systems Biology, Switzerland

09:55 Visualizing (Proteo) Omics: proteOMICS and Society

Beth Anderson, Arkitek Scientific, USA

10:15 Economical Contingency of (Prote)
Omics

Omics

Hanno Langen, F. Hoffmann-La Roche Ltd, Switzerland

Donna Edmonds, Immunarray Ltd, USA

10:35 Coffee Break

11:00 How Do I Start and Conduct a (Big)
Project: Idea, Collaborations,
Collaborators, Grant (Concrete
Example)

Luigi Ferrucci, National Institute on Aging (NIA), USA

Catherine Costello, Boston University School of Medicine. USA

11:20 Proteomics Academia/Industry: "Collaboration/Common Goals Academia and Industry"

> Henry Rodriguez, National Cancer Institute. USA

Jeff Chapman, SCIEX, USA

11:45 Proteomics Industry: "How to Prepare a Career in Industry, What and When"

> Leigh Anderson, SISCAPA Assay Technologies, USA

Christie Hunter, SCIEX, USA

12:10 Proteomics in 20 Years: "Challenges to Meet in the Future"

> John R. Yates III, The Scripps Research Institute, USA

12:30 Lunch

14:00 Mentoring Day Part 3: **Table Workshop Session** 

09:00 - 15:30 Technology Day: On Disruptive Technologies in Omics

> CHAIR: CHRISTOPH BORCHERS, CANADA **ROOM 12**





REFRESHMENTS AND LUNCH PROVIDED

#### MAIN SPONSORS:



Genome



**Genome**Canada

#### SPEAKER SPONSOR:

Genome BC PROTEOMICS CENTRE

09:00 Welcome

09:05 **Nanomechanical Mass** Spectrometry: Toward Native Single-Molecule Analysis

> Michael L. Roukes, California Institute of Technology, USA

09:40 **Disruption in the Protein Sciences** 

> John R. Yates III, The Scripps Research Institute, USA

10.15 Coffee Break

10:30 **Ultrahigh Resolution Mass Spectrometry: Extending the Size** and Detail of Protein Structure **Analysis** 

> Alan Marshall, Florida State University, USA

11:05 Study of Cancer Cell Signalling and **Drug Sensitivity Using CRISPR-**CAS9 sqRNA Libraries

> Stephane Angers, University of Toronto, Canada

11:40 Lunch

12:40 **High Specificity Sequencing of** Circulating Tumor DNA for Liquid **Biopsy and Early Detection Applications** 

> Andre Marziali. Boreal Genomics. Canada

13:15 Imaging Mass Cytometry -**Technology and Progress in Multiparameter Assays** 

> Olga Ornatsky, Fluidigm Corp., Canada

13:50 Coffee Break

14:05 **Towards Genomic Medicine for Cancer Populations** 

> Marco Marra, Genome Sciences Centre, BC Cancer Agency, Canada

14:40 After Revolutionizing Identification, Can MALDI-TOF be Used for Other Applications in the Microbiology Laboratory?

> Nathan Ledeboer, Medical College of Wisconsin, USA

#### 09:00 - 15:30 Education Day (Ticketed Session)

CHAIR: GARRY CORTHALS, NETHERLANDS ROOM 17





REFRESHMENTS AND LUNCH PROVIDED

09:00 **Arrival and Welcome** 

09:15 PeptideAtlas - A

Submitting to and Exploring **PeptideAtlas** 

Luis Mendoza, Institute of Systems Biology, Seattle

10:00 **Coffee Break** 

10:15 PeptideAtlas - B Using SRMAtlas to Design SRM Assays

> Ulrike Kusebauch, Institute of Systems Biology, Seattle

11:00 ProteinAtlas - How, When, and Why to Use the Protein Atlas Information and Antibodies

> Cecilia Lindskog, Science for Life Laboratory, Sweden

11:45 ProteinAtlas - Human Protein Atlas Antigens and Antibodies for Array-Based Profiling of Plasma and CSF

> Peter Nilsson, Science for Life Laboratory, KTH - Royal Institute of Technology, Sweden

12:30 Lunch

13:00 Charcterization of PTMs in **Proteomics** 

> Martin Larsen. University of Southern Denmark, Denmark

14:30 Coffee Break

14:45 **Quantitative Targeted Proteomics** Technologies (MRM, PRM, iMALDI, SISCAPA)

> Dominik Domanski, Institute of Biophysics and Biochemistry PAS, Poland

15:30 **Quantitative Targeted Proteomics** Clinical Applications (Blood, Dried Blood Spots, Urine, CSF, etc.)

> Andrew Percy. University of Victoria. Canada

#### 09:00 - 15:30 Clinical Day (Ticketed Session)

**ROOM 2+3** 



REFRESHMENTS AND LUNCH PROVIDED

#### 09:00 - 10:30 Part 1: Omics Technologies Improving Patient Care

Chairs: Bruce McManus, Canada & Pei Pei Ping, USA

#### 09:00 **Next-Generation Sequencing Clinical Oncology Panel**

Christina Lockwood, University of Washington, USA

09:25 **Alzheimer Disease Diagnostics** 

> Mari DeMarco, University of British Columbia, Canada

09:50 **Proteomics & Informatics for Amyloid Typing** 

Surendra Dasari, Mayo Clinic, USA

10:15 **Moderated Discussion** 

10:30 Coffee Break

#### 11:00 - 12:30 Part 2: The Devil is in the Details: Developing Clinical-Grade Assavs

Chairs: Emma Zheng, Canada & Leonard Foster, Canada

#### 11:00 **Validating Complex Diagnostics**

Stephen Master, Weill Cornell Medical College, USA

11:25 MALDI-TOF MS Clinical Assay Development

> Michael X. Chen. Jewish General Hospital; McGill University, Canada

11:50 Clinical Considerations for Tryptic Digestions

> Irene Van den Broek, Cedars Sinai Medical Center, USA

**Moderated Discussion** 12:15

12:30 Lunch

#### 14:00 - 15:30 Part 3: Town-Hall Event - Balancing Innovation and **Regulation of Laboratory Tests**

Chairs: Christina Lookwood, USA & Daniel Holmes, Canada Panelists: Erick Koonick. University of Washington, USA, Daniel Chelsky, Caprion Proteome Inc., Canada, Ross Molinaro, Siemens, USA Victoria Zhang, University of Rochester, USA

10:00 - 11:00 - Bioinformatics Hub - Meet the Expert Session

Room 20

12:30 – 14:00 HUPO National Society **President's Lunch** 

(by invitation only)

Room 16

18:00 - 19:35 PL 01: Opening Plenary Session

> **Chairs: Christoph Borchers,** Canada & Pierre Thibault. Canada

Plenary Hall (Hall A)

18:00 **Official Opening** 

18:05 Honourable Amrik Virk, Minister of Technology, Innovation and Citizens' Services, British Columbia, Canada

18:10 Cindy Bell, Interim President and

**CEO, Genome Canada** 

18:15 **Population Proteomics: Embracing Genomic Variability** 

> Ruedi Aebersold, ETH Zurich, Institute for Systems Biology. Switzerland

18:55 Opening Up New Areas of Drug **Discovery with High Quality** 

**Research Tools** 

Aled Edwards, University of Toronto, Canada

15:45 - 17:45 **HUPO Council Meeting** (by invitation only)

> Chairs: Mark Baker, HUPO President & Gyorgy Marko-Varga, HUPO Secretary General

Room 1

19:35 - 21:00 Welcome Reception Exhibit Hall (Hall B)

# SECTION 4 PROGRAM MONDAY, SEPTEMBER 28

#### **PROGRAM**

#### MONDAY, SEPTEMBER 28, 2015

Registration Open	07:00 - 17:30
Speaker Ready Room Open	07:00 - 17:30
Exhibit Hall Open	10:00 - 17:30
Bioinformatics Hub	08:00 - 17:00

#### 07:30 - 09:00 HPP 01: Cancer HPP

CHAIRS: HUI ZHANG, USA & CONNIE JIMENEZ, NETHERLANDS & EDWARD NICE, USA ROOM 1

FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 92 IN THIS PROGRAM BOOK.

#### 07:30 - 09:00 HPP 02: HPPP (Plasma)

CHAIRS: JOCHEN SCHWENK, CANADA & ERIC DEUTSCH, USA ROOM 2+3

FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 93 IN THIS PROGRAM BOOK.

#### 07:30 - 09:00 HPP 03: Cardiovascular Initiative Workshop

CHAIR: POTHUR SRINIVAS, USA ROOM 8+15

FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 94 IN THIS PROGRAM BOOK.

#### 07:30 - 09:00 HPP 04: HDPP - Diabetes

CHAIRS: PETER BERGSTEN, SWEDEN & JEAN-CHARLES SANCHEZ, SWITZERLAND ROOM 11

FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 95 IN THIS PROGRAM BOOK.

#### 07:30 - 09:00 HPP 05: Human Antibody Initiative

CHAIRS: MATHIAS UHLEN, SWEDEN & TOVE ALM, SWEDEN & EMMA LUNDBERG, SWEDEN ROOM 12

- BREAKFAST WILL BE PROVIDED DURING THIS SESSION.
- FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 96 IN THIS PROGRAM BOOK.

07:30 - 09:00 HPP 06: EyeOME Proteomics: Towards
Understanding Biological
Pathways in the Eye

CHAIRS: RICHARD SEMBA, USA & MARIUS UEFFING, GERMANY & HYEWON CHUNG, KOREA ROOM 19

FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 97 IN THIS PROGRAM BOOK.

#### 07:30 - 09:00 BioBank Workshop

CHAIRS: GYORGY MARKO-VARGA, **SWFDFN** 

**ROOM 18** 

#### 07:30 **Biobanking in Practice**

Beatrix Knudsen, Cedars Sinai Hospital & Medical Center, USA

#### 07:35 The Cenralized Biobank in Southern Swedish Healthcare

Johan Malm, Lund University, Sweden

#### 07:40 **Utilising Biobank Resources to** Discover Proteins Impact in Disease

Carol L. Nilsson, University of Texas Medical Branch, USA

#### 07:45 Truly Sustainable Biobanking -A Call to Action

Frik Steinfelder, ESBB President. The Netherlands

#### 07:50 Pharma Biobanking

Thomas Fehniger, Lund University, Sweden

#### 07:55 TBA

Brent Schachter, ISBER, Canada

#### 09:15 - 10:00 PL 02: Plenary Session Chair: Leigh Anderson, USA

Plenary Hall (Hall A)

#### Quantitative Proteomics in Biology. **Chemistry and Medicine**

Steven A. Carr. Broad Institute. USA

10:00 - 11:10

**Networking Break and Poster Viewing** 

(Even Poster Numbers)

Exhibit Hall (Hall B)

#### 10:00 - 11:00 → Bioinformatics Hub - Meet the Expert Session

Room 20

#### 11:10 - 13:00 CS 01: Cancer Protoemics

CHAIRS: SCOTT GERBER, USA & MARTIN LARSEN, DENMARK

ROOM 1

#### 11:10 CS01.01: Chromosome Instability. **Protein Homeostasis and** Mechanisms of Drug Resistance in Cancer

Scott A. Gerber, Geisel School of Medicine at Dartmouth, USA

#### 11:35 CS01.02: Cancer Biomarkers -Searching for the Needle in the Havstack

Martin Larsen, University of Southern Denmark, Denmark

#### 12:00 CS01.03: Proteomic Characterization of Pancreatic **Ductal Adenocarcinoma**

Sheng Pan, University of Washington, **USA** 

#### 12:15 CS01.04: Proteolytic Processing in the Progression of Low-Grade Astrocytomas to Glioblastoma Multiforme

Zon Lai, Insitute of Molecular Medicine and Cell Research, Germany

#### 12:30 **CS01.05: Autoantibody Profiling** of Glioma Serum Samples Using **Human Proteome Arrays**

Sanjeeva Srivastava, IIT Bombay,

#### 12:35 **CS01.06: Large-Scale Proteomic** Characterization of Ovarian High-**Grade Serous Carcinoma**

Zhen Zhang, Johns Hopkins University, USA

# 12:40 CS01.07: Coupling an EML4-ALK Centric Interactome with RNAi Screen to Identify Sensitizers to ALK Inhibitors

Guolin Zhang, H. Lee Moffitt Cancer Center & Research Institute. USA

### 12:45 CS01.08: MicroRNAs Upregulated in Colorectal Cancer Metastasis Target Multiple Overlapping Proteins

Ignacio Casal, Centro de Investigaciones Biológicas, Spain

12:50 CS01.09: Identification of Cancer-Associated HLA Antigens as Targets for Soluble TCR-Based Immunotherapy

Geert PM Mommen, Immunocore, UK

### 12:55 CS01.10: Protein Expression Profiling of the Chemoresistant AML Proteome

Elise Aasebø, University of Bergen, Norway

#### 11:10 - 13:00 CS 02: Neurological Disorders

CHAIRS: BRADFORD GIBSON, USA & DANIEL MARTINS-DE-SOUZA, BRAZIL ROOM 2+3

# 11:10 CSO2.01: Proteomic Analysis of Synaptosomes Isolated from a Huntington Mouse Model: A Cautionary Tale

Bradford Gibson, Buck Institute for Research on Aging, USA

#### 11:35 CS02.02: Employing Proteomics to Unravel the Molecular Underpinnings of Schizophrenia

Daniel Martins-De-Souza, University of Campinas, Brazil

#### 12:00 CS02.03: Aggregation of Physiological and Parkinson-Synucleins Revealed by Ion Mobility-MS and HDX- MS

Michael Przybylski, Steinbeis Centre for Biopolymer Analysis and Biomedical Mass Spectrometry, Germany

#### 12:15 CSO2.04: CSF Proteome Resource (CSF-PR) as a Tool for Proteomics Biomarker Discovery in Multiple Sclerosis

Astrid Guldbrandsen, University of Bergen, Norway

#### 12:30 CS02.05: Investigating TDP-43-Mediated Neurodegeneration by Mass Spectrometry

Yuzi Zheng, University of British Columbia, Canada

#### 12:35 CS02.06: Mitochondrial Networks Reveals Novel Components Associated with Neurological Disorders

Mohan Babu, University of Regina, Canada

# 12:40 CS02.07: Quantitative Proteomics Analysis of Human Autoptic Pineal Glands to Study Autism Spectrum Disorders

Mariette Matondo, Institut Pasteur, France

#### 12:45 CS02.08: Development of Cerebrospinal Fluid Signatures of Lewy Bodies and Neuronal Loss

Vladislav A. Petyuk, Pacific Northwest National Laboratory, USA

# 12:50 CS02.09: Analyzing Laser Microdissected Neuromelanin Granules from Human Post Mortem Substantia Nigra

Katrin Marcus, Ruhr-University Bochum, Germany

12:55 CS02.10: Q&A

#### 11:10 - 13:00 CS 03: Glycomics in Biology and Diseases

CHAIRS: NICOLLE H. PACKER, AUSTRALIA & CATHERINE COSTELLO, USA ROOM 8+15

#### 11:10 CS03.01: Glycomics-Assisted Glycoproteomics: Deciphering the Complexity

Nicolle H. Packer, Macquarie University, Australia

11:35	CSO3.02: Evolving Approaches for Separation and Tandem MS of Disease-related Glycans and Glycoconjugates	11:10 - 1	3:00	CS 04: Imaging Mass Spectrometry	
	Catherine E. Costello, Boston Univ. School of Medicine, USA		RICH	RS: RON HEEREN, NETHERLANDS & ARD CAPRIOLI, USA	
12:00	CS03.03: N-Acetylglucosaminyl- transfease III (GnT-III) Is a Novel Drug Target for Alzheimer's Disease	11:10		4.01: Types of Tumors: Imaging	
	Naoyuki Taniguchi, RIKEN, Japan			Difference	
12:15	CS03.04: N- and O-Glycomics on Formalin-Fixed Paraffin-Embedded (FFPE) Clinical Specimens by PGC- LC ESI-MS/MS			Heeren, Maastricht University, erlands	
		11:35	Spec	CSO4.02: Imaging Mass Spectrometry: Molecular Microscopy for Biological and Clinical Research	
	Daniel Kolarich, Max Planck Institute of Colloids and Interfaces, Germany				
12:30	CS03.05: Identification of Biomarkers from Oral Cancer Patient Serum by Glycoproteomic Approaches			ard Caprioli, Vanderbilt ersity School of Medicine, USA	
		12:00	CS04.03: Phospholipid MALDI Imaging MS Stratification of		
	Chuan-Fa Chang, National Cheng Kung University, Taiwan			lorectal Cancer Liver Metastasis nical Biopsies	
12:35	CS03.06: MALDI Imaging Mass Spectrometry of Glycans on Formalin-Fixed Paraffin-Embedded Ovarian Tumours Matthew T. Briggs, The University of Adelaide, Australia			e Chaurand, Université de réal, Canada	
		12:15	Base	4.04: Optimizing MALDI-MS d Virtual 2D Gel Method for	
				ein Characterization Liu, UCLA, USA	
12:40	CS03.07: Lectin RCA-I Specifically Binds to Metastasis-Associated Cell Surface Glycans in TNBC	12:30	Tissu on Ti	4.05: Peptide and Glycan ie Imaging Mass Spectrometry issue Micro Arrays for Cancer	
	Sheng-ce Tao, Shanghai Jiao Tong University, China		-	nostics r Hoffmann, The University of	
12:45	CS03.08: Glycan Analyses of Murine Plasma and Lung Membrane to Find Biomarker Candidate for COPD		Adel	aide, Australia	
		12:35	Stud	4.06: MSI and Proteomic ies of Rat Spinal Cord Injury:	
	Miyako Nakano, Hiroshima University, Japan			Caudal Segment for Possible Therapy Target	
12:50	CS03.09: Confident, Automated and Quantitative N-Glycoproteomics			hanie Devaux, INSERM U1192 vratoire PRISM, France	
	Analysis in Exosome Samples Scott Peterman, Thermo Scientific, USA	12:40	Ische	CS04.07: Protein Profiling of Brain Ischemia by MALDI-Imaging-Mass-	
12:55	CS03.10: Development of a Method for Large-Scale Analysis of the Site- Specific Glycomes of Glycoproteins		•	trometry	
				or Llombart, Vall Hebron Institute esearch, Spain	

Hiroyuki Kaji, National Institute

Technology, Japan

of Advanced Industrial Science &

12:45

CS04.08: Multiplexed Imaging of

**Biomolecules in Tissues by MALDI-**

Christoph H. Borchers, University of

Victoria, Canada

# 12:50 CS04.09: Applying Mass Spectrometry Imaging for the Acceleration of Drug Discovery and Development

Kenichi Watanabe, Lund University, Sweden

#### 12:55 CSO4.10: MALDI - MS Imaging Reveals Calreticulin Overexpression in Penile Cancer

Elisângela J. Silva, AC Camargo Cancer Center. Brazil

#### 11:10 - 13:00 CS 05: Proteomics at Pharma

CHAIRS: HANNO LANGEN, SWITZERLAND & TASSO MILLIOTIS, SWEDEN ROOM 12

#### 11:10 CS05.01: Application of Proteomics Technologies in the Pharmaceutical Industry

Hanno Langen, F. Hoffmann-La Roche Ltd. Switzerland

# 11:35 CS05.02: Automated MRM - Applied to Quantification of Circulating Proteins Associated with Insulin Sensitivity Improvement following Bariatric Surgery

Tasso Miliotis, AstraZeneca R&D, Sweden

#### 12:00 CS05.03: Screening of Drug-Induced Protein Expression - Quantifying Cytochrome P450 Enzymes and Transporter

Oliver Poetz, NMI Natural and Medical Sciences Institute at the University of Tuebingen, Germany

#### 12:15 CS05.04: Development of a Protease Inhibition Assay Based on Targeted Top down Quantitation

Phillip Chu, Genenetech, USA

#### 12:30 CS05.05: The Proteome of Human Cells Is Altered by Toxins of Clostridium Dificile

Andreas Pich, Hannover Medical School, Germany

#### 12:35 CS05.06: ISDetect: Rapid, Semi-Automated Protein Terminal Characterization by Mass Spectrometry

Corey E. Bakalarski, Genentech, Inc., USA

#### 12:40 CS05.07: Label-Free Method for Profiling Human Liver Enzymes: Validation with QconCAT

Brahim Achour, University of Manchester, UK

#### 12:45 CS05.08: Phosphoproteomics in Drug Discovery - Application to Cancer Drug Resistance

Hans Voshol, Novartis Institutes for BioMedical Research, Switzerland

#### 12:50 CS05.09: Monkey, Dog, Rat and Men - Safety Biomarker across Species

Oliver Poetz, NMI Natural and Medical Sciences Institute at the University of Tuebingen. Germany

#### 13:15 - 14:15 HPP 07: HPP Bioinformatic Session

CHAIR: ERIC DEUTSCH, USA ROOM 12



FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 98 IN THIS PROGRAM BOOK.

#### 13:15 - 14:15 **EDRN Workshop:**

**Proteomic Biomarkers** for Cancer Detection and **Diagnosis in Precision** Medicine

Chairs: Sam Hanash, USA & Sudhir Srivastava, USA

Room 18

The development of new biomarkers for early cancer detection that can change clinical practice and ultimately have an impact on overall survival and mortality from the disease is a lengthy process that begins with the discovery of promising candidate biomarkers, rigorous validation, and implementation in the clinic. The success of this process requires a complex, dedicated infrastructure that facilitates the coordination, management and collaboration among many institutions, both from academia and industry, with the involvement of scientists and clinicians with diverse expertise. Since its inception. the main focus of the EDRN has been to bring new biomarkers to clinical validation. Early on, EDRN investigators recognized that the biomarker field was quite nascent, and consequently took on the responsibility to establishing guidelines for a phasebased biomarker development, as well as study design criteria for rigorous clinical validation. These have now been well accepted and adopted by the biomarker research community at large.

Over the past five years, EDRN investigators invested significant efforts for enriching the proteomic biomarker development pipeline to address significant unmet clinical needs in the early detection of cancer. The proposed session will highlight the proteomics in early cancer detection and its implication for precision medicine.

#### 13:15 Onco-proteomics and its **Implications for Precision Detection** and Diagnosis

Jacob Kagan, National Cancer Institute, USA, Sudhir Srvastava, National Cancer Institute, USA

#### 13:30 The Search for Cancer Biomarkers Using Proteomics - What Have We Learned?

Sam Hanash. The University of Texas MD Anderson Cancer Center. USA

#### 13:45 **Proteomics of Proximal Biospecimens for Discovery of Early Detection Ovarian Cancer Biomarkers**

Steven Skates, Massachusetts General Hospital, USA

#### 14:00 From Shotgun Proteomics to Molecular Imaging for the Early **Detection of Lung Cancer**

Pierre Massion, Vanderbilt University Medical Center, USA

#### 13:15 - 14:15

Thermo Scientific: From Markers to Assavs: **Accelerating Translation Proteomics** 

#### Room 1



For further information. please visit the Industry Session pages in this program book

#### 13:15 - 14:15

**Bruker Daltonics: New Solutions in LC/MS Based Proteomics** 

#### Room 2+3



For further information, please visit the Industry Session pages in this program book

#### 13:15 - 14:15

**Waters Corporation: Improving Multi-omic** Workflows for the Discovery and Development of Novel **Biomarkers** 

#### Room 8+15



For further information, please visit the Industry Session pages in this program book

13:15 - 14:15 Agilent Technologies: Multi-omic Analysis for Integrated Biology

Room 11

0

For further information, please visit the Industry Session pages in this program book

#### 14:30 - 16:20 CS 06: New Technological Advances in Proteomics

CHAIRS: BERND BODENMILLER, SWITZERLAND & RICHARD D. SMITH, USA ROOM 1

#### SESSION GENEROUSLY SUPPORTED BY



Cambridge Isotope Laboratories, Inc. isotope.com

14:30 CS06.01: Imaging Mass Cytometry:
A Novel Imaging Modality to
Visualize Dozens of Biomarkers in a
Targeted and Simultaneous Manner
in Tumor Samples

Bernd Bodenmiller, University of Zurich, Switzerland

14:55 CS06.02: Advances in Proteomics
Based upon Ion Mobility in
Structures for Lossless Ion
Manipulations

Richard D. Smith, Pacific Northwest National Laboratory, USA

15:20 CSO6.03: Methods to Increase Reproducibility of a Multi-Analyte MRM MS Assay for Analysis of Plasma Samples

Xiao-jun Li, Integrated Diagnostics Inc.. USA

15:35 CSO6.04: PALM (Pulse
Azidohomoalanine Labeling in
Mammals): Tissue Analysis of
Newly-Synthesized Proteins

Dan McClatchy, The Scripps Research Institute, USA

15:50 CS06.05: Extending the Reach of Data Independent Acquisition

Christie Hunter, SCIEX, USA

15:55 CS06.06: Rapid and Automated
Quantitation of Candidate Disease
Biomarkers in Mouse Plasma and
Tissues

Sarah Michaud, MRM Proteomics, Inc., Canada

16:00 CS06.07: It's Easy: Ultra-High Resolution Separations for the Complete Analysis of the Yeast Proteome

Barbara Dunn, Stanford University, USA

16:05 CS06.08: Enhanced Trypsin
Digestion for Improved
Biomarker Sensitivity and Peptide
Identification

Kevin Meyer, Perfinity Biosciences, USA

#### 14:30 - 16:20 CS 07: Translational Proteomics

CHAIRS: JEAN-CHARLES SANCHEZ, SWITZERLAND & HENRY RODRIGUEZ, USA ROOM 2+3

#### **SESSION GENEROUSLY SUPPORTED BY**



**ELSEVIER** 

14:30 CS07.01: Discovery of Brain
Biomarkers and Their Translation to
Clinical Settings

Jean-Charles Sanchez, University of Geneva. Switzerland

14:55 CS07.02: CPTAC Omics Data Combined with TCGA Omics Data Produces a Unified Snapshot of Tumors

> Henry Rodriguez, National Cancer Institute, USA

15:20	CS07.03: Serum Diagnostic Glycoprotein Biomarkers for Esophageal Adenocarcinoma
	Michalla M. Hill. The University of

Michelle M. Hill, The University of Queensland, Australia

15:35 CS07.04: Plasmatic RBP4 and GFAP as Biomarkers to Differentiate Ischemic from Hemorrhagic Stroke

> Teresa García-Berrocoso, Vall Hebron Institute of Research, Spain

15:50 CS07.05: Neutrophil Extracellular Traps in Ulcerative Colitis - A **Proteome Analysis of Intestinal Biopsies** 

> Tue B. Bennike, Aalborg University, Denmark

15:55 CS07.06: Targeted Discovery of Subtype-Differentiating Biomarkers for Early Diagnosis of Breast Cancer

David Juncker, mcGill University, Canada

16:00 CS07.07: Quantitative Proteomic Analysis of Microdissected Oral **Epithelium for Cancer Progression** 

> Hua Xiao, Shanghai Jiao Tong University, China

16:05 CS07.08: Method Comparison of an Immuno-MALDI Plasma Renin Activity (PRA) Assay with Two Clinical Methods

> Michael X. Chen. Jewish General Hospital, Canada

16:10 CS07.09: Targeted Quantitation of **Human Gastric Fluid Proteins for Gastric Cancer Detection** 

> Siok Yuen Kam, National University of Singapore, Singapore

16:15 CS07.10: Correlation of Gene and **Protein Tissue Expression for Treatment Decisions in Early Stage Lung Cancer** 

> Ferdinando Cerciello, James Thoracic Center, James Cancer Center, The Ohio State University Medical Center, USA

#### 14:30 - 16:20 CS 08: Proteomics and Cell **Immunity**

CHAIRS: CHRISTOPHER OVERALL. CANADA & ANTHONY PURCELL, AUSTRALIA **ROOM 8+15** 

14:30 CS08.01: Proteolytic Events by the Paraacaspase MALT1 Integrate NFkB Signaling in Lymphocytes Revealed by TAILS N-Terminomics

> Christopher Overall, Centre for Blood Research, Canada

14:55 CS08.02: Heterogeneity in the Immunopeptidome Impacts on the Outcome of Human Disease

> Anthony W. Purcell, Monash University, Australia

15:20 CS08.03: Global Proteogenomics Analysis of Polymorphic Human **MHC Class I-Associated Peptides** 

> Diana Paola Granados. Universite de Montreal, Canada

15:35 CS08.04: Characterization of Regulatory T Lymphocytes Using **Label-Free Quantitative Proteomics** 

> Anne Gonzalez De Peredo. CNRS Université de Toulouse, France

15:50 CS08.05: Proteomic Characterization of the Antigen-**Specific Antibody Repertoire Elicited by Vaccination** 

> Daniel Boutz, University of Texas at Austin, USA

15:55 CS08.06: HLA Ligandomics Drives Immunotherapies Based on High Affinity Soluble TCRs

Ricardo J. Carreira, Immunocore Ltd, UK

16:00 CS08.07: An Open-Source **Computational and Data Resource** to Analyze Digital Maps of **Immunopeptidomes** 

> Etienne Caron, ETH Zurich, Switzerland

### 16:05 CS08.08: Insights into Immune Responses to Commensal Bacteria through MHC Class II Antigen Quantification

Jennifer Abelin, Broad Institute of MIT and Harvard, USA

### 16:10 CSO8.09: Multi-Omics to Examine Proteolytic Cleavage, Expression and Abundances in Macrophage Differentiation

Nestor Solis, University of British Columbia. Canada

### 16:15 CS08.10: Proteomics Analysis of Tumor Associated Macrophages-Derived Exosomes

Yinghui Zhu, Beijing Institute of Genomics, Chinese Academy of Sciences, China

### 14:30 - 16:20 CS 09: Chemical Proteomics and Drug Discovery

CHAIRS: HO JEONG KWON, KOREA & KAREN WANG, USA
ROOM 11

# 14:30 CS09.01: Chemical Proteomics Based Target Identification of Small Molecule towards Translational Studies

Ho Jeong Kwon, Yonsei University, Korea, Republic of

### 14:55 CS09.02: An Integrated Proteomics Strategy for Drug-Proteins Interactions and Compound Mode of Action

Markus Schirle, Novarts Institutes for BioMedical Research, USA

### 15:20 CS09.03: Target Selectivity of Clinical JAK Inhibitors in Peripheral Blood Monocytes

Hans Christian Eberl, Cellzome GmbH, a GSK Company, Germany

### 15:35 CS09.04: Proteomics Tools to Predict Nanoparticles Targeting and Uptake Capability

Susana Cristobal, Linköping University, Sweden

### 15:50 CS09.05: Selectivity Profiling of 200 Clinical Kinase Inhibitors Using Chemical Proteomics

Susan Klaeger, Technical University of Munich, Germany

### 15:55 CS09.06: High-Throughput Detection of Endogenous Protein Targets Bound by Bioactive Small Molecules

Hui Peng, University of Toronto, Canada

### 16:00 CS09.07: An R Package for the Analysis of Thermal Proteome Profiling Experiments

Holger Franken, Cellzome GmbH, a GSK Company, Germany

### 16:05 CS09.08: Chemical Proteomics for Development NDPKA/Nm23-H1 Activator

Jae-Jin Lee, EWHA Womans University, Korea, Republic Of

# 16:10 CS09.09: Serine Hydrolase Activities in Urine from Patients Undergoing Cardiac Bypass Surgery

Mario A. Navarrete, Manitoba Centre for Proteomics & Systems Biology, Canada

### 16:15 CS09.10: MALDI-MSI Analysis of a Small Molecule and Its Target Protein Interaction on Tissues

Yonghyo Kim, Chemical genomics National Research Laboratory, Yonsei University, Korea, Republic of

### 14:30 - 16:20 CS 10: Epigenetics and **Histone Landscape**

CHAIRS: BENJAMIN A. GARCIA, USA & MICHAEL FREITAS, USA **ROOM 12** 

### 14:30 CS10.01: Towards Understanding Cellular Signaling into Chromatin

Benjamin A. Garcia, University of Pennsylmania School of Medicine. USA

### 14:55 CS10.02: Interrogation of the **Dynamic Role of Linker Histone Modifications in Cancer**

Michael Freitas, The Ohio State University Medical Center, USA

### 15:20 CS10.03: Accelerating Epigenetic Cancer Drug Discovery Using a **High Throughput Histone Analysis Platform**

Kan Zhu. Novartis Institute for BioMedical Research, USA

15:35 CS10.04: Identification of Cofactors Influencing Smyd1's Histone Methyltransferase Activity via ChIP-MS

Aman Makaju, University of Utah, USA

### 15:50 CS10.05: Modification-Specific **Chromatin Proteomics:** Phosphorylated RNA Polymerase II Associated Proteins

Andrey Tvardovskiy, University of Southern Denmark, Denmark

### 15:55 CS10.06: In Gel Derivatization for Histone PTMs Analysis in Arabidopsis Thaliana

Jiajia Chen, Fudan University, China

### 16:00 CS10.07: Iron Induces Histone Deacetylation in the Human Pathogen Trichomonas Vaginalis

Jung-Hsiang Tai, Institute of Biomedical Sciences, Academia Sinica, Taiwan

16:05 CS10.08: AP-MS and BioID **Generates Comprehensive** Interactome for Chromatin-**Associated Protein Complexes** 

Brett Larsen, LTRI, Canada

### 16:10 CS10.09: Comparison and Combination of Search Engines to Discover and Characterize Identifications and PTM Signatures in Biology

Xiaovue Jiang, Thermo Fisher Scientific, USA

### 16:15 CS10.10: Monitoring Histone PTM **Dynamics in Anti-Cancer Drug Resistant Cells Using MRM**

Byoung-Kyu Cho, Seoul National University, Korea, Republic Of

16:20 - 17:30

**Networking Break and** Poster Viewing

(Even Poster Numbers)

Exhibit Hall (Hall B)

### 17:30 - 18:15 PL 03: Plenary Session **Chair: Pierre Legrain, France**

Plenary Hall (Hall A)

### A New Chapter in Liver Physiology & Pathology Is Being Written with Big Data

Fuchu He. The Academy of Military Medicine Science. China

# SECTION 5 PROGRAM TUESDAY, SEPTEMBER 29

### **PROGRAM**

### TUESDAY, SEPTEMBER 29, 2015

Registration Open	07:00 - 17:30
Speaker Ready Room Open	07:00 - 17:30
Exhibit Hall Open	10:00 - 17:30
Bioinformatics Hub	08:00 - 17:00

07:30 - 09:00 HPP 08: CPTAC HPP - CPTAC Data, Tools, and Assays for Cancer Biology

CHAIR: HENRY RODRIGUEZ, USA ROOM 1

FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 99 IN THIS PROGRAM BOOK.

07:30 - 09:00 HPP 09: Proteomics Standards Initiative and ProteomeXchange Consortium

> CHAIRS: ERIC DEUTSCH, USA & HENNING HERMJAKOB, UK ROOM 2+3

FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 100 IN THIS PROGRAM BOOK.

07:30 - 09:00 HPP 10: B/D-GPP (Biology/Disease-driven Glycoproteome Project)

> CHAIR: HISASHI NARIMATSU, JAPAN ROOM 8+15

FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 101 IN THIS PROGRAM BOOK.

07:30 - 09:00 HPP 11: Toxicoproteomics

CHAIRS: LEKHA SLENO, CANADA & OLIVER POETZ, GERMANY ROOM 11

TOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 102 IN THIS PROGRAM BOOK.

07:30 - 09:00 HPP 12: HBPP - Brain

CHAIR: HELMUT E. MEYER, GERMANY ROOM 12

FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 103 IN THIS PROGRAM BOOK.

07:30 - 09:00 HPP 13: PediOme Paediatrics and Proteomics:
Back to the Beginning

CHAIR: VERA IGNJATOVIC, AUSTRALIA ROOM 19

FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 104 IN THIS PROGRAM BOOK.

### 07:30 - 09:00 Affinity - Mass Spectrometry Workshop

CHAIRS: CHRISTOPH BORCHERS. CANADA & MICHAEL O. GLOCKER, GERMANY & MICHAEL PRZYBYLSKI, **GFRMANY** 

**ROOM 18** 

This workshop focuses on research activities and methodology development of affinity isolation and determination strategies combined with mass spectrometry. Pre-fractionation methods are the key issue when it comes to addressing the complexity of biological samples and when analyzing low abundant analytes from biological/clinical material. Many applications of affinity-based separation methods have been used and are continuously developed to increase the selectivity and sensitivity in mass spectrometry-based proteomics; now spreading out into many scientific and medical application areas.

Lately, immuno-affinity approaches which make use of defined sets of specific capture molecules such as antibodies have enabled the rapid and unequivocal identification of binding structures and surfaces (e.g. epitopes) by mass spectrometry, particularly by new developments of online MS approaches. With novel state-of-the-art "wet-lab" as well as "drv-lab" developments quantitative and functional analyses in model studies and even in patient samples can be tackled using affinity-MS procedures, thereby opening the field of structure-/function correlations with broad application potentials in cutting-edge research areas

### 07:30 Welcome and Introduction to the Workshop as well as a Brief Overview about Affinity-MS Developments

Michael O. Glocker, University Medicine Rostock, Germany

### 07:35 **Rostock Risk Assessment of** Preterm Newborns by Affinity Mass Spectrometry

Michael O. Glocker, University Medicine Rostock, Germany

### 07:45 A Novel Mass Spectrometry-Based Approach in Immuno-Diagnostics

Petr Novak, Charles University, Czech Republic

### 07:55 Computational Tools for Storing. Scoring and Showing Affinity **Proteomics Data**

Anne-Claude Gingras, Lunenfeld-Tanenbaum Research Institute, Canada

### 08:05 Discussion

Christoph H. Borchers, University of Victoria, Canada

### 08:15 iMALDI for Quantifying Akt1 and Akt2 Expression and **Phosphorylation in Colorectal** Cancer

Christoph H. Borchers, University of Victoria, Canada

### 08:25 Studying Protein-Small Molecule **Affinities by Quantitative Proteomics**

Hans Christian Eberl, Cellzome GmbH. a GSK company, Germany

### 08:35 **Multiplexed Protein Quantification Using Peptide Group-Specific** Capture Molecules and Mass Spectrometry

Oliver Poetz, NMI Natural and Medical Sciences Institute at the University of Tuebingen, Germany

### 08:45 **Online Biosensor-Mass Spectrometry Combination: Principles and Application to Elucidation of Antibody Epitopes**

Michael Przybylski, Steinbeis Centre for Biopolymer Analysis and Biomedical Mass Spectrometry. Germany

### 08:55 **Final Discussion and Farewell**

Michael Przybylski, Steinbeis Centre for Biopolymer Analysis and Biomedical Mass Spectrometry, Germany

### 07:30 - 09:00 Workshop: Proteomics in Food and Nutrition

CHAIR: PAOLA RONCADA, ITALY ROOM 17

The central role of food proteins in nutritional science are indisputable, the well known affirmation that 'we are what we eat' and that food can be our medicine is not just philosophy but a true story. In fact it is clear that the food after ingestion is transformed and also contains proteins that our body uses, in a complex direct relationship. Study of the proteome of a given food makes us aware that, once it has been ingested and transformed by the human organism, it can change the structure of the proteins in the latter. Furthermore, every nutritional process involves huge number of proteins that are expressed at different levels, from cell to whole organism. Moreover, the global composition of diet, from microbiome to nutrient, including life style, can affect every step from gene expression to protein synthesis until degradation, lead to modulation of metabolic function in a multi-factorial way. Proteomics can help personalized medicine and nutrition, play important role in solving major nutrition problem in human and animals, on the verge of one health approach. including obesity, metabolic and cardiovascular disease, cancer, ageing, allergy and fetal health and development, also in relation to gut microbiome. Profiling food, microbiome, and biomarkers of nutritional status and disease from proteomics point of view lead to a new pillar of personalized medicine. This include also a special focus to food safety issues, providing new insights relate to safety aspects. from microbioma and consortia, food authenticity. detection of animal species in the food, until identification of food allergens.

### 07:30 Introduction - Proteomics in Food and Nutrition: A Matter of Public Health

Paola Roncada, Istituto Sperimentale Italiano L. Spallanzani, Italy

### 07:40 The Proteomics of What We Eat

Mark S. Baker, Macquarie University, Australia

### 08:00 Metaproteomics Data Analysis: Charting War and Peace in a Microbiome

Lennart Martens, Faculty of Medicine, Belgium

# 08:20 MS-Based Proteomic Biomarker Discovery in 1,000 Human Plasma Samples Reveals Candidates for Personalized Nutrition

Loïc Dayon, Nestlé Institute of Health Sciences SA. Switzerland

### 08:40 Table Round New Initiatives, Discussion and Closing Remarks

Paola Roncada, Istituto Sperimentale Italiano L. Spallanzani, Italy

07:30 - 09:00 Workshop: Translating
Proteomics in Diabetes
and Metabolic Diseases

CHAIRS: PETER BERGSTEN, SWEDEN & SALVATORE SECHI, USA ROOM 16



### BREAKFAST PROVIDED

The aim of the workshop is to present some novel aspects on diabetes and metabolic diseases and their complications thus stimulating discussions between people addressing these topics by using different approaches. The format of the workshop will be six short presentations followed by a general discussion. The presentations will cover omics, cellular and patient data giving new aspects of pathophysiology and biomarkers of diabetes and metabolic disease. The translational approach of the workshop prompted the involvement of the HUPO journal "Translational Proteomics" that will publish a special issue to be entitled "Diabetes and Metabolic Disease".

### 07:30 Serum Proteomes Distinguish Children Developing Type-1 Diabetes

Young Ah Goo, University of Maryland, USA

# 07:45 Translating Integrative Personalized Omics Profiling in Type II Diabetes and other Metabolic Diseases

Christine Y. Yeh, Stanford University, USA

08:00 Identifying Novel Signaling
Mechanisms Underlying Insulin
Release from Glucose Stimulated
Beta Cells

Pia Jensen, University of Southern Denmark, Denmark

08:15 Heterogeneity in the Immunopeptidome Impacts on the Outcome of Human Disease

Anthony W. Purcell, Monash University, Australia

08:30 Multi-Omics Characterization of a Human Thyrotoxicosis Model – Towards the Identification of New Biomarkers of Hyperthyroidism

Uwe Voelker, University Medicine Greifswald, Germany

08:45 Factors and Mechanisms of Pancreatic β-cell Proliferation Revealed by Quantitative Proteomics and Phosphoproteomics

David G. Camp, PNNL, USA

09:15 - 10:00 PL 04: Plenary Session
Chair: David Wishart, Canada

Plenary Hall (Hall A)

Metabolomics - An Important Piece in the 'Omics Puzzle

Ute Roessner, The University of Melbourne, Australia

10:00 - 11:10

Networking Break and Poster Viewing

(Odd Poster Numbers)

**Exhibit Hall (Hall B)** 

10:00 - 11:00 - Bioinformatics Hub - Meet the Expert Session

Room 20

### 11:10 - 13:00 CS 11: Hot Topics

CHAIRS: ANDREW EMILI, CANADA ROOM 1

11:10 CS11.01: Exploring Mitosis Dynamics by Combining Data Dependent and Data Independent Strategies

Angela Bachi, IFOM, the FIRC Institute of Molecular Oncology, Italy

11:35 CS11.02: Sportomics: Building a New Concept in Metabolic Studies and Exercise Science

> L. C. Cameron, Federal University of State of Rio de Janeiro. Brazil

12:00 CS11.03: How to Unravel the Brain Proteome

Evelina Sjöstedt, Royal Institute of Technology (KTH), Sweden

12:15 CS11.04: High-Throughput
Detection of Protein Targets Bound
by Bioactive Small Molecules

Andrew Emili, University of Toronto, Canada

12:30 CS11.05: CPTAC Assay Portal: A Public Repository for Well-Characterized Quantitative Targeted Assays

> Jeff Whiteaker, Fred Hutchinson Cancer Research Center, USA

12:35 CS11.06: BatMass: A Software Platform for Visualization and Analysis of Raw MS Data and Processed Results

Dmitry Avtonomov, University of Michigan, USA

12:40 CS11.07: Visual and Intuitive Access to Repository Data

Grant M. Fujimoto, Pacific Northwest National Laboratory, USA

12:45 CS11.08: SuperQuant: A Data Pre-Processing Algorithm for Increasing Quantitative Proteome Coverage

> Vladimir Gorshkov, University of Southern Denmark. Denmark

12:50 CS11.09: New Functionality for the Trans-Proteomic Pipeline: Tools for the Analysis of Proteomics Data

> Luis Mendoza, Institute for Systems Biology, USA

12:55 CS11.10: Q&A

### 11:10 - 13:00 CS 12: Metabolomics and Metabolomic Diseases

CHAIRS: OLIVER FIEHN, USA & DAVID WISHART, CANADA

ROOM 12

### SESSION GENEROUSLY SUPPORTED BY



Cambridge Isotope Laboratories, Inc. isotope.com

### 11:10 CS12.01: How Metabolomics is Changing our Understanding of Human Disease

David Wishart, University of Alberta, Canada

11:35 CS12.02: Using Metabolomics to Investigate Pulmonary Diseases in Human Cohorts and Animal Models

> Oliver Fiehn, West Coast Metabolomics Center, USA

12:00 CS12.03: The Unanticipated Complexity of Bile Acid Pools in Human and Mouse

> Jun Han, University of Victoria -Genome BC Proteomics Centre, Canada

12:15 CS12.04: Digestomics: A New Paradigm for Investigating Pathogenic Diseases in Humans

lan A. Lewis, University of Calgary, Canada

12:30 CS12.05: Exploring S-(1,2-Dichlorovinyl)-L-Cysteine (DCVC) Nephrotoxicity in the Rat Using UPLC-MS

Nicola Gray, Imperial College London,

12:35 CS12.06: A Lipidomic Analysis of Cancer Cells

Ling Lin, Fudan University, China

### 12:40 CS12.07: Plasma Metabolomic Profiling of Diabetic Retinopathy

Lei Zhou, Singapore Eye Research Institute. Singapore

12:45 CS12.08: LC-MS/MS Quantitation of Malondialdehyde (MDA) as a Biomarker of Oxidative Stress in Human Plasma

Constance A. Sobsey, University of Victoria, Canada

12:50 Q&A

### 11:10 - 13:00 CS 13: Regenerative Medicine and Stem Cells

CHAIRS: BONGHEE LEE, KOREA & JEROEN KRIJGSVELD, GERMANY ROOM 8+15

# 11:10 CS13.01: Proteome Meets Genome: Dynamics of Chromatin Organization in Embryonic Stem Cells

Jeroen Krijgsveld, European Molecular Biology Laboratory (EMBL), Germany

11:35 CS13.02: Direct Conversion of Stem Cells Cells by Changing Protein Dynamics

Bonghee Lee, Gachon University, Korea, Republic of

12:00 CS13.03: Identifying Key Stem
Cell-Associated Proteins in Normal
Blood Development and Leukemia

Erwin M. Schoof, University Health Network, Canada

12:15 CS13.04: Super-SILAC Mix for Quantitative Proteomics of Bone Marrow-Derived Mesenchymal Stem Cells

> Virginia Sanchez-Quiles, University Of Southern Denmark, Denmark

12:30 CS13.05: Pathological Variability of Motor Neuron Disorders in Patent-Derived iPSC Using SWATH-MS

> Andrea Matlock, Cedars-Sinai Medical Center, USA

# 12:35 CS13.06: Identification of Novel Protein Signatures for Subtypes of Breast Cancer Stem/Progenitor Cells

Ayodele Alaiya, King Faisal Specialist Hospital and Research Centre, Saudia Arabia

# 12:40 CS13.07: Systematic Identification of Single Amino Acid Variants in Glioma Stem Cell Lines

Ekaterina Mostovenko, University of Texas Medical Branch, USA

# 12:45 CS13.08: Extracellular Matrix Quantification: Defining the Scaffolding of Regenerative Medicine and Disease

Ryan C. Hill, University of Colorado-Denver, Anschutz Medical Campus, USA

# 12:50 CS13.09: Proteome-Scale Analysis of Transcription Factors in Liver Regeneration

Chen Ding, Beijing Proteome Research Center, China

12:55 CS13.10: Q&A

### 11:10 - 13:00 **CS 14: Membrane Proteomics**

CHAIRS: YU-JU CHEN, TAIWAN & IGOR STAGLJAR, CANADA

ROOM 11

# 11:10 CS14.01: Exploring Plasma Membrane Proteome by MetalDirected Glycoproteomic Approach

Yu-Ju Chen, Academia Sinica, Institute of Chemistry, Taiwan

### 11:35 CS14.02: Membrane Protein Interactomes in Health & Disease: Application to Lung Cancer

Igor Stagljar, University of Toronto, Canada

# 12:00 CS14.03: Membrane Proteome Profiling to Discover Therapeutic Targets for HTLV-1 Associated Myelopathy

Makoto Ishihara, University of Tokyo, Japan

### 12:15 CS14.04: A β-Induced Protein Phosphorylation Changes in the Mouse Synaptosome

Hwan-Ching Tai, National Taiwan University, Taiwan

# 12:30 CS14.05: Accurate Determination of Cellular Membrane Protein Copy Numbers

Ansgar Poetsch, Ruhr University Bochum, Germany

### 12:35 CS14.06: Membrane Proteins of Leukocyte-Inspired Nanoparticles Improve Their Therapeutic Efficacy

Claudia Corbo, Fondazione IRCCS SDN, Italy

### 12:40 CS14.07: Comparison of Membrane Enrichment Coupled Proteomics Methods for Immune Target Discovery

Deniz Baycin Hizal, MedImmune, USA

### 12:45 CS14.08: Analysis of Membrane Proteins - Opening the Treasure Chest Protected by the Phospholipid Bilayer

Jiri Petrak, First Medical Faculty, Charles University in Prague, Czech Republic

### 12:50 CS14.09: TGFβ1 Induces Membrane Proteomce Changes in Colorectal Cancer Cells

Harish R. Cheruku, Macquarie University. Australia

12:55 CS14.10: Q&A

### 11:10 - 13:00 CS 15: Cardiovascular and Haematological Proteomics

CHAIRS: PEIPEI PING, USA & JENNIFER VAN EYK, USA ROOM 2+3

### 11:10 CS15.01: Complications of Life

Jennifer van Eyk, Cedars Sinai Medical Center, USA

### 11:35 CS15.02: Dynamics of Life

Peipei Ping, NIH BD2K Center of Excellence at UCLA. USA

### 12:00 CS15.03: Antibody Proteomics in Plasma for Diseases Affecting the Cardiovascular System

Jochen M. Schwenk, Science for Life Laboratory, KTH - Royal Institute of Technology, Sweden

12:15 CS15.04: Cardiac Recovery: Targeting Novel Cell Type and Chamber Specific Markers

Rebekah L. Gundry, Medical College of Wisconsin, USA

12:30 CS15.05: Label-Free Quantification of Hypoxia-Induced Changes of the Cardiac Fibroblast Secreted Proteome

Jake Cosme, University of Toronto, Canada

12:35 CS15.06: Source Specific cGMP Activates Distinct PKG Signaling Pathways in Cardiac Myocytes

> Ronald J. Holewinski, Cedars Sinai Medical Center, USA

12:40 CS15.07: Studying the Functional Role of Reactive Oxygen Species in Atherosclerosis by Redox Proteomics

Juergen Kast, University of British Columbia, Canada

12:45 CS15.08: iTRAQ Comparison of Human Plasma Proteins in HCM and Selected Cardiovascular Disorders

> Alena Fucikova, Faculty of Military Health Sciences, UoD, Czech Republic

12:50 CS15.09: Discovery of Cardiovascular Disease Biomarkers in Human Plasma Using MRM-MS

Gabriela Cohen Freue, University of British Columbia, Canada

12:55 CS15.10: Q&A

### 13:15 - 14:15 HPP 14: C-HPP PIC Meeting

CHAIR: YOUNG-KI PAIK, KOREA ROOM 12



BREAKFAST PROVIDED



FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 104 IN THIS PROGRAM BOOK

13:15 - 14:15

Thermo Scientific:
Pushing the Boundaries of
Comprehensive Proteome
Profiling

### Room 1



For further information, please visit the Industry Session pages in this program book

13:15 - 14:15

Wako Laboratory Chemicals: A Versatile Protein Tagging System for Recombinant Protein Production, Isolation, and Detection in Mammalian Cells

### Room 2+3



For further information, please visit the Industry Session pages in this program book

13:15 - 14:15

SCIEX: Testimonials in OneOmics™: Next Generation Proteomics at Work

### Room 8+15



For further information, please visit the Industry Session pages in this program book

### 14:30 - 16:20 CS 16: New Advances in **Biomarker Discovery**

CHAIRS: MAXEY C.M. CHUNG. SINGAPORE & BRUCE MCMANUS, CANADA

ROOM 1

### 14:30 CS16.01: Sieving through the Secretome of Colorectal Cancer Cells

Maxev C.M. Chung, National University of Singapore, Singapore

### 14:55 CS16.02: Multi-Omic Signatures for Monitoring Patients with Limb-Girdle Muscular Dystrophy

Bruce M. McManus. PROOF Centre of Excellence, Canada

### CS16.03: The Potential Clinical 15:20 Impact of the Human Protein Atlas

Cecilia Lindskog, Immunology, Genetics and Pathology, Sweden

### 15:35 CS16.04: Equalizer- and TMT-Based **Detection of Cellular Proteins in** Clinical Peritoneal Dialysis Effluents

Klaus Kratochwill, Medical University of Vienna. Austria

### 15:50 CS16.05: Proteomic Alterations in Human Renal Epithelial Cells Exposed to Nephrotoxins

Laxmikanth Kollipara, Leibniz-Institut für Analytische Wissenschaften -ISAS - e.V., Germany

### 15:55 CS16.06: Detection of Biomarkers of Sepsis Using Affimer Microarrays

Vincent Puard, Avacta Life Sciences, UK

### CS16.07: Proteomic Biomarker 16:00 Discovery in 1'000 Plasma Samples for Personalized Nutritional Intervention

Loïc Dayon, Nestlé Institute of Health Sciences SA, Switzerland

### 16:05 CS16.08: Identifying Exosome **Biomarkers for Radiation Exposure** Using a DDA and DIA Combined Workflow

Emily I. Chen, Columbia University Medical Center, USA

### 16:10 CS16.09: Large Scale Metabolic **Exploration of Human CSF Proteins Using SILAV**

Nicolai Bache. Bruker daltonics. Denmark

### 16:15 CS16.10: A SWATH-MS Approach for a Comprehensive Characterization of the Secretome under Oxidative Stress

Sandra Anio. Center for Neuroscience and Cell Biology - University of Coimbra, Portugal

### 14:30 - 16:20 CS 17: Protein Networks and **Computational Biology**

CHAIRS: ANNE-CLAUDE GINGRAS, CANADA & ALEXEY NESVIZHSKII. USA **ROOM 8+15** 

### 14:30 CS17.01: Keynote Presentation

Anne-Claude Gingras, Mount Sinai Hospital, Canada

### 14:55 CS17.02: Computational Advancements and Challenges in MS-Based Proteomics

Alexey Nesvizhskii, University of Michigan-Ann Arbor, USA

### 15:20 CS17.03: Using SRM-MS to Uncover Signaling Networks Regulating **Mammalian Cell Differentiation**

Mary N. Teruel, Stanford University, USA

### 15:35 **CS17.04: Sensitive Peptide** Identification in Data-Independent **Acquisition by Spectral Library** Search

Nuno Bandeira, University of California, USA

### 15:50 CS17.05: The Interaction Proteome of the Human Kinome: Biochemical and Biomedical Implications

Matthias Gstaiger, Institute of Molecular Systems Biology, Switzerland

### 15:55 CS17.06: Construction of the Methylproteome Network Reveals a **Novel Regulatory System in the Cell**

Gene O. Hart-Smith, UNSW, Australia

### 16:00 CS17.07: Mapping Dynamic Protein Interaction Landscapes Using a Novel Whole Network Enrichment Approach

Benjamin D. Stein, The Scripps Research Institute. USA

### 16:05 CS17.08: Identifying Novel Sequences in the PRIDE Archive through Spectrum Clustering

Juan Antonio Vizcaino, EMBL-European Bioinformatics Institute, UK

### 16:10 CS17.09: Predicting Mutations Impact in Protein Interaction Networks in Cancer

Mohamed Helmy, University of Toronto, Canada

### 16:15 CS17.10: Small and Big Data in Proteomics: Reprocess Public Data to Design Better Experiments

Marc Vaudel, University of Bergen, Norway

### 14:30 - 16:20 CS 18: Subcellular Proteomics

CHAIRS: KOJI UEDA, JAPAN & LEONARD J. FOSTER, CANADA

ROOM 12

### 14:30 CS18.01: Tumor Liquid Biopsy by Circulating Extracellular Vesicles

Koji Ueda, Japanese Foundation for Cancer Research, Japan

### 14:55 CS18.02: The Mitochondrial Interactome and Its Response to Apoptosis

Leonard J. Foster, University of British Columbia, Canada

### 15:20 CS18.03: High Throughput Structure-Function Analysis of the Centriole-Cilia Interface

Etienne Coyaud, UHN - Princess Margaret Cancer Centre, Canada

### 15:35 CS18.04: A Protein Marker-Based Physical Map of a Human Cell

Christopher Go, Mount Sinai Hospital, Canada

### 15:50 CS18.05: Plasma Membrane Proteomic Study of HIV Latent Infection

Lijun Zhang, Shanghai Public Health Clinical Center, China

### 15:55 CS18.06: Novel Components of Rods and Rings - A Subcellular Structure with Unknown Function

Marie Skogs, Science for Life Laboratory, Sweden

### 16:00 CS18.07: Pathogenic E. Coli Infection Alters the Mitochondrial Proteome and Mitochondrial Proteolysis

Natalie C. Marshall, University of British Columbia, Canada

### 16:05 CS18.08: Cancer-Associated Lipid Raft Function Revealed by Subcellular Proteomics and Computational Analysis

Michelle M. Hill, The University of Queensland, Australia

# 16:10 CS18.09: Abundance and Turnover of Synaptic Proteins by Mass Spectrometry and Super-Resolution Microscopy

Sunit Mandad, Max Planck Institute for Biophysical Chemistry, Germany

### 16:15 CS18.10: A Dynamic Picture of the Ubiquitinome upon Proteasome Inactivation

Jeroen AA Demmers, Erasmus MC, Netherlands

### 14:30 - 16:20 CS 19: Human Proteome **Project**

CHAIRS: GILBERT S. OMENN. USA & YOUNG-KI PAIK, KOREA ROOM 11

### 14:30 CS19.01: The Progress and Challenges of the HUPO Human **Proteome Project**

Gilbert S. Omenn, University of Michigan, USA

### 14:55 CS19.02: Strategic Points for **Dealing with Missing Protein** Mapping in the C-HPP

Young-Ki Paik, Yonsei University, Korea, Republic Of

### 15:20 CS19.03: Controlling False Discovery Rates (FDRs) in Genome-Wide Proteomics Datasets

Juergen Cox. Max Planck Institute for Biochemistry, Germany

### 15:35 CS19.04: How Does an Extra Chromosome 21 Modulate the Quantitative Human Proteome?

Yansheng Liu, ETH Zurich. Switzerland

### 15:50 CS19.05: Mining Missing Proteins Base on the Transcriptomics and Proteomics to the Individual Testis Tissues

Qidan Li, Beijing Institute of Genomics, Chinese Academic of Sciences, China

### 15:55 CS19.06: Call for a Testis-**Epididymis Proteome Project**

Charles Pineau, Inserm U1085 - Irset, France

### 16:00 CS19.07: Refining the Human Proteome: Analyzing Human Tissues by RNA-Sea. Proteomics and Antibodies

Hannes Hahne. Technische Universität München, Germany

### 16:05 CS19.08: Urinary Proteins **Originating Uniquely from Each Nephron Segment**

Tadashi Yamamoto, Niigata University, Japan

### 16:10 CS19.09: Detection of Chromosome 16 Missing Proteins - Spanish HPP

Concha Gil. Universidad Complutense de Madrid, Spain

16:15 CS19.10: Q&A

### 14:30 - 16:20 CS 20: Protein **Modifications (Other than** Phosphoproteins)

CHAIRS: THIBAULT MAYOR, CANADA & BRIAN RAUGHT, CANADA **ROOM 2+3** 

### 14:30 CS20.01: Ubiquitin and the Kiss of **Death under Stress Conditions**

Thibault Mayor. The University of British Columbia, Canada

### 14:55 CS20.02: Keynote Presentation

Brian Raught, UHN - Princess Margaret Cancer Centre, Canada

### 15:20 CS20.03: Using the Ubiquitin-**Modified Proteome to Monitor Protein Homeostasis Function**

Eric Bennett, UCSD, USA

### 15:35 CS20.04: An Effective Method to Site-Specifically Analyze N-Sialoglycosylated Proteome on the Cell Surface

Ronghu Wu, Georgia Institute of Technology, USA

### 15:50 CS20.05: Development of Methods for Site-Specific Analysis of N-Linked Protein Glycosylation

Honggiang Qin, Dalian Institute of Chemical Physics, China, China

### 15:55 CS20.06: A Chemical **Proteomics Approach for Lysine Monomethylome Profiling**

Minjia Tan, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

16:00 CS20.07: Analysis of Arginine **Methylation in Primary T Cells Reveals Roles in Cell Signalling and** Fate

> Vincent Geoghegan, Lancaster University, UK

16:05 **CS20.08: Protein Citrullination** - Novel Insight into Triggers of **Autoimmune Diseases** 

> Allan Stensballe, Aalborg University, Denmark

16:10 CS20.09: Lysine Succinylome **Analysis of the Model** Cyanobacterium Synechococcus sp. **PCC 7002** 

> Feng Ge, Institute of Hydrobiology, Chinese Academy of Sciences, China

16:15 CS20.10: Q&A 16:20 - 17:30

**Networking Break and Poster Viewing** 

(Odd Poster Numbers)

Exhibit Hall (Hall B)

17:30 - 18:15

PL 05: Plenary Session

Chairs: Joshua LaBaer, USA

Plenary Hall (Hall A)

17:30 **Using Mass Spectrometry to** Understand Cystic Fibrosis as a **Protein Misfolding Disease** 

> John R. Yates. The Scripps Research Institute, USA

18:30 - 19:30 HUPO General Assembly

Room 1

This is the official General **Assembly Meeting of the** Members of HUPO. All active **HUPO** members are welcome and encouraged to attend.

Chairs: Mark Baker, HUPO President & Gyorgy Marko-Varga, HUPO Secretary General

19:30 - 22:30 HUPO Congress Night: **Hockey Night in Canada** 

(Ticketed Event)

East Ballrooms A+B+C



# Join us for a TITELY Canada

The Vancouver Convention Centre East Ballroom will be magically transformed into a hockey ice rink!

Dance along with our amazing cover band and enjoy a casual Vancouver West Coast Style buffet dinner.

Tuesday, September 29, 2015 20:00-23:00

Vancouver Convention Centre, East Building, Ballrooms A+B+C



Includes skate rentals and commemorative photos with various hockey players!

# SECTION 6 PROGRAM WEDNESDAY, SEPTEMBER 30 THURSDAY, OCTOBER 1

### **PROGRAM**

### WEDNESDAY, SEPTEMBER 30, 2015

Registration Open	07:00 - 16:30
Speaker Ready Room Open	07:00 - 16:30
Exhibit Hall Open	10:00 - 16:30
Bioinformatics Hub	08:00 - 17:00

07:30 - 09:00 HPP 15: mtHPP (mitochondria)

CHAIR: MAURO FASANO, ITALY ROOM 1

FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 105 IN THIS PROGRAM BOOK.

### 07:30 - 09:00 HPP 16: Human Liver Proteome Initiative

CHAIRS: FERNANDO CORRALES, SPAIN & PUMIN ZHANG, USA ROOM 2+3

FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 106 IN THIS PROGRAM BOOK.

### 07:30 - 09:00 HPP 17: iMOP (Multi Organism Proteomes)

CHAIR: EMOKE BENDIXEN, DENMARK ROOM 8+15

FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 107 IN THIS PROGRAM BOOK.

### 07:30 - 08:15 HPP 18a: Human Proteomics at Extreme Conditions

CHAIRS: EVEGENIY NILOLAEV, RUSSIAN FEDERATION & IRINA LARINA, RUSSIAN FEDERATION ROOM 11

FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 108 IN THIS PROGRAM BOOK

### 08:15 - 09:00 HPP 18b: Skeletal Muscle Proteome

CHAIRS: LUIGI FERRUCCI, USA & KURT HOJLUND, DENMARK ROOM 11

FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 109 IN THIS PROGRAM BOOK.

07:30 - 09:00 HPP 19: Infectious Diseases (HID)-BD-HPP

> CHAIRS: CONCHA GIL, SPAIN & ILEANA M. CRISTEA, USA ROOM 12

FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 110 IN THIS PROGRAM BOOK.

### 07:30 - 09:00 HPP 20: Proteomics of **Protein Misfolding and Aggregation Diseases**

CHAIRS: MELINDA REZELI, SWEDEN & PAOLA PICOTTI, SWITZERLAND **ROOM 19** 

FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 111 IN THIS PROGRAM BOOK.

09:15 - 10:00 PL 06: Plenary Session

Chair: Bruno Domon, Luxembourg

Plenary Hall (Hall A)

Deciphering Functional Proteomes in the Human Protein Atlas - Organelles, Substructures and the Cell Cycle

Emma Lundberg, Science for Life Laboratory, KTH - Royal Institute of Technology, Sweden

10:00 - 11:10



**Networking Break and Poster Viewing** 

(Even and Odd Poster Numbers)

**Exhibit Hall (Hall B)** 

10:00 - 11:00 - - : - Bioinformatics Hub - Meet the Expert Session

Room 20

### 10:15 - 11:00 **Early Career Manuscript Competition - Presentations** of Award Finalists

### Room 1

Burcu Ayoglu, KTH-Royal Institute of Technology, Sweden

Justyna Fert-Bober, Cedars Sinai . Heart Institute. USA

Olga Schubert, HHMI / UCLA, USA

### 11:10 - 13:00 CS 21: Proteomics of Microbes and Infectious **Diseases**

CHAIRS: STUART CORDWELL. AUSTRALIA & JULIAN HISCOX, UK ROOM 1

11:10 CS21.01: The N-linked Glycosylation System of Campylobacter Jejuni: A **Functional Proteomics Approach** 

> Stuart Cordwell, The University of Sydney, Australia

11:35 CS21.02: High Resolution Analysis of Ebola Virus Biology: from Patient to Cell

> Julian Hiscox, University of Liverpool, UK

12:00 CS21.03: Pathogenic E. Coli Manipulate Global Proteolysis within Human Intestinal Cells during Infection

> Natalie C. Marshall, University of British Columbia, Canada

12:15 CS21.04: A Proteomics Approach for Characterization of the Human Adaptive Immune Response to S. Aureus

> Frank Schmidt, University Medicine Greifswald, Germany

### 12:30 CS21.05: A Novel Proline Specific Protease from C. Difficile Involved in Adhesion

Paul J. Hensbergen, Leiden University Medical Center, Netherlands

12:35 CS21.06: Quantitative Mass
Spectrometry Meets Molecular
Epidemiology and Vaccinology:
Factor H Binding Protein (fHbp)
from Neisseria Meningitidis

Massimiliano Biagini, GSK Vaccine, Italy

12:40 CS21.07: The Listeria Monocytogenes Proteotype

Maria Pavlou, ETH, Switzerland

12:45 CS21.08: A DIA-MS Approach for the Investigation of S. Aureus Specific In Vivo Host-Pathogen Interactions

> Stephan Michalik, University Medicine Greifswald, Germany

12:50 CS21.09: Phosphorylation and Thiol-Redox Modifications as Molecular Switches in Host-Microbe Interactions

Falko Hochgräfe, University of Greifswald, Germany

12:55 CS21.10: Proteomic Investigation of a Potential Type I Secretion System in the Syphilis Spirochete, Treponema Pallidum

Claudia Gaither, University of Victoria, Canada

### 11:10 - 13:00 CS 22: Phosphoproteomics and Cell Signaling

CHAIRS: JESPER OLSEN, DENMARK & DANIEL FIGEYS, CANADA ROOM 2+3

# 11:10 CS22.01: Multi-Layered Proteomics Reveals Molecular Switches Dictating Biased Ligand-Dependent EGFR Signaling

Jesper V. Olsen, Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Denmark

### 11:35 CS22.02: The Chronoproteome of the Brain

Daniel Figeys, Ottawa Institute of Systems Biology, Canada

12:00 CS22.03: Kinome, Total Proteome and Phosphoproteome Analysis of the CRC64 Cell Line Panel

Martin Frejno, University of Oxford, UK

12:15 CS22.04: Integrated Proteomic and Phosphoproteomic Analysis of TCGA Ovarian Tumors

Karin D. Rodland, Pacific Northwest National Laboratory, USA

12:30 CS22.05: Selective Enrichment of Phosphotyrosine Peptides Using Plastic Antibodies

> Silje B. Torsetnes, University of Southern Denmark, Denmark

12:35 CS22.06: Profiling Protein Expression, Modifications and Interactions with Antibody Microarrays

> Steven Pelech, Kinexus Bioinformatics Corporation. Canada

12:40 CS22.07: Mapping Signalling
Network Intersection Downstream
of Major Cell Surface Receptors

Emily S. Humphrey, Max Planck Institute for Biochemistry, Germany

12:45 CS22.08: Phosphoproteome
Analysis Identifies Oncogenic
Kinases in Hepatocellular Carcinoma

Ying Jiang, Beijing Proteome Research Center, China 12:50 CS22.09: In-Depth **Phosphoproteomic Analysis of** Immune Signaling Pathways in Response to Salmonella Infection

> Alexander Schmidt, University of Basel. Switzerland

CS22.10: The Molecular Mechanism 12:55 of PI3K Mutations Implicated in **Immunodeficiencies** 

> Gillian L. Dornan, University of Victoria, Canada

### 11:10 - 13:00 CS 23: Integrated OMICS

CHAIRS: ROBERT MORITZ, USA & MATHIAS UHLEN, SWEDEN **ROOM 8+15** 

11:10 CS23.01: Integrated Omics to Study the Human Proteome

> Mathias Uhlen, Science for Life Laboratory, KTH - Royal Institute of Technology, Sweden

11:35 CS23.02: Keynote

> Robert Moritz. Institute for Systems Biology, USA

12:00 CS23.03: Integrative Analysis of RNA, Translation and Protein Level Variation across Humans

Can Cenik, Stanford University, USA

CS23.04: A Multi-Omics Perspective 12:15 of a Population-Based Cohort - A Molecular Epidemiology Approach

> Uwe Voelker, University Medicine Greifswald, Germany

12:30 CS23.05: Multi-Omics to Study the Effects of Diclofenac on Wild Type and Hepatic Reductase Null (HRN) Mice

Nicola Gray, Imperial College London,

12:35 CS23.06: Omic Analysis of **Lung Cancer Reveals Proteome** Signatures with Prognostic Impact

> Michael F. Moran, University of Toronto, Canada

### 12:40 CS23.07: Serum Proteomes **Distinguish Children Developing** Type-1 Diabetes

Dave Goodlett, University of Maryland Baltimore, USA

12:45 CS23.08: Multilavered Genetic and Omics Dissection - A New Age for **Biomedical Researches** 

Yibo Wu, ETH Zurich, Switzerland

12:50 CS23.09: Impact of THS 2.2 and Conventional Cigarette Smoke on the Lung Proteome of ApoE-/- Mice

> Catherine Nurv. Philip Morris International. Switzerland

12:55 CS23.10: Utilizing Proteomic and Genetic Methodologies to Discover **Pathways Affecting Cytokinesis** 

> Janel Beckley, Vanderbilt University, **USA**

### 11:10 - 13:00 **CS 24: Sample Preparation** for Proteomics

CHAIRS: JOSHUA LABAER, USA & PIERRE CHAURAND, CANADA ROOM 11

11:10 CS24.01: High-Throughput Protein Microarrays for Personalized Diagnostics

> Joshua LaBaer, The Biodesign Institute at Arizona State University. USA

11:35 CS24.02: Sample Collection **Method Bias Effects in Quantitative Phosphoproteomics** 

> Evgeny Kanshin, Institute for Research in Immunology and Cancer, University of Montreal, Canada

12:00 CS24.03: Targeted Quantification of 97 Proteins in Dried Blood Spots

> Jingxi Pan, University of Victoria, Canada

12:15 CS24.04: An Integrated Sample **Preparation System for Targeted Proteomics** 

> Fred E. Regnier, Purdue University, USA

12:30 CS24.05: Comparison of Acetone Precipitation and FASP II for Protein Identification through Bottom up MS

> Carolyn Kachuk, Dalhousie University, Canada

12:35 CS24.06: Solvent-Based Protein
Precipitation as a Tool for Detergent
Removal Ahead of LC/MS

Alan A. Doucette, Dalhousie University, Canada

12:40 CS24.07: A Simple Affinity
Proteomics System for Fast,
Sensitive, Quantitative Analysis of
Proteins in Plasma

John P. O'Grady, Perfinity Biosciences, USA

12:45 CS24.08: Isolation and Identification of Human Cell Line Proteins Using Acid-Labile Detergents on LC-ESI-TOF

Robert May, Labor Dr. Spranger und Partner, Germany

12:50 CS24.09: Automated Sample Preparation Solutions for MS-Based Proteomics

Previn Naicker, Council for Scientific and Industrial Research, South Africa

12:55 CS24.10: Optimized Clinical Use of RNALater and FFPE Samples for Quantitative Proteomics

Kenneth Kastaniegaard, Aalborg University, Denmark

### 11:10 - 13:00 CS 25: Top Down Proteomics and Macromolecular Complexes

CHAIRS: LJILJANA PASA TOLIC, USA & NEIL L. KELLEHER, USA
ROOM 12

11:10 CS25.01: Top-Down Mass Spectrometry: What Does the Future Hold?

> Ljiljana Pasa-Tolic, Pacific Northwest National Laboratory (PNNL), USA

11:35 CS25.02: Native and Top Down MS – Revisited

Neil L. Kelleher, Northwestern University, USA

12:00 CS25.03: Top-Down, High-Throughput Proteomics of Allergens Using Complementary MS/MS Fragmentation Strategies

Daniel Lopez-Ferrer, Thermo Fisher Scientific, USA

12:15 CS25.04: Applying a Proteoform Profiling Method for Neurological Disorder Biomarker Discovery

> Michael B. Andersen, Bruker Daltonics, Denmark

12:30 CS25.05: Top-Down Structural
Analysis of Intact Antibodies Using
H/D Exchange and ETD on an
Orbitrap-MS

Suping Zhang, MRM Proteomics Inc., Canada

12:35 CS25.06: MS3ID: A Novel MS3-Based Method Coupled to a Supervised Learning Algorithm for Top-Down Proteomics

> Mathieu Lavallée-Adam, The Scripps Research Institute, USA

12:40 CS25.07: Intact Protein Signatures in Substantia Nigra Associated with Lewy Bodies and Neuronal Loss

Paul D. Piehowski, Pacific Northwest National Laboratory, USA

### 12:45 CS25.08: Comprehensive **Glycosylation Characterization** of Therapeutic mAbs by Top- and Middle-Down MS

Young Ah Goo, University of Marvland, USA

### 14:30 - 16:20 CS 26: Structural Proteomics

CHAIRS: ANDREA SINZ, GERMANY & EVGENY V. PETROCHENKO, CANADA **ROOM 8+15** 

### 14:30 CS26.01: The Advancement of Cross-Linking/Mass Spectrometry in Structural Proteomics

Andrea Sinz, Martin Luther University Halle-Wittenberg, Germany

### 14:55 CS26.02: Towards Solving Protein **Structures by Structural Proteomics**

Evgeny V. Petrotchenko, University of Victoria, Canada

### 15:20 CS26.03: Investigating the Basis of Nav1.5 Fast Inactivation Using a Crosslinking Unnatural Amino Acid and MS

Christopher Murray, University of British Columbia, Canada

### CS26.04: Large-Scale Detection of 15:35 **Unstructured Protein Regions by Pulsed Proteolysis**

Roman Körner, MPI of Biochemistry, Germany

### 15:50 CS26.05: Global Analysis of Protein Structural Changes in Complex **Proteomes**

Yuehan Feng, ETH Zurich, Switzerland

### 15:55 CS26.06: Investigation of Protein-RNA Interactions by UV **Induced Cross-Linking and Mass** Spectrometry

Kundan Sharma, Max Planck Institute for Biophysical Chemistry, Germany

### 16:00 CS26.07: Protein-RNA and Protein-**DNA Cross-Link Identification** Pipeline Integrated in Proteome Discoverer 2.0

Oliver Kohlbacher, University of Tübingen, Germany

### 16:05 CS26.08: Role of Drosophila Memory Related Fatty Acid Binding **Protein on Transporting Fatty Acids**

Yi-Yun Cheng, National Tsing Hua University/National Health Research Institute, Taiwan, ROC, Taiwan

### 16:10 CS26.09: Enrichment of Cross-**Links from Complex Samples by Charge-Based Fractional Diagonal** Chromatography

Verena Tinnefeld, Leibniz-Institut für Analytische Wissenschaften - ISAS e.V., Germany

### 16:15 CS26.10: Ion Mobility and Surface **Topology Mapping Reveals the** Cause of the Protein G-IgG Affinity Switch

Yelena Yefremova, Proteome Center Rostock, Germany

### 14:30 - 16:20 CS 27: CNPN

CHAIRS: PIERRE THIBAULT, CANADA & JUERGEN KAST, CANADA **ROOM 2+3** 

SESSION GENEROUSLY SUPPORTED BY



### 14:30 CS27.01: From Edman Sequencing to Tandem Mass Spectrometry: 25 Years of Protein Research to Understand the Role of PARPs in Cell Death, Cancer Biology and Therapy

Guy G. Poirier, Laval University, Canada

### 14:55 CS27.02: Prognostic Significance of Head and Neck Cancer Biomarkers: Translation into Oral Surgery Clinics

K.W. Michael Siu, University of Windsor, Canada

### 15:20 CS27.03: Diagnosis of Urological Disorders with Protein Biomarkers Measured in Seminal Plasma

Andrei P. Drabovich, University of Toronto, Canada

# 15:35 CS27.04: Proteomic Analyses of Macrophage Response to Mycobacterium Tuberculosis Infection

Yossef Av-Gay, University of British Columbia, Canada

# 15:50 CS27.05: Using TAILS N-Terminomics to Identify Missing Proteins and Study Inflammatory Gingival Diseases

Ulrich Eckhard, Centre for Blood Research, Canada

# 15:55 CS27.06: Antibody Colocalization Microarray Quantifies 108 Proteins in 35 µL of Serum at fM Concentration

David Juncker, McGill University, Canada

### 16:00 CS27.07: Quantifying the Active Kinases in Ovarian Cancer Cell Lines to Explore Cisplatin Resistance

Brett Larsen, Mount Sinai Hospital, Canada

### 16:05 CS27.08: Investigation of the CK2-Dependent Phosphoproteome Using Mass Spectrometry

Adam J. Rabalski, Western University, Canada

# 16:10 CS27.09: Negative Phosphoregulation of Protein Interaction Domains by Tyrosine Kinase Receptors

Ugo Dionne, University Laval, CHU de Québec, Canada

# 16:15 CS27.10: Assessment of SUMO/ Ubi Kinetic in Human Cells Using an Optimized Peptide Immunopurification

Frederic Lamoliatte, Institute for Research in Immunology and Cancer, Canada

### 14:30 - 16:20 CS 28: Personalized Medicine

CHAIRS: MICHAEL SNYDER, USA & TADASHI KONDO, JAPAN ROOM 1

### 14:30 CS28.01: Integrative Personal Omics Profiling During Periods of Disease, Weight Gain and Loss

Michael Snyder, Stanford University School of Medicine, USA

### 14:55 CS28.02: Cancer Proteomics in the Era of Precision Medicine

Tadashi Kondo, National Cancer Center Research Institute, Japan

### 15:20 CS28.03: Identification of Tumor Antigens for Personalized Immunotherapy by Analysis of the HLA Peptidome

Arie Admon, Technion - Israel Inst. of Technology, Israel

### 15:35 CS28.04: Immune Response Proteins Predict HCV Treatment Outcome

Daniel Chelsky, Caprion Proteome, Inc., Canada

### 15:50 CS28.05: Substrate and Chaperone Binding Sites in α-Galactosidase Identified by Proteolytic Affinity MS

Michael Przybylski, Steinbeis Centre for Biopolymer Analysis and Biomedical Mass Spectrometry, Germany

### 15:55 CS28.06: Risk Assessment of Development Impairment in Preterm Babies by Cord Blood Proteome Profiling

Manja Wölter, University Medicine Rostock, Germany

# 16:00 CS28.07: Urine Proteome Analysis for Differential Diagnostics of Respiratory Tract Pathologies in Newborns

I. A. Popov, Moscow Institute of Physics and Technology, Russian Federation

### 16:05 CS28.08: Prediction of Mortality in Acute Respiratory Distress Syndrome

Maneesh Bhargava, University of Minnesota, USA

### 16:10 CS28.09: Serological Epithelial Component Proteins Identify Intestinal Complications in Crohn's Disease

Yunki Y. Yau, Concord Repatriation General Hospital, Australia

16:15 CS28.10: Tear Proteome Correlates with Better Clinical Signs and Symptoms in Glaucoma Patients

Roger Beuerman, University of Tampere. Finland

# 15:55 CS29.06: Impact of Individual Single Nucleotide Variants on Signal Transduction Networks in Cancer Cell Lines

Karsten Krug, University of Tuebingen, Germany

16:00 CS29.07: Proteome-Scale Discovery of Protein Isoforms, including Those Predicted from RNA-Seq Analysis

Gene O. Hart-Smith, UNSW, Australia

16:05 CS29.08: Dynamic Linking of Public Proteomics Data in Ensembl Using TrackHubs

> Juan Antonio Vizcaino, EMBL-European Bioinformatics Institute, UK

### 14:30 - 16:20 CS 29: Proteogenomics

CHAIRS: VINEET BAFNA, USA & AKILESH PANDEY, USA ROOM 11

14:30 CS29.01: Keynote Presentation Akilesh Pandey, Johns Hopkins, USA

14:55 CS29.02: Proteogenomics to Identify Ig Proteins

Vineet Bafna, University California San Diego, USA

15:20 CS29.03: Towards Improving the Genome Annotation of the Honey Bee (Apis mellifera)

> Alison McAfee, University of British Columbia, Canada

15:35 CS29.04: Deep Proteogenomic Profiling of 55 Breast Cancer Cell Lines Reveals Novel Insights in Cancer Biology

> Arzu Umar, Erasmus MC Cancer Institute, Netherlands

15:50 CS29.05: Peppy 2.0: New Software Addressing the Sensitivity Problem in Proteogenomics

Mohamed Helmy, University of Toronto, Canada

### 14:30 - 16:20 CS 30: Standardization in Proteomics

CHAIRS: FERNANDO J. CORRALES, SPAIN & ALBERT SICKMANN, GERMANY ROOM 12

14:30 CS30.01: A Multi-Centric Study to Evaluate the Use of Relative Retention Times in Targeted Proteomics

Fernando J. Corrales, Center for Applied Medical Research, Spain

14:55 CS30.02: Keynote Presentation

Albert Sickmann, Leibniz-Institut fuer Analytische Wissenschaften, Germany

15:20 CS30.03: Multi-Site Assessment of Quantitative and Qualitative Performance of SWATH Mass Spectrometry

Yansheng Liu, ETH Zurich, Switzerland

15:35 CS30.04: Can Certified Reference Materials Support the Validation of Biomarkers?

Amalia Muñoz, Joint Research Centre - IRMM, Belgium

### 15:50 CS30.05: Affinity Binder Knock-Down Initiative

Tove L. Alm, Science for Life Laboratory, KTH - Royal Institute of Technology, Sweden

15:55 CS30.06: DIGESTIF: A Universal Quality Standard for the Control of Bottom-Up Proteomics Experiments

Virginie Brun, CEA/INSERM/UGA, France

16:00 CS30.07: Comparison of iTRAQ
Data Processing Approaches with
Respect to Analytical and Biological
Variability

Li Chen, Johns Hopkins University, USA

16:05 CS30.08: Harmonization of Proteomics Analyses: A Simple Method to Assess System Suitability

A. Bourmaud, L.I.H., Luxembourg

16:10 CS30.09: Glycome Profiling of Mouse Tissues Using a Standardized Method Combined LMD and Lectin Microarray

> Xia Zou, Glycomedicine Technology Research Center, National Institute of Advanced Industrial Science and Technology (AIST), Japan

16:20 - 16:30



(Even and Odd Poster Numbers)

**Exhibit Hall (Hall B)** 

### 16:30 - 18:30 PL 07: Closing Plenary Session with Award Lectures

Chairs: Christoph Borchers, Canada & Pierre Thibault, Canada & Mark Baker, Australia & Martin Larsen, Denmark & Gyorgy Marko-Varga, Sweden

	Plenary Hall (Hall A)
16:30	Welcome
	Martin Larsen, University of Southern Denmark, Denmark
16:35	Presentation of CNPN Award
16:40	Poster and Travel Award Presentations
16:50	Keynote Talk: Distinguished Achievement in Proteomics Sciences Award - Amanda Paulovich
	Amanda Paulovich, Fred Hutchinson Cancer Research Center, USA
17:10	Keynote Talk: Discovery in Proteomic Sciences Award - Bernhard Kuster
	Bernhard Kuster, Technische Universität München, Germany
17:20	Keynote Talk: Discovery in Proteomic Sciences Award - Akhilesh Pandey
	Akhilesh Pandey, Johns Hopkins, USA
17:30	Keynote Talk: Science & Technology Award - Leigh Anderson, Morteza

### Jennifer Van Eyk, Cedars Sinai Medical Center, USA 18:10 Distinguished Service Award Presentation - Catherine Costello

Razavi & Terry Pearson

Proteomics Award -Jennifer van Evk

**Keynote Talk: Translational** 

**18:15** Comments and Reflections
Alan Winter, President and CEO,
Genome BC

### 18:20 Comments and Reflections

Christoph Borchers, University of Victoria, Canada & Pierre Thibault, Universite de Montreal, Canada Invitation to HUPO 2016, Taiwan

18:25 Invitation to HUPO 2016, Taiwan18:30 Formal Close/See You in Taiwan

Mark S. Baker, Macquarie University, Australia

17:50

### **PROGRAM**

### THURSDAY, OCTOBER 1, 2015

08:30 - 17:45 Post-Congress HPP **Workshop Day** (Ticketed Session)

> CHAIR: GIL OMENN, USA SFU HARBOUR CENTRE, JOSEPH AND **ROSALIE SEAGAL CENTRE, 515 WEST** HASTINGS STREET



**REGISTRATION FEE: 50 CAD** 



LIGHT KEF LIGHT REFRESHMENTS AND LUNCH



FOR DETAILED SESSION INFORMATION PLEASE SEE PAGE 112 IN THIS PROGRAM BOOK.

# SECTION 7 HPP SESSIONS

### SUNDAY, SEPTEMBER 27, 2015

### 08:30 - 17:00 HPP General Investigators Meeting

CHAIR: GIL OMENN, USA ROOM 11

An opportunity to review all aspects of the HPP prior to the congress start. Participation in this meeting is included in registration.

08:30 Gathering/Coffee/Interactions within Groups & SSAB

09:00 HPP.01: Progress of the Human Proteome Project - Overview and Metrics

Gilbert S. Omenn, University of Michigan, USA

09:20 HPP.02: C-HPP Highlights

Young-Ki Paik, Yonsei University, Korea, Republic of

09:40 HPP.03: B/D-HPP Highlights

Jennifer Van Eyk, Cedars Sinai Medical Center, USA

10:00 HPP.04: neXtProt & PeptideAtlas 2015 Updates

Eric W. Deutsch, Institute for Systems Biology, USA Lydie Lane, Swiss Institute of Bioinformatics, Switzerland

10:20 HPP.05: Human Protein Atlas 2015

Emma Lundberg, KTH - Royal Institute of Technology, Sweden Mathias Uhlen, KTH - Royal Institute of Technology, Sweden

10:40 HPP.06: Highlights of the JPR C- HPP 2015 Special Issue

Gilbert S. Omenn, University of Michigan, USA

11:30 Lunch and Breakouts

Breakout 1 (Room 18): C-HPP Working Session – Young-Ki Paik, Korea Breakout 2 (Room 19): B/D-HPP Working Session – Jennifer van Eyk, USA & Fernando Corrales. USA

13:30 HPP.07: Project on Plasma Proteome Variation

Michael Snyder, Stanford University School of Medicine, USA

14:00 HPP.08: Panel on the Testis Proteome: Highly Enriched for Missing Proteins

Charles Pineau, France & Siqi Liu, China & Ghasem Salekdeh, Iran & Cecilia Lindskog, Sweden

15:00 HPP.09: Panel on Membrane Proteins: Special Challenges

Lead Discussant: Alexey Nesvizhskii, University of Michigan-Ann Arbor, USA Yu-Ju Chen, Taiwan & Takeshi Tomonaga, Japan & Akhilesh Pandey, USA & Mathias Uhlen, Sweden

16:00 HPP.10: Reports from Breakout Sessions

Fernando Corrales, Cedars Sinai Medical Center, USA & Jennifer van Eyk, Cedars Sinai Medical Center, USA & Young-Ki Paik, Yonsei University, Korea

16:30 HPP.11: Discussion of Plan of HPP Activities for the Week

12:00 - 13:00 HPP Working Group on Cross-linking plus mass spectrometry to analyze protein complexes (XL-MS)

CHAIR: JURI RAPPSILBER, UK

ROOM 11

### MONDAY, SEPTEMBER 28, 2015

07:30 - 09:00 HPP 01: Cancer HPP

CHAIRS: HUI ZHANG, USA & CONNIE JIMENEZ, NETHERLANDS & EDWARD NICE, USA ROOM 1

Understanding the proteomic differences in multiple human tumor types is the current requisite and central theme of the cancer human proteome project (Cancer-HPP) with the ultimate goal of defining expression and interactions of these proteins. This will greatly increase our knowledge of human cancer biology and disease progression. Overall, the Cancer-HPP attempts to characterize different cancer proteomes, determine the correlation of transcriptome and proteome, identify the high priority proteins for each tumor type and generate and disseminate assays and resources to support the analysis of complex biological networks or clinical specimens underlying different disease processes. The use of immunoassays and protein assays as well as the emerging mass spectrometry (MS)-based platforms such as selected reaction monitoring (SRM), Parallel reaction monitoring (PRM), and targeted data extraction for candidate proteins from SWATH-MS data have become reliable popular methods for quantitative analysis of high priority target proteins. Data from multiple laboratories studying different cancer types has confirmed the supremacy of these technologies over conventional assays. Therefore, we propose an international cancer proteomic effort similar to The Cancer Genome Atlas (TCGA) project to identify and validate cancer proteins for different cancer types. Data deposition, quality control, and public availability are always a priority for the key proteomics journals and some funded programs such as CPTAC and EDRN. and they are the key components of the Cancer-HPP. We will further support and propose an open discussion on procedures how to accrue/share data for a list of target proteins from each cancer type, the strategy for assay development, quality control, and procedure and materials needed for disseminate the established assays to cancer biology or clinical laboratories. Toward this goal, it will be essential to involve the whole cancer community including not only proteomics but also genomics and cancer biologists and clinical oncologists in Cancer-HPP.

- 07:30 HPP01.01: Integrative Analysis of the Colorectal Cancer Proteome and Its Subtypes with Differential Prognosis
  - Connie R. Jimenez, VU University Medical Center, Netherlands
- 07:40 HPP01.02: Translation of Membrane Proteome Interactions into Novel Colorectal Cancer Tissue Biomarkers
  - Mark S. Baker, Macquarie University, Australia
- 07:55 HPP01.03: The First Glimpse of the Proteomic Landscape of Cancer from CNHPP
  Jun Qin, Beijing Proteome Research Center, China
- **08:10 HPP01.04: Advances in Breast Cancer Proteomics: Paving the Way towards the Clinic**Arzu Umar, Erasmus MC Cancer Institute, Netherlands
- 08:25 HPP01.05: Glycomics Approaches for the Identification of Cancer Biomarkers Using Targeted Glycoproteomic, Glycomic, and Functional Analyses to Identify a Unique N-Linked Glycan Structure Prevalent in Ovarian Cancer
  - Karen Abbott, University of Arkansas for Medical Sciences, USA
- 08:40 HPP01.06: Individualized Phosphoproteomics-Guided Screening of Tissue Signatures in Non-Small Cell Lung Cancer
  - Yu-Ju Chen, Academia Sinica, Taiwan

### MONDAY, SEPTEMBER 28, 2015

### 07:30 - 09:00 HPP 02: HPPP (Plasma)

CHAIRS: JOCHEN SCHWENK, SWEDEN & ERIC DEUTSCH, USA ROOM 2+3

Due to its circulation throughout the human body and ease of acquisition, blood provides a unique window into human health and disease. However, analyzing blood plasma or serum still poses one of the major challenges for proteomics in terms of sensitivity and analytical depth. With growing numbers of plasma samples being systematically collected, stored, and made available through biobanks, proteomic methods and technologies advancing, and the remaining need for novel clinical markers to determine and monitor health and disease, the effort to understand the plasma proteome is becoming an increasingly active area of research. This HPPP session will host a selection of short talks on recent advances in plasma protein analysis that cover different technologies, diseases, and concepts. We bring together different contributions to the field in mass spectrometry and affinity-based assays. The presentations will demonstrate success stories, technological possibilities, viewpoints and perspectives on how plasma proteomics has and will continue to advance. The invited speakers will cover topics from the field of biomarker research to their translation into clinical use.

### 07:30 HPP02.01: Welcome and Introduction

Jochen M. Schwenk, Science for Life Laboratory, KTH - Royal Institute of Technology, Sweden

- 07:40 HPP02.02: Sensitive Biomarker Discovery in Plasma for Myocardial Injury
  Hasmik Keshishian, Broad Institute, USA
- 07:50 HPP02.03: Quantitative Variability of Plasma Proteins Post-Translational Modifications in a Human Twin Population

George Rosenberger, ETH Zurich, Switzerland

08:00 HPP02.04: A Novel Proteomic Method for Plasma Biomarker Quantification

Michal Harel, Tel Aviv University, Israel

08:10 HPP02.05: Antibody Microarrays for Plasma Proteomics

David Juncker, McGill University, Canada

08:20 HPP02.06: Liaison of Immunocapture MS with Affinity Arrays

Claudia Fredolini, Science for Life Laboratory, KTH - Royal Institute of Technology, Sweden

08:30 HPP02.07: Towards Clinical Measurement by iMALDI

Robert Popp, University of Victoria, Canada

08:40 HPP02.08: PeptideAtlas

Eric W. Deutsch, Institute for Systems Biology, USA

08:50 HPP02.09: Summary and End of Session

Eric W. Deutsch, Institute for Systems Biology, USA

### MONDAY, SEPTEMBER 28, 2015

### 07:30 - 09:00 HPP 03: Cardiovascular Initiative Workshop

CHAIR: POTHUR SRINIVAS, USA ROOM 8+15

The HUPO Cardiovascular Initiative Workshop updates cardiovascular researchers and general biological scientists with progresses in the Cardiovascular Human Proteome Project (HPP), whose goal is to understand proteome regulations in cardiovascular diseases and promote the translation of proteome technologies. The Cardiovascular Workshop this year will take place on Monday, September 28th 7:30 am to 9:00 am in Vancouver, Canada (hupo2015.com). The Workshop will feature the work of multiple young investigators from around the world. Selected topics will include advances in redox modifications, their regulations, and their particular importance in the diagnosis and prognosis of cardiovascular diseases; proteomics toolsets to elucidate context-dependent disease pathways in aortic aneurysm; novel quantification workflow using TMT10-TAIL; data science methods to expedite the translation of targeted quantification assays for cardiovascular-centric proteins; and others. Dr. Pothur Srinivas from NHLBI will begin the Workshop session with an overview on the current achievements and future directions of cardiovascular proteomics. A panel discussion period will be dedicated for open discussion to promote interactions with our panelists on the growth of cardiovascular proteomics.

- **O7:30 HPPO3.01: Current Achievements and Future Directions of Cardiovascular Proteomics**Pothur Srinivas, National Heart, Lung, and Blood Institute, USA
- 07:35 HPP03.02: Optimizing a Proteomic Toolset to Elucidate Context-Dependent Disease Pathways in Aortic Aneurysm

Sarah J. Parker, Cedars Sinai Medical Center, USA

07:50 HPP03.03: Novel CaMKII Phosphorylation Sites Identified on NaV1.5 by Label-Free Mass Spectrometry

Anthony W. Herren, University of California, Davis, USA

08:05 HPP03.04: TMT10-TAILS Analysis of Lymphocytes to Unravel the Role of Proteolysis in B Cell Activation

Theo Klein, University of British Columbia, Canada

08:15 HPP03.05: Visualization of Protein Signaling Networks Through Publication Distance

Maggie Lam, NIH BD2K Center of Excellence at UCLA, USA

08:25 HPP03.06: The Complexity of Oxidative Modifications

Mark E. McComb, Boston University School of Medicine, USA

08:35 HPP03.08: Panel Discussion

### MONDAY, SEPTEMBER 28, 2015

07:30 - 09:00 HPP 04: HDPP - Diabetes

CHAIRS: PETER BERGSTEN, SWEDEN & JEAN-CHARLES SANCHEZ, SWITZERLAND ROOM 11

The aim of the HUPO Human Diabetes Proteome Project (HDPP) initiative is to enhance the understanding of mechanisms in diabetes development by performing and analyzing large-scale network biology-based experiments.

Diabetes is a disease characterized by inability of normalizing circulating levels of glucose resulting in hyperglycemia. In addition, persons with diabetes often have increased concentrations of fatty acids especially if they are overweight or obese. Therefore, elevated circulating concentrations of glucose and lipid, separated or combined have been implicated in the impaired function observed in different cell types and tissues in individuals with diabetes. Within the HUPO community special expertise is available to generate and analyze complex data sets generated from cells and tissues obtained from healthy and diabetic subjects, animal models of the disease or cell lines.

At previous HDPP workshops, which are held twice a year with one at the HUPO meeting, persons with interest in pursuing diabetes research related to the aim of HDPP have been invited to join the initiative. The resulting group of researchers has worked on different topics. One topic has been to define sets of proteins of interest for understanding diabetes and identify how these sets could be measured and analyzed in an efficient way. Information from these workshops has been disseminated to the general public by the HDPP homepage (www.hdpp.info).

The 8th HDPP workshop, to be held at the HUPO 2015 meeting in Vancouver, will focus on how sets of proteins of interest discovered by classical omics strategies can be translated in robust assay development to be applied on large cohort of patients. Among the speakers are Dave Goodlett and Ann-Catrin Andersson, who together with the chair and co-chair of the session will address the topic.

- 07:30 HPP04.01: Introduction: Progresses since the 13th HUPO meeting in Madrid

  Jean-Charles Sanchez, University of Geneva, Switzerland
- 07:45 HPP04.02: Discovery and Validation of Serum Proteome Biomarkers of Type 1 Diabetes Developing Children
  - Dave Goodlett, University of Maryland Baltimore, USA
- 08:05 HPP04.03: Beta-JUDO: From Pathway Analysis to Target Selection
- Peter Bergsten, Uppsala University, Sweden **08:25 HPP04.04: Proximity Extension Assays in Diabetes Research** 
  - Ida Grundberg, O-link, Sweden
- 08:40 HPP04.05: General Discussion and Proposals

### MONDAY, SEPTEMBER 28, 2015

07:30 - 09:00 HPP 05: Human Antibody Initiative

CHAIRS: MATHIAS UHLEN, SWEDEN & TOVE ALM, SWEDEN & EMMA LUNDBERG, SWEDEN ROOM 12



BREAKFAST WILL BE PROVIDED DURING THIS SESSION.

The recent discussions within the scientific community and in journals about reproducibility and the quality of antibodies throw light on topics that impact the daily work of most life science researchers. Antibodies and other affinity reagents are commonly used tools across all disciplines of life science, including proteomics, and they are well known to be cross-reactive and have variable success depending on the application. There is a strong need to improve reproducibility in antibody-based proteomic research. Undertaking a number of steps will help reach this goal; first of all affinity reagents must be properly identified and secondly proper validated for the particular application is needed. This session will focus on research programs and initiatives working on identification and quality improvement for affinity reagents, and how we all can contribute to higher quality in proteomic research.

07:30 HPP05.01: Opening & Welcome

Emma Lundberg, Science for Life Laboratory, KTH - Royal Institute of Technology, Sweden

- 07:40 HPP05.02: RRIDs The Standard for Research Resource Citation
  - Anita Bandrowski, Rancho BioSciences, UCSD, USA
- 07:50 HPP05.03: Exploration and Validation of Protein Expression Patterns Using an Integrated Omics Approach

Cecilia Lindskog, Immunology, Genetics and Pathology, Sweden

- 08:00 HPP05.04: Antibody Validation Using siRNA and GFP-Tagged Proteins
  - Marie Skogs, Science for Life Laboratory, KTH Royal Institute of Technology, Sweden
- 08:10 HPP05.05: Affinity Binder Knockdown Initiative

Tove L. Alm, Science for Life Laboratory, KTH - Royal Institute of Technology, Sweden

08:20 HPP05.06; NCI Antibody Characterization Program - An Update Report

Henry Rodriguez, National Cancer Institute, USA

08:30 HPP05.07: Alleviating Antibody Anxiety: Generation of Antibodies with Demonstrated Specificity and Reproducibility

Deepa Shankar, Thermo Fisher Scientific (Life Technologies), USA

08:40 HPP05.08: Concluding Remarks

Mathias Uhlen, Science for Life Laboratory, KTH - Royal Institute of Technology, Sweden

### MONDAY, SEPTEMBER 28, 2015

07:30 - 09:00 HPP 06: EyeOME - Proteomics: Towards Understanding Biological Pathways in the Eye

CHAIRS: RICHARD SEMBA, USA & MARIUS UEFFING, GERMANY & HYEWON CHUNG, KOREA ROOM 19

The EyeOME session has eight speakers who place an emphasis upon biological pathways in the eye that have been revealed through proteomic approaches. The topics include identification of pathways and biomarkers associated with age-related macular degeneration through study of aqueous humor (Hyewon Chung) and tears (Lei Zhou) using SWATH-MS, use of laser capture microdissection and pressure cycle technology to study specific retinal substructures (Sascha Dammeier), and discovery of molecular networks in diabetic retinopathy using a novel transgenic pig model (Stefanie Hauck). New mechanisms of glaucoma have been found through proteomic investigation of the trabecular meshwork (Sanjoy Bhattacharya) and retina (Franz Grus). SWATH-MS has been used to identify dynamic changes in the proteome of human induced pluripotent stem cells in their differentiation to retinal pigment epithelial cells (Richard Semba). A screening approach was used to identify retinal substrates for a disease-associated variant in the protease CAPN5 (Vinit Mahajan).

07:30 HPP06.01: SWATH-based Comparative Proteomic Analysis of the Aqueous Humor in Patients with Dry Age-related Macular Degeneration

Hyewon Chung, Konkuk University Medical Center, Korea

07:40 HPP06.02: Tear Protein Biomarkers for Detection of Age-Related Macular Degeneration

Lei Zhou, Singapore Eye Research Institute, Singapore

07:50 HPP06.03: Use of Laser Capture Microdissection with Pressure Cycle Sample Preparation to Analyze the Proteome of Retinal Sub-Structures

Sascha Dammeier. University of Tuebingen. Germany

08:00 HPP06.04: Ocular Pathology in the INSC94Y Transgenic Pig, a Novel Model for

Stefanie M. Hauck, Research Unit Protein Science, Helmholtz Center Munich, Germany

08:10 HPP06.05: Lack of Basement Membrane Protein Degradation in Glaucomatous
Trabecular Meshwork

Sanjoy K. Bhattacharya, University of Miami, USA

Diabetic Retinopathy

08:20 HPP06.06: Dynamic Changes in the Proteome During the Differentiation of Human Induced Pluripotent Stem Cells into Retinal Pigment Epithelium

Richard Semba, Johns Hopkins School of Medicine, USA

08:30 HPP06.07: Glaucoma-Associated Proteomic Changes Provide New Insights in Neurodegenerative Pathways

Franz Grus, University Medical Center, Johannes Gutenberg-University, Germany

08:40 HPP06.08: Protease Proteomics: Global Identification of Biological Pathways that Activate Uveitis, Retinal Angiogenesis and Degeneration, and Intraocular Fibrosis

Vinit B. Mahajan, University of Iowa, USA

### MONDAY, SEPTEMBER 28, 2015

13:15 - 14:15 HPP 07: HPP Bioinformatic Session

CHAIRS: ERIC DEUTSCH, USA

ROOM 12

In this workshop, the current and future HPP data guidelines will be discussed. The goal of the workshop is to understand where the existing guidelines have served the HPP well and poorly, and discuss a proposed set of new guidelines, specifically in the context of advancing confident detections of missing proteins. Each subtopic will be introduced separately, followed by discussion by the workshop participants. Full audience participation is encouraged. The major subtopics include: current HPP data guidelines, data deposition in ProteomeXchange, the 1% protein-level FDR requirement, manual inspection of extraordinary claims, consideration of alternate explanations of the data, use of synthetic reference peptides, and the use of SRM to confirm shotgun results.

### 13:15 HPP07.01: HPP Bioinformatics Workshop

Eric Deutsch, Institute for Systems Biology, USA

### TUESDAY, SEPTEMBER 29, 2015

07:30 - 09:00 HPP 08: CPTAC HPP - CPTAC Data, Tools, and Assays for Cancer Biology

CHAIR: HENRY RODRIGUEZ, USA ROOM 1

The Clinical Proteomics Tumor Analysis Consortium represents a network of proteomic scientists at multiple locations who coordinate research approaches and data sharing to comprehensively interrogate genomically characterized specimens, initially obtained from The Cancer Genome Atlas collection of highly annotated tumor samples. CPTAC is dedicated to combining state-of-the-art standardized proteomic technologies with genomic analysis and a technological tour de force approach in order to deeply interrogate biospecimen cohorts sized for adequate statistical power. The desired outcome is not only new insights into cancer but also the development of publicly available tools (data, assays, reagents) in proteomics for future studies by the cancer research community. In this workshop CPTAC investigators will describe the tools under development as part of the initial analysis of TCGA tumor specimens, leading to a discussion of the best strategies for moving forward to develop the most informative targeted assays of disease insight.

07:30 HPP08.01: Overview of CPTAC Henry Rodriguez, National Cancer Institute, USA 07:35 HPP08.02: CPTAC Data Coordinating Center: Data Availability Christopher Kinsinger, National Cancer Institute, USA 07:45 HPP08.03: NetGestalt: CPTAC's portal for Cancer Proteogenomics Bing Zhang, Vanderbilt University Medical Center, USA 08:00 HPP08.04: Targeted Assays for Verification of Biological Insights Stefani Thomas, Johns Hopkins University, USA 08:15 HPP08.05: CPTAC Assav Portal Jeff Whiteaker, Fred Hutchinson Cancer Research Center, USA HPP08.06: Moderated Discussion 08:30

### TUESDAY, SEPTEMBER 29, 2015

07:30 - 09:00 HPP 09: Proteomics Standards Initiative and ProteomeXchange Consortium

CHAIRS: ERIC DEUTSCH, USA & HENNING HERMJAKOB, UK **ROOM 2+3** 

The HUPO Proteomics Standards Initiative (PSI) defines community standards for data representation in proteomics to facilitate data comparison, exchange and verification. We contribute to data management and integration in all other HUPO initiatives, and have published a modular set of standards for proteomics data representation. For details of the HUPO PSI please see www.psidev.info. Based on the HUPO PSI standards, we have developed ProteomeXchange. an international consortium to standardize collection and dissemination of public proteomics data worldwide (www.proteomexchange.org). In this session, we will provide an overview of current PSI activities, with an emphasis on the formats currently in development that need further input from the community. We will also present the current status and future plans for aspects of data deposition in ProteomeXchange. In addition to presentation, there will be time for open discussion and feedback from the community on these activities.

07:30 HPP09.01: The Proteomics Standards Initiative - Introduction and Status Report Eric W. Deutsch, Institute for Systems Biology, USA 07:45 HPP09.02: Fine-Grained Modelling of Molecular Interactions in PSI MI XML 3.0 Henning Hermjakob, EMBL-European Bioinformatics Institute, UK 08:00 HPP09.03: Mass Spectrometry Informatics Formats in Progress Juan Antonio Vizcaino, EMBL-European Bioinformatics Institute, UK 08:15 HPP09.04: Open Discussion Focused on Future Projects of the PSI 08:30 HPP09.05: ProteomeXchange Consortium - Introduction and Status Report Henning Hermiakob, EMBL-European Bioinformatics Institute, UK 08:45 HPP09.06: Open Discussion Focused on Experiences and Future Projects of ProteomeXchange

### TUESDAY, SEPTEMBER 29, 2015

07:30 - 09:00 HPP 10: B/D-GPP (Biology/Disease-driven Glycoproteome Project)

CHAIR: HISASHI NARIMATSU, JAPAN ROOM 8+15

### Session theme

Coordination of proteomics and glycomics for establishment of Glycoproteome Atlas

Most of proteins in the living body are glycosylated and present as glycoproteins. In the previous glycomics initiatives, many technologies were focusing on the analysis of glycans released from glycoproteins. Since two years ago, the Biology/Disease-driven Glycoproteome Project has been aiming at development of new glycoproteomics technologies that are applicable to the biological and medical studies. Glycoproteomics is an Omics-technology for analysis of (1) glycosylation sites, (2) glycan structures, and (3) peptide sequences of intact glycopeptides. This workshop introduces the latest glycoproteomics technologies with six leading researchers who would provide us the recent updates on MS-based glycoproteomics approach, lectin array-based glycan profiling and its application, and perspective on rapidly advancing glycan-related databases. Although there still remain technical difficulties toward the "perfect" glycoproteomics analysis of biological samples such as serum and tissue, we will discuss the possibility of our current technologies for application in the biological and medical areas.

- 07:30 HPP10.01: Isomer Specific Glycan and Glycopeptide Sequencing as Tools for Unraveling Disease Glycosylation Signatures
  - Daniel Kolarich, Max Planck Institute of Colloids and Interfaces, Germany
- 07:45 HPP10.02: Development and Application of a Method to Reveal Large-Scale Glycosylation Site-Specific Glycan Compositions

Hiroyuki Kaji, National Institute of Advanced Industrial Science & Technology, Japan

08:00 HPP10.03: Alteration in Protein Abundance, Glycoside Occupancy, and Site-Specific Glycosylation Heterogeneity

Hui Zhang, Johns Hopkins University, USA

08:15 HPP10.04: Lectin Microarray for Cell Surface Glycosylation Analysis and Biomarker Identification

Sheng-ce Tao, Shanghai Jiao Tong University, China

08:30 HPP10.05: Differential Glycome Profiling Analysis of Mouse Tissue Based on Lectin Microarray

Xia Zou, Shanghai Jiao Tong University, China

08:40 HPP10.06: From UniProtKB to UniCarbKB and Back Again

Nicolle H. Packer, Macquarie University, Australia

### TUESDAY, SEPTEMBER 29, 2015

### 07:30 - 09:00 HPP 11: Toxicoproteomics

CHAIRS: LEKHA SLENO, CANADA & OLIVER POETZ, GERMANY ROOM 11

### 07:30 HPP11.01: Welcome

Lekha Sleno, UQAM, Canada

### Part 1 - Discovery - Chair Lekha Sleno, Canada

### 07:35 HPP11.02: Reactive Drug Metabolites and Covalent Binding

Lekha Sleno, UQAM, Canada

### 07:50 HPP11.03: Virtual-Experimental 2-DE Together with ESI LC-MS/MS as a **Toxicoproteomics Platform in Study of Biomarkers**

Stanislav Naryzhny, B.P. Konstantinov Petersburg Nuclear Physics Institute, National Research Center "Kurchatov Institute", Russian Federation

### Part 2 - Mechanism and Drug-Drug Interaction

### 08:05 HPP11.04: Non-Genotoxic Carcinogens - a Functional Proteomic Study Using High-Content Western-Blotting

Markus F. Templin, NMI Natural and Medical Sciences Institute at the University of Tuebingen, Germany

### Part 3 - Safety Toxicology

### 08:20 HPP11.05: Proteomic Plasma Profiling Within Human Drug-Induced Liver Injury

Maria Mikus, SciLifeLab, KTH - Royal Institute of Technology, Sweden

### 08:35 HPP11.06: Monkey, Dog, Rat and Men - Safety Protein Biomarker Across Species

Oliver Poetz, NMI Natural and Medical Sciences Institute at the University of Tuebingen, Germany

### 08:50 **HPP11.07: Closing Remarks**

Oliver Poetz, NMI Natural and Medical Sciences Institute at the University of Tuebingen, Germany

### TUESDAY, SEPTEMBER 29, 2015

07:30 - 09:00 HPP 12: HBPP - Brain

CHAIR: HELMUT E. MEYER, GERMANY ROOM 12

The HUPO Brain Proteome Project (HBPP) is an international interdisciplinary initiative focusing the investigation of the human brain. The brain is the most complex organ of the human system. which shows various patterns of different tissue layers and cells. In order to investigate the function of the human brain the HBPP members use a broad spectrum of methods combined with a couple of functional analyses such as: mass spectrometry coupled with label free quantification studies, immunohistochemistry, immunological techniques and laser-micro dissection. The strong cooperation between scientist from different fields (affinity proteomics, bioinformatics and biostatistics, proteomics, analytical biotechnology, clinical science, neurobiology, biochemistry, neuroanatomy, neuropathology) is triggered by the aim to understand the biogenesis of neurodegenerative diseases. Special attention is given to the biogenesis of the most common form of dementia, Alzheimer's Disease (AD), Parkinson's Disease (PD), Frontotemporal Dementia (FTD) and other neurodegenerative diseases are topics of the HBPP initiative. The search for biomarkers is also an essential task of the HBPP initiative.

The 24th HUPO Brain Proteome Project (HBPP) workshop will focus on new insights in methods of biomarker research of neurodegenerative diseases. A special tribute will be given to the most important part of the human brain, the hippocampus. But also new hypothesis of the biogenesis of neurodegenerative diseases will be discussed at the 24th HBPP workshop.

The HUPO BPP is an open project - thus, anyone interested in the project shall be welcomed cordially. The latest information will always be publicly available at www.hbpp.org.

- 07:30 HPP12.01: Welcome Address
  - Helmut E. Meyer, Leibniz-Institut für Analytische Wissenschaften ISAS e.V., Germany
- 07:35 HPP12.02: What Are the Triggers of Alzheimer's Disease? Helmut E. Mever, Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V., Germany
- HPP12.03: Platelet Extracellular Vesicles (PL-EVs) Are Carriers of Proteins Involved in 07:47 Vascular- and Neurodegenerative Diseases
  - Gerd Schmitz, Institute for Clinical Chemistry and Laboratory Medicine, Germany
- 07:59 HPP12.04: Proteome-wide Characterization of Signalling Interactions in the Hippocampal Ca4/dg Subfield of Patients with Alzheimer's Disease
  - Young Mok Park, Institute for Basic Science (IBS), Korea
- 08:11 HPP12.05: Human Protein Atlas Enabled Neuroproteomic Profiling of Body Fluids Anna Häggmark, SciLifeLab, KTH - Royal Institute of Technology, Sweden
- 08:23 HPP12.06: H2S Role in Amyotrophic Lateral Sclerosis: Unravelling New Cellular and Molecular Mechanisms
  - Andrea Urbani, Santa Lucia Foundation, Italy
- 08:35 HPP12.07: Chitinase 3-Like Proteins as Candidate Cerebrospinal Fluid Biomarkers for **Multiple Sclerosis** 
  - Philippe Marin, Institut de Génomique Fonctionnelle, France
- 08:47 HPP12.08: The Past, the Present and the Future of HBPP

Katrin Marcus, KTH - Royal Institute of Technology, Sweden Peter Nilsson, KTH - Royal Institute of Technology, Sweden Daniel Martins-De-Souza, University Campinas, Brazil

### TUESDAY, SEPTEMBER 29, 2015

07:30 - 09:00 HPP 13: PediOme - Paediatrics and Proteomics: Back to the Beginning

CHAIRS: ALLEN EVERETT, USA & HANNO STEEN, USA **ROOM 19** 

In this session recent advances in pediatric proteomics will be presented and discussed. The presentations will highlight the use of a wide range of proteomics technologies in different clinically relevant settings pertaining to pediatric patient population. Examples will include the application of a wide range of technologies including iTRAQ, SILAC, label free quantification, data independent acquisition methods, SomaScan and ELISA to identify and verify biomarkers for a wide range of pediatric diseases: i) diagnostic urinary biomarkers for different causes of abdominal pain, ii) prognostic serum biomarkers to prognosticate onset and/or activity of Type 1 Diabetes (T1D) before the appearance of T1D associated autoantibodies, and iii) predictive serum biomarkers to predict disease progression and response to therapies Duchene muscular dystrophy patients. A part of the session will be devoted to a discussion led by the session chairs about the progress of the PediOme to date, as well as the specific plan for future progress of this important initiative.

07:30 HPP13.01: Introduction to the PediOme

Allen Everett, Johns Hopkins, USA

07:40 HPP13.02: Proteomics Starts with a Pee - Urine Proteomics for the Discovery of **Biomarkers for Pediatric Diseases** 

Hanno Steen, Boston Children's Hospital, USA

HPP13.03: Serum Proteomes Distinguish Children Developing Type-1 Diabetes 08:00 Dave Goodlett, University of Maryland Baltimore, USA

08:20 HPP13.04: Development and Implementation of Biomarkers in Duchenne Muscular Dystrophy

Yetrib Hathout, Children's National Medical Center, USA

08:40 HPP13.05: Discussion

13:15 - 14:15 HPP 14: C-HPP PIC Meeting

> CHAIR: YOUNG-KI PAIK, KOREA ROOM 12

13:15 HPP14.01: C-HPP PIC Meeting

Young-Ki Paik, Yonsei University, Korea, Republic of

### WEDNESDAY, SEPTEMBER 30, 2015

### 07:30 - 09:00 HPP 15: mtHPP (mitochondria)

CHAIR: MAURO FASANO, ITALY ROOM 1

In this session the speakers will focus on the update of the mitochondrial HPP project, an initiative started as an activity of the Italian Proteome Association and subsequently extended to involve collaborators from other countries. After a broad summary of previous activities, four talks will span from interactomics to metabolism, from methodology to spatial proteomics. Sufficient time is allotted for general discussion at the end of the session.

07:30	HPP15.01: Introduction and Resume
07:40	HPP15.02: Mitochondrial Networks and Their Association with Neurodegenerative Disorders
	Mohan Babu, University of Regina, Canada
07:53	HPP15.03: The Mitochondrial Proteome as Observed in the Human Protein Atlas
	Emma Lundberg, Science for Life Laboratory, KTH - Royal Institute of Technology, Sweden
08:06	HPP15.04: Mitochondrial Proteomic Analysis of Triple-Negative Breast Cancer Cells
	Italia Bongarzone, Fondazione IRCCS Istituto Nazionale Tumori, Italy
08:19	HPP15.05: High Density Coverage of Mitochondrial Proteome: A Progress Update
	Maurizio Ronci, University of Chieti-Pescara, Italy
08:28	HPP15.06: The Multi-Mode Acquisition Analysis of Mitochondrial Proteins.
	Hans Vissers, Waters Corporation, UK
08:36	HPP15.07: Discussion and Perspectives

### WEDNESDAY, SEPTEMBER 30, 2015

07:30 - 09:00 HPP 16: Human Liver Proteome Initiative

CHAIRS: FERNANDO CORRALES, SPAIN & PUMIN ZHANG, USA **ROOM 2+3** 

### Topics for discussion:

- Configuration of protein priority lists in regard of liver physiology and disease (NAFLD. liver fibrosis. HCC).
- Proteogenomics in the liver (interactions with TCGA and CPTAC).
- Meetings

The liver is a central organ in human body that controls metabolic homeostasis, provide essential substances to the organism and allow detoxification of xenobiotics. In addition to its biological function, liver physiology is peculiar in different aspects, including its regeneration capacity. Despite the intense research performed during the last couple of decades, there are still many open questions in regard of the molecular mechanisms underlying liver function and, most importantly, liver disease. This constraint largely restricts the development of more efficient diagnostic and therapeutic strategies for the better management of the patients. In the postgenomic era, the Human Liver Initiative started in 2002 aiming to define a comprehensive and dynamic map of the human liver proteome. During this session latest results about key issues in liver biology will be presented and discussed, including methods to define cell specific proteome profiles within the liver. definition of factors responsible for maintaining the differentiated phenotype of hepatocytes and mechanisms by which regulation of the protein methylation pattern might contribute to liver injury.

07:30	HPP16.01: Liver Proteome with A Cellular Resolution
	Chen Ding, Beijing Proteome Research Center, China
07:45	HPP16.02: Maintenance of Hepatocyte Identity

Pumin Zhang, Baylor College of Medicine, USA

HPP16.03: Methylthioadenosine Phosphorylase as Regulator of the 08:00 Methylproteome in Liver Cells

Fernando Corrales, Cancer Research Center, Spain

08:15 HPP16.04: Presentation - Title TBC Pengyuan Yang, Fudan University, China

08:30 HPP16.05: General Discussion

### WEDNESDAY, SEPTEMBER 30, 2015

07:30 - 09:00 HPP 17: iMOP (Multi Organism Proteomes)

> CHAIR: EMOKE BENDIXEN, DENMARK **ROOM 8+15**

iMOP, the initiative on multi organism proteomes, aims to present proteome research from nonhuman species. iMOP members are working with classical animal models to study human diseases but also focus on a wide range of species which greatly affect human health, including farm animals and crop species, pathogens, as well as the microbiome of humans and farm animals. This year's workshop will include presentations on animal models for studying inflammatory bowel disease (Allan Stensballe) and protegenomic approaches to improving the health state of honeybees (Leonard Foster), HipA-mediated mechanisms in E.coli (Maia Semaniscki), and studies of mucosal microbiota from rat colon, (Nico Jehmlich). As always, we will include a plenum discussion on how the iMOP community can improve proteome research in non-human species.

- 07:30 HPP17.01: Animal Models for Inflammatory Bowel Diseases Allan Stensballe, Aalborg University, Denmark
- 07:50 HPP17.02: Protegenomics and Selection of Health Traits in Honeybees Leonard J. Foster, University of British Columbia, Canada
- 08:10 HPP17.03: Proteomic Characterization of HipA-Mediated Mechanisms of Bacterial Persistence in E.coli

Maja Semanjski, University of Tuebingen, Germany

08:25 HPP17.04: Revealing the Response of the Active Mucosal Microbiota from the Rat Colon to a Change in Diet

Nico Jehmlich, Helmholtz-Centre for Environmental Research, Germany

08:40 HPP17.05: Plenum Discussion of iMOP Work and Progress

### WEDNESDAY, SEPTEMBER 30, 2015

07:30 - 08:15 HPP 18a: Human Proteomics at Extreme Conditions

CHAIRS: EVGENY NIKOLAEV, RUSSIAN FEDERATION & IRINA LARINA, RUSSIAN FEDERATION ROOM 11

This will be the second session of the Extreme Conditions initiative. This year discussion of research in molecular bases of physiology of sport of high achievements will be included into the program.

### 07:30 HPP18a.01: The New Approaches to the Quantitative Analysis of a Long Flight Influence on the Blood Proteome

Eugene N. Nikolaev. The Institute of Energy Problems of Chemical Physics RAS. Russian Federation

### 07:35 HPP18a.02: Mass-Spectrometry Based Blood Serum Peptidome Analysis of Athletes under Physical Overstrain

Georgii Arapidi. Shemyakin-Oychinnikov Institute of Bioorganic Chemistry, RAS, Russian Federation

### 07:40 HPP18a.03: Analysis of Protein and Biological Processes Dynamics Based on Urine of Healthy Volunteers Exposed 105-day Isolation

Irina Larina, IMBP RAS, Russian Federation

### 07:45 HPP18a.04: Permanent Proteins in the Urine of Healthy Humans During the Mars-500 **Experiment**

Liudmila Pastushkova, IMBP RAS, Russian Federation

### 07:50 HPP18a.05: Proteome and Metabolome Analysis of Exhaled Breath Condensate Before and After Space Flight, Proteomics Study of Human Body Adaptation During the Space-flight: Correlation Between Blood, Urine and Exhaled Breath Condensate Assays

Igor Popov, Emanuel Institute of Biochemical Physics RAS, Moscow Institute of Physics and Technology, Russian Federation

### 07:55 HPP18a.06: Sportomics: Building a New Concept in Metabolic Studies and Exercise Science

L. C. Cameron, Adriana Bassini, Laboratory of Protein Biochemistry - Center of Innovation in Mass Spectrometry - Federal University of State of Rio de Janeiro, Department of Biochemistry and Sportomics - Olympic Laboratory, Olympic Committee - Brazil

### 08:00 HPP18a.07: Monitoring of Physiological Changes Occurring as a Result of Impact of Ervthropoietin

Marina G. Rodchenkova, Emanuel Institute for Biochemical Physics, Russian Academy of Sciences, Moscow, Russia, Russian Federation

### 08:05 HPP18a.08: Development of The New Approaches To Proteome Analyses of Physiologically Diluted Urine, HYPERLINK

Andrew Percy, University of Victoria Genome British Columbia Proteomics Centre, Canada

### 08:10 HPP18a.09: Variation of Urine Proteome During MARS 500 Program

Bruno Domon, Luxembourg Clinical Proteomics Center, Luxembourg

### WEDNESDAY, SEPTEMBER 30, 2015

08:15 - 09:00 HPP 18b: Skeletal Muscle Proteome

CHAIRS: LUIGI FERRUCCI, USA & KURT HOJLUND, DENMARK ROOM 11

Maintenance of the contractile function and energy metabolism of skeletal muscle is essential for autonomy and quality of life in humans. Though, the health and function of muscle is threatened in many situations. Muscle dystrophy in its many forms is the main genetic diseases affecting children and young adults. A progressive decline in muscle mass and strength as well as changes in energy metabolism and mitochondria in muscle are a hallmarks of aging that may cause physical disability. A rapid decline in muscle mass, often referred as cachexia, accompanies debilitating diseases, such as chronic infections, cancer, kidney failure and heart failure. Common chronic diseases, such as diabetes, autoimmune diseases and osteoarthritis often accelerate the age-associated decline in muscle mass and contribute to disability. The specific mechanisms that lead to impaired muscle function in these conditions have been poorly characterized but probably include functional anomalies in energetic metabolism. Etiological diagnoses are based on medical history and physical examination complemented by genetic studies and histological examination of biopsies. which are laborious and have limited sensitivity and specificity. A comprehensive proteomic analysis of skeletal muscle biopsies may increase our understanding of the mechanisms leading to different clinical forms of muscle pathology and also improve diagnosis. Likely specific skeletal muscle proteins undergo specific changes in abundance and/or post translational modifications (PTMs) such as e.g. phosphorylation and acetylation in aging, type 2 diabetes and different other pathologies and the stochiometric relationships between different proteins and their PTMs change as well. A number of studies have reported maps of skeletal muscle proteins humans, using a number of different discovery-mode and targeted proteomic technologies, usually in small sample on unselected individuals or patients with selected diseases. An assemblage of the data from these studies suggests that as many as 7000 proteins can be detected in muscle tissues. However, an analysis of changes in muscle proteins with aging in individuals free of major diseases and drug treatments is currently not available. These data could serve as a critical reference to dissect changes in proteins that occur with disease as opposed to "normal" aging, therefore increasing their contribution in our understanding of musculoskeletal diseases and expanding their diagnostic value.

In this session, we will provide both an introductory overview of the potential values and uses of skeletal muscle proteomics in aging, type 2 diabetes and other diseases. We present the design and preliminary data from the Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT) a study performed by the Intramural Program of the National Institute on Aging in Baltimore whose aims include the characterization of muscle proteins with aging in a group of very healthy men and women dispersed over a wide age range (20-100 years). Finally, we present studies of the proteomes and phosphoproteomes of human skeletal muscle and isolated muscle mitochondria, as well as quantitative studies of changes in the muscle proteome associated with obesity and type 2 diabetes.

Both the introductory remarks and the examples reported should stimulate a wider interest in proteomic characterization of muscle in humans and, hopefully, will encourage more collaborative research between international groups of this important research topic.

### 08:15 HPP18b.01: Mapping the Skeletal Muscle Proteome: A Functional Approach

Kurt Hoilund, University of Southern Denmark, Denmark Luigi Ferrucci, National Institute on Aging (NIA), USA

### WEDNESDAY, SEPTEMBER 30, 2015

07:30 - 09:00 HPP 19: Infectious Diseases (HID)-BD-HPP

CHAIRS: CONCHA GIL, SPAIN & ILEANA M, CRISTEA, USA ROOM 12

The HID-BD-HPP initiative was established last year at the HUPO-2014 in Madrid. The main goal of this initiative is to organize a community of scientists working in Infectious disease proteomics. Infectious diseases are caused by pathogenic microorganisms, such as bacteria, viruses, parasites or fungi. These infectious are a leading cause of illness and death throughout the world, in particular in low income countries. Lower respiratory infections, HIV/AIDS and diarrheal diseases are ranked in the top ten causes of death globally, whereas malaria and tuberculosis are two of the major ten causes of death in low income countries. In developed countries infectious diseases are also important in immunosuppressed patients and transplant recipients. New diagnostic tests, therapeutic agents and vaccines are required to control these infectious diseases. International collaboration of scientists working in Infectious diseases and proteomics is essential to promote these researches.

### 07:30 HPP19.01: Introduction

Ileana Cristea, Princeton University, USA

### 07:40 HPP19.02: The Current State Of-Art of Proteomics Investigations on Infectious Diseases (Viruses, Bacteria, Fungi and Parasites)

Sanjeeva Srivastava, IIT Bombay, India

Joshua LaBaer, The Biodesign Institute at Arizona State University, USA

Frank Schmidt, University Medicine Greifswald, Germany

Concha Gil, Universidad Complutense de Madrid, Spain

### 08:30 HPP19.03: Round Table

Manuel Fuentes, Cancer Research Center, Spain Catherine Costello, Boston University School of Medicine, USA

### Topics for discussion:

- How can the scientists working in Infectious disease proteomics collaborate?
- Development of SRM methods for detection and quantification of human and microbial proteins
- Detection and quantification of these proteins by affinity or antibodies based technologies
- Building of a web page to freely-access data
- Diffusion of HID-HPP activities (reports, special issues...)
- Organization and future actions.

### WEDNESDAY, SEPTEMBER 30, 2015

07:30 - 09:00 HPP 20: Proteomics of Protein Misfolding and Aggregation Diseases

CHAIRS: MELINDA REZELI, SWEDEN & PAOLA PICOTTI, SWITZERLAND ROOM 19

Protein misfolding and aggregation diseases (PMAD), exemplified by Parkinson's or Alzheimer's disease and systemic amyloidoses, are characterized by an abnormal deposition of protein aggregates of regular three-dimensional structure (amyloid). The B/D PMAD working group aims at developing proteomics assays for proteins that are relevant to the study, diagnosis and therapy of protein aggregation diseases. These assays are tested and refined on a set of relevant patient samples (for clinical applications) and on samples from model organisms and cell culture (for basic research). Besides developing assays for measuring protein abundances, a peculiarity of our initiative is that it will attempt also the development of proteomics assays for "aberrant protein conformations", those typically generated in PMADs. In this workshop of the PMAD working group we will present the current status of the project, summarize the assays for PMAD targets developed and validated so far and discuss future directions.

HPP20.02: Alpha-Synuclein Proteoforms in Parkinson's Disease
Melinda Rezeli, Lund University, Sweden
HPP20.03: : Probing the Mechanism of Aggresome Formation in Parkinson Disease
Catherine E. Costello, Boston University School of Medicine, USA
HPP20.04: Probing the Conformational Changes of Amyloidogenic Proteins in Biological Samples
Yuehan Feng, ETH Zurich, Switzerland
HPP20.05: Targeted Proteomics to Study Neuronal Physiology
Hanno Langen, F. Hoffmann-La Roche Ltd, Switzerland
HPP20.06: Narrow Range pl Plasma Protein Abundances as Alzheimer Disease Biomarker

Mohammad Pirmoradian, Karolinska Institute, Sweden

08:40 Wrap Up

07:30

HPP20.01: Introduction

### THURSDAY, OCTOBER 1, 2015

### 08:30 - 17:45 Post-Congress HPP Workshop Day

CHAIR: GIL OMENN, USA

SFU HARBOUR CENTRE, JOSEPH AND ROSALIE SEAGAL CENTRE, 515 WEST HASTINGS ST.

**REGISTRATION FEE: 50 CAD** 

**★** X

LIGHT REFRESHMENTS AND LUNCH WILL BE INCLUDED

08:30 Highlights from Sunday-Wed from HPP
(Selected Workshop Presentations from C-HPP and B/D-HPP, 4min each)

### 09:30 Strategies for Identifying the neXtProt and HPP "Missing Proteins"

 Lessons from Multiple HPP Groups and JPR Manuscripts and Monday Bioinformatics Workshop

Eric Deutsch, Institute for Systems Biology, USA

Validation of Claims of Detecting Missing & Novel Proteins and Isoforms

Alexey Nesvizhskii, University of Michigan-Ann Arbor, USA

Searching for and Credibly Identifying or Proteins

Eric Deutsch, Institute for Systems Biology, USA

Bonghee Lee, Gachon University, Korea

Michael L. Tress, Spanish National Cancer Research Centre (CNIO), Spain

· More Stringent Guidelines Established by Peptide Atlas & neXtProt

Lydie Lane, Swiss Institute of Bioinformatics, Switzerland

 Realizing That Some Predicted Proteins Will Not Be Detectable by Mass Spectrometry, Should We Adjust the Denominator?

Fernando Corrales, Cancer Research Center, Spain, Ulrike Kusebauch, Institute for Systems Biology, USA

11:15 SRM/SWATH-MS: How to Assist HPP Investigators and the Broad Community to Utilize These Advances from the B/D-HPP? How to Improve the Workflows, Especially for Low-Abundance Proteins and Complex Tissues?

Robert L. Moritz, Institute for Systems Biology, USA, Jennifer van Eyk, Cedars Sinai Medical Center, USA, Christoph Borchers, University of Victoria, Canada

12:00	Lunch
13:00	HPP Deliverables for 2016: C-HPP
14:00	HPP Deliverables for 2016: B/D-HPP
15:00	HPP Deliverables for 2016: Anitobody Pillar
15:20	HPP Deliverables for 2016: MS Pillar
15:40	Summary and Discussion of Goals and Deliverables for 2016-2017
16:30	Reception

# SECTION 8 INDUSTRY SESSIONS

### AT A GLANCE

MONDAY, SEPTEMBER 28 13:15-14:15 TUESDAY, SEPTEMBER 29 13:15-14:15

### Room 1

### Thermo Scientific

From Markers to Assays: Accelerating Translational Proteomics

### **Thermo Scientific**

Pushing the Boundaries of Comprehensive Proteome Profiling

### **Room 2+3**

### **Bruker Daltonics**

New Solutions in LC/MS Based Proteomics

### Wako Laboratory Chemicals

A Versatile Protein Tagging System for Recombinant Protein Production, Isolation, and Detection in Mammalian Cells

### Room 8+15

### **Waters Corporation**

Improving Multi-omic Workflows for the Discovery and Development of Novel Biomarkers

### **SCIEX**

Testimonials in OneOmics™: Next Generation Proteomics at Work

### Room 11

### **Agilent Technologies**

Multi-omic Analysis for Integrated Biology

**MONDAY, SEPTEMBER 28** 

Monday, September 28 | 13:15-14:15

LUNCH WILL BE PROVIDED FOR ALL SESSIONS

Space is limited for Industry Sessions.

To register and for further information please visit: hupo2015.com/program/industry-seminars/

### Room 1 Thermo Scientific From Markers to Assays: Accelerating Translational **Proteomics**

- An Integrated Molecular View of Triple Negative Breast Cancer SPEAKER: JUDIT VILLEN, PH.D., UNIVERSITY OF WASHINGTON GENOME **SCIENCES**
- Advances in Parallel Reaction Monitoring: Quantifying Protein Pathways SPEAKER: BRUNO DOMON, PH.D., LUXEMBOURG CLINICAL PROTEOMICS CENTER

### Room 2+3 **Bruker Daltonics** New solutions in LC/MS based proteomics

- Novel and Robust nanoLC/UHR Q-TOF MS Workflow Solution for Deep Proteome Characterization SPEAKER: DR. OLE VORM, BRUKER DALTONICS, ODENSE
- Where Genomics Can't Go: Practical Applications of Proteomics in Agriculture and Medicine SPEAKER: DR. LEONARD FOSTER, DIRECTOR, CENTRE FOR HIGH THROUGHPUT BIOLOGY, UBC
- Quantitative Protein Degradomics: TAILS Strategies to **Identify Missing Proteins** SPEAKER: DR. CHRIS OVERALL, CENTRE FOR BLOOD RESEARCH, UBC

### **MONDAY, SEPTEMBER 28**

# Room 8+15 Waters Corporation Improving Multi-omic Workflows for the Discovery and Development of Novel Biomarkers

- Quantitative Multi-Omic Solutions for Translational Research SPEAKER: DAVID HEYWOOD, SENIOR MANAGER, OMICS BUSINESS DEVELOPMENT, WATERS CORPORATION
- Pushing the Limits for Targeted Mass Spectrometry SPEAKER: PROFESSOR HASMIK KESHISHIAN, BROAD INSTITUTE OF MIT AND HARVARD

# Room 11 Agilent Technologies Multi-omic analysis for Integrated Biology

- Mass Spectrometry Based Metabolomics the Nuts and Bolts SPEAKER: UTE ROESSNER, PH.D. – METABOLOMICS AUSTRALIA, SCHOOL OF BIOSCIENCES, THE UNIVERSITY OF MELBOURNE
- Enhancing Statistical and Pathway Analysis of Protein Discovery Results with Peptide-level Information SPEAKER: CHRISTINE MILLER, AGILENT TECHNOLOGIES

### **TUESDAY, SEPTEMBER 29**

### Tuesday, September 29 | 13:15-14:15

LUNCH WILL BE PROVIDED FOR ALL SESSIONS

Space is limited for Industry Sessions.

To register and for further information please visit: hupo2015.com/program/industry-seminars/

### Room 1 Thermo Scientific **Pushing the Boundaries of Comprehensive Proteome Profiling**

- How to Boost your nanoLC-MS Performance and Throughput in Proteomics
  - SPEAKER: PAUL TAYLOR, THE HOSPITAL FOR SICK CHILDREN
- Pushing the Boundaries of Proteomics through Accurate Multiplexed Quantification

SPEAKER: WILHELM HAAS, PH.D., MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER AND HARVARD MEDICAL SCHOOL

### Room 2+3 **Wako Laboratory Chemicals** A Versatile Protein Tagging System for Recombinant Protein **Production, Isolation, and Detection in Mammalian Cells**

SPEAKERS:

DR. JUNICHI TAKAGI. PROFESSOR, LABORATORY OF PROTEIN SYNTHESIS AND EXPRESSION, INSTITUTE FOR PROTEIN RESEARCH, OSAKA UNIVERSITY

MR. TAKU FUNAKOSHI, GENE TECHNOLOGY UNIT LEADER, NEW PRODUCTS DEVELOPMENT DEPARTMENT, WAKO PURE CHEMICAL INDUSTRIES

**TUESDAY, SEPTEMBER 29** 

### Room 8+15 SCIEX

Testimonials in OneOmics™: Next-Generation Proteomics at Work

- Prostate Cancer Companion Biomarker Discovery Using SWATH® Acquisition 2.0 and OneOmics™
   SPEAKER: HUGO GAGNON, PH.D., CHIEF OPERATING OFFICER, PHENOSWITCH BIOSCIENCE
- Combining Next Generation Proteomics and NGS through OneOmics™ to Gain New Insights Into Human Spermatogenesis SPEAKER: CHARLES PINEAU, PH.D., DIRECTOR OF THE PROTEOMICS CORE FACILITY BIOGENOUEST



# The Chromosome-Centric Human Proteome Project

### **GUEST EDITORS**

Young-Ki Paik Yonsei University

Gilbert S. Omenn University of Michigan

### **CO-EDITORS**

Chris Overall University of British Columbia

William S. Hancock Northeastern University

tinyurl.com/JPRChromosomelssue



# SECTION 9 POSTERS

### **POSTERS**

### POSTERS WILL BE DISPLAYED FOR THE ENTIRE DURATION OF THE CONGRESS

### **Poster Setup Time:**

Sunday, September 27 19:30 - 21:00 during Welcome Reception

Monday, September 28 07:30 - 10:00

### **Poster Take Down:**

Wednesday, September 30 By 16:30

POSTERS NOT TAKEN DOWN BY 17:00 ON WEDNESDAY WILL BE DISCARDED BY MANAGEMENT

### **Presenting Author Stand By Time**

Time in which Poster Presenters remains at his/her poster board and is available to discuss their research personally with interested delegates.

### **ENDING ON ODD POSTER NUMBER**

Monday, September 28 10:00-11:10 and 16:20-17:30 (Networking Breaks)

### ENDING ON EVEN POSTER NUMBERS

Tuesday, September 29 10:00-11:10 and 16:20-17:30 (Networking Breaks)

All Oral and Mini Oral Abstract Presenters have been invited to prepare a Poster in addition to their Oral/Mini Oral **Presentations. Poster presentations** for Oral and Mini Oral Presenters will be labeled with their Oral/Mini Oral Presentation number (eg CS01.01)

P01	Human Proteome Project
P02	Sample Preparation for Proteomics
P03	Regenerative Medicine and Stem Cells
P04	New Technological Advances in
	Proteomics
P05	Top Down Proteomics and
	Macromolecular Complexes
P06	Cancer Proteomics
P07	New Advances in Biomarker Discovery
P08	Proteomics at Pharma
P09	Proteomics of Microbes and Infectious
	Diseases
P10	Structural Proteomics
P11	Other
P12	Epigenetics and Histone Landscape
P13	<b>Protein Networks and Computational</b>
	Biology
P14	Membrane Proteomics
P15	Phosphoproteomics and Cell Signaling

**Neurological Disorders** P16 P17 Translational Proteomics

P18 Cardiovascualr and Haematological **Proteomics** 

P19 **Protein Modifications** (Other than Phosphoproteins)

P20 **Imaging Mass Spectrometry** P21 Glycomics in Biology and Diseases

P22 Subcellular Proteomics

P23 Personalized Medicine **Proteogenomics** 

P25 Metabolomics and Metabolic Diseases

P26 **Chemical Proteomics and Drug** Discovery

P27 **Proteomics and Cell Immunity** 

P28 Integrated OMICS

P29 Standardization in Proteomics

P24

### PO1 - HUMAN PROTEOME PROJECT

### P01.01: Virtual-Experimental 2-DE in Combination with ES LC-MS Gives a Clearer View of Proteomes

Stanislav Naryzhny, Institute of Biomedical Chemistry, Russian Federation

### P01.02: New Insights into the Evolutionary **Characteristics of Missing-Protein-Encoding** Genes

Dong Yang, Beijing Proteome Research Center, China

### P01.03: Antibodypedia - The Wiki of Antibodies Tove L. Alm, Science for Life Laboratory, KTH -

Royal Institute of Technology, Sweden

### P01.04: Most Genes Have a Single Highly **Expressed Dominant Splice Isoform**

Michael L. Tress, Spanish National Cancer Research Centre (CNIO), Spain

### P01.05: Automated Quantitative Method for Biomarker Assessment of Salivary Proteins

Andrew J. Percy, University of Victoria, Canada

### P01.06: Gene-centric Knowledgebase as a Tool for Estimating Protein Species Number

Elena A. Ponomarenko, Institute of Biomedical Chemistry, Russian Federation

### P01.07: Platelet-Derived Extracellular Vesicles -A Key to Understand Alzheimer's Disease

Fouzi El Magraoui, Leibniz Institute for Analytical Sciences (ISAS), Germany

### P01.08: Proteomics Analysis of Human Ureter for Urine Biomarker Discovery

Yoshitoshi Hirao, COI-s Biofluid Biomarker Center, Institute for Research Collaboration and Promotion, Japan

### P01.09: Proteogenomics Analysis of Novel Transcripts and Isoforms Using the Human MiTranscriptome Assembly

Fernando J. Corrales, Center for Applied Medical Research, Spain

### P01.10: Changes on the Methyl Proteome Triggered by a Deficiency on MTAP in Liver Cells

Fernando J. Corrales, Center for Applied Medical Research, Spain

### P01.11: New features of GenomewidePDB v 2.0

Seul-Ki Jeong, Yonsei Proteome Research Center, Korea

### P01.12: SRM-Assay Database for Reproducible Protein Quantification in Different Types of **Biomaterial**

Ekaterina V. Ilgisonis, IBMC, Russian Federation

### P01.13: The First Master Proteome of Single Chromosome: Example of Human Chromosome 18

Alexander I. Archakov, Institute of Biomedical Chemistry, Russian Federation

### P01.14: The Combo-Spec Search Method Improves the Current Search Methods Used to **Identify Missing Proteins**

Jin-Young Cho, Yonsei Proteome Research Center, Korea

### P01.15: What Can Housekeeping Gene/Protein Studies Tell Us?

Bingyun Sun, Simon Fraser University, Canada

### P01.16: Chromosome-Centric Approach to **Unraveling the Human Interactome**

Ekaterina V., Poverennaya, Institute of Biomedical Chemistry, Russian Federation

### P01.17: Reference Molecular Map of Individual Monocyte Lineages of the Spanish Healthy **Population**

Fernando Corrales, ProteoRed-ISCIII, Center for Applied Medical Research (CIMA), Spain

### P01.18: Comprehensive Proteome Analysis of OCT Embedded Frozen Human Renal Cortex by LC-MS/MS

Bo Xu, Niigata University, Japan

### P01.19: Human Proteome Project in Cancer Hui Zhang, Johns Hopkins University, USA

### P01.20: Quantitative Nuclear Proteomics of Schizophrenia

Gilberto B. Domont, Federal University of Rio de Janeiro, Brazil

### P01.21: Integration of -Omics Datasets for Comprehensive Protein Expression Profiling for the C-HPP

Manuel Fuentes, Cancer Research Center, Spain

### P01.22: Chromosome-Based Proteomic Study for Identifying Novel Protein Variants from **Human Hippocampus**

Heeyoun Hwang, Korea Basic Science Institute, Korea

### P01.23: Mass-Spectrometry Based Blood Serum Peptidome Analysis of Athletes under Physical Overstrain

Georgij Arapidi, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS, Russian Federation

### P01.24: Proteomics of Ocular Diseases

Jeya Maheshwari Jayapal, Aravind Medical Research Foundation, India

### P01.25: Alternatively Spliced Homologous Exons Are Highly Enriched at the Protein Level

Michael L. Tress, Spanish National Cancer Research Centre (CNIO), Spain

# P01.26: Bioinformatic Approach for Analyzing Missing Proteins in neXtprot Database

Amr Elguoshy, Niigata University, Japan

### PO1.27: MI-PVT: Michigan Proteome Visualization Tool

Bharat Panwar, University of Michigan, USA

### PO2 - SAMPLE PREPARTION FOR PROTEOMICS

### PO2.01: Evaluation of a 96-well Immunodepletion Platform for Multiplex MRM Assay of Proteins in Human Plasma

Gordon Nicol, Sigma Aldrich, USA

# P02.02: Sample Preparation for Low Amount Cumulus Samples

Claudia Fortes, Functional Genomics Center Zurich, Switzerland

# P02.03: Phosphopeptide Enrichment Strategies for Mass Spectrometry Analysis

Jae Choi, Thermo Fisher Scientific, USA

# P02.04: STAGE-Diging: A Novel In-Gel Digestion Processing for Proteomic Samples

Paolo Soffientini, IFOM, the FIRC Institute of Molecular Oncology, Italy

### P02.05: The SingleShot Workflow: Parallel Analysis of Changes in Gene and Protein Expression

Anton Posch, Bio-Rad Laboratories, Germany

### PO2.06: An Efficient Platform for Basic Reversed-Phase Off-Line Fractionation Enables Deep Proteome Coverage

Dorte B. Bekker-Jensen, Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Denmark

# PO2.07: A High-Performance, Scalable and Universal Phosphoproteomics Platform

Sean J. Humphrey, Max Planck Institute for Biochemistry, Germany

# P02.08: A Novel Approach for Fabricating Functionalized Plate for Sample Enrichment and MS Analysis

Chao-Jung Chen, China Medical University, Taiwan

### PO2.09: Comparison of Protein Extraction Efficiencies of Dried Blood Spots and Dried Plasma Spots

Dieter Stoll, University of Applied Sciences Albstadt-Sigmaringen, Germany

# PO2.10: Strong Cation Exchange Separation of Peptides Using a Spin Column Format (ProTrap XG)

Kirsten M. Jones, Dalhousie University, Canada

### PO2.11: Quantitative Peptide Assay for Optimized and Reproducible Sample Preparations

Paul Fayad, Thermo Fisher Scientific, Canada

### PO2.12: A Systematic Investigation Reveals an Unexpected Side Modification Caused by Lysine Guanidination

Xumin Zhang, Fudan University, China

### PO2.13: High pH Reversed-Phase Peptide Fractionation in a Convenient Spin-Column Format

Sergei Snovida, Thermo Fisher Scientific, USA

### PO2.14: Methodology Development for Quantification of Tightly Adsorbed Proteins

Ameya V. Ranade, Simon Fraser university, Canada

# PO2.15: Automated Protein Digestion to Reduce the Sample Preparation Bottleneck

Christie Hunter, SCIEX, USA

# PO2.16: Protein Fractionation Using a Dissolvable Acrylamide Gel and Its Application to Top-Down Proteomics

Nobuaki Takemori, Ehime University, Japan

# PO2.17: Low Cost Semi-Automated In-Gel Tryptic Digest for High-Throughput Proteomics Michelle M. Hill. The University of Queensland

Michelle M. Hill, The University of Queensland, Australia

### P02.18: Trypsin Coated Polymer Nanofibers and Its Application to Protein Digestion under the **Pressure Cycle**

Han Sol Kim, Korea University, Korea

### P02.19: Improved Speed & Reproducibility of Protein Digestion Using Novel Sample **Preparation Technology**

Kevin Doolan, Thermo Fisher Scientific, UK

### PO3 - REGENERATIVE MEDICINE AND STEM CELLS

### P03.01: Proteomic Analysis of Infantile Haemangioma

Jonathan Dunne, Gillies McIndoe Research Institute, New Zealand

### P03.02: Candidate Surface Biomarkers of Transformed Mesenchymal Stem Cells by Quantitative (Glyco)Proteomics

Julian Saba, Thermo Fisher Scientific, USA

### PO4 - NEW TECHNOLOGICAL ADVANCES IN PROTEOMICS

### PO4.01: HiRIEF LC/MRM-MS: Toward Increased Coverage of the Human Plasma Proteome Vincent R. Richard, McGill University, Canada

### P04.02: Accuracy and Sensitivity of Proteome Quantitation Using TMT - An Evaluation of **Recent Developments**

Anna Chen, Mission San Jose High School, USA

### PO4.03: TMT 10-Plex Quantitation by Travelling Wave IMS-QTof Mass Spectrometry

Roy Martin, Waters Corp, UK

### PO4.04: ELISA-PLA: A Sensitive and Specific **Protein Post Translational Modification Detection Method**

Qing He Tong, Fudan University, China

### PO4.05: Extending the Quantitative Information of the Glioblastoma Proteome Using SuperQuant

Frank Kjeldsen, University of Southern Denmark, Denmark

### P04.06: Improved Peptide Identification Using Variable Window SWATH Acquisition, UPLC and **DIA-Umpire**

Brett Larsen, Mount Sinai Hospital, Canada

### PO4.07: Behavioral and Proteomic Analysis of Stress Response in Zebrafish(Danio rerio)

Sameh Magdeldin, Niigata University, Japan

### P04.08: Protein Post-Translational Modifications of Mouse Kidney Using OFFGel Prefractionation

Sameh Magdeldin, Niigata University, Japan

### P04.09: Development of LC-Electrochemistry-MS for Disulfide Mapping: Application to Notch3 **Protein Fragments**

Linda Switzar, Leiden University Medical Center, Netherlands

### PO4.10: Targeted Tissue-Enriched Proteomics in **Kidney Tissue**

Masato Habuka, Institute of Nephrology, Medical and Dental School, Niigata University, Japan

### PO4.11: Molecular Dissection of a Proteome

Rebecca A.T. Pattison, Centre for Proteome Research, Institute of Integrative Biology, UK

### PO4.12: The Thermal Stability of the Human Proteome

Bernhard Kuster, Technische Universität München, Germany

### P04.13: Zeptomole Detection of Serum **Biomarkers Using Surface Plasmon Resonance** Imaging (SPRi)

Marinella G. Sandros, University of North Carolina at Greensboro, USA

### P04.14: High-Density Protein Microarrays for Antibody Validation and Autoimmunity Profiling

Ronald Sjöberg, KTH - Royal Institute of Technology, Sweden

### P04.15: Electrochemical Detection of Ovarian Cancer Biomarker HE4 Based on µQLISA Principle

Zuzana Bilkova, University of Pardubice, Czech Republic

### P04.16: Systematic Exploration of Subcellular Redox Status by Methionine-Containing Peptide Enrichment

Ya-Ju Hsieh, Chang Gung University, Taiwan

### PO4.17: Sensitive Approach to Identify HLA-DR Peptides Facilitating Individual Patient Characterization

Tina Heyder, Karolinska Institutet/University Hospital, Sweden

### PO4.18: Click-MS: Tagless Protein Enrichment Using Bioorthogonal Chemistry for Quantitative Proteomics

Annika Borrmann, Radboud University, Netherlands

### PO4.19: Why to Use Ultra-High Resolution Quadrupole Time of Flight Instruments for Proteomics Applications?

Stephanie Kaspar, Bruker Daltonik GmbH, Germany

### PO4.20: Towards a "Load and Play" Solution for Parallel Reaction Monitoring Assays

Bruno Domon, L.I.H., Luxembourg

### PO4.21: Human Proteome Array Revealed That hnRNP K Binds and Affects the Accumulation of Mature miR-122

Chien-Sheng Chen, National Central University, Taiwan

### PO4.22: A New Approach for Better Identification of Cellular Peptide Using Tandem Mass Spectrometry

Yet-Ran Chen, Academia Sinica, Taiwan

### PO4.23: mzDB: A File Format Optimized for the Efficient Analysis of Large LC-MS/MS and SWATH-MS Datasets

David Bouyssié, CNRS; IPBS (Institut de Pharmacologie et de Biologie Structurale), France

# PO4.24: A Comprehensive Database and Search Method for Large-Scale Metaproteomics

Sandip Chatterjee, The Scripps Research Institute, USA

### PO4.25: SWATH-ID: An Instrument Method Which Combines Identification and Quantification in a Single Analysis

Stephen A. Tate, Sciex, Canada

### PO4.26: An Alternative Mass Spectrometry View of the Proteome

LeRoy B. Martin, Waters Corporation, USA

### PO4.27: Immunoaffinity-MS Platform for Antibody Screening and Native Protein Analysis in Biological Fluids

Dimitrios Korbakis, University of Toronto, Canada

### PO4.28: Increased MS Protein Identification Rates Using 75 cm Long Nano LC C18 Separation Columns

Stephan Meding, Thermo Fisher Scientific, Germany

### PO4.29: A Novel MS1-Based Strategy for Accurate Proteomic Quantitation with Extremely Low Missing Value

Jun Qu, University at Buffalo, CBLS, USA

### PO4.30: Deep, Single Shot Human Cell Line Protein Profiling Using DIA and Spectronaut on a Q Exactive HF

Oliver Rinner, Biognosys AG, Switzerland

## P04.31: A Robust SRM Assay for UMOD and Albumin in Urine

Qin Fu, Cedar Sinai Medical Center, USA

### PO4.32: Data Aquisition and Processing to Apply Inter-Peak Isotope Spacing for Turnover Analysis

John C. Price, Brigham Young University, USA

### PO4.33: Ultrafast, High Sensitive microLC/MS/ MS for Peptide Quantitation in Highly Targeted Assays

Remco Van Soest, SCIEX, USA

# PO4.34: Compression and Rapid Visualisation of Quantitative LC-MS Data Based on Raw Signal Decomposition

Andrew W. Dowsey, University of Liverpool, UK

# PO4.35: A High-Efficient Yeast BiFC Approach for Genome-Wide Interactome Mapping

Jian Wang, Beijing Institute of Radiation Medicine, China

### PO4.36: A Comparison of Three-Dimensional Strategies in Mining the Human Plasma Proteome

Yan Zhao, State Key Laboratory of Proteomics, China

### P04.37: Functionalized Polymer Material for Enrichment and In-Situ Digestion of Membrane Proteins

Mingxia Gao, Fudan University, China

### PO4.38: High Retention Time Precision and Mass Accuracy LCMS Platform for Deep Label-Free Proteome Profiling

Alexander Boychenko, Thermo Fisher Scientific, Germany

### PO4.39: A QPrEST Derived Peptide Resource for **Targeted Proteomics**

Fredrik Edfors, Science for Life Laboratory, KTH -Royal Institute of Technology, Sweden

### P04.40: Ultrasensitive Proteome Analysis by On-Line Cell Digestion and Nano-LC-MS Identification

xiangmin Zhang, Fudan University, China

### P04.41: A New Method to Control Ratio **Distortion in Isobaric Labeling Experiments**

Erik Ahrné, Biozentrum, University of Basel, Switzerland

### P04.42: Probing Plasma of Patients with Cardiovascular Disease Using a 120-plex Immuno-MRM Assay

Eric W. Kuhn, Broad Institute, USA

### P04.43: Development of a Reference Peptide Library for Targeted Serum Proteomics Using a **Cell-Free System**

Nobuaki Takemori, Ehime University, Japan

### P04.44: A Cross-Platform Comparison of Data **Independent Acquisition Methods for Proteomic**

Xin Ku, Shanghai Jiaotong University, China

### P04.45: Quantitative Profiling of Cyp P450s Using DIA and Processed Using Cloud Computing

Sibylle Heidelberger, Sciex, UK

### P04.46: Low Attomole Limit of Quantification on the Orbitrap Fusion Lumos Tribrid Mass Spectrometer

Romain Huguet, Thermo Fisher Scientific, USA

### PO4.47: DOSCAT: Double Standards in **Proteomics for Mass Spectrometry and Quantitative Western Blotting**

Richard J. W. Bennett, Centre for Proteome Research, University of Liverpool, UK

### P04.48: Identification of Peptide Fragments of **Gut Microbiota Proteins in Human Blood Serum**

Georgij Arapidi, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS, Russian Federation

### P04.49: Retention Time Independent SWATH **Acquisition Scoring**

Stephen A. Tate, SCIEX, USA

### PO5 - TOP DOWN PROTEOMICS AND **MACROMOLECULAR COMPLEXES**

### P05.01: Middle-Down HDX-MS for Structural Characterization of Antibodies at Single **Residue Resolution**

Jingxi Pan, University of Victoria, Canada

### P05.02: Metaproteomic Analysis, next **Generation Environmental Assessment**

Susana Cristobal, Linköping University, Sweden

### P05.03: Interactome Analysis of Key Protein Complexes Responsive to DNA Damage and Replication Stress

Barbora Salovska, Faculty of Military Health Sciences in Hradec Kralove, Czech Republic

### P05.04: Cold Vaporization of Tissue with a Picosecond Infrared Laser for Top down **Proteomics**

Hartmut Schlueter, University Medical Center-Hamburg-Eppendorf, Germany

### P05.05: Optimizing Top down Analysis of **Proteins on an Orbitrap Fusion Lumos Tribrid** Mass Spectrometer

Romain Huguet, Thermo Fisher Scientific, USA

### **P06 - CANCER PROTEOMICS**

### P06.01: avβ6, Plasminogen and Latent TGF-β **Drive Colorectal Cancer Aggression**

David Cantor, Macquarie University, Australia

### P06.02: Quantitative Mass Spectrometry **Reveals Markers for Colorectal Tumors**

Anuli C. Uzozie, University of Zurich, Switzerland

### P06.03: Multiplexed Immunoassays for Cytokine Profiling in 3D-In Vitro Tumor-Stroma **Cell Culture Models**

Dieter Stoll, University of Applied Sciences Albstadt-Sigmaringen, Germany

### P06.04: Data Independent Quantitation of the Rab GTPase Family

Franziska C. Hundt, Ruhr-University Bochum, Germany

### P06.05: Proteomic Analysis of Circulating Extracellular Vesicle for Diagnostic Biomarker of Breast Cancer

Pyong-Gon Moon, Kyungpook National University, Korea

### P06.06: Development of a Risk Stratification Test to Discern Aggressive and Non-Aggressive Prostate Cancer

Sandra Goetze, Swiss Federal Institute of Technology Zurich (ETH), Switzerland

### P06.07: Large-Scale Analysis of Melanoma Tissue Samples

Maria E. Yakovleva, Lund University, Sweden

### PO6.08: Quantitation and Evaluation of Candidate Biomarkers of Pancreatic Cancer in Plasma Using MRM Method

Weimin Zheng, Department of Chemistry, Fudan University, China

# P06.09: Functional Characterization of a Novel NF1-Related Protein TCTP by the Interactome Analysis

Daiki Kobayashi, Kumamoto University, Japan

# P06.10: Hypoxia-Induced Alternative Splicing Proteomics in Cancer Cell Lines

Pang-Hung Hsu, National Taiwan Ocean University, Taiwan

### PO6.11: Discovery of Pulmonary Disorder Biomarkers by In-Depth Proteomic Analysis of Pleural Effusions

Pei-Jun Liu, Chang Gung University, Taiwan

# P06.12: A Proteomic Investigation for Detection of Early Stage CRC Biosignatures

Mark S. Baker, Macquarie University, Australia

# P06.13: Cell Phase Specific Proteomic Profiling of Newly Synthesized Proteins Using SILAC-TMT Quantification

Eva Papachristou, Cancer Reasearch UK Cambridge Institute, University of Cambridge, UK

# P06.14: Immuno-MALDI for Quantifying Akt1 and Akt2 Phosphorylation in Colorectal Cancer

Robert Popp, University of Victoria, Canada

### P06.15: SWATH-MS Profiling of NSCLC Cell Lines: Defining Mechanisms of Erlotinib Resistance

Sarah A. Hayes, Bill Walsh Translational Cancer Research Laboratory, Australia

### PO6.16: Optimizing MS Based Methods to Characterize MHC-I Peptidome in Response to Cellular Stimulation

Qui Phung, Genentech, Inc., USA

### PO6.17: Discovery of Biomarkers for Oral Cancer by Proteomic Profiling of Tumor Interstitial Fluids

Chia-Wei Hsu, Chang Gung University, Taiwan

# PO6.18: Molecular Consequences of PC1/3 Inhibition in Macrophages and Application in Immunotherapy

Marie Duhamel, Laboratoire PRISM, Inserm U-1192, France

### P06.19: Acidosis-Induced Proteome Pattern of AT-1 Prostate Carcinoma Cells

Christian Ihling, Martin Luther University Halle-Wittenberg, Germany

### P06.20: Proteomic Analysis of Tumor-Associated Macrophages in an In Vivo Tumor Microenvironment

Evelyne Maes, University of Antwerp, Belgium

### P06.21: Identication of Tyrosine-Phosphorylated Proteins Upregulated during EMT Induced with TGF-B

Akiko Okayama, Yokohama City University, Japan

# P06.22: Comprehensive Transcriptomic and Proteomic Analysis of Retinoblastoma

Ravikanth Danda, Sankara Nethralaya, India

### P06.23: Proteomic Analysis of the Resection Margin at Different Distances of a Gastric Cancer

Gilberto B. Domont, Federal University of Rio de Janeiro, Brazil

# P06.24: Tracing Growth Factor Driven Resistance to EGFR Inhibition by Chemical- and Phosphoproteomics

Heiner Koch, Technische Universitaet Muenchen, Germany

### P06.25: Proteomic Analysis of the Transcriptional Program Induced by TWIST in Human Fibroblasts

Ignacio Casal, Centro de Investigaciones Biológicas, Spain

### PO6.26: SWATH Quantitation Using Ion Libraries from Multiple Cancer Cell-Types Identifies Drug Resistance

Christoph Krisp, Australian Proteome Analysis Facility, Australia

### P06.27: Verification of Serological Biomarkers for Lung Adenocarcinoma by Targeted Mass Spectrometry

Pao-Chi Liao, National Cheng Kung University College of Medicine, Taiwan

### P06.28: YBX1 Induces Oncogenicity via Release of Angiogenic Factors into the Tumour Microenvironment

David W. Greening, La Trobe Institute for Molecular Science, Australia

### P06.29: Detection of Aggressive Prostate Cancer Subforms by LC-MS and MALDI Imaging

Corinna Henkel, Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V., Germany

### P06.30: In-Depth Proteome Characterization of Intraductal Papillary Mucinous Neoplasm **Pancreatic Cysts**

Misol Do, Seoul National University College of Medicine, Korea

### P06.31: Epithelial to Mesenchymal Transition **Induced by SNAI1 Operates throughout** Epigenetic Mechanisms

Camila Palma, Ribeirao Preto Medical School -University of Sao Paulo, Brazil

### P06.32: Large Scale Systematic Proteomic **Quantification from Non-Metastasis to Metastasis Colorectal Cancer**

Hong Jin, Fudan University, China

### P06.33: HSP60-Silencing Disrupts **Mitochondrial Proteostasis and Promotes Tumor Progression**

Haiping Tang, Tsinghua University, China

### P06.34: Protein-Chain Quantitation by Targeted MS for Exploration of the Cancer-**Thrombosis Connection**

Yassene Mohammed, University of Victoria, Canada

### P06.35: Characterization of the Interactome of RSK Isoforms to Decipher Their Roles in Cancer Cells

Antoine Méant, Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Canada

### P06.36: Verification of Biomarkers in Uterine Aspirates by LC-PRM to Improve Diagnosis in **Endometrial Cancer**

Elena Martínez, Vall D'Hebrón Research Institute, Spain

### P06.37: TP53-Mediated Regulation of Exosome Proteins and microRNA

Xiaohang Zhao, Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China

### P06.38: Quantification of Mutant SPOP Proteins in Prostate Cancer Using SRM-MS

David Camp, Pacific Northwest National Laboratory, USA

### P06.39: SRM Verification of Circulating Ovarian **Cancer Biomarkers at Early Detection Research** Network (EDRN)

Karin Rodland, Pacific Northwest National Laboratory, USA

### P06.40: Elucidating Metastatic Changes during **Ovarian Cancer Progression by LCM Proteomics**

Fabian Coscia, Max Planck Institute of Biochemistry, Germany

### P06.41: Exosome Omics Study for Molecular **Backgrounds of Drug Response towards** Personalized Medicine

Kosuke Hirota, National Cancer Center Research Institute, Japan

### P06.42: Drug-Centric Proteomics for Molecular Backgrounds of Drug Response towards **Personalized Medicine**

Zhiwei Qiao, National Cancer Center Research Institute, Japan

### P06.43: Discover the Interactome of the Potent **Oral Cancer Oncoproteins by Quantitative Proteomics Analysis**

Lang-Ming Chi, Chang Gung Medical Foundation, Taiwan

### P06.44: A Multiplexed Cytokeratin MRM Panel for the Classification of Lung Cancer Patient **Pleural Effusions**

Anna Perzanowska, Institute of Biophysics and Biochemistry PAS, Poland

### P06.45: Quantitative Analysis of AKT/mTOR Pathway Using Immunoprecipitation and **Targeted Mass Spectrometry**

Bhavin Patel, Thermo Fisher Scientific, USA

### P06.46: Single-Shot Proteomics Profiling and **Quantification of Human Prostate Cancer Cells**

Wei Yang, Cedars-Sinai Medical Center, USA

### P06.47: Proteomic Profile of EGF-Stimulated Ovarian Cancer Cells during Epithelial to Mesenchymal Transition

Mariana L. Grassi, Ribeirao Preto Medical School -University of Sao Paulo, Brazil

# P06.48: Proteomic Identification of Malignant Pleural Mesothelioma-Related Molecules

Kiyoshi Yanagisawa, Nagoya University Graduate School of Medicine, Japan

# P06.49: Interactome-Wide Analysis Reveals the Actin-Regulating Function of TNFAIP2 in NPC Cells

Hao-Ping Liu, National Chung Hsing University, Taiwan

### P06.50: Profiling of Autoantibodies for the Stratification of Prostate Cancer

Elisa Pin, Science for Life Laboratory, KTH - Royal Institute of Technology, Sweden

### P06.51: Secretome of Naïve Senescent Mesenchymal Stromal Cell Promotes Senescence in ARH-77 Myeloma Cells

Servet Ozcan, Erciyes University, Turkey

### P06.52: New Workflows Combine Albumin Depletion and On-Bead Digestion, for Quantitative Serum Proteomics

Matthew Kuruc, Biotech Support Group LLC, USA

### P06.53: Statistical and Pathway Analysis of Protein Data

Christine Miller, Agilent Technologies, USA

### P06.54: Ubiquitination Profiling Identifies Sensitivity Factors for IAP Antagonist Treatment

Anita Izrael-Tomasevic, Genentech, Inc., USA

### P06.55: A Novel DIA Workflow for More Sensitive and Accurate SILAC Quantitation for Protein Kinome

Scott Peterman, Thermo Scientific, USA

### P06.56: Omega-3 Fatty Acid-Enriched Diet Favors a Reduction of Murine TRAMP-C2 Prostate Tumor Growth Compared to Omega-6 Fatty Acid-Enriched Diet

Nikunj R. Gevariya, Cancer Research Center, Laval University, Canada

# P06.57: Proteomics Analysis of Cisplatin Resistance in Ovarian Cancer Cells

Yuling Chen, Tsinghua University, China

### PO6.58: SWATH-MS and Proseek® Oncology Proteomic Biosignatures of Dukes' Staged Colorectal Cancer

Mark S. Baker, Macquarie University, Australia

### P06.59: Verification of Biological Insights Gained from Global Proteomic Analysis Using SWATH and SRM

Stefani Thomas, Johns Hopkins University, USA

### P06.60: Discovery of Metastasis-Related Biomarkers in Lung Cancer by Quantitative Tissue Proteomics

Chia-Jung Yu, Chang Gung University, Taiwan

# P06.61: NetGestalt CPTAC Portal: Empowering Biologists with Cancer Proteogenomic Data

Bing Zhang, Vanderbilt University Medical Center, USA

### P06.62: Quantitative Proteomics of Isogenic BAP1-Deficient Cells Lines for Targeted Therapy Discovery

Jenna Kenyani, Institute of Translational Medicine, UK

### P06.63: Studying of Malignant Ascites as a Unique Tumor Microenvironment

Victoria Shender, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS, Russian Federation

### P06.64: Insight on Colorectal Carcinoma Infiltration by Studying Perilesional Extracellular Matrix

Cinzia Magagnotti, Ospedale San Raffaele, Italy

# P06.65: Quambalarine B Induces Metabolic and Proteomic Rearrangement in Leukemia Cells

Petr Novak, Charles University, Czech Republic

# P06.66: Proteomic/Transcriptomic Characterisation of a Prostate Cancer Cell Line Model of Spontaneous EMT

David J. Boocock, Nottingham Trent University, UK

# P06.67: Proteomic Analysis of Serum Biomarkers for Gastric Cancer

Lylia Drici, University of Southern Denmark, Denmark

# P06.68: Development of Assays for Measuring CUZD1, a Pancreas-Specific Protein, in Biological Fluids

Sofia Farkona, University of Toronto, Canada

### P06.69: Stroma COL6A3 Is a Prognosis Marker of Colorectal Carcinoma Revealed by **Quantitative Proteomics**

Feng Liu, Institutes of Biomedical Sciences, Fudan University, China

### P06.70: Development of a Global **Phosphotyrosine Proteomic Method for** Analysis of Cancer Cell Lines

Yuichi Abe, National Institute of Biomedical Innov ation, Health and Nutrition, Japan

### P06.71: Proteomic Study Revealing Roles of MET and Caveolins in Exosome-Induced **Hepatoma Motility**

Terence C. W. Poon, University of Macau, Macau

### P06.72: Novel Protein Biomarkers for Subtype Stratification and Immunotherapy in Pancreatic Cancer

Laura Kuhlmann, DKFZ, Germany

### PO7 - NEW ADVANCES IN BIOMARKER DISCOVERY

### P07.01: Narrow-Range pl Plasma Protein Abundances as Alzheimer Disease Biomarker

Mohammad Pirmoradian, Karolinska Institutet, Sweden

### P07.02: Overcoming the Challenges in Data Independent Acquisition (DIA) via Orbitrap Technology

Yue Xuan, Thermo Fisher Scientfic, Germany

### P07.03: Quantitative Analysis of the Soluble Proteome of Airway Epithelial Cells in COPD

Tina Heyder, Karolinska Institutet/University Hospital, Sweden

### P07.04: MRM-Based Proteins Diagnostic of Chronic Obstructive Pulmonary Disease Exacerbations

Zsuzsanna Hollander, PROOF Centre of Excellence, Canada

### P07.05: Evaluation of New Biomarkers of Resistance to Trastuzumab in the Treatment of **HER2+ Breast Cancer**

Barbara Cardinali, IRCCS AOU San Martino - IST National Institute for Cancer Research, Italy

### P07.06: Intelligent Workflows for Proteomics **Data Analysis**

Arzu Tugce Guler, Leiden University Medical Center, Netherlands

### P07.07: Respiratory Disease Confirmation via Proteome Analysis of Exhaled Breath Condensate

Eugene N. Nikolaev, Energy Problems Of Chemical Physics Russian Acad. Sc., Russian Federation

### P07.08: Discovery of Autoantibody Biomarkers for Oral Cancer Detection Using Protein-Array **Analyses**

Ya Ting Chang, Molecular Medicine Research Center, Taiwan

### P07.09: Tear Proteins of Dry Eye Patients **Respond to Environmental Stress**

Roger Beuerman, Singapore Eye Research Institute, Singapore

### P07.10: Systems-Wide Proteome Analysis of **Hepatocellular Carcinoma Tissues by Targeted Proteomic Platform**

Dohyun Han, Seoul National University Hospital, Korea

### P07.11: Development of Meta-Markers for Recurrence Lung Cancer Using Multiple **Reaction Monitoring**

Yong-In Kim, BK21 Plus and Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Korea

### P07.12: Affinity Proteomics for the Identification of Biomarkers of Drug-Induced Liver Injury in

Maria Mikus, KTH - Royal Institute of Technology, Sweden

### P07.13: A Biomarker Panel to Rule-Out CT-Scan Lesions in Mild Traumatic Brain Injury

Linnea Lagerstedt, University of Geneva, Switzerland

### P07.14: Proteomic Investigation of Biomarkers **Associated with Regression of Tumor Diseases** after HDT/ASCT

Zuzana Bilkova, University of Pardubice, Czech Republic

### P07.15: Refinement of PRM Methods to Improve Sensitivity and Accuracy in Peptide Quantification

Sebastien Gallien, L.I.H., Luxembourg

# P07.16: Biomargin: Protein Biomarkers of Renal Graft Injuries in Kidney Allograft Recipients

Inge Mertens, VITO, Belgium

### P07.17: Differential Proteomics Identifies CFH Proteolytic Species as Possible Early Cancer Biomarkers

Yen-Chun Huang, Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taiwan

### P07.18: Towards Minimally Invasive Diagnosis of Prostate Cancer

Betty Friedrich, Institute of Molecular Systems Biology, ETH Zurich, Switzerland

### P07.19: Serum Cytokines, Chemokines and Soluble Receptors for Evaluation of Pulmonary Tuberculosis

Rihwa Choi, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

### P07.20: Identification of Prognostic Biomarkers for Oral Cancer by Low-Molecular-Mass Secretome Profiling

Jau-Song Yu, College of Medicine, Chang Gung University, Taiwan

# P07.21: Absolute Quantification of the Marker Candidates in Ascites Using Multiple Reaction Monitoring

Minsoo Son, Seoul National University College of Medicine. Korea

### P07.22: SOMAscanTM Assay: A Proteomic Platform That Can Also Detect SNPs

Sheri K. Wilcox, SomaLogic, Inc., USA

### PO7.23: Stable Isotope Labeled Peptide Kits for Multiplexed Analysis of Biologically Relevant Protein Sets

Lawrence Eckler, JPT Peptide Technologies GmbH, Germany

# P07.24: Efficacy Assessment of a Dietary Functional Food on Diabetic Subjects

Mohd M. Khan, University of Maryland School of Pharmacy, USA

### P07.25: SRMAtlas: Towards Defining Tuberculosis Biomarkers

Ulrike Kusebauch, Institute for Systems Biology, USA

### PO7.26: Simple and Efficient Fractionation via Solid-Phase Extraction for In-Depth Proteome Profiling

Young-Jin Choi, ProtAnBio, Korea

### P07.27: Identification of CLIC1 as the Potential Diagnostic Marker for Epithelial Ovarian Cancers

Yuling Chen, Tsinghua University, China

### PO7.28: Identification of Blood-Based Cancer Biomarkers by Deep Microparticle Proteomics Using PROMIS-Quan

Michal Harel, Tel Aviv University, Israel

### PO7.29: Affinity Proteomic Profiling Reveals Molecular Subgroups in Systemic Lupus Erythematosus

Arash Zandian, Affinity Proteomics - SciLifeLab, KTH - Royal Institute of Technology, Sweden

# P07.30: Characterization of the Differences in Cervical Mucus Composition during the Menstrual Cycle

Giuseppe Grande, Catholic University - Rome, Italy

### PO7.31: Alterations in PBMCs from Bulbar and Spinal ALS Patients with Different Rate of Disease Progression

Ella Leoni, Proteome Sciences, UK

# PO7.32: In-Depth Analysis of Plasma Proteome for Discovery of Age-Related Macular Degeneration Biomarkers

Seong-Jun Park, Korea Institute of Science and Technology, Korea

### PO7.33: Discovery and Validation of Biomarker Peptides in Plasma Using Two Types of Stable-Isotope Tags

Yoshio Kodera, Kitasato University School of Science, Japan

### P07.34: An Effective Method for Exploring Tumor-Characteristic Glycoforms of Cell Surface Mucins

Atsushi Matsuda, National Institute of Advanced Industrial Science and Technology (AIST), Japan

# P07.35: Differential Expression of C3a and C5a in Allergic Asthma

ChenXi Yang, Centre for Heart + Lung Innovation, University of British Columbia, Canada

# P07.36: Fibulin-5 Is a New Biomarker Candidate for Hepatic Fibrosis

Thilo Bracht, Ruhr-Universität Bochum, Germany

### P07.37: MRM-Based Quantifications of Blood Biomarkers Using a Quantification Peptide-**Tagged Fusion Proteins**

Noriaki Arakawa, Yokohama City University, Japan

### P07.38: Analysis of Cryosections Enables Disease Classification, Validation and **Correlation Clinical Data**

Garry L. Corthals, University of Amsterdam, Netherlands

### P07.39: Rapid and Automated Quantitation of **Protein Biomarkers for Nutrition Status from Dried Blood Spots**

Gary Kruppa, MRM Proteomics Inc., Canada

### P07.40: Use of Spectral Deconvolution Centroiding to Find More Robust, Sample-**Discriminating Biomarkers**

Luke V. Schneider, Target Discovery, Inc., USA

### P07.41: More Biomarkers Discovered with Spectral Deconvolution Centroiding (Part 1)

Luke V. Schneider, Target Discovery, Inc., USA

### P07.42: More Biomarkers Discovered with Spectral Deconvolution Centroiding (Part 2)

Luke V. Schneider, Target Discovery, Inc., USA

### PO8 - PROTEOMICS AT PHARMA

### P08.01: Improved Method for Assessing **Immunoreactivity Coverage in Detecting Host** Cell Protein in Biologics

WenKui Lan, Bristol-Myers Squibb, USA

### P08.02: Comparison of SPRi, Nano-SPRi and ELISA in the Evaluation of rhGH in Crude Samples

Marinella G., Sandros, University of North Carolina at Greensboro, USA

### P08.03: Creating Quantitative Protein Maps as Remineable Resources in Pharmacodynamic **Studies**

Thomas Lau, Pfizer, USA

### P08.04: Determination of Biorelevant HA Content in Influenza Vaccines Using SEC and Quantitative MS

Jonathan L. Bundy, US Centers For Disease Control and Prevention, USA

### PO8.05: In Vitro Metabolism of Small Bioactive Peptides in Plasma, Liver and Kidney Subcellular Fractions

Irina Zvereva, Moscow Antidoping Centre, Russian Federation

### P08.06: PEAKS AB - A Reliable Workflow for Monoclonal Antibody Characterization Using MS/MS

Lin He, Bioinformatics Solutions Inc., Canada

### P08.07: Robust and Sensitive Nano LC-MS Targeted Quantification of Rituximab™ in **Complex Bio-Matrices**

Alexander Boychenko, Thermo Fisher Scientific, Germany

### PO9 - PROTEOMICS OF MICROBES AND INFECTIOUS DISEASES

### P09.01: Detecting and Quantifying Dengue Viral Proteins and Virus Maturation by MRM-MS

Steven J. McArthur, University of British Columbia, Canada

### P09.02: Identification of Biological Species **Using Spectral Libraries**

Magnus Palmblad, Leiden University Medical Center, Netherlands

### P09.03: MTB Proteome Microarray for **Global Studies of Protein Function and Immunogenicity**

Sheng-ce Tao, Shanghai Jiao Tong University,

### P09.04: Proteome Profiling in the Search for Cerebrospinal Fluid Biomarkers of **Pneumococcal Meningitis**

Richard J. W. Bennett, University of Liverpool, UK

### P09.05: Mechanistic Basis of Phenotypic Drug Resistance in Mycobacteria

Jonathan Blackburn, University of Cape Town, South Africa

### P09.06: Search for a T. Pallidum Antigen Test: **Revealing Protein Targets for Diagnostic Test** Development

Kara K. Osbak, Institute of Tropical Medicine Antwerp, Belgium

### PO9.07: Evaluation of DIA Analysis on Orbitrap Fusion for Detection of Bacterial Infection in Human Samples

Florence Roux-Dalvai, Centre de Recherche CHU de Québec, Canada

# P09.08: Rapid Discrimination between MRSA and MSSA Using MALDI-TOF Mass Spectrometry

Kazuyuki Sogawa, Azabu University, Japan

### P09.09: Leishmania Mitochondria: New Targets for Drug Development

W. Robert McMaster, University of BC, Canada

# P09.10: Proteomics Analysis of EV71-Infected Cells Reveals the Involvement of NEDD4L in EV71 Replication

Chih-Ching Wu, Chang Gung University, Taiwan

# P09.11: Characterization of the Oral Proteome by Metaproteome Analysis

Manuela Gesell Salazar, University Medicine Greifswald, Germany

# P09.12: CE-MS for the Detection of Carbapenemases in (Multi-)Drug-Resistant Gram-Negative Bacteria

Frank Fleurbaaij, Leids Universitair Medisch Centrum, Netherlands

# PO9.13: Decoding Bacterial Adaption Code: How Does Pseudomonas Aeruginosa Adapt to the Cystic Fibrosis Lung?

Mark P. Molloy, Australian Proteome Analysis Facility, Australia

# PO9.14: FUT1 Gene Control Gut Bacteria through Fucosylation of Gut Mucosa Proteins

Emøke Bendixen, Aarhus University, Denmark

### PO9.15: Proteomic Characterization of HipA-Mediated Mechanisms of Bacterial Persistence in Escherichia Coli

Maja Semanjski, University of Tuebingen, Germany

### PO9.16: Quantitative Proteomic Analysis Reveals Major Cues for Severe Vivax Malaria

Sanjeeva Srivastava, IIT Bombay, India

### PO9.17: In Vitro Endosomal Recruitment Proteomics Strategy to Study Bacterial Protein Toxin Translocation

Ryan Ratts, Dartmouth Geisel School of Medicine, USA

### PO9.18: Revealing the Response of the Active Mucosal Microbiota from the Rat Colon to a Change in Diet

Nico Jehmlich, Helmholtz-Centre for Environmental Research, Germany

### PO9.19: Label Free Study for Control of Listeria Monocytogenes to Enhance Food Safety

Cristian Piras, Universitty of Milan, DIVET, Italy

### P09.20: Protein Signature during Biofilm Formation in Staphylococcus Aureus Food Isolates

Paola Roncada, Istituto Sperimentale Italiano L. Spallanzani, Italy

### P09.21: Immunoproteome Analysis of Bordetella Bronchiseptica by IP- nLC-MS/MS

Servet Ozcan, Erciyes University, Turkey

### PO9.22: SILAC Labelling Dynamics in Staphylococcus Aureus MSSA/MRSA Strains Isolated Form Mastitis

Alessio Soggiu, University of Milan, Italy

### PO9.23: Proteomics Investigation of Pseudomonas Fluorescens Chromogenic Strains: Insight in Blue-Mozzarella

Viviana Greco, Santa Lucia Foundation, Italy

# P09.24: Investigating HIV-Mediated Dynamics of Cullin RING E3 Ligases by AP-MS and Proximity Biotinylation

Ruth Huttenhain, University of California San Francisco, USA

# PO9.25: Elucidation of the Ebola Virus VP24 Cellular Interactome

Stuart Armstrong, University of Liverpool, UK

### P09.26: High-Throughput Genetic Analysis of Salmonella-Host Interactions

Nat F. Brown, University of British Columbia, Canada

### PO9.27: Endogenous Peptidomics Links Hemoglobin Digestion to Drug Resistance in the Malaria Parasite

David H. Perlman, Princeton University, USA

# P09.28: Genetic Changes in HIV Effecting Drug Resistance and Immune Response

Saeed Khan, Dow University of Health Sciences, Pakistan

### P09.29: Proteogenomic Characterization of Aniline Degrading Bacterium, Burkholderia Sp. **K24**

Sang-Yeop Lee, Korea Basic Science Institute, Korea

### P09.30: Comparative Proteomic Analysis of C. **Difficile Clinically Relevant Ribotypes**

Jiri Dresler, Military Health Institute, Czech Republic

### P09.31: Proteomic Characterization of Vascular Adhesins from the Syphilis Spirochete, Treponema Pallidum

Karen V. Lithgow, University of Victoria, Canada

### P09.32: Effects of LPS Stimulation in Bovine **Uterine Epithelial Cells Model**

Paola Roncada, Istituto Sperimentale Italiano L. Spallanzani, Italy

### P09.33: Functional Analysis of Gut Microbiome Samples Using Large-Scale Metaproteomics and Activity-Based Probes

Gregory Stupp, The Scripps Research Institute, USA

### **P10 - STRUCTURAL PROTEOMICS**

### P10.01: A Structural Proteomics Study of Native Alpha-Synuclein in Solution

Nicholas I. Brodie, University of Victoria, Canada

### P10.02: A Crosslinking Study of Fibrin Polymerization

Karl A.T. Makepeace, University of Victoria, Canada

### P10.03: A Feature Analysis of Lower Solubility **Proteins in Unstressed and Heat-Shocked Yeast** Cells

Mang Zhu, The University of British Columbia, Canada

### P10.04: Structural Proteomic Study of High **Density Lipoprotein (HDL)**

Jason J. Serpa, University of Victoria, Canada

### P10.05: Investigation of Structural Dynamics of Aguoporin Z at High Osmolar Environment with **HDXMS**

Qingsong Lin, National University of Singapore, Singapore

### P10.06: In Vivo Measurement of Mammalian Ribosome Maintenance

John C. Price, Brigham Young University, USA

### P10.07: Crosslinking Study of IAPP Oligomers

Ryan Riley, University of Victoria - Genome BC Proteomics Centre, Canada

### P11 - OTHER

### P11.01: Permanent Proteins in the Urine of Healthy Humans during the Mars-500

Liudmila Pastushkova, IMBP, Russian Federation

### P11.02: Dynamics of Proteome Urine of Healthy Volunteers Exposed 105-Day Isolation

Irina Larina, IMBP, Russian Federation

### P11.03: Proteomic Changes Associated with Reproductive Periods in Male Polychaetous **Neanthes Arenaceodentata**

KONDETHIMMANAHALLI Chandramouli, King Abdullah University of Science and Technology, Saudia Arabia

### P11.04: Redox Regulation of SAT1 Activity

Gary Gang Chen, Douglas Mental Health Institute, Canada

### P11.05: Effects of Different Glaucoma Drugs on **Proteomic Expression Levels in Corneal and** Conjunctival Cells

Janika Nättinen, University of Tampere, Finland

### P11.06: A Highly Sensitive Strategy for **Quantitative Analysis of Cancer Related** Protease in Living Cells

Duan Feng, Beijing Proteome Research Center,

### P11.07: A Strategy for Large-Scale Analysis of Asymmetric Inheritance of Old-Age Proteins at **Cell Division**

Keiji Kito, Meiji University, Japan

### P11.08: Proteomic Profiling of Six Snake Venoms in Taiwan for Discovering Snakebite Biomarkers

Chien-Chun Liu, Chang Gung University, Taiwan

### P11.09: Resolving Discrepancies in Nephelometric Total IgG and Subclass Measurements with Mass Spectrometry

Andre Mattman, St Paul's Hospital, Canada

# P11.10: Proteomic Profiling of the [PSI+] Yeast Prion Strain by Quantitative Mass Spectrometry

Patrick Hau Wing Chan, UBC, Canada

# P11.11: Colims: An Open Source Lims System to Automate Proteomics Data Management, Processing and Analysis

Niels Hulstaert, University of Ghent - VIB, Belgium

# P11.12: Gas Phase Interactions of Nucleosides with Organomercuric Compounds

Latifa Latrous, Université de Tunis El Manar, Faculté des Sciences de Tunis, Tunisia

### P11.13: Crowdsourcing Cardiac Mitochondrial Proteomics Knowledge in Gene Wiki

Jessica M. Lee, NIH BD2K Center of Excellence at UCLA, USA

### P11.14: Novel Serum Biomarkers Differentiate Psoriatic Arthritis from Psoriasis without Psoriatic Arthritis

Vinod Chandran, University of Toronto, Toronto Western Hospital, Canada

### P11.15: STD Pathogens Determined in Semen Using PCR And "FLOW-Through" Hybridization Technology

Dr. Rubina Ghani, Baqai Medical University, Pakistan

### P11.16: L-FABP Up-Regulates Cellular Angiogenesis and Migration in Hepatocellular Carcinoma

Jung-Yaw Lin, National Taiwan Normal University, Taiwan

# P11.17: Genipin Inhibites Hepatocellular Carcinoma by Modulating the AKT/mTOR Pathway

Hsuan-Yuan Lin, National Taiwan Normal University, Taiwan

### P11.18: Automatic Fast Standard Curve Generation Using Qualis-SIS for Quantifying Hundreds of Peptides

Yassene Mohammed, University of Victoria, Canada

### P11.19: Multiplexed Quantification of Preterm Infant Plasma Proteins by MS-Based Immunoassays

Oliver Poetz, NMI Natural and Medical Sciences Institute at the University of Tuebingen, Germany

### P11.20: A Library Containing MRM-Suitable Peptide Surrogates for All Human Proteins

Yassene Mohammed, University of Victoria, Canada

# P11.21: Nanoparticle Ferric Pyrophosphate in Iron Deficiency, Its Impact on Plasma Proteins in Vivo

Bindu Y. Srinivasu, St John's Research Institute, India

### P11.22: LFQProfiler - A Free Plugin for Label-Free Quantification in Proteome Discoverer Johannes Veit, University of Tübingen, Germany

# P11.23: Mining of Proteins Related to Prevention of Adipogenic Differentiation by Vitamin A in Cattle

Hong Gu Lee, Konkuk University, Korea

### P11.24: Affinity Proteomics on Glycemic Deterioration - A DIRECT Study

Elin Birgersson, Science for Life Laboratory, KTH -Royal Institute of Technology, Sweden

### P11.25: Assessment of Awareness about Immunization among Parents in Population of Karachi, Pakistan

Bilal H. Khan, Dow University of Health Sciences, Pakistan

### P11.26: Host Defense-Related Proteins in Bovine Milk during Subclinical Staphaylococcus Aureus Mastitis

Shaimaa W. Abdelmegid, University of Guelph, Canada

### P11.27: Pulmonary Fibrosis: TAILS N-Terminomics Unravels the Role of MMP12

Giada Marino, Centre for Blood Research, Department of Oral Biological and Medical Sciences, University of British Columbia, Canada

# P11.28: A Cross-Sectional Study on Dietary Factors among Teenagers in Karachi

Bilal H. Khan, Dow University of Health Sciences, Pakistan

### P11.29: Antidiabetic Natural Flavonol

Nawal M. Al Musayeib, King Saud University, Saudia Arabia

# P11.30: Glygosylation Sites and Oligomerization of MRJP1 - Application of Bottom up, Top down and HDX-MS

Marcelo V. De Sousa, University of Brasilia, Brazil

### P11.31: Proteomic Analysis of **Rhodopsudomonas Palustris CGA009 Grown** under Simulated Microgravity

Tae-Sung Yoon, UST/KRIBB campus, Korea

### P11.32: Integrated Systems Biology Lung **Analysis of OMICS Endpoints for Product** Assessment

Ashraf Elamin, Philip Morris International, Switzerland

### P12 - EPIGENETICS AND HISTONE LANDSCAPE

### P12.01: Towards Understanding Cellular Signaling into Chromatin

Benjamin A. Garcia, University of Pennsylvania School of Medicine, USA

### P12.02: Characterization of Histone PTM Crosstalk by Middle-Down Mass Spectrometry and Data Integration

Veit Schwämmle, University of Southern Denmark, Denmark

### P13 - PROTEIN NETWORKS AND **COMPUTATIONAL BIOLOGY**

### P13.01: Characterization of the Protein Complex **Landscape of Murine Tissues**

Nichollas E. Scott, University of British Columbia, Canada

### P13.02: Global Survey of Protein Complexes in Nematode Species (WormMap)

Zhongming (Lucas) Hu, University of Toronto, Canada

### P13.03: Targeted Proteomics-Driven Computational Modeling of the Signaling Pathways in the Immune System

Aleksandra Nita-Lazar, National Institute of Allergy and Infectious Diseases, USA

### P13.04: Identifying Cell Cycle Feedback Loops via Single Cell Proteomics in Xenopus Laevis

Kyle M. Kovary, Stanford University, USA

### P13.05: The Protease Web: A Pervasive and Complex Network Generating a Multitude of **Protein Isoforms**

Nikolaus Fortelny, UBC Vancouver, Canada

### P13.06: Identification of Disease Related Pathways by Integration of Phosphor and Global **Proteome Profiling**

Hyobin Jeong, Institute for Basic Science, Korea

### P13.07: Highest Connected Isoforms and Their Protein-Level Expression for the Human

Gilbert S. Omenn, University of Michigan, USA

### P13.08: An Algorithm for a Complex Filtering **Query System of Proteomics Data**

Salvador Martínez-Bartolomé, The Scripps Research Institute, USA

### P13.09: Efficient Identification of Cross-Linked Peptides with StavroX and MeroX in Structural **Proteomics**

Michael Götze, University Halle-Wittenberg, Germany

### P13.10: ProHits 2.0: A Bioinformatics **Management and Analysis System Optimized** for Interaction Studies

James Knight, Mount Sinai Hospital, Canada

### P13.11: Visualizing and Analyzing Protein Interactome Data

James Knight, Mount Sinai Hospital, Canada

### P13.12: A High Throughput Software Solution for **Treating Data Independent Acquisition Results** Ken Miller, Thermo Fisher Scientific, USA

### P13.13: ProteomeXchange: Enabling Proteomics **Data Sharing in the Public Domain**

Juan Antonio Vizcaino, EMBL-European Bioinformatics Institute, UK

### P13.14: Oxidative Stress Dependent Regulation of DJ-1: An Interatomic Point of View

Sandra Anjo, Center for Neuroscience and Cell Biology - University of Coimbra, Portugal

### P13.15: Large Scale Quantitation of SILAC Proteomes Using Retention and Drift Time Profiling

Andrew Collins, University of Liverpool, UK

### P13.16: PSEA-Quant: A Protein Set Enrichment **Analysis on Quantitative Proteomics Datasets**

Mathieu Lavallée-Adam, The Scripps Research Institute, USA

### P13.17: PRIDE Proteomes: A Protein Centric View of PRIDE Archive Data

Noemi Del Toro, EMBL-European Bioinformatics Institute, UK

### P13.18: Systems Biology Analysis of Common and Disease-Specific Pathways in Neurodegeneration

Mauro Fasano, University of Insubria, Italy

### P13.19: Reactome: Pathway Analysis of Proteomics Data

Henning Hermjakob, European Molecular Biology Laboratory, UK

### P13.20: Sequence-Based Identification of Cis-Regulatory Elements in Intrinsically Disordered Protein Regions

Joerg Gsponer, University of British Columbia, Canada

# P13.21: Assessment of Network Systems Using Background Information to Reveal Relevance of Proteomic Data

Susana S. Novoa-Herran, Universidad Nacional de Colombia, Colombia

# P13.22: jPOST: Development of Japan ProteOme STandard Repository/Database

Shin Kawano, Research Organization of Information and Systems, Japan

### P13.23: Real-Time Peptide Sequencing

Bin Ma, University of Waterloo, Canada

### P13.24: An Automated Alignment Strategy to Obtain Comprehensive Data Matrices in Targeted Proteomics Data

Hannes Röst, ETH Zurich, Switzerland

### P13.25: ProteoSuite - An Open Source Framework for Quantitative Proteomics Based on PSI Data Standards

Simon Perkins, University of Liverpool, UK

### P13.26: A Deeper Understanding of mRNA Processing through Proximity Proteomics

Anne-Claude Gingras, Lunenfeld-Tanenbaum Research Institute, Canada

### P14 - MEMBRANE PROTEOMICS

# P14.01: Expression & Association of CDK10 with ETS2 during Human Corneal Wound Healing

Shamim Mushtaq, Ziauddin University, Pakistan

# P14.02: An Effective Plasma Membrane Proteomics Approach for Small Tissue Samples

Geert Baggerman, VITO/University of Antwerp, Belgium

### P15 - PHOSPHOPROTEOMICS AND CELL SIGNALING

# P15.01: Identification of Adaptor Proteins Included in the TNFR2 Signaling Complex

Haruhiko Kamada, National Institute of Biomedical Innovation and Nutrition, Japan

### P15.02: The NCI60 Phosphoproteome

Benjamin Ruprecht, Technical University of Munich, Germany

### P15.03: Target Recognition Properties of Pin1 Revealed by Quantitative Peptide Microarray

Yih-Cherng Liou, National University of Singapore, Singapore

### P15.04: Proteomics of ALK Signaling in Neuroblastoma

Anna-Kathrine Pedersen, Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Denmark

### P15.05: Phosphoproteomic Analysis of Signaling Networks during Egg Activation in Sea Urchin

Hongbo Guo, University of Toronto, Canada

### P15.06: Quantitative Proteomics Analysis Unravels Functional Roles of Englerin A in Renal Cancer

Asfa Alli Shaik, Institute of Molecular and Cell Biology, Singapore

# P15.07: Elucidating Dynamic Receptor Tyrosine Kinase Signaling with Deep Phospho-Seq

Tanveer S. Batth, Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Denmark

# P15.08: Targeted Quantitation Evolved: HD-PRM

Michael Blank, Thermo Fisher Scientific, USA

### P15.09: Multi-Layered Proteomics Unveils Molecular Switches of Ligand-Dependent EGFR Outputs

Moreno Papetti, NNF Center for Protein Research University of Copenhagen, Denmark

# P15.10: Fast and Accurate Site Localisation of Phosphopeptides via Spectral Library Matching

Garry L. Corthals, University of Amsterdam, Netherlands

### P15.11: Enrichment of Multiphosphorylated Peptides Using Novel Magnetic TiO2-Based Nanomaterial

Zuzana Bilkova, University of Pardubice, Czech Republic

### P15.12: Protein Kinase Substrate Specificity **Determination by Prediction Algorithms and** Peptide Microarrays

Steven Pelech, Kinexus Bioinformatics Corporation, Canada

### P15.13: Protein Kinase Substrate Specificity **Determination by Prediction Algorithms and** Peptide Microarrays

Steven Pelech, Kinexus Bioinformatics Corporation, Canada

### P15.14: Metal-Immobilized Magnetic Nanoparticles for Enrichment of **Phosphopeptides by Mass Spectrometry**

Rui Zhai, Beijing Proteome Research Center, China

### P15.15: Regulatory Roles of Conserved Phosphorylation Sites in the Activation T-Loop of the MAP Kinase ERK1

Steven Pelech, Kinexus Bioinformatics Corporation, Canada

### P15.16: Preservation of Phosphorylation **Signaling States with Heat Stabilization for Bottom-Up Proteomics**

Mats Borén, Denator, Sweden

### P15.17: Production and Characterization of Polyclonal Generic Phosphotyrosine-Specific **Antibodies**

Steven Pelech, Kinexus Bioinformatics Corporation, Canada

### P15.18: Evaluation of Protein Kinase Inhibitors **Using Motif-Targeting Phosphoproteomics**

Naoyuki Sugiyama, Kyoto University, Japan

### P15.19: Proteomic and Phosphoproteomic Study of Human Macrophage Kinome after Interaction with Candida Cells

Concha Gil, Universidad Complutense de Madrid, Spain

### P15.20: Identifying Novel Signaling Mechanisms Underlying Insulin Release from Glucose Stimulated Beta Cells

Pia Jensen, University of Southern Denmark, Denmark

### P15.21: Phosphoproteomic Analysis Using the WW and FHA Domains as Biological Filters

Md H. Shohag, Nagoya University, Japan

### P15.22: MS-Based Analysis of Thiol-Redox and **Phosphorylation Cross Talk in Human Bronchial Epithelial Cells**

Rolf Nölker, University of Greifswald, Germany

### P15.23: Comparison of Label-Free and TMT **Quantification for Phosphoproteome Analysis** of Apoptotic Cells

Emmanuelle Lezan, Biozentrum, University of Basel, Switzerland

### P15.24: Comparison of SWATH, MS1 Intensity and Spectral Counting for Quantitation of **Interaction Partners**

Sylvie Bourassa, CHU de Québec/Laval University, Canada

### P15.25: Low-Bias Phosphopeptide Enrichment from Scarce Samples Using Plastic Antibodies

Katrin Marcus, Ruhr-University Bochum, Germany

### P16 - NEUROLOGICAL DISORDERS

### P16.01: DBP Associated with the Aspirin in the **Prevention of Cerebral Thrombosis**

Shilian Liu, Department of Biochemistry and Molecular Biology, China

### P16.02: Proteomic Analysis of Cerebrospinal Fluid from Acutely Injured Spinal Cord Patients

Jason Rogalski, University of British Columbia, Canada

### P16.03: Chitinase 3-Like Proteins as Candidate **Cerebrospinal Fluid Biomarkers for Multiple** Sclerosis

Philippe Marin, Institut de Génomique Fonctionnelle, CNRS UMR5203, INSERM U1191, Université de Montpellier, France

### P16.04: Quantitative Analysis of the **Hippocampal Postsynaptic Density Using DIA** LC-MS

Ute Distler, University Medical Center of the Johannes-Gutenberg University Mainz, Germany

### P16.05: PC12 Cells Expressing a Dp71Δ78-79 **Dystrophin Mutant That Stimulates Neurite** Outgrowth

Candelaria Merino-Jiménez, Cinvestav, Mexico

### P16.06: Semi-Quantification of Cerebrospinal Fluid Biomarkers for Autism Spectrum Disorder and ADHD

Jessica Holmén Larsson, University of Gothenburg, Sweden

# P16.07: Structure Associated Proteins as Key Players in the Hippocampal Progression of Alzheimer's Disease

Andreas Schroetter, Leibniz-Institut fuer Analytische Wissenschaften - ISAS - e.V., Germany

# P16.08: Anoctamin 2 as an Autoimmune Target in Multiple Sclerosis

Peter Nilsson, SciLifeLab, KTH - Royal Institute of Technology, Sweden

### P16.09: Neuroproteomic Profiling of 277 Brain-Enriched Proteins in CSF and Plasma

Anna Häggmark, SciLifeLab, KTH - Royal Institute of Technology, Sweden

# P16.10: HIV-1 Clade B Induces a Pro-Apoptotic While Clade C an Anti-Apoptotic Mechanism in Human Astrocytes

Luis Cubano, Universidad Central del Caribe, Puerto Rico

# P16.11: Identification of Synaptic Tau Hyperphosphorylation Sites Induced by $\beta$ Amyloid in APP/PS1 Mice

Hwan-Ching Tai, National Taiwan University, Taiwan

### P16.12: Reveal the Pathophysiology of the Chronic Fatigue Syndrome with a Quantitative Proteomic Approach

Jia Mi, Uppsala University, Sweden

### P16.13: Utilizing Single-Shot Proteomics to Monitor Synaptic Health in Alzheimer's Disease

SATYA Saxena, Johnson and Johnson, USA

### P16.14: Quantitative Analysis of APPswe/PS1dE9 Brains: An Amyloid Plaques Mouse Model of Alzheimer Disease

Pernille Lassen, University of Southern Denmark, Denmark

# P16.15: Quantitative Proteomics Reveals New Insights into Chaperone Malfunction Linked Neurodegeneration

Laxmikanth Kollipara, Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V., Germany

### P16.16: H2S Role in Amyotrophic Lateral Sclerosis: Unravelling New Cellular and Molecular Mechanisms

Andrea Urbani, Santa Lucia Foundation, Italy

# P16.17: Implementation of Mass Spectrometry for Detection Amyloid-β Peptides in Plasma

Marina G. Rodchenkova, Emanuel Institute for Biochemical Physics, Russian Academy of Sciences, Moscow, Russia, Russian Federation

# P16.18: Functional Analysis of Protein Complexes in Alzheimer's Disease

Nikhat Ahmed Siddiqui, Ziauddin University, Pakistan

### P16.19: Identification of Brain-Related Cerebrospinal Fluid Proteins in Neurodegenerative Diseases

Ilijana Begcevic, University of Toronto, Canada

### P16.20: Advancing Alzheimer Disease Diagnostics: A Clinical Assay to Quantitate Amyloid-Beta Peptides in CSF

Mari DeMarco, University of British Columbia & St Paul's Hospital/Providence Health Care, Canada

# P16.21: Cell-Type and Brain-Region Resolved Mouse Brain Proteome

Kirti Sharma, Max Planck Institute for Biochemistry, Germany

# P16.22: Pathophysiology of Human Parkinson's Disease Involves Multiple Proteostatic Systems Garry Wong, University of Macau, Macau

### P16.23: Quantitative Analysis of N-Linked Glycoprotein in the Brain of Alzheimer's Disease Model

Pan Fang, Institute of Biomedical Science, Fudan University, China

# P16.24: Proteomic Analysis of Human Microglial Cells Activated by Amyloid $\beta$ Peptide

Young Mok Park, Institute for Basic Science (IBS), Korea

### P17 - TRANSLATIONAL PROTEOMICS

# P17.01: Plasma Kininogen and Diabetes Related Kidney Disease

Juliana Almada Colucci, Universidade Federal de São Paulo, Brazil

### P17.02: Proteins of the Human Eye. From **Bottom-Up Proteomics to Top-Down Peptidomics**

Peter D.E.M. Verhaert, Lund University, Sweden

### P17.03: Characterizing the Urinary Peptidome to Infer Protease Activity in the Diabetic Kidney

Julie A. D. Van, University of Toronto, Canada

### P17.04: Extended Boiling of Peanuts Reduces IgE Reactivity While Retaining Allergen **Peptides**

Timothy K. Chataway, Flinders University, Australia

### P17.05: Proteome Profiling in Rat Tears by High **Resolution Mass Spectrometry**

Toshiyuki Mikami, Sumitomo Dainippon Pharma, Japan

### P17.06: Multiple Sclerosis Lesion Stage Markers from Quantitative Brain Proteomics of Mouse Models

Frode S. Berven, University of Bergen, Norway

### P17.07: Microfluidics Coupled Mass Spectrometry for Multi-omics/Targeted Assays in Translational Research

James Langridge, Waters Corp, UK

### P17.08: Gel Based and Shotgun Approaches to Identify Salt Stress Responsive Proteins of **Panax Ginseng**

Sun Tae Kim, Pusan National University, Korea

### P17.09: Comparative Proteomic Analyses of Soybean Seed Cultivars Differing in Protein and Oil Content

Sun Tae Kim, Pusan National University, Korea

### P17.10: Selected Reaction Monitoring (SRM) for Quantification of Angiotensin-II Signature **Proteins in Urine**

Ana Konvalinka, Toronto General Hospital, University of Toronto, Canada

### P17.11: Biomarker Combination to Predict Infection in Aneurysmal Subarachnoid Haemorrhage

Jean Charles Sanchez, Centre Medical Universitaire, Switzerland

### P17.12: Identification of TEX101 Protein Interactome in Testicular Germ Cells by Immunoprecipitation-MS

CHRISTINA Schiza, University of Toronto, Canada

### P17.13: Discovery of Novel Subtype-Specific Ovarian Cancer Biomarkers via Integrated **Tissue Proteomics**

Felix Leung, Mount Sinai Hospital, Canada

### P17.14: Protein Biomarkers Link Olfactory Signal Transduction to Social Immunity

M Marta Guarna, University of British Columbia, Canada

### P17.15: Multiplexed SRM Assay for Measurement of Tissue Kallikrein-Related Peptidases in **Biological Fluids**

Theano D. Karakosta, Mount Sinai Hospital, Canada

### P17.16: Stress Chaperone GRP78 Confers **Protection against Neurocognitive Impairment** in HIV+ Polydrug Users

Nawal Boukli, Universidad Central del Caribe, Puerto Rico

### P17.17: Proteome Analysis of Skeletal Muscle from a Tailored Pig Model of Duchenne Muscular Dystrophy

Thomas Frohlich, Ludwig-Maximilians-Universitaet Muenchen, Germany

### P17.18: Early Embryo Development in Mammals: mSRM Based Quantification of 27 Key Proteins in 9 Stages

Georg J. Arnold, Ludwig-Maximilians-Universitaet Muenchen, Germany

### P17.19: A Multi-Proteomics Approach to Biological Fluids: A Key to Translate a Discovery into Utility

Claudia Fredolini, KTH - Royal Institute of Technology, Sweden

### P17.20: The Oxidized Proteome of Peripheral **Blood Mononuclear Cells**

daniel Lopez-Ferrer, Thermo Fisher Scientific, USA

### P17.21: Pre-Cardiac Surgery Urinary Biomarkers to Identify Risk for Acute Kidney Injury

Michael Merchant, University of Louisville, USA

### P17.22: Characterization of Chronic Venous Ulcers through Its Inflamatory Exudate: A **Translational Approach**

Lucilene D. Santos, Botucatu Medicine School (FMB-UNESP)/Center for the Study of Venoms and Venomous Animals (CEVAP), Brazil

### P17.23: Bubalus Bubalis Buffaloes Blood Plasma Proteome Applied Translational Medicine

Leticia G. Pontes, Botucatu Medicine School (FMB-UNESP)/Center for the Study of Venoms and Venomous Animals (CEVAP), Brazil

# P18 - CARDIOVASCULAR AND HAEMATOLOGICAL PROTEOMICS

# P18.01: Peptide MRM Comparison Using Integrated Microfluidics/Nanoscale LC with High/Low Resolution MS

Johannes P.C. Vissers, Waters Corp, UK

### P18.02: Proteomic Analysis of Human Cardiac Endothelial, Smooth Muscle, Myocytes, and Fibroblasts

Jake Cosme, University of Toronto, Canada

# P18.03: Smyd1 Interactome in Skeletal and Cardiac Myocytes and Its Involvement in Novel Cellular Functions

Christopher M. Tracy, University of Utah, USA

### P18.04: Identification of Altered Cell Signaling Pathways in B- Lymphocytic Chronic Leukemia

Manuel Fuentes, Cancer Research Center, Spain

### P18.05: Quantification of 90 Proteins by MRM in Biobank Samples from Patients with Myocardial Infarction

Melinda Rezeli, Lund University, Sweden

# P18.06: Cardiac Proteome Changes Induced by Radiation Exposure in a Mouse Model

Mark E. McComb, Boston University School of Medicine, USA

### P18.07: Proteomics and Metabolomics of Starvation Response in Heart Tissue under Normal and MetS Conditions

Joel A. Kooren, Cedars Sinai Medical Center, USA

# P18.08: Human Macrophage Redox and Phosphorylation Signaling in Cardiomyopathy from T. Cruzi Infection

John E. Wiktorowicz, University of Texas Medical Branch, USA

# P18.09: Moving from Inventory to Personalized Medicine: Reducing Cardiovascular Mortality

Albert Sickmann, Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V., Germany

### P18.10: Establishing a High Throughput Proteomic Assay for Cardiac Troponin I in Heart Disease Diagnostics

Daniel Soetkamp, Cedars-Sinai Medical Center, USA

### P18.11: Alterations of the Proteome and Transcriptome in Induced Sputum Samples in Early-Stage COPD Subjects

Ashraf Elamin, Philip Morris International, Switzerland

# P18.12: Prioritizing Proteomics Translation Using Literature Data

Maggie PY. Lam, UCLA, USA

### P18.13: Autoantigen Identification from Mitral Valve Proteomic Profiles of Rheumatic Heart Disease Patients

A Chakraborti, Post Graduate Institute of Medical Education and Research, India

### P18.14: High Definition Lipoproteomics Identifies Novel Proteins Predictive of Coronary Artery Disease

Sanjay S. Bhandari, University of Leicester, UK

# P19 - PROTEIN MODIFICATION (OTHER THAN PHOSPHOPROTEINS)

# P19.01: Truncated Protein Isoforms and Their Genesis in the Human Proteome

Nikolaus Fortelny, University of British Columbia, Canada

### P19.02: Quantifying N-Glycosylation Distribution in Therapeutic Antibodies

Jenny Albanese, Sciex, USA

### P19.03: Quantitative Site-Specific ADP-Ribosylation Profiling of DNA-Dependent PARPs

Guy G. Poirier, Centre de recherche du CHU de Quebec, Canada

### P19.04: The Quantitative Multiple PTMomics Study in INS-1E Cells in Response to Cytokines Stimulation

Honggang Huang, University of Southern Denmark, Denmark

Research, USA

### P19.05: Large-Scale Identifications of Post-Translational Methylation by LC-MS/MS Are Subject to High FDRs

Gene O. Hart-Smith, UNSW, Australia

### P19.06: Proteome-Wide Prediction of the **Human Protein Ubiquitination Sites**

Dong Li, The Academy Of Military Medicine Science, China

### P19.07: A Universal Chemical Enrichment Method for Mapping Protein N-glycosylation Weixuan Chen, Georgia Institute of Technology,

**USA** 

### P19.08: Proteomic-Based Discovery of the **Human Arginine Methylome**

Rebecca Pferdehirt, Genentech, Inc., USA

### P19.09: Characterization of Intact Glycoproteins by CESI-MS under Native and Denaturing Conditions

Rosa Viner, Thermo Fisher Scientific, USA

### P19.10: Assessment of RA-Specific Citrullinated Peptides in Synovial Fluid by PRM-MS Analysis

Min Jueng Kang, Seoul National University, Korea

### P19.11: Ubiquitin and the Kiss of Death under **Stress Conditions**

Thibault Mayor, The University of British Columbia, Canada

### P19.12: Targeted PTM Analysis by SWATH-MS: High Confidence Site Assignment and Quantification

George Rosenberger, ETH Zurich, Switzerland

### P19.13: Impact of Limited Proteolysis on Protein Function in Breast Cancer Mapped by Positional **Proteomics**

Philipp F. Lange, University of British Columbia, Canada

### P19.14: Identifying the Interactome of Human RNA-Binding E3-Ubiquitin Ligases

Eric Wolf, University of Toronto, Canada

### P19.15: Analysis of N-Terminal Acetylation on RNA Polymerase II in Saccharomyces Cerevisiae Selene Swanson, Stowers Institute for Medical

### P19.16: SWATH-MS Technology for Citrullination: A Target for Neurodegenerative Diseases

Justyna Fert-Bober, Cedars-Sinai Medical Center, **USA** 

### P19.17: A Dynamic Picture of the Ubiquitinome upon Proteasome Inactivation

Jeroen AA. Demmers, Erasmus MC, Netherlands

### P19.18: Comprehensive Proteomic Analysis of N-Terminal Acetylated Proteins in Caenorhabditis Elegans

Don-Ha Park, Yonsei Proteome Research Center, Yonsei University, Korea

### P19.19: Modulation of Surface Sialylation of HeLa Cells upon Different Growth Factor Stimulus

Maria Ibáñez-Vea, University of Southern Denmark, Denmark

### P19.20: Characterizing the Dynamic Change of Global and Site-Specific S-Nitrosoproteome and Glutathionylome

Yi-Ju Chen, Academia Sinica, Taiwan

### P19.21: SanxotGhost: Toward the Global **Analysis of the Posttranslational Modificome**

Navratan Bagwan, Centro Nacional de Investigaciones Cardiovasculares, Spain

### P19.22: Automating Optimization of **Compensation Voltages for Differential Mobility Separation Using Skyline**

Jenny Albanese, SCIEX, USA

### P19.23: PAD4 Regulates Cellular Polyamine **Production through Citrullinating the Negative Regulator Antizyme**

Chien-Yun Lee, National Chung Hsing University-Academia Sinica, Taiwan

### P19.24: Protein-Adductome Analysis for Human **Exposure-Monitoring with Environmental and Endogenous Mutagens**

Takayoshi Suzuki, National Institute of Health Sciences, Japan

### P19.25: Identifying Protein Targets of Reactive Metabolite Covalent Binding by LC-MS/MS Lekha Sleno, UQAM, Canada

### P19.26: Mass Spectrometry-Based Analysis of **Dynamic Protein Cysteine Modifications**

Yi-Yun Chen, Academia Sinica, Taiwan

### P19.27: Enhanced Purification of Ubiquitinated Proteins by Hybridized Ubiquitin-Binding **Domains**

Ping Xu, Beijing Proteome Research Center, China

### **P20 - IMAGING MASS SPECTROMETRY**

# P20.01: Matrix Coating Assisted by an Electric Field (MCAEF)-LDI Imaging of Prostate Cancer Tissue Biomarkers

Xiaodong Wang, University of Victoria, Canada

# P20.02: An Investigation into Multi-Model Tissue Imaging on a Single Section by DESI and MALDI MS

David Heywood, Waters, UK

P20.03: Enhancing the Analytical Capabilities of DESI Imaging Using Ion Mobility Separation Justin Chang, Waters, UK

P20.04: Megapixel Tissue Imaging at High-Speed: Evaluation of a MALDI-TOF Prototype Michael Becker, Bremen Daltonik GmbH, Germany

### P20.05: MALDI Imaging of a Novel and Orally Bioavailable Glucokinase Activator in Rat Kidney Tissue

Ping Cao, Amgen, USA

### **P21 - GLYCOMICS IN BIOLOGY AND DISEASES**

# P21.01: Interplay between High Glucose Levels and Aspirin on Human Platelets

Jean-Charles Sanchez, University of Geneva, Switzerland

# P21.02: Development of Bioinformatics Support for Quantitative Glycomics Using Tandem Mass Tags

Tara Schroeder, Thermo Fisher Scientific, USA

# P21.03: mO-glycobase - An Integrated Database for O-glycosylation

Jiangming Huang, Fudan University, China

# P21.04: Salivary Glycoprotein Characterisation Using Lectin Magnetic Bead Arrays

Michael Caragata, The University of Queensland, Australia

# P21.05: Development of Specificity-Enhanced PSA by Rapid Glycan Profiling

Yoshimi Haga, The University of Tokyo, Japan

# P21.06: N-Glycosylation Analysis of Formalin Fixed Paraffin Embedded Samples by Capillary Electrophoresis

Andras Guttman, University of Debrecen, Hungary

# P21.07: Investigation of QTOF Collision Energies to Allow Identification of Complete N- and O-Glycopeptide

Stephanie Kaspar, Bruker Daltonik GmbH, Germany

### P21.08: In-Depth Analysis of Site-Specific N-Glycosylation in Vitronectin from Human Plasma

Heeyoun Hwang, Korea Basic Science Institute, Korea

# P21.09: Millibeads-Based Lectin Array toward the Fully Automated Glycan Profiling

Atsushi Kuno, National Institute of Advanced Industrial Science and Technology (AIST), Japan

### **P22 - SUBCELLULAR PROTEOMICS**

# P22.01: Deep Proteomics of Nucleocytoplasmic Partitioning and the CRM1-Dependent Nuclear Exportome

Samir Karaca, Max Planck Institute for Biophysical Chemistry, Germany

### P22.02: Potential of Exosomes in Relation to Diagnostics in Lung-Related Diseases and Cancers

Malene M. Joergensen, Aalborg University Hospital, Denmark

### P22.03: Reinforcement-Polarity Dependently Regulated Synaptic Proteins in a Learning Paradigm in Mice

Thilo Kähne, University Magdeburg, Germany

# P22.04: Towards the Elucidation of the Complete Mitochondrial Protein-Protein Interaction Network

Matthew Jessulat, University of Regina, Canada

### P22.05: The Potential of Exosomes as Diagnostic Markers for Non-Small Cell Lung Cancer

Rikke Baek, Aalborg University Hospital, Denmark

# P22.06: Multiplexed Quantitative Profiling of Mitochondria from the USP30 Knockout Mouse Lilian Phu, Genentech, USA

### P22.07: Subcellular Proteomic Study of Skeletal Muscle by Evaluated Fatty Acid Level

Sai Ming Ngai, The Chinese University of Hong Kong, Hong Kong

### P23 - PERSONALIZED MEDICINE

### P23.01: Phosphopeptide LCMS Immunoassays to Assess Active Tumor Signaling and **Application to Core Biopsies**

Kimberly A. Lee, Cell Signaling Technology, USA

### P23.02: Development of Companion Diagnostics for RCC (Renal Cell Carcinoma) Treatment with mTOR Inhibitor

Ryosuke Watanabe, National Institute of Biomedical Innovation, Japan

### P23.03: Discovery of Biomarker Candidates for **NSCLC Treatment Using CTOS (Cancer Tissue-**Originated Spheroid)

Ryosuke Watanabe, National Institute of Biomedical Innovation, Japan

### P23.04: Array-Based Signaling Pathway **Profiling for Cancer Therapy Personalization**

Tesshi Yamada, National Cancer Center Research Institute, Japan

### P23.05: Targeting Modified Single Amino **Acid Variants in Cancer Cell Lines by Parallel** Reaction Monitoring

Christoph Taumer, University of Tuebingen, Germany

### P23.06: Molecular You Corporation (MYCO): **Comprehensive Omic Analysis for Personalized Preventive Medicine**

Anna Prudova, University of British Columbia, Canada

### P24 - PROTEOGENOMICS

### P24.01: LncRNA Proteomics: A Novel Mass **Spectrometry Data Identification Database of** Long-Noncoding RNA

ZhuoXin Chen, Fudan University, China

### P24.02: Profiling Molecular Changes during Malignant Transformation and Response to Different Oxygen Levels

Frida Danielsson, Royal Institute of Technology (KTH), Sweden

### P24.03: PGA: An R Package for Identification of Novel Peptides by Customized Database Derived from RNA-Seq

Bo Wen, BGI-Shenzhen, China

### P24.04: A Proteogenomic Study on p53 Mutant Peptide Detection Reveals Biological and **Technical Limitations**

Lampros Dimitrakopoulos, University of Toronto, Canada

### P25 - METABOLOMICS AND METABOLIC DISEASES

### P25.01: Characterization and Collision Cross Section Determination of Lipids from Obese Mouse Models

Lee Gethings, Waters Corp, UK

### P25.02: Analysis of Low-MW Aldoses, Ketoses, and Carboxylates by Single Chemical Derivatization/LC-MS/MS

Karen Lin, University of Victoria, Canada

### P25.03: Creation of Metabolite Libraries for Metabolomics Screening of Yeast Strains Used in Beer Production

daniel Lopez-Ferrer, thermo fisher scientific, USA

### P25.04: Adding Information to Metabolic Pathway Understanding of Rat Liver Tissue **Changes on High Fat Diets**

Devin L. Drew, Thermo Fisher Scientific, USA

### P25.05: MetTailor: Post-Alignment **Preprocessing Package for Mass Spectrometry Data in Metabolomics**

Gengbo Chen, National University of Singapore and National University Health System, Singapore

### P25.06: Application of Quantitative Metabolomics in Maternal, Prenatal and **Neonatal Disease Studies**

Jennifer Reid, University of Alberta, Canada

### P25.07: Global Activity Survey of Transcription Machinery in Circadian Rhythm of Mammals

Mingwei Liu, Beijing Proteome Research Center, China

### P25.08: AltitudeOmics: Red Blood Cell Metabolic Adaptation to High Altitude Hypoxia

Travis Nemkov, University of Colorado-Denver, Anschutz Medical Campus, USA

### P25.09: Qualitative and Quantitative Profiling of Naphthenic Acids in Oil Sands Process Water

Darryl Hardie, University of Victoria, Canada

### P25.10: SIRT5 Desuccinylates Mitochondrial Isocitrate Dehydrogenase 2 and Regulates **Tumorgenesis**

Lei L. Xu, Fudan University, China

### **P26 - CHEMICAL PROTEOMICS AND DRUG DISCOVERY**

### P26.01: Assessing Biotherapeutics Stability **Using Raman Spectroscopy**

Marinella G. Sandros, University of North Carolina at Greensboro, USA

### P26.02: Cell-Based, High-Throughput Screen to Overcome Drug Resistance by CIN (Chromosomal Instability)

Ryosuke Watanabe, National Institute of Biomedical Innovation, Japan

### P26.03: Evaluation and Optimization of Immunodepletion of Plasma from Common **Preclinical Animal Models**

Chris Melm, Sigma-Aldrich Corporation, USA

### P27 - PROTEOMICS AND CELL IMMUNITY

### P27.01: Unbiased & System-Wide **Characterization of MHC-Bound Peptides & Epitopes**

Queenie W. T. Chan, University of British Columbia, Canada

### P27.02: Profiling of Alum Adjuvants-Induced Host Cell Immune Response, by a Systems Vaccinology Approach

Sietske Kooijman, Intravacc, Netherlands

### P27.03: The Human T Cell Secretome. Physiological Responses to ex vivo Transfer, and to in vitro Activation

Peter D.E.M. Verhaert, Lund University, Sweden

### P27.04: MS-Based Quantitative Proteomics for Serum Biomarker Discovery in Systemic Lupus **Erythematosus**

Deniz Baycin Hizal, MedImmune, USA

### P27.05: Proteomic Analysis of Serum Antibody Repertoires

Andrew Horton, University of Texas at Austin, USA

### P27.06: Neonatal Screening for Immuno-Deficiencies by Profiling of Dried Blood Spots on Antibody Bead Arrays

Mahya Dezfouli, Karolinska Institutet, Sweden

### **P28 - INTEGRATED OMICS**

### P28.01: Multi-Omics Analysis of Estradiol Treatment Effects in MCF7 Cells as Part of **Human Toxome Project**

Vadiraja B. Bhat, Agilent Technologies, USA

### P28.02: Integrated Molecular Phenotyping in Chondrocytes Identifies Pathways Disrupted in Osteoarthritis

Theodoros Roumeliotis, Wellcome Trust Sanger Institute, UK

### P28.03: Mitochondria-Driven Cancer Pathways in Triple Negative Breast Cancer

Vadiraja B. Bhat, Agilent Technologies, USA

### P28.04: Using Integrative Multi-Omics to **Detemine Biomolecular Changes in Weight Gain** and Insulin Resistance

Christine Y. Yeh, Stanford University, USA

### P28.05: Integrating Genomics and Proteomics to Reveal Loci Underpinning Social Immunity in **Honey Bees**

M Marta Guarna, University of British Columbia, Canada

### P28.06: SIMPLEX - A Multimolecular Omics Approach for Systems Biology

René P. Zahedi, Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V., Germany

### P28.07: An Integrated Omics Approach Reveals Synaptic Plasticity Changes in an Alzheimer'S Mouse Model

Stefan J. Kempf, Southern University of Denmark, Denmark

### P28.08: Sportomics: Building a New Concept in Metabolic Studies and Exercise Science

L. C. Cameron, Federal University of State of Rio de Janeiro, Brazil

### P28.09: Combined Targeted Analysis of **Proteins and Metabolites in Tear Fluid**

Sascha Dammeier, University of Tuebingen, Germany

### P28.10: Visualizing Proteomics Data in Genomic **Context Using the UCSC Genome Browser**

Eric W. Deutsch, Institute for Systems Biology, USA

### P28.11: Integrated Proteomics for Identification of the Specific Network in Cancer Stem Cells

Norie Araki, Kumamoto University, Japan

### P28.12: The Principles of the Relationship between Gene Intrinsic Properties and **Phenotypic Features**

Dong Yang, Beijing Proteome Research Center, China

### P28.13: Multi-Omic Blood Biomarker Signatures of the Late Phase Asthmatic Response

Amrit Singh, University of British Columbia, Canada

### P28.14: Multi-Omics Analysis of Primary Cytotrophoblasts from Second Trimester and **Term Placentas**

Christie Hunter, SCIEX, USA

### P28.15: A Component-Based Classifier Can Diagnose AECOPD by Integrating across Omics **Data Types**

Casey Shannon, PROOF Centre of Excellence, Canada

### P28.16: Proteomic Identification of Natural **Substrates for Matriptase-2**

Reinhild Kappelhoff, University of British Columbia, Canada

### P28.17: An Integrated NMR-MS Metabonomic Approach for Classification of Pleural Effusions: **New Criteria**

Ching Wan Lam, The University of Hong Kong, Hong Kong

### P29 - STANDARDIZATION IN PROTEOMICS

### P29.01: Study on Gradient Selection for Peptide Separate in RPLC

Wenyuan Lu, Fudan University, China

### P29.02: The Power of Predicted Spectral Libraries to Unlock Data Independent Acquisition

Andreas FR. Huhmer, Thermo Fisher Scientific, USA

### P29.03: Proteomics Data Analysis Workflow for **Accumulated LCMS Files in Public Database**

Yasushi Ishihama, Kyoto University, Japan

### P29.04: Modified Coomassie Staining Supports **Different Imaging Formats for Quantitative Top-Down Proteomics**

Nour Noaman, University of Western Sydney, Australia

### P29.05: A Universal Method for Peptide Identification

Shannon Eliuk, Thermo Fisher Scientific, USA

**All Oral and Mini Oral Abstract Presenters** have been invited to prepare a Poster in addition to their Oral/Mini Oral **Presentations. Poster presentations** for Oral and Mini Oral Presenters will be labeled with their Oral/Mini Oral Presentation number (eg CS01.01)

# SECTION 10 AUTHOR INDEX

# 10/ AUTHOR INDEX

### **AUTHOR INDEX**

### Authors highlighted in bold = **Presenting Author for this abstract**

### Α

Aapola Ulla	CS28.10, P07.09, P11.05
Aaron Shawn D	
Aartsma-Rus Annemieke	P04.09
Aasebø Elise	CS01.10
Abascal Federico	P01.25
Abbade Luciana P.F	P17.22
Abbineni Prabhodh S	
Abdelmegid Shaimaa W	P11.26
Abelin Jennifer	CS08.08
Abe Yasuhiro	P15.01
Abe Yuichi	P06.70
Acar Mustafa B	P06.51, P09.21
Achour Brahim	CS05.07
Acuto Oreste	CS20.07
Adachi Jun	
Adair-Kirk Tracy	P02.01
Adamec Jiri	
Adar Fran	P26.01
Adhami Mojarad Bahareh	CS18.03
Adiutori Rocco	
Admon Arie	CS28.03
Adwg Nci Cptac	
Aebersold Ruedi	
CS23.08, CS30.03,	CS30.06. P04.23. P05.03.
P07.18. P0	7.38. P13.24. P15.10. P19.12
Aerts Johannes M.F.G	
Aguilar-Mahecha Adriana	
Ahammad Rijwan U	
Ahern Christopher	
Ahmad Intakhar	
Ahn Jeeyun	
Ahn Seong Beom	
Ahn Seong Joon	
Ahrends Robert	
Ahrens Christian	
Ahrens Maike	
Ahrné Erik	
Aicheler Fabian	
Aita Giuliano	
Aittokallio Tero	
Aiyetan Paul	CS01.06, P06.59
Alabdulkarim Balgis	
Alaiya Ayodele	
Albanese Jenny	
Albarello Luca	
Alberio Tiziana	
Alesawi Anwar	P06.56
Alessio Nicola	P06.51
Alfano Massimo	
Al-Fageeh Khaled	
Al Feteisi Hajar	
Alfieri Alan	
Al-Gizawiy Mona	

Allard Rene	CS28.04
Allevi Raffaele	P06.64
Alli Shaik Asfa	P15.06
Alloggio IsabellaF	P09.19, P09.23
Almada Colucci Juliana	P17.01
Al-Majdoub Mahmoud	CS26.10
Al-Mazrou Amer	CS13.06
Almeida Julia	
Alm Tove LCS	
Al Musayeib Nawal M	
Alpizar Adan	
Al-Tweigeri Taher	
Amann Joseph M	
Amano Mutsuki	
Ameling Sabine	
Anaev Eldar C.	
Anand Ganesh S	
Anania Veronica	
Ancheva Lina	
Anckarsäter Henrik	
Andell PontusAndereggen Elisabeth	
Anderloni Giulia	
Andersen Melvin E	
Andersen Michael B	
Andersen VibekeCS07.05, CS2	
Andersson Eni	
Andolfo Annapaola	
Andres Allen	
An Eunkyung	
Angermann Bastian R	
Anglicheau Dany	
Angres Brigitte	
Anikanov NikolayP01.23, P	
Anjo SandraC	
Antonarakis Stylianos	CS19.04
Aoki HiroyukiCS	02.06, P22.04
Appelqvist Roger	CS04.09
Apte Arun	P21.02
Aquino Priscila F	P06.23
Aragón Jorge	
Arakawa Noriaki	
Araki NorieP06.09, P13.22,	
Arapidi GeorgijP01.23, P0	
Araujo Luiz	
Araya Natsumi	
Archakov Alexander IP01.01,	
Arckens Lutgarde	
Arita Danielle Y	
Armstrong Stuart	
Arnold Georg J	
Arora P	
Asif Abdul R	
Asplund Anna	
Assunção Nilson	
Astorri Anna Laura	
Astrup Arne	
Astrup Arrie	

Atalla Heha	P11.26	Basler Konrad	CS30.06
	CS02.09		CS11.02. P28.08
	P19.13, P28.16		CS04.10
	CS16.04		P04.27, P16.19, P17.03, P17.10
	CS09.09		P15.07
	CS23.08		CS16.09
	CS27.04		P04.02
	CS27.04		P22.06
Avtonomov Dmitry	<b>CS11.06</b> , P04.06	Baycin Hizal Deniz	CS14.07, P27.04
Awasthi Shivangi	CS25.08	B. Bekker-Jensen Dort	e <b>P02.06</b> , P15.04
Ayers Deborah	P07.22	Becher Dörte	P09.21
Ayoglu BurcuP04	4.14, P07.29, P16.08, P16.09, P17.19	Bech Joan J	CS04.07
Ayoub Daniel	P04.20, P07.15	Becker Lisa	P06.72
Ayres Antonio F	P06.23	Becker Michael	P20.04
	CS30.01	Beckley Janel R	CS23.10
Azurmendi Leire	P17.11		CS15.04
_			P20.04
В		,	P16.19
			P06.45
	P07.36		P06.29
	<b>CS02.06</b> , P22.04		P06.54
	CS16.09		P22.02
	CS21.04		CS02.07
	<b>CS11.01</b> , P02.04		P09.14
	P18.06		P09.14
	P18.02		CS02.08, CS25.07
	CS17.09, P13.02		CS20.03
	CS21.08, CS30.03		CS16.04
	P06.05		P04.47, P09.04
	P22.02, <b>P22.05</b>		<b>CS07.05</b> , CS20.08, CS24.10
			P05.03
	P06.20, P07.16, <b>P14.02</b>	,	CS05.08
	<b>P19.21</b>		P06.56
			P07.02
	P16.02 <b>CS05.06</b> , P06.54, P22.06		P16.21
	CS03.06, P00.34, P22.06		P16.12
	CS14.09, P06.01, <b>P06.12</b> , <b>P06.58</b>		P18.00
			P17.04
	P06.66		P17.04
	P16.02, P28.15		HPP03.03
	P13.08		P09.23
	CS16.08, <b>CS17.04</b> , P13.10, P13.13		CS01.10, CS02.04, CS17.10, <b>P17.06</b>
	P17.08		P06.56
	P19.10		P13.25
	CS09.03		CS12.07, <b>CS28.10</b> , <b>P07.09</b> , P11.05
	P02.19		CS19.04
	P28.10		CS16.06, P04.11, P04.47, P09.04
	CS05.07		CS18.10, CS29.04, P19.17
Barbieri Christopher	P06.38		P04.34
Barbour Andrew P	CS07.03		P18.14
	CS19.09		CS28.08
Barkovits Katalin	P07.36, P15.25		CS15.04
Barnabas Georgina	P07.28		P06.53, <b>P28.01</b> , <b>P28.03</b>
Barnea Eilon	CS28.03		CS23.07
Barraviera Benedito	P17.22, P17.23		CS21.06
Barr John N	P09.25	Bigaud Emilie	P01.10
	P08.04	Bi Lijun	P09.03
Barsnes Harald	CS02.04, CS17.10, P17.06	Bilkova Zuzana	P04.15, P07.14, P15.11
	P18.04		P28.02
Bartolomé Ruben A	CS01.08, P06.25		P11.02
Bartova Simona	P06 65	Ringol Baris	P22.06

Bartsch Joerg W......CS01.04

Basik Mark ......CS07.06, P06.14

Bingol Baris......P22.06

Biniossek Martin.....CS01.04

Biolchi Alessia.....CS21.06

Diracrasan Elin	CC1E 07 <b>D11 24</b>	Drand Martin	CS02.01
	CS15.03, <b>P11.24</b>		P02.05
	CS07.05, CS20.08, CS24.10	-	CS01.03
	P07.30		CS02.08
	CS27.09, P15.24		P17.21
	CS28.08		<b>CS03.06</b> , CS04.05
Blackburn Jonathan	P09.05	Brinc Davor CS27.03,	P04.27, P06.68, P16.19, P17.12
Blagoev Blagoy	CS13.04, P15.09	Brito Rui	P13.14
Blankenburg Sascha	P15.22	Broadhurst David	P25.06
Blank Michael	CS06.07, CS10.09, HPP03.04,	Brodie Nicholas I	P10.01
·	P13.12, <b>P15.08</b> , P17.20, P29.02		CS21.04
	P04.07		CS04.07
,	CS04.06		CS27.07
	P06.68		P09.26
	P07.38		P04.11, P04.47
	P16.06		CS22.09
	CS22.05		P04.23
	P07.05		CS21.06
	P02.09		CS30.06
•	P16.04		CS30.06
	P28.01	_	CS01.10
	CS26.05		P16.15
Bøgsted Martin	CS07.05	Buffoli Federico	P06.02
Bø Lars	P17.06	Bugrova Anna E	CS28.07, P16.17
Bölte Sven	P16.06	Bulgarelli Adriana	CS04.10
	P02.03, P02.11, P02.13,		P07.13
	P06.45, P13.12		P17.14
	CS07.05		P08.04
	CS05.08		P04.42
	09.19, P09.20, P09.22, P09.23		CS21.06
	CS08.03, CS27.10, P06.35		CS22.10
			CS08.04, P04.23, P09.07
	. <b>CS04.08</b> , CS06.06, CS07.08, D9, CS12.03, CS12.08, CS15.09,		P04.25
	0, CS24.03, CS25.05, CS26.02,	-	CS07.04
	04.01, P05.01, P06.14, P06.34	•	P09.21
	P07.36, P07.39, P10.01, P10.02,		P06.62
	, P10.07, P11.18, P11.20, P20.01,		P16.09, P17.19
	P25.02, P25.09	•	•
Borel Christelle	CS19.04	С	
Borén Mats	P15.16		
Borrmann Annika	P04.18	Cadkova Michaela	P04.15
	P28.09		P07.41, P07.42
	P04.39		CS13.08
	CS28.04		P07.09
•	P04.38	•	CS17.07
	P28.01		CS21.10, P09.31
	P16.10, <b>P17.16</b>		P11.10
	P28.13		CS08.07, P07.25
	P09.07, <b>P15.24</b> , P19.03	•	<b>P06.38</b> , P06.39
	CS02.07		P06.36
	CS30.08	· ·	P06.36
Boarmaaa /	<b>CS08.05</b> , P27.05		CS04.07, CS30.01
	P04.23		P09.14
	CS07.09		P05.05
Bowen Michael A	CS14.07, P27.04	Cantor David	CS14.09, <b>P06.01</b>
	P04.38, P08.07		CS07.07
	CS29.04		P20.05
	P07.36		P21.04
	P04.01, P17.19		CS07.10
Brancia Francesco L	P04.45	Cardinali Barbara	P07.05

±			
Care Natasha	P06.26	Chen Anna	P04.02
Carillo De Santa Pau Enri	queP01.04	Chen Ann Y	CS01.07
Carli Franca	P07.05	Chen Chao-Jung	P02.08
Carlsen Thomas G	CS07.05	Chen Chi-De	P06.11
Carmargo Caio C	P17.22	Chen Chien-Sheng	P04.21
Caron Etienne	CS08.07	Chen David	CS07.03
Caron-Lizotte Olivier	CS08.03, CS27.10	Chen Emily I	CS16.08
Carreira Ricardo J	CS01.09, <b>CS08.06</b>	Chen Gary Gang	P11.04
Carrera Monica CS	S06.07, CS25.03, P17.20, P25.03	Cheng Ching-Yu	CS12.07
Carrol Enitan	CS16.06, P04.11, P09.04	Chen Gengbo	P25.05
	P09.25	Cheng Kai	CS20.05
	CS08.08, P04.42		CS03.07
	P11.09	•	P06.27
	CS21.06		CS26.08
	P06.23	-	CS20.06
	CS01.08, P06.25		CS10.06
	P17.01		P06.59, P15.25
	P07.30	-	CS01.06, <b>CS30.07</b>
	P13.14		CS01.00, <b>CS30.07</b>
	P16.05	·	CS01.06
•			
	P16.05		CS12.07
	CS23.03		P11.09
	CS07.10		CS07.08
	P06.65		P04.40
	P27.04	-	P28.01
	P06.38		CS01.03
	CS15.06		P06.69
	P18.13		CS06.02
Chambers Andrew GC	CS07.08, CS24.03, P06.14, P11.18	•	P07.04, P28.15
Chamot-Rooke Julia	CS02.07	Chen Weixuan	CS20.04, <b>P19.07</b>
	1.06, CS30.03, CS30.07, P06.59		CS08.10
Chandramouli Kondethin	nmanahalli <b>P11.03</b>	Chen Yet-Ran	P04.22
Chandran Vinod	P11.14	Chen Yi-Ju	P19.20
Chan Eric	CS12.07	Chen Yi-Yun	P19.26
Chang Chia-Wei	D10.2C	Chan VII. III	
	P19.26	CHEH TU-JU	P06.27, P16.11, P19.20
-	CS03.05		P06.27, P16.11, P19.20
Chang Chuan-Fa		Chen Yuling	
Chang Chuan-Fa Chan Gerard T	<b>CS03.05</b>	Chen YulingChen Zhuoxin	P06.57, P07.27
Chang Chuan-Fa Chan Gerard T Chang Hsiao-Jen	<b>CS03.05</b> P10.03 P06.27	Chen Yuling Chen Zhuoxin Chernev Aleksandar	
Chang Chuan-FaChan Gerard TChang Hsiao-JenChang Justin	CS03.05 P10.03 P06.27 P20.03	Chen Yuling Chen Zhuoxin Chernev Aleksandar Cheruku Harish R	P06.57, P07.27 P24.01 C\$26.07 C\$14.09, P06.01
Chang Chuan-Fa		Chen Yuling Chen Zhuoxin Chernev Aleksandar Cheruku Harish R Cheung Gemmy	P06.57, P07.27 P24.01
Chang Chuan-Fa		Chen Yuling	P06.57, P07.27 P24.01 CS26.07 CS14.09, P06.01 CS12.07 CS18.03
Chang Chuan-Fa		Chen Yuling	P06.57, P07.27
Chang Chuan-Fa		Chen Yuling	P06.57, P07.27
Chang Chuan-Fa		Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P19.23 CS03.05 P04.22 CS26.08 P07.08	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P19.23 CS03.05 P04.22 CS26.08 P07.08 P07.08	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P19.23 CS03.05 P04.22 CS26.08 P07.08 P06.27 P06.17, P06.60, P07.20	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P06.27 P20.03 P06.17, P07.08, P07.08 P06.17, P06.60, P07.20 CS10.03	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P19.23 CS03.05 P04.22 CS26.08 P07.08 P06.27 P06.67 P06.60, P07.20 CS10.03 P11.10	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P19.23 CS03.05 P04.22 CS26.08 P07.08 P06.27 P06.17, P06.60, P07.20 CS10.03 P11.10 P17.14, P27.01	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P19.23 CS03.05 P04.22 CS26.08 P07.08 P06.27 P06.17, P06.60, P07.20 CS10.03 P11.10 P17.14, P27.01 P10.04	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P19.23 CS03.05 P04.22 CS26.08 P707.08 P06.27 P06.17, P06.60, P07.20 CS10.03 P11.10 P17.14, P27.01 P10.04 P06.71	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P04.22 CS26.08 P06.27 P06.11, P06.17, P06.60, P07.20 CS10.03 P11.10 P17.14, P27.01 P10.04 P06.71 CS07.09	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P19.23 CS03.05 P04.22 CS26.08 P07.08 P06.27 P06.27 P06.11, P06.60, P07.20 CS10.03 P11.10 P17.14, P27.01 P10.04 P06.71 CS07.09 P09.07	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P19.23 CS03.05 P04.22 CS26.08 P07.08 P06.27 P06.11, P06.60, P07.20 CS10.03 P11.10 P17.14, P27.01 P10.04 P06.71 CS07.09 P09.07 P24.04	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P19.23 CS03.05 P04.22 CS26.08 P07.08 P06.27 P06.17, P06.60, P07.20 CS10.03 P11.10 P17.14, P27.01 P10.04 P06.71 CS07.09 P09.07 P09.07 P24.04 P16.05	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P19.23 CS03.05 P04.22 CS26.08 P07.08 P06.27 P06.11, P06.60, P07.20 CS10.03 P11.10 P17.14, P27.01 P10.04 P06.71 CS07.09 P09.07 P24.04	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P19.23 CS03.05 P04.22 CS26.08 P07.08 P06.17, P06.60, P07.20 CS10.03 P11.10 P17.14, P27.01 P10.04 P06.71 CS07.09 P09.07 P24.04 P16.05 CS27.09 P17.04	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P19.23 CS03.05 P04.22 CS26.08 P07.08 P06.27 P06.17, P06.60, P07.20 CS10.03 P11.10 P17.14, P27.01 P10.04 P06.71 CS07.09 P09.07 P24.04 P16.05 CS27.09	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P19.23 CS03.05 P04.22 CS26.08 P07.08 P06.17, P06.60, P07.20 CS10.03 P11.10 P17.14, P27.01 P10.04 P06.71 CS07.09 P09.07 P24.04 P16.05 CS27.09 P17.04	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P19.23 CS03.05 P04.22 CS26.08 P07.08 P06.27 P06.17, P06.60, P07.20 CS10.03 P11.10 P17.14, P27.01 P10.04 P06.71 CS07.09 P09.07 P24.04 P16.05 CS27.09 P17.04 P16.05 CS27.09 P17.04	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P19.23 CS03.05 P04.22 CS26.08 P07.08 P06.27 P06.17, P06.60, P07.20 CS10.03 P11.10 P17.14, P27.01 P10.04 P06.71 CS07.09 P09.07 P24.04 P16.05 CS27.09 P17.04 P16.05 CS27.09 P17.04 P09.33 P17.04 P09.33 P18.11	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P19.23 CS03.05 P04.22 CS26.08 P07.08 P06.27 P06.17, P06.60, P07.20 CS10.03 P11.10 P17.14, P27.01 P10.04 P06.71 CS07.09 P09.07 P09.07 P24.04 P16.05 CS27.09 P17.04 P09.33 P18.11 CS04.03	Chen Yuling	P06.57, P07.27
Chang Chuan-Fa	CS03.05 P10.03 P06.27 P20.03 P06.17, P07.08, P07.20 P19.23 CS03.05 P04.22 CS26.08 P07.08 P06.27 P06.17, P06.60, P07.20 CS10.03 P11.10 P17.14, P27.01 P10.04 P06.71 CS07.09 P09.07 P24.04 P16.05 CS27.09 P17.04 P09.33 P18.11 CS04.03 CS02.07	Chen Yuling	P06.57, P07.27

Christiansen Gunna	CS07.05	Coyaud Etienne	<b>CS18.03</b> , CS18.04
Christie Sean	P16.02	Coyle Rachael	P28.02
Chuchalin Alexander G	P07.07	Craig Colleen	P28.04
Chung Maxey C.M	CS16.01	Creighton Chad J	P28.03
Chu Phillip	CS05.04	Cretu Daniela	P11.14
Ciavarini Steve	P04.26		CS09.04, P05.02
Ciliberto Andrea	CS11.01		P06.01
Cizkova Dasa	CS04.06		CS13.05, CS15.06, P19.16
Clague Michael J	P06.62	Cubano Luis	P16.10
Clarke Blaise			P17.16
Clarke Stephen		Cui Liang	P25.05
C. Larsen Sara			P06.69
Claude Emmanuelle			P23.06
Clawson Hiram		•	P02.03
Clemente Felipe			P28.05
Clemmer David		Czajkowsky Daniel M	CS03.07
Coberly Suzanne	P20.05	_	
Codreanu Simona G	CS07.10	D	
Cohen Freue Gabriela			
Colás Eva			P09.05
Colella Alex			P06.44
Cole Robert N			P13.24
Collins Andrew			P04.09, P09.02
Collins Ben		_	P25.08
Colomé-Calls Núria			P04.12
Colwill Karen			P09.23
Colyer John			P28.09
Coman Cristina	P28.06		P26.02
Comartin David			P06.22
Comb Michael J			P24.02
Cominetti Ornella			P05.02
Co Ngai Na			CS04.10
Conner Kaitlyn			P18.04
Connett John E			P09.14
Consortium The Direct			P09.07
Conti Elena			P03.01
Contrepois Kevin P.F			P23.06
Conway Ed M		=	CS16.07
Coombes Kevin R			P06.18
Coorssen Jens R			CS21.06
Corbo Claudia			P19.13
Cordes Volker			P09.02
Coresh Joe			P15.24, P19.03
Cornille Karen		_	CS26.05
Corno Andrea			CS11.07
Corpuz Racquel		=	P01.21
Corrales Fernando			P17.11
Corrales Fernando J			CS01.07
Corthals Garry L		= -	CS28.07
Corthésy John Coscia Fabian			CS26.06
			P09.02
Cosciani Cunico Elena Cosme Jake			P25.01 CS18.10, P19.17
Costantino Paolo			CS08.05
Côté Carolino			CS10.09
Côté Caroline Cottle Andrew			P01.21
			P01.21
Coulson Judy M Covas Dimas			P06.16
Coveney Clare			P07.03
Cox David			P04.36
Cox Jennifer		_	CS21.06
Cox Juergen			C321.00
Coxson Harvey O			
55.5511 Hai vey O	77.04	_ 5 _ 6 6 6 7	

Demarco MariCS0			<b>P06.67</b> , P19.19
Demenkov Pavel			CS21.05
Demmers Jeroen A	<b>CS18.10</b> , CS29.04, <b>P19.17</b>		P07.12
Demonte Naveen L	P01.24	Droit Arnaud	P09.07, P15.24, P19.03
Deng Chunhui		Droste Conrad	P01.21
Deng Haiteng	P06.33, P06.57, P07.27	D'Santos Clive	P06.13
Deng Jiaoyu	P09.03	Dubois Marc	P04.23
Deng Liulin	CS06.02	Duchateau Magalie	CS02.07
Denning Kendall	P18.03	Ducom Jean-Christophe.	P09.33
Depke Maren		Duempelfeld Birgit	CS09.03
De Sousa Marcelo V			CS08.09, P19.13, P28.16
Desouza Leroi V			CS08.04
Deutsch Daniela R			P06.18
Deutsch Eric			CS02.07
Deutsch Eric W			CS07.06
Devaux Stéphanie			P06.55
Devis Laura			P06.55
Dev Sanjoy			CS18.04, P13.26
			<b>CS06.07</b> , P25.03
Dezfouli Mahya Diamandis Eleftherios			
			P03.01
Diamandis Eleftherios P		•	iP06.66
P17.03,			CS30.06
Dianes Jose A			CS03.09
Diaz De La Guardia Rafael			P04.15, P07.14
Di Ciccio Pierluigi A			P25.08
Dick John E		Dyal Rachel	CS13.08
Diedrich Jolene K		_	
Diekhans Mark		E	
Dietrich Dimo			
Diez Paula			CS09.03
Dijon Sophie	CS23.09, P18.11	Ebersole Jeremy	P02.03
Di Meo Ashley	P17.03	Eckert Mark	P06.40
Dimitrakopoulos Lampros	P24.04	Eckey Maren	P07.23
Dincer Tevfik U	P11.13, P18.12	Eckhard Ulrich	<b>CS27.05</b> , P11.27
Ding Chen	CS13.09, P25.07	Eckler Lawrence	P07.23
Ding Xiaofan			P04.10, <b>P04.39</b> , P17.19
Ding Ying		Edwards Nathan	P06.61
Dionne Ugo			5P07.13
Distler Ute	The state of the s		CS28.05
D. Kelstrup Christian			CS07.08
Dobrokhotov Igor			P07.36, P15.25
Domanski Dominik			P04.17, P07.03
Do Misol			P01.27
Domon Bruno			CS23.09, <b>P11.32</b> , <b>P18.11</b>
Domon Brano			P06.22
Domont Gilberto B			P01.26
Döncző Boglárka			P01.26
Donenko Feodor			P06.16
Donti Taraka R			
Doolan Kevin			P29.05
Dornan Gillian L		•	CS02.01
Douada Tariq			CS07.05
Doucette Alan A		•	CS08.05
Do Vale Luis Henrique F		•	P01.07
Dowall Stuart			CS30.01
Dowsey Andrew W		•	P01.26
Drabovich Andrei P			P15.04
			CS09.06, P13.02, P15.05, P19.14
Dragan Irina	CS21.05	Emons Hendrik	CS30.04
Dreier Roland	CS22.09	Enany Shymaa	CS19.08
Dresler Jiri	P09.30		CS23.04
Drew Devin L	CS10.09, <b>P25.04</b>	Endo Hiroko	P23.03
Drewes Gerard			CS03.03
Drewry David H		Engholm-Keller Kasper	P15.20
-		- ***	

Eng Jimmy K			P16.14, P28.07
Erdmann Jelena			P28.13, P28.15
Erkkilä T			P09.03
Erlinge David		•	CS28.04
Escudero-Paniagua Beatriz		•	P09.12
Espona Lucia			CS29.08
Essig Marie		•	P06.65
Ethier Chantal			P19.15
Evangelopoulos Michael			CS29.04
Evans Eric			P15.05
Everest-Dass Arun V			P07.24
Eyers Claire			CS06.03
Ezcurdia lakes			P21.01
Ezkurdia lakes			P28.01
Ezzati Peyman	CS09.09	•	CS18.09
F			P17.04
г			P13.05, P19.01
Fabian Mana	CC10 04 D17 2C		P02.02
Fabian Marc			
Fabregat Mundo Antonio			9.01, P09.26, P13.01, P16.02, P17.14,
Faca Vitor M			P19.03, P27.01, P28.05
Fagerberg Linn			P09.07
Fan Baochang			CS04.06, P06.18
Fang Bin			P06.56
Fang Cai-Yun			P06.56
Fang Pan			P15.04, P15.07, P15.09
Fan Jun			CS15.09, P10.04
Fan Kang-Hsu		•	CS27.07
Fan Yao-Yun			CS09.07
Farabbad Marian			
Farahbod Marjan			CS10.04, P18.03
Faria Tiago Farinha Ana P			P23.06
			CS15.03, P04.39, <b>P17.19</b>
Farkona Sofia			P06.46
Farris StephenFasani Rick A			CS10.02
			<b>CS22.03</b> , P06.24
Fasano Mauro Fatalska Agnieszka			P06.72 <b>P07.18</b>
Fayad Paul		•	
Fedida David			CS23.04
Fedorchenko Kristina Y		•	CS05.08
Fehniger Thomas E			<b>P17.17</b> , P17.18
Feifei Ma			P07.30
Felix Stephan B			P09.11
Feller Stephan M.			CS15.08, P09.30
Feng Duan			CS19.09, P01.17, <b>P01.21</b> , <b>P18.04</b>
Feng Yuehan			CS13.03, 1 01.17, <b>P 01.21</b> , <b>P 10.04</b>
Fenyo David			P02.16
Ferguson Duncan			<b>CS11.07</b> , CS25.07
Fernandez-Aceñero Maria Jesus			CS19.08, P01.18, P04.07, P04.08
Fernandez-Lucendo Maria			CS03.08
Fernandez Patricia		,	P28.10
Ferreira Germano			P23.02
Ferreira Junior Rui S			HPP03.04
Ferro Myriam		•	
Fert-Bober Justyna			P20.04
Fidock David A		. 4220.01 / 1110	20.04
Fiehn Oliver		G	
Figeys Daniel	· ·	-	
Filippou Giota		Gabelle Audrev	CS16.09, CS25.04
Fillmore Thomas			P21.06
Finamore Francesco			P19.03
Finlay* B Brett			P06.29
Finoulst Inez			CS21.10

Galan Jacob A			P18.05 CS19.09. P15.19
Gallardo Jose Manuel			CS08.07, P13.24, P19.12
Gallien Sebastien CS30.0			P06.39
Galozzi Sara			P06.36
Gambaro Karen			CS10.08, CS17.04, CS18.03,
Gamer Martin			4, CS27.07, CS30.03, P04.06,
Ganapathy Kalaivani			
Ganapathy Ramesh			CS07.04
Gandhi Tejas			CS27.09
Ganief Naadir			CS21.06
Gan Yutian			P04.41
Gao Huafang	CS03.07	Glerup Henning	CS07.05
Gao Jifang	P16.01	Glocker Michael O	CS26.10, CS28.06
Gao Lisa	P11.14	Glogauer Michael	CS27.05
Gao Mingxia	<b>P04.37</b> , P04.40	Gnad Florian	P19.08
Gao Yuan	P19.27	Goan Yih-Gang	P06.27
Gao Yuqian	P06.38	Gobom Johan	P16.06
Garcia Angel	P06.36	Go Christopher	CS10.08, CS18.04
Garcia Benjamin A	P12.01	Goel Apury	P09.13
García-Berrocoso Teresa	CS04.07, <b>CS07.04</b>	Goepel Wolfgang	P11.19
García-Dorival Isabel	P09.25	Goetze Sandra	CS30.06, <b>P06.06</b>
García Montero Andrés	P01.17	Goh Yaw Chong	CS07.09
Garcia-Palmero Irene	CS01.08, P06.25		P19.25
Garg Nisha	P18.08	Gómez-Baena Guadalupe	P09.04
Garimella Sandilya V.B			CS18.03
Garin Jérôme		Goncharov Tatiana	P06.54
Garin-Muga Alba			P06.51
Garlid Anders O			<b>CS08.04</b> , P04.23, P09.07
Gasparov Slavko			P13.25
Gautier Benoit			P18.04
Gautier Jean-Charles			CS19.09
Gauvreau Gail			P18.04
Gebhardt Christoph			P01.21
Ge Feng			CS26.03
Geiger Tamar			P27.03
Gekle Michael			<b>CS23.07</b> , CS25.08, P07.24
Gendron Josh		•	<b>CS25.08</b> , P07.24
Genovese Luca			P06.28
Geoghegan Vincent			P15.16
Georgiou George			P22.01
Gerber Isak Gerber Scott A			<b>CS11.08</b> , P04.05
Gerdes Kenn			P01.20
Gerencser Akos			P13.22, P29.03
Gerhard Ralf			P18.07
Gerlach Manfred			P13.09
Germain Ronald N			CS02.07
Gerner Lyn			CS02.07
Geromanos Scott			P01.23, P04.48, P06.63
Gesell Salazar Manuela			P06.22
Gethings Lee			CS08.08
Gevariya Nikunj R			CS15.05, P18.02
Gezelius Emelie		-	P07.30
Ghali Fawaz		• •	CS16.10, P13.14
Ghani Dr. Rubina			CS16.09
Gharbi Severine			P06.31, <b>P06.47</b>
Ghebeh Hazem			CS12.05, CS23.05
Gheiratmand Ladan			
Ghosh S			<b>P09.23</b> , P09.32, P16.16
Gibaja Veronica			P06.28
Gibson Bradford			P09.02
Gibson John			P16.07
	P09.05	Griss Johannes	

	P06.65	Hardie DarrylCS25	
	P06.02	Hardy Marie-Pier	
	CS02.03, CS26.10	Hare Brian	
	P04.31	Harel Michal	
	P04.17, P07.03	Harman Victoria	P04.11
	P11.10, P13.01, <b>P13.20</b>	Harpur Brock A	CS29.03, P28.05
	CS17.05	Harte Rachel A	
Guan Yuanfang	P01.27, P13.07	Hartl Ulrich F	CS26.04
Guarna M Marta	P17.14, P28.05	Hart-Smith Gene O	CS17.06, CS29.07, P19.05
Guedj Emmanuel	P18.11	Hartung Thomas	P28.01
	P28.04	Harvie Rozelle	P06.15
Guha Chandan	CS16.08	Harwell Justin	P10.06
Guillemin J-C	P11.12	Hasan Beena	P16.18
Guimarães Gustavo	CS04.10	Hasegawa Hitoshi	P04.43
Guldbrandsen Astrid	CS02.04	Haseltine Eric	CS28.04
Guler Arzu Tugce	<b>P07.06</b> , P09.02	Hashiguchi Kazunari	P23.02
Gunaratne Jayantha	P15.06	Hashimoto Yasuhiro	CS03.03
Gundelfinger Eckart	P22.03	Hashimoto Yuuki	P23.02
Gundry Rebekah L	CS15.04	Hasovits Csilla	P06.15
Gunnarsson Iva	P07.29	Haura Eric	CS01.07
Guo Ailan	CS20.07, P23.01	Haussler David	P28.10
	CS14.04, P16.11	Hayashi Yuu	
Guo Honabo	CS09.06, <b>P15.05</b>	Hayes Sarah A	P06.15
	CS03.07, P09.03	Hayward Clive	
	P27.04	Heckendorf Christian	
•	P06.37	Heemskerk Anthonius AM	
	CS18.03	Heeren Ron	
	P17.08, P17.09	He Fuchu	
	CS01.05	Heidelberger Sibylle	
	P28.10	Heidenreich Axel	
	P21.06	Heinrich Marco	
	P07.16		
	PU7.16	Heinsen Helmut	P16.07
		Heinsen Helmut Heinzlmeir Stephanie	
	P07.16	Heinzlmeir Stephanie	CS09.05
Gygax Daniel		Heinzlmeir Stephanie Heitner Steve	CS09.05 P28.10
		Heinzlmeir Stephanie Heitner Steve He Jintang	
Gygax Daniel	P06.06	Heinzlmeir StephanieHeitner SteveHe JintangHe JintangHeld Jason	
H Haag Sabrina	P06.06	Heinzlmeir Stephanie Heitner Steve He Jintang Held Jason He Lin	CS09.05 P28.10 P06.38 CS30.03 P08.06
H  Haag Sabrina Haange Sven-Bastiaan	P06.06  P04.17  P09.18	Heinzlmeir Stephanie Heitner Steve He Jintang Held Jason He Lin Helling Stefan	C\$09.05 P28.10 P06.38 C\$30.03 P08.06 P15.25
H  Haag Sabrina Haange Sven-Bastiaan Habuka Masato	P06.06	Heinzlmeir StephanieHeitner SteveHe JintangHeld JasonHe LinHelling StefanHelliström Cecilia	C\$09.05 P28.10 P06.38 C\$30.03 <b>P08.06</b> P15.25 P04.14
H  Haag Sabrina Haange Sven-Bastiaan Habuka Masato Haeussler Maximillian		Heinzlmeir StephanieHeitner SteveHe JintangHeld JasonHe LinHelling StefanHelling StefanHellström Cecilia.	CS09.05 P28.10 P06.38 CS30.03 P08.06 P15.25 P04.14CS09.05, P04.03, P15.02
H  Haag Sabrina Haange Sven-Bastiaan Habuka Masato Haeussler Maximillian Haga Yoshimi	P06.06  P04.17  P09.18  P04.10  P28.10  P21.05	Heinzlmeir StephanieHeitner SteveHe JintangHeld Jason He LinHelling StefanHellström Cecilia.Helm DominicHelmy Mohamed	CS09.05 P28.10 P06.38 CS30.03 P08.06 P15.25 P04.14CS09.05, P04.03, P15.02 CS17.09, CS29.05
H  Haag Sabrina Haange Sven-Bastiaan Habuka Masato Haeussler Maximillian Haga Yoshimi Hager Jörg	P06.06  P04.17  P09.18  P04.10  P28.10  P21.05  CS16.07	Heinzlmeir Stephanie	C\$09.05 P28.10 P06.38 C\$30.03 P08.06 P15.25 P04.14 C\$09.05, P04.03, P15.02 C\$17.09, C\$29.05
H  Haag Sabrina Haange Sven-Bastiaan Habuka Masato Haeussler Maximillian Haga Yoshimi Hager Jörg Häggmark Anna	P06.06  P04.17 P09.18 P04.10 P28.10 P21.05 CS16.07 P16.09, P17.19	Heinzlmeir Stephanie	CS09.05 P28.10 P06.38 CS30.03 P08.06 P15.25 P04.14CS09.05, P04.03, P15.02 CS17.09, CS29.05 P06.71CS14.07
H  Haag Sabrina Haange Sven-Bastiaan Habuka Masato Haeussler Maximillian Haga Yoshimi Hager Jörg Häggmark Anna Hagiwara Kozue	P06.06  P04.17  P09.18  P04.10  P28.10  P21.05  CS16.07  P16.09, P17.19  CS30.09	Heinzlmeir Stephanie	C\$09.05 P28.10 P06.38 C\$30.03 P08.06 P15.25 P04.14 C\$09.05, P04.03, P15.02 C\$17.09, C\$29.05 P06.71 C\$14.07 P06.50, P17.19
H  Haag Sabrina		Heinzlmeir Stephanie Heitner Steve He Jintang Held Jason Helling Stefan Helling Stefan Helm Dominic Helmy Mohamed He Mian Henjes Frauke	CS09.05 P28.10 P06.38 CS30.03 P08.06 P15.25 P04.14 CS09.05, P04.03, P15.02 CS17.09, CS29.05 P06.71 CS14.07 P06.50, P17.19 P06.29
H  Haag Sabrina Haange Sven-Bastiaan Habuka Masato Haeussler Maximillian Haga Yoshimi Hager Jörg Häggmark Anna Hagiwara Kozue Hahne Hannes Haldys V	P06.06  P04.17  P09.18  P04.10  P28.10  P28.10  P21.05  CS16.07  P16.09, P17.19  CS30.09  CS19.07, P04.12  P11.12	Heinzlmeir Stephanie Heitner Steve He Jintang Held Jason He Lin Helling Stefan Hellström Cecilia Helm Dominic Helmy Mohamed He Mian Henault Jill Henies Frauke Henkel Corinna	CS09.05 P28.10 P06.38 CS30.03 P08.06 P15.25 P04.14 CS09.05, P04.03, P15.02 CS17.09, CS29.05 P06.71 CS14.07 P06.50, P17.19 P06.29 CS07.09
H  Haag Sabrina Haange Sven-Bastiaan Habuka Masato Haeussler Maximillian Hage Jörg Häggmark Anna Hagiwara Kozue Hahne Hannes Haldys V Hallström Björn	P06.06  P04.17 P09.18 P04.10 P28.10 P28.10 P21.05 CS16.07 P16.09, P17.19 CS30.09 CS19.07, P04.12 P11.12 CS16.03, CS19.07	Heinzlmeir Stephanie	C\$09.05 P28.10 P06.38 C\$30.03 P08.06 P15.25 P04.14 C\$09.05, P04.03, P15.02 C\$17.09, C\$29.05 P06.71 C\$14.07 P06.50, P17.19 P06.29 C\$07.09 C\$21.05, P09.12
H  Haag Sabrina Haange Sven-Bastiaan Habuka Masato Haeussler Maximillian Haga Yoshimi Hager Jörg Häggmark Anna Hagiwara Kozue Hahne Hannes Haldys V Hallström Björn Hamaguchi Tomonari	P06.06  P04.17 P09.18 P04.10 P28.10 P21.05 CS16.07 P16.09, P17.19 CS30.09 CS19.07, P04.12 P11.12 CS16.03, CS19.07 P15.21	Heinzlmeir Stephanie	C\$09.05 P28.10 P06.38 C\$30.03 P08.06 P15.25 P04.14 C\$09.05, P04.03, P15.02 C\$17.09, C\$29.05 P06.71 C\$14.07 P06.50, P17.19 P66.29 C\$07.09 C\$21.05, P09.12 P06.03
H  Haag Sabrina Haange Sven-Bastiaan Habuka Masato Haeussler Maximillian Hage Yoshimi Hager Jörg Häggmark Anna Hagiwara Kozue Hahne Hannes Haldys V Hallström Björn Hamaguchi Tomonari Hamaduchi Tomonari Hamid Ahmed	P06.06  P04.17 P09.18 P04.10 P28.10 P21.05 CS16.07 P16.09, P17.19 CS30.09 CS19.07, P04.12 P11.12 CS16.03, CS19.07 P15.21 CS06.02	Heinzlmeir Stephanie Heitner Steve	C\$09.05 P28.10 P06.38 C\$30.03 P08.06 P15.25 P04.14 C\$09.05, P04.03, P15.02 C\$17.09, C\$29.05 P06.71 C\$14.07 P06.50, P17.19 P06.29 C\$07.09 C\$21.05, P09.12 P06.03 P28.06
H  Haag Sabrina	P06.06	Heinzlmeir Stephanie	CS09.05 P28.10 P06.38 CS30.03 P08.06 P15.25 P04.14 CS09.05, P04.03, P15.02 CS17.09, CS29.05 P06.71 CS14.07 P06.50, P17.19 P06.29 CS07.09 CS21.05, P09.12 P06.03 P28.06 CS17.08, CS29.08, P13.13,
H  Haag Sabrina	P06.06  P04.17  P09.18  P04.10  P28.10  P28.10  P28.07  CS16.07  P16.09, P17.19  CS30.09  CS19.07, P04.12  P11.2  CS16.03, CS19.07  P15.21  CS06.02  P27.06  CS23.04	Heinzlmeir Stephanie	CS09.05 P28.10 P06.38 CS30.03 P08.06 P15.25 P04.14 CS09.05, P04.03, P15.02 CS17.09, CS29.05 P06.71 CS14.07 P06.50, P17.19 P06.29 CS07.09 CS21.05, P09.12 P06.03 P28.06 CS17.08, CS29.08, P13.13, P13.17, P13.19, P13.25
H  Haag Sabrina	P06.06  P04.17 P09.18 P04.10 P28.10 P28.10 P28.10 P10.05 CS16.07 P16.09, P17.19 CS30.09 CS19.07, P04.12 P11.12 CS16.03, CS19.07 P15.21 CS06.02 P27.06 CS23.04 CS95.03	Heinzlmeir Stephanie Heitner Steve	CS09.05 P28.10 P06.38 CS30.03 P08.06 P15.25 P04.14 CS09.05, P04.03, P15.02 CS17.09, CS29.05 P06.71 CS14.07 P06.50, P17.19 P06.29 CS07.09 CS21.05, P09.12 P06.03 P28.06 CS17.08, CS29.08, P13.13, P13.17, P13.19, P13.25 CS19.09
H  Haag Sabrina	P06.06  P04.17 P09.18 P04.10 P28.10 P21.05 CS16.07 P16.09, P17.19 CS30.09 CS19.07, P04.12 P11.12 CS16.03, CS19.07 P15.21 CS06.02 P27.06 CS23.04 CS05.03 CS21.08	Heinzlmeir Stephanie	CS09.05 P28.10 P06.38 CS30.03 P08.06 P15.25 P04.14 CS09.05, P04.03, P15.02 CS17.09, CS29.05 P06.71 CS14.07 P06.50, P17.19 P06.29 CS07.09 CS21.05, P09.12 P06.03 P28.06 CS17.08, CS29.08, P13.13, P13.17, P13.19, P13.25 CS19.09 P15.19
H  Haag Sabrina Haange Sven-Bastiaan Habuka Masato Haeussler Maximillian Hager Jörg Häggmark Anna Hagiwara Kozue Hahne Hannes Hallström Björn Hamaguchi Tomonari Hamid Ahmed Hammer Elke Hammer Elke Hammer Helen Han Dohyun	P06.06  P04.17 P09.18 P04.10 P28.10 P21.05 CS16.07 P16.09, P17.19 CS30.09 CS19.07, P04.12 P11.12 CS16.03, CS19.07 P15.21 CS06.02 P27.06 CS23.04 CS55.03 CS21.08 P06.30, P07.10	Heinzlmeir Stephanie	CS09.05 P28.10 P06.38 CS30.03 P08.06 P15.25 P04.14 CS09.05, P04.03, P15.02 CS17.09, CS29.05 P06.71 CS14.07 P06.50, P17.19 P06.29 CS07.09 CS21.05, P09.12 P06.03 P28.06 CS17.08, CS29.08, P13.13, P13.17, P13.19, P13.25 CS19.09 P15.19 CS07.04
H  Haag Sabrina	P06.06  P04.17  P09.18  P04.10  P28.10  P28.10  P28.10  P10.05  CS16.07  P16.09, P17.19  CS30.09  CS19.07, P04.12  P11.12  CS16.03, CS19.07  P15.21  CS06.02  P27.06  CS23.04  CS05.03  CS21.08  P06.30, P07.10  P02.11, P02.13	Heinzlmeir Stephanie	CS09.05 P28.10 P06.38 CS30.03 P08.06 P15.25 P04.14 CS09.05, P04.03, P15.02 CS17.09, CS29.05 P06.71 CS14.07 P06.50, P17.19 P06.29 CS07.09 CS21.05, P09.12 P06.03 P28.06 CS17.08, CS29.08, P13.13, P13.17, P13.19, P13.25 CS19.09 CS07.04
H  Haag Sabrina	P06.06  P04.17  P09.18  P04.10  P28.10  P28.10  P28.10  P21.05  CS16.07  P16.09, P17.19  CS30.09  CS19.07, P04.12  P11.12  CS16.03, CS19.07  P15.21  CS06.02  P27.06  CS23.04  CS05.03  CS21.08  P06.30, P07.10  P02.11, P02.13  CS04.08, CS12.08,	Heinzlmeir Stephanie	CS09.05 P28.10 P06.38 CS30.03 P08.06 P15.25 P04.14 P06.38 P05.25 P04.17 P06.71 P06.50, P17.19 P06.50, P17.19 P06.39 P06.30 P28.06 CS17.08, CS29.08 P18.19 P06.03 P28.06 CS17.08, CS29.08 P18.19
H  Haag Sabrina	P06.06  P04.17 P09.18 P04.10 P28.10 P21.05 CS16.07 P16.09, P17.19 CS30.09 CS19.07, P04.12 P11.12 CS16.03, CS19.07 P15.21 CS06.02 P27.06 CS23.04 CS05.03 CS21.08 P06.30, P07.10 P02.11, P02.13 CS04.08, CS12.08, P20.01, P25.02	Heinzlmeir Stephanie Heitner Steve	CS09.05 P28.10 P06.38 CS30.03 P08.06 P15.25 P04.14 CS09.05, P04.03, P15.05 P06.71 CS14.07 P06.50, P17.19 P06.29 CS07.09 CS21.05, P09.12 P06.03 P28.06 CS17.08, CS29.08, P13.13, P13.17, P13.19, P13.25 CS19.09 P15.19 CS07.04
H  Haag Sabrina	P06.06  P04.17 P09.18 P04.10 P28.10 P21.05 CS16.07 P16.09, P17.19 CS30.09 CS19.07, P04.12 P11.12 CS16.03, CS19.07 P15.21 CS06.02 P27.06 CS23.04 CS05.03 CS21.08 P06.30, P07.10 P02.11, P02.13 CS04.08, CS12.08, P20.01, P25.02, P25.09 P06.72	Heinzlmeir Stephanie	CS09.05 P28.10 P06.38 CS30.03 P08.06 P15.25 P04.14 CS09.05, P04.03, P15.02 CS17.09, CS29.05 P06.71 CS14.07 P06.50, P17.19 P06.29 CS07.09 CS21.05, P09.12 P06.03 P28.06 CS17.08, CS29.08, P13.13, P13.17, P13.19, P13.25 CS19.09 P15.19 CS07.04 CS01.10 HPP03.03 P04.32 CS16.04
H  Haag Sabrina Haange Sven-Bastiaan Habuka Masato Haeussler Maximillian Haga Yoshimi Hager Jörg Häggmark Anna Hagiwara Kozue Hahne Hannes Hallström Björn Hamaguchi Tomonari Hamid Ahmed Hammarström Lennart Hammer Elke Hammer Elke Hammer Helen Hammer Helen Han Dohyun Han Dohyun Han Jun  Hanke Sabrina Han Maria	P06.06  P04.17 P09.18 P04.10 P28.10 P21.05 CS16.07 P16.09, P17.19 CS30.09 CS19.07, P04.12 P11.2 P11.2 CS16.03, CS19.07 P15.21 CS06.02 P27.06 CS23.04 CS23.04 CS05.03 CS21.08 P06.30, P07.10 P02.11, P02.13 CS04.08, CS12.08, P20.01, P25.02, P25.09 P06.72 P06.72 P22.02	Heinzlmeir Stephanie	CS09.05 P28.10 P06.38 CS30.03 P08.06 P15.25 P04.14 CS09.05, P04.03, P15.02 CS17.09, CS29.05 P06.71 CS14.07 P06.50, P17.19 P06.29 CS07.09 CS21.05, P09.12 P06.03 P28.06 CS17.08, CS29.08, P13.13, P13.17, P13.19, P13.25 CS19.09 P15.19 CS07.04 CS01.10 HPP03.03 P04.32 CS16.04 CS18.04
H  Haag Sabrina	P06.06  P04.17  P09.18  P04.10  P28.10  P28.10  P21.05  CS16.07  P16.09, P17.19  CS30.09  CS19.07, P04.12  P11.12  CS16.03, CS19.07  P15.21  CS06.02  P27.06  CS23.04  CS05.03  CS23.04  CS05.03  CS21.08  P06.30, P07.10  P02.11, P02.13  CS04.08, CS12.03, CS12.08,  P20.01, P25.02, P25.09  P06.72  P22.02  CS16.09	Heinzlmeir Stephanie	C\$09.05 P28.10 P06.38 C\$30.03 P08.06 P15.25 P04.14 P05.25 P04.17 P06.71 C\$14.07 P06.71 C\$14.07 P06.09 C\$29.05 P06.03 P28.06 C\$17.09, C\$29.05 P06.03 P15.25 P06.01 P06.03 P15.25 P06.03 P15.25 P06.03 P28.06 P15.25 P15.19 P
H  Haag Sabrina	P06.06  P04.17  P09.18  P04.10  P28.10  P28.10  P28.10  P21.05  CS16.07  P16.09, P17.19  CS30.09  CS19.07, P04.12  P11.12  CS16.03, CS19.07  P15.21  CS06.02  P27.06  CS23.04  CS05.03  CS21.08  P06.30, P07.10  P02.11, P02.13  CS04.08, CS12.03, CS12.08, P20.01, P25.02, P25.09  P06.72  P22.02  CS16.09  CS13.08, P25.08	Heinzlmeir Stephanie Heitner Steve	C\$09.05 P28.10 P06.38 C\$30.03 P08.06 P15.25 P04.14 P05.25 P04.17 P06.50, P17.19 P06.50, P17.19 P06.03 P28.06 C\$17.08, C\$29.08, P13.13, P13.19, P13.25 C\$19.09 P15.19 P06.03 P15.10 P15.1
H  Haag Sabrina	P06.06  P04.17 P09.18 P04.10 P28.10 P21.05 CS16.07 P16.09, P17.19 CS30.09 CS19.07, P04.12 P11.12 CS16.03, CS19.07 P15.21 CS06.02 P27.06 CS23.04 CS05.03 CS21.08 P06.30, P07.10 P02.11, P02.13 CS04.08, CS12.03, CS12.08, P20.01, P25.02, P25.09 P06.72 P22.02 CS16.09 CS13.08, P25.08 P05.04	Heinzlmeir Stephanie	CS09.05 P28.10 P06.33 P08.06 P15.25 P04.14 P05.25 P04.14 P06.29 P06.71 P06.50, P17.19 P06.29 CS07.09 CS21.05, P09.12 P06.03 P28.06 P13.17, P13.19, P13.25 CS17.09 CS07.09 P15.19 P06.03 P15.19
H  Haag Sabrina	P06.06  P04.17  P09.18  P04.10  P28.10  P28.10  P28.10  P21.05  CS16.07  P16.09, P17.19  CS30.09  CS19.07, P04.12  P11.12  CS16.03, CS19.07  P15.21  CS06.02  P27.06  CS23.04  CS05.03  CS21.08  P06.30, P07.10  P02.11, P02.13  CS04.08, CS12.03, CS12.08, P20.01, P25.02, P25.09  P06.72  P22.02  CS16.09  CS13.08, P25.08	Heinzlmeir Stephanie Heitner Steve	CS09.05 P28.10 P06.38 CS30.03 P08.06 P15.25 P04.14 CS09.05, P04.03, P15.02 CS17.09, CS29.05 P06.71 CS14.07 P06.50, P17.19 P06.29 CS07.09 CS21.05, P09.12 P06.03 P28.06 CS17.08, CS29.08, P13.13, P13.17, P13.19, P13.25 CS17.08 CS07.09 CS07.09 CS07.09 CS18.04 CS07.04 CS01.05 CS18.04 CS01.06 CS19.09 P15.19 CS07.04 CS01.10 CS07.04 CS01.10 CS07.04 CS01.10 CS18.04 P09.14 P09.25 P04.17, P07.03 P20.02

Hido Yuya	Hida Vous	D07.77	Iliana Dannia	DOC 70
Higashisaka Kazuma				
Higgins Leann				
Higos Renee	=			
High John S.   CS15.09   Huang Kun.   CS07.03 (CS18.08 PO2.17 P21.04   Huang Linl.   P.00.11				
Hill Michelle M. CS07,03, CS18,08 P021,7 P2104   Huang Ling-Ling.   P06.11   P02.12   Huang Ling-Ling.   P06.13   Huang Ling-Ling.   P06.13   Huang Ling-Ling.   P06.13   Huang Ling-Ling.   P06.13   Huang Ling-Ling.   P07.17, P07.17   P				
Hill Michelle M. CS07.05, CS18.08, PO2.17, P21.04 Hill Ryan C. CS13.08 Hill Ryan C. CS13.08 Hill Ryan C. CS13.08 Hinsoburg Hannes			•	
Hill Ryan C				
Hinneburg Hannes			Huang Ling-Ling	P06.43
Hinsinger Geoffrey.  Pilirano Hisashi.  PO6.21, PO7.37 Hirao Yoshitoshi.  CS19.08, PO1.08, PO1.18, PO1.26 Hirayama Mio.  CS30.03, PO6.09 Hira Constitution.  CS30.03, PO6.09 Hira Constitution.  PO9.15 Hirayama Mio.  CS30.03, PO6.09 Hira Constitution.  CS16.09, CS25.04 Hirac Kosuke PO6.41, PO6.42 Huber Volfigang.  CS09.07 Huber Jason.  P18.20 Huber Jason.  P19.41 Hugher Jason.  P18.20 Hugher Jason.  P19.41 Hugher Jason.  P19.43 Hugher Jason.  P19.43 Hugher Jason.  P19.43 Hugher Jason.  P19.43 Hugher Jason.  P18.20 Huber Jason.  P19.43 Huber Jason.  P18.20 Huber Jason.  P18.20 Huber Jason.  P19.43 Hugher Jason.  P19.43 Hugher Jason.  P19.43 Huber Jason.  P19.44 Huber Jason.  P19.45 Huber Jason.	Hinneburg Hannes	CS03.04, P21.07	Huang Lulu	CS24.06
Hirano Hisashi	Hinrichs Angie S	P28.10	Huang Yen-Chun	P07.17, <b>P07.17</b>
Hiray was hirbshi	Hinsinger Geoffrey	P16.03	Huang Yenlin	P06.17
Hirayam Mio.				
Hirofa Kosuke				
Hirtz Christophe				
Hiscox Julian.				
Hochgrafe Falko	•			
Hoefig Namia				
Hoffee Romina				
Hoffmann Andreas-Claudius				
Hoffmann Peter				
Hogrebe Alexander				
Höhndorf Jens				
Hoi Kam				
Ho Julie				
Ho Kendall				
Hollewinski Ronald J.   CS13.05, CS15.06, P19.16   Hollander Zsuzsanna.   P07.04, P28.15   Hollander Zsuzsanna.   P07.04, P28.15   Hundt Franziska C.   P06.04   Hundt Franziska C.   P06.06   Hundt Franziska C.   P06.07   Hundt Franziska C.   P06.08   Hundt Franziska C.   P06.08   Hundt Franziska C.   P06.09   P06.09   Hundt Franziska C.   P06.09   Hundt Franziska C.   P06.09   Hundt Franziska C.   P06.09   P06.09   Hundt Franziska C.   P06.09   Hundt Franziska C.   P06.09   P06.09   Hundt Franziska C.   P06.09   Hundt Franziska C.   P06.09   P06.09   P06.09   P06.19   P09.20   Hundt Franziska C.   P06.09   P06.19   P09.20   Hundt Franziska C.   P06.09   P06.10   P09.20   Hundt Franziska C.   P06.09   P06.10   P09.20   Hundt Franziska C.   P06.09   P06.10   P09.20   P09.23   P09.20   P09.2				
Holle Armin	Holewinski Ronald J	CS13.05, <b>CS15.06</b> , P19.16		
Holman Stephen   P04.47   Hunsucker Stephen W.   CS06.03   CS06.03   CS06.03   CS06.03   CS06.05   CS30.03   CS06.03   CS06.05   CS30.03   CS06.05   CS06.05   CS30.03   CS06.05   CS06.	Hollander Zsuzsanna	<b>P07.04</b> , P28.15	Hundt Franziska C	P06.04
Holmdahl Rikard	Holle Armin	P20.04		
Holmén Larsson Jessica				
Holmes Daniel T.				
Holtappels Gabriele				
Holtfreter Silva				
Ho Mengfatt	• •			
Homuth Georg				
Hong Hye Kyoung				
Hong Mun-Gwan				
Hoofnagle Andrew				
Hoopmann Michael				
Hoover Shelley				
Horakova Lucie				
Horn David				
Horn David M	Hörnaeus Katarina	P16.12	Hyman Bradley T	CS14.04, P16.11
Horton Andrew	Horn David	CS10.09, P05.05, P29.02	Hyöty H	CS23.07
Horvatovich Peter			_	
Hou Guixue			ı	
Hourdel Véronique         CS02.07         Ibáñez-Vea Maria         P06.67, P19.19, P28.07           Hou Sijian         P02.11, P02.13         Ibarrola Nieves         P01.21           Houston Simon         P09.31         Ibrahim Yehia M         CS06.02           Howard Louisa         P09.17         Idborg Helena         P07.29           Howell Viive         P06.15         Iglesias Mariajesus         CS15.03, P17.19           Hruzova Veronika         P09.30         Ignatchenko Alex         CS15.05, P18.02           Hsieh Ya-Ju         P04.16         Ignatchenko Vladimir         CS15.05           Hsu Chia-Wei         P06.11, P06.17, P09.10         Ihling Angelika         P06.19, P13.09           Hsue Chuen         P06.60         Ikram M K         CS12.07           Hsu Hong-Ming         CS10.07         Ilgisonis Ekaterina V         P01.12           Hsu Pang-Hung         CS10.07, P06.10         Illionen J         CS23.07				
Hou Sijian         P02.11, P02.13         Ibarrola Nieves         P01.21           Houston Simon         P09.31         Ibrahim Yehia M.         CS06.02           Howard Louisa         P09.17         Idborg Helena         P07.29           Howell Viive         P06.15         Iglesias Mariajesus         CS15.03, P17.19           Hruzova Veronika         P09.30         Ignatchenko Alex         CS15.05, P18.02           Hsieh Ya-Ju         P04.16         Ignatchenko Vladimir         CS15.05           Hsu Chia-Wei         P06.17, P09.10         Ihling Angelika         P06.19           Hsu Chiung-Hung         P06.60         Ihling Christian         P06.19, P13.02           Hsu Hong-Ming         CS10.07         Ilgisonis Ekaterina V.         P01.12           Hsu Pang-Hung         CS10.07, P06.10         Illionen J.         CS23.07				
Houston Simon         P09.31         Ibrahim Yehia M.         CS06.02           Howard Louisa         P09.17         Idborg Helena         P07.29           Howell Viive         P06.15         Iglesias Mariajesus         CS15.03, P17.19           Hruzova Veronika         P09.30         Ignatchenko Alex         CS15.05, P18.02           Hsieh Ya-Ju         P04.16         Ignatchenko Vladimir         CS15.05           Hsu Chia-Wei         P06.17, P09.10         Ihling Angelika         P06.19           Hsu Chiung-Hung         P06.60         Ihling Christian         P06.19, P13.09           Hsu Hong-Ming         CS10.07         Ilgisonis Ekaterina V.         P01.12           Hsu Pang-Hung         CS10.07, P06.10         Illonen J.         CS23.07	·			
Howard Louisa.         P09.17         Idborg Helena         P07.29           Howell Viive         P06.15         Iglesias Mariajesus         CS15.03, P17.19           Hruzova Veronika         P09.30         Ignatchenko Alex         CS15.05, P18.02           Hsieh Ya-Ju         P04.16         Ignatchenko Vladimir         CS15.05           Hsu Chia-Wei         P06.11, P06.17, P09.10         Ihling Angelika         P06.19           Hsu Chiung-Hung         P06.60         Ihling Christian         P06.19, P13.09           Hsu Hong-Ming         CS10.07         Ilgisonis Ekaterina V         P01.12           Hsu Pang-Hung         CS10.07, P06.10         Illonen J         CS23.07	•	•		
Howell Viive         P06.15         Iglesias Mariajesus         CS15.03, P17.19           Hruzova Veronika         P09.30         Ignatchenko Alex         CS15.05, P18.02           Hsieh Ya-Ju         P04.16         Ignatchenko Vladimir         CS15.05           Hsu Chia-Wei         P06.11, P06.17, P09.10         Ihling Angelika         P06.19           Hsu Chiung-Hung         P06.60         Ihling Christian         P06.19, P13.09           Hsueh Chuen         P06.60         Ikram M K         CS12.07           Hsu Hong-Ming         CS10.07         Ilgisonis Ekaterina V         P01.12           Hsu Pang-Hung         CS10.07, P06.10         Illonen J         CS23.07				
Hruzova Veronika         P09.30         Ignatchenko Alex         CS15.05, P18.02           Hsieh Ya-Ju         P04.16         Ignatchenko Vladimir         CS15.05           Hsu Chia-Wei         P06.11, P06.17, P09.10         Ihling Angelika         P06.19           Hsu Chiung-Hung         P06.60         Ihling Christian         P06.19, P13.09           Hsueh Chuen         P06.60         Ikram M K         CS12.07           Hsu Hong-Ming         CS10.07         Ilgisonis Ekaterina V         P01.12           Hsu Pang-Hung         CS10.07, P06.10         Illonen J         CS23.07				
Hsieh Ya-Ju         P04.16         Ignatchenko Vladimir         CS15.05           Hsu Chia-Wei         P06.11, P06.17, P09.10         Ihling Angelika         P06.19           Hsu Chiung-Hung         P06.60         Ihling Christian         P06.19, P13.09           Hsueh Chuen         P06.60         Ikram M K         CS12.07           Hsu Hong-Ming         CS10.07         Ilgisonis Ekaterina V         P01.12           Hsu Pang-Hung         CS10.07, P06.10         Illonen J         CS23.07				
Hsu Chia-Wei       P06.11, P06.17, P09.10       Ihling Angelika       P06.19         Hsu Chiung-Hung       P06.60       Ihling Christian       P06.19, P13.09         Hsueh Chuen       P06.60       Ikram M K       CS12.07         Hsu Hong-Ming       CS10.07       Ilgisonis Ekaterina V       P01.12         Hsu Pang-Hung       CS10.07, P06.10       Illonen J       CS23.07				
Hsu Chiung-Hung       P06.60       Ihling Christian       P06.19, P13.09         Hsueh Chuen       P06.60       Ikram M K       CS12.07         Hsu Hong-Ming       CS10.07       Ilgisonis Ekaterina V       P01.12         Hsu Pang-Hung       CS10.07, P06.10       Illonen J       CS23.07				
Hsueh Chuen       P06.60       Ikram M K       CS12.07         Hsu Hong-Ming       CS10.07       Ilgisonis Ekaterina V       P01.12         Hsu Pang-Hung       CS10.07, P06.10       Illonen J       CS23.07				
Hsu Hong-Ming       CS10.07       Ilgisonis Ekaterina V       P01.12         Hsu Pang-Hung       CS10.07, P06.10       Illonen J       CS23.07				
			Ilgisonis Ekaterina V	P01.12
Huang Chung-Ying	Hsu Pang-Hung	CS10.07, <b>P06.10</b>		
	Huang Chung-Ying	P07.25	Imanishi Susumu	P15.10

	P06.05		CS22.08
	P16.17		CS18.05
	CS28.08		P01.22
	P23.03		P01.19
		•	
	CS28.07 P17.14		P07.21
	P04.42		P20.05
			<b>P22.02</b> , P22.05
	P09.28		P19.02
•	CS16.07		P17.19
	P11.07		CS27.07
	P09.08		P09.24
	P13.22, P15.18, <b>P29.03</b>		P17.08
	CS14.03		CS29.08. P13.15. P13.25
	P13.03		P18.14
	P04.43		P20.02, P20.03
	P18.02		P02.19
	CS30.09		P02.10
	P03.01	Joos Thomas OC	S05.03, CS05.09, P06.03, P11.19
Ito Hiroyuki	P06.21	Jordaan Justin	CS24.09
	P11.01, P11.02		CS13.04
Ivanov Alexander R	P19.09	Josef Ittig Simon	P15.23
Ivanova Olga	P01.23, P04.48	Joshi Virendra	CS07.03
Ivanov Nikolai V	CS23.09, P18.11	J. Rossner Moritz	P16.21
Ivanov Vadim	P01.23, P04.48	Juehne Tom	P02.01
lwaki Jun	CS30.09	Julian Colleen G	P25.08
Iwamura Masatsugu	P07.33	Juncker David	CS07.06, CS27.06
lyyanar Paul P.R	P01.24	Junemann Johannes	CS05.05
Izrael-Tomasevic Anita	<b>P06.54</b> , P19.08	Jung Hye Jin	CS09.10
_			P11.23
J			P01.20
		•	P06.37
	CS08.08, P04.42		CS05.05
	CS28.08	Jylhä Antti	CS28.10, P07.09, P11.05
	P22.02	17	
	CS01.09, CS08.06	K	
	P22.05		20017
	P19.19		P09.17
Jakobsson Per-Johan			
Jalili Pedan			P06.45
•	P02.01	Kachuk Carolyn	<b>CS24.05</b> , CS24.06
Jameel Nazia	P02.01 P11.15	Kachuk Carolyn Kacprowski Tim	<b>CS24.05</b> , CS24.06
Jameel Nazia Jang Jin Young	P02.01P11.15P06.30	Kachuk Carolyn Kacprowski Tim Kadek Alan	
Jameel Nazia Jang Jin Young Jankevics Andris	P02.01 P11.15 P06.30 P04.34	Kachuk Carolyn Kacprowski Tim Kadek Alan Kagan Jacob	CS24.05, CS24.06 
Jameel Nazia Jang Jin Young Jankevics Andris Jankovicova Barbora	P02.01 ————————————————————————————————————	Kachuk Carolyn Kacprowski Tim Kadek Alan Kagan Jacob Kagan Olga	CS24.05, CS24.06 CS23.04 CS14.08 P06.38, P06.39 P19.14
Jameel Nazia	P02.01 P11.15 P06.30 P04.34 P07.14 CS27.03, P17.12	Kachuk Carolyn Kacprowski Tim Kadek Alan Kagan Jacob Kagan Olga Kähne Thilo	CS24.05, CS24.06 CS23.04 CS14.08 P06.38, P06.39 P19.14 P22.03
Jameel Nazia	P02.01 P11.15 P06.30 P04.34 P07.14 CS27.03, P17.12 P01.24	Kachuk Carolyn	CS24.05, CS24.06 CS23.04 CS14.08 P06.38, P06.39 P19.14 P22.03 CS26.05
Jameel Nazia	P02.01	Kachuk Carolyn	CS24.05, CS24.06  CS23.04  CS14.08  P06.38, P06.39  P19.14  P22.03  CS26.05  P15.21
Jameel Nazia	P02.01	Kachuk Carolyn Kacprowski Tim Kadek Alan Kagan Jacob Kagan Olga Kähne Thilo Kahraman Abdullah Kaibuchi Kozo Kaidar-Person Orit	CS24.05, CS24.06  CS23.04  CS14.08  P06.38, P06.39  P19.14  P22.03  CS26.05  P15.21  P07.28
Jameel Nazia	P02.01 P11.15 P06.30 P04.34 P07.14 CS27.03, P17.12 P01.24 P09.01 P09.18 P09.18	Kachuk Carolyn	C\$24.05, C\$24.06 C\$23.04 C\$14.08 P06.38, P06.39 P19.14 P22.03 C\$26.05 P15.21 P07.28 P28.03
Jameel Nazia Jang Jin Young Jankevics Andris Jankovicova Barbora Jarvi Keith Jayapal Jeya Maheshwari Jean François Jehmlich Nico Jelinek Chrisitne Jenkins Rosalind E.	P02.01 P11.15 P06.30 P04.34 P07.14 CS27.03, P17.12 P01.24 P09.01 P09.18 P04.31 P04.45	Kachuk Carolyn	CS24.05, CS24.06 CS23.04 CS14.08 P06.38, P06.39 P19.14 P22.03 CS26.05 P15.21 P77.28 P28.03 CS03.10, CS30.09
Jameel Nazia Jang Jin Young Jankevics Andris Jankovicova Barbora Jarvi Keith Jayapal Jeya Maheshwari Jean François Jehmlich Nico Jelinek Chrisitne Jenkins Rosalind E Jennings Paul	P02.01 P11.15 P06.30 P04.34 P0714 CS27.03, P17.12 P01.24 P09.01 P09.18 P04.31 P04.45 P04.45 CS16.05	Kachuk Carolyn Kacprowski Tim Kadek Alan Kagan Jacob Kagan Olga Kähne Thilo Kahraman Abdullah Kaibuchi Kozo Kaidar-Person Orit Kaipparettu Benny A Kaji Hiroyuki Kalaora Shelly	CS24.05, CS24.06 CS23.04 CS14.08 P06.38, P06.39 P19.14 P22.03 CS26.05 P15.21 P07.28 P28.03 CS03.10, CS30.09 CS28.03
Jameel Nazia	P02.01 P11.15 P06.30 P04.34 P07.14 CS27.03, P17.12 P01.24 P09.01 P09.18 P04.31 P04.45 CS16.05 P16.14	Kachuk Carolyn Kacprowski Tim Kadek Alan Kagan Jacob Kagan Olga Kähne Thilo Kahraman Abdullah Kaibuchi Kozo Kaidar-Person Orit Kaipparettu Benny A Kaji Hiroyuki Kalaora Shelly Kallionpaa H	CS24.05, CS24.06  CS23.04  CS14.08  P06.38, P06.39  P19.14  P22.03  CS26.05  P15.21  P07.28  P28.03  CS03.10, CS30.09  CS28.03  CS28.03  CS28.03
Jameel Nazia	P02.01 P11.15 P06.30 P04.34 P07.14 CS27.03, P17.12 P01.24 P09.01 P09.18 P04.31 P04.45 CS16.05 P16.14 CS10.05, CS22.05, P12.02	Kachuk Carolyn	CS24.05, CS24.06 CS23.04 CS14.08 P06.38, P06.39 P19.14 P22.03 CS26.05 P15.21 P07.28 P28.03 CS31.0, CS30.09 CS28.03 CS28.03 CS28.03 CS28.03 P15.01
Jameel Nazia Jang Jin Young Jankevics Andris Jankovicova Barbora Jarvi Keith Jayapal Jeya Maheshwari Jean François Jehmlich Nico Jelinek Chrisitne Jenkins Rosalind E. Jennings Paul Jensen Katrine B. Jensen Ole N. Jensen Pia.	P02.01 P11.15 P06.30 P04.34 P07.14 CS27.03, P17.12 P01.24 P09.01 P09.18 P04.31 P04.45 CS16.05 P16.14	Kachuk Carolyn Kacprowski Tim Kadek Alan Kagan Jacob Kagan Olga Kähne Thilo Kahraman Abdullah Kaibuchi Kozo Kaidar-Person Orit Kaipparettu Benny A Kaji Hiroyuki Kalaora Shelly Kallionpaa H Kamada Haruhiko Kamath Karthik S	CS24.05, CS24.06 CS23.04 CS14.08 P06.38, P06.39 P19.14 P22.03 CS26.05 P15.21 P07.28 P28.03 CS03.10, CS30.09 CS28.03 CS26.05 P15.01 P07.18
Jameel Nazia Jang Jin Young Jankevics Andris Jankovicova Barbora Jarvi Keith Jayapal Jeya Maheshwari Jean François Jehmlich Nico Jelinek Chrisitne Jenkins Rosalind E Jensen Katrine B Jensen Ole N Jensen Pia Jeong Byeong-Ho	P02.01 P11.15 P06.30 P04.34 P07.14 CS27.03, P17.12 P01.24 P09.01 P09.18 P04.31 P04.45 CS16.05 P16.14 CS10.05, CS22.05, P12.02 P15.20	Kachuk Carolyn Kacprowski Tim Kadek Alan Kagan Jacob Kagan Olga Kähne Thilo Kahraman Abdullah Kaibuchi Kozo Kaidar-Person Orit Kaipparettu Benny A Kaji Hiroyuki Kalaora Shelly Kallionpaa H Kamada Haruhiko Kamath Karthik S Kampf Caroline	CS24.05, CS24.06 CS23.04 CS14.08 P06.38, P06.39 P19.14 P22.03 CS26.05 P15.21 P77.28 P28.03 CS03.10, CS30.09 CS28.03 CS28.03 CS23.07 P15.01 P09.13 CS11.03
Jameel Nazia Jang Jin Young Jankevics Andris Jankovicova Barbora Jarvi Keith Jayapal Jeya Maheshwari Jean François Jehmlich Nico Jelinek Chrisitne Jenkins Rosalind E Jennings Paul Jensen Katrine B Jensen Ole N Jensen Pia Jeong Byeong-Ho Jeong Hoi Keun	P02.01 P11.15 P06.30 P04.34 P07.14 P07.14 P09.18 P09.01 P09.18 P04.31 P04.45 CS16.05 P16.14 CS10.05, CS22.05, P12.02 P15.20 P07.19	Kachuk Carolyn Kacprowski Tim Kadek Alan Kagan Jacob Kagan Olga Kähne Thilo Kahraman Abdullah Kaibuchi Kozo Kaidar-Person Orit Kaipparettu Benny A Kaji Hiroyuki Kalaora Shelly Kallionpaa H Kamada Haruhiko Kamath Karthik S Kampf Caroline Kam Siok Yuen	CS24.05, CS24.06  CS23.04  CS14.08  P06.38, P06.39  P19.14  P22.03  CS26.05  P15.21  P07.28  P28.03  CS03.10, CS30.09  CS28.03  CS28.03  CS28.03
Jameel Nazia Jang Jin Young Jankevics Andris Jankovicova Barbora Jarvi Keith Jayapal Jeya Maheshwari Jean François Jehmlich Nico Jelinek Chrisitne Jenkins Rosalind E Jennings Paul Jensen Katrine B Jensen Ole N Jensen Pia	P02.01 P11.15 P06.30 P04.34 P07.14 P07.14 P09.01 P09.18 P04.31 P04.45 CS16.05 P16.14 CS10.05, CS22.05, P12.02 P15.20 P07.19 P21.08	Kachuk Carolyn Kacprowski Tim Kadek Alan Kagan Jacob Kagan Olga Kähne Thilo Kahraman Abdullah Kaibuchi Kozo Kaidar-Person Orit Kaipparettu Benny A Kaji Hiroyuki Kalaora Shelly Kallionpaa H Kamada Haruhiko Kamath Karthik S Kampf Caroline Kan Siok Yuen Kanagala Prathab	CS24.05, CS24.06 CS23.04 CS14.08 P06.38, P06.39 P19.14 P22.03 CS26.05 P15.21 P07.28 P28.03 CS03.10, CS30.09 CS28.03 CS23.07 P15.01 P09.13 CS11.03 CS07.09
Jameel Nazia Jang Jin Young Jankevics Andris Jankovicova Barbora Jarvi Keith Jayapal Jeya Maheshwari. Jean François Jehmlich Nico. Jelinek Chrisitne Jenkins Rosalind E Jennings Paul Jensen Katrine B Jensen Ole N Jensen Pia. Jeong Byeong-Ho Jeong Hoi Keun Jeong Hyobin Jeong Jieun	P02.01 P11.15 P06.30 P04.34 P09.13 P01.24 P09.01 P09.18 P04.31 P04.45 CS16.05 P16.14 CS10.05, CS22.05, P12.02 P15.20 P07.19 P21.08 P13.06	Kachuk Carolyn	CS24.05, CS24.06  CS23.04  CS14.08  P06.38, P06.39  P19.14  P22.03  CS26.05  P15.21  P07.28  P28.03  CS30.10, CS30.09  CS28.03  CS28.03
Jameel Nazia Jang Jin Young Jankevics Andris Jankovicova Barbora Jarvi Keith Jayapal Jeya Maheshwari Jean François Jehmlich Nico Jelinek Chrisitne Jenkins Rosalind E Jennings Paul Jensen Katrine B Jensen Ole N Jensen Pia Jeong Byeong-Ho Jeong Hyobin Jeong Jieun Jeong Seul-Ki	P02.01 P11.15 P06.30 P04.34 P07.14	Kachuk Carolyn Kacprowski Tim Kadek Alan Kagan Jacob Kagan Olga Kähne Thilo Kahraman Abdullah Kaibuchi Kozo Kaidar-Person Orit Kaipparettu Benny A Kaji Hiroyuki Kalaora Shelly Kallionpaa H Kamada Haruhiko Kamath Karthik S Kampf Caroline Kam Siok Yuen Kanagala Prathab Kandhavelu Jeyalakshm Kang Mee Joo.	CS24.05, CS24.06 CS23.04 CS14.08 P06.38, P06.39 P19.14 P22.03 CS26.05 P15.21 P07.28 P28.03 CS30.09 CS28.03 CS26.05 P15.01 P09.13 CS11.03 CS07.09 P18.14 P01.24
Jameel Nazia Jang Jin Young Jankevics Andris Jankovicova Barbora Jarvi Keith Jayapal Jeya Maheshwari Jean François Jehmlich Nico Jelinek Chrisitne Jenkins Rosalind E Jensen Katrine B Jensen Ole N Jensen Pia Jeong Byeong-Ho Jeong Hyobin Jeong Jieun Jeong Seul-Ki Jeon Kyeongman	P02.01 P11.15 P06.30 P06.30 P04.34 P07.14  CS27.03, P17.12 P01.24 P09.01 P09.18 P04.31 P04.45 CS16.05 P16.14 CS10.05, CS22.05, P12.02 P07.19 P21.08 P13.06 CS10.10 P01.11, P01.14	Kachuk Carolyn Kacprowski Tim Kadek Alan Kagan Jacob Kagan Olga Kähne Thilo Kahraman Abdullah Kaibuchi Kozo Kaidar-Person Orit Kaipparettu Benny A Kaji Hiroyuki Kalaora Shelly Kallionpaa H Kamada Haruhiko Kamada Haruhiko Kamada Prathab Kan Siok Yuen Kangala Prathab Kandhavelu Jeyalakshm Kang Mee Joo Kang Min Jueng	CS24.05, CS24.06 CS23.04 CS14.08 P06.38, P06.39 P19.14 P22.03 CS26.05 P15.21 P07.28 P28.03 CS310, CS30.09 CS28.03 CS23.07 P15.01 P09.13 CS11.03 CS07.09 P18.14 P01.24 P01.24
Jameel Nazia Jang Jin Young Jankevics Andris Jankovicova Barbora Jarvi Keith Jayapal Jeya Maheshwari Jean François Jehmlich Nico Jelinek Chrisitne Jenkins Rosalind E Jennings Paul Jensen Katrine B Jensen Ole N Jensen Pia Jeong Byeong-Ho Jeong Hyobin Jeong Jieun Jeong Seul-Ki Jeon Kyeongman Jessulat Matthew Jhunjhunwala Suchit	P02.01 P11.15 P06.30 P06.30 P04.34 P07.14	Kachuk Carolyn Kacprowski Tim Kadek Alan Kagan Jacob Kagan Olga Kähne Thilo Kahraman Abdullah Kaibuchi Kozo Kaidar-Person Orit Kaipparettu Benny A Kaji Hiroyuki Kalaora Shelly Kallionpaa H Kamada Haruhiko Kamath Karthik S Kampf Caroline Kam Siok Yuen Kanagala Prathab Kandhavelu Jeyalakshm Kang Mee Joo Kang Min Jueng Kang Taewook	CS24.05, CS24.06 CS23.04 CS14.08 P06.38, P06.39 P19.14 P22.03 CS26.05 P15.21 P07.28 P28.03 CS03.10, CS30.09 CS28.03 CS23.07 P15.01 P09.13 CS11.03 CS07.09 P18.14 P01.24 P06.30 CS10.10, P19.10
Jameel Nazia Jang Jin Young Jankevics Andris Jankovicova Barbora Jarvi Keith Jayapal Jeya Maheshwari Jean François Jehmlich Nico Jelinek Chrisitne Jenkins Rosalind E Jensen Katrine B Jensen Ole N Jensen Pia Jeong Byeong-Ho Jeong Hyobin Jeong Jieun Jeong Seul-Ki Jeon Kyeongman Jessula Matthew Jhunjhunwala Suchit	P02.01 P11.15 P06.30 P04.34 P07.14 P07.14 P09.01 P09.18 P04.31 P04.45 CS16.05 P16.14 CS10.05, CS22.05, P12.02 P15.20 P07.19 P21.08 P13.06 CS10.10 P01.11, P01.14 P07.19 P22.04	Kachuk Carolyn	CS24.05, CS24.06 CS23.04 CS14.08 P06.38, P06.39 P19.14 P22.03 CS26.05 P15.21 P07.28 P28.03 CS3.10, CS30.09 CS28.03 CS23.07 P15.01 P09.13 CS11.03 CS07.09 P18.14 P01.24 P06.30 CS10.10, P19.20

Kanshin Evgeny	CS24 02	Kim So Wun	P17.08, P17.09
Kao C. C			P17.08, P17.09
Kapandji Natacha			P06.21
Kappelhoff Reinhild			CS09.10
Kappert Christin	·		<b>P07.11</b> , P07.26
Karaca Samir			P06.30, P07.10, P07.21
Karakosta Theano D			P07.35, P28.13
Karger Barry L			CS19.08, P01.26
Karimi Reza			P06.61, P28.10
Kariya Minoru			P11.26
Karolchik Donna			P11.01
Kashima-Haddad Simone			CS15.06
Kaspar Stephanie			P06.54, P22.06
Kass David A			P22.01
Kassem Moustapha			P01.06
Kastaniegaard Kenneth			P23.02, P23.03, P26.02
Kast Juergen			CS13.03, CS15.05, P18.02
Kato Rika		_	P06.44
Kaupp U B			CS03.03, CS03.08
Kaur Gurjeet			P11.07
Kawai Akira			P04.45
Kawano Shin	·		CS03.03
Kawashima Hitoshi			CS11.08, <b>P04.05</b>
Kawashima Yusuke			<b>CS09.05</b> , CS22.03, P06.24
Kearney Paul		_	P28.01
Keers Sharon			P17.21
Kelleher Neil L			CS18.07, CS21.03, <b>HPP03.04</b>
Keller Eva			P09.30
Kelly Isabelle			CS24.08
Kempf Stefan J.			P15.22
Kennedy Susan			aCS04.05
Kenney Louise			CS04.05
Kent W. James			P04.45
Kenvani Jenna			CS22.03
Kenyon Chris R.			P07.23
Kerner Alexnader			P10.06
Kersten Gideon F.A			CS10.08, CS18.03, CS18.04,
Keshishian Hasmik			<b>P13.10</b> , <b>P13.11</b> , P13.26
Kesseli Juha			CS23.07
Ketchum Karen			P06.03
Khademi Mohsen			P06.29
Khan Ayesha			CS04.10
Khan Bilal H			<b>P06.09</b> , P13.22, P28.11
Khan Mohd M.			CS03.08
Khan Saeed	·		P06.18
Khoo Kay-Hooi			CS23.04, P09.11
Khryapova Elena	·		P06.24
Kiani Parnian			P15.25
Kilgour David P.A			P16.08
Kim Eunhee G		•	P07.33
Kim Han Sol			CS16.06, P04.11
Kim Hye-Jung			P17.05
Kim Jihye			CS08.07
Kim Jinhee			
Kim Jin Young			P04.17, P07.03
Kim Ji Soo			P04.17, P07.03
Kim Jungbae			P07.36
Kim Ki Woong			P02.03
Kim Kristine M			P07.19
Kim Kwang Hoe			<b>CS03.04</b> , P21.07
Kim Kwang-Youl			P06.65
Kim Sangtae			P06.65
Kim Sang Yoon			CS16.08
Kim Seung II	·		CS16.05, P16.15
Kiiri Jeuriy II		Nompara Laximkanun	

Kaladziai Angala	D22.07	Kunkal laramy	DO7 03
	P22.03 <b>CS28.02</b> , P06.41, P06.42		P03.02
	P11.30		CS03.09
	CS07.09		P18.06
			P09.10
	P16.17		P07.17
	P11.01		P07.14, P15.11
	P17.03, <b>P17.10</b>		ingamP01.24
Kooiiman Sietske	P27.02		P06.21
	CS01.07	Kurosky Alexander	P18.08
Kooren Joel A	P18.07	Kurpad Anura	P11.21
Kopylov Arthur T	P01.12, P01.13	Kuruc Matthew	P06.52
Korac Petra	CS03.04	Kuruvilla Jacob	CS09.04, P05.02
Korbakis Dimitrios	.CS27.03, <b>P04.27</b> , P06.68, P17.12	Kusebauch Ulrike	CS21.08, <b>P07.25</b>
Korecka Lucie	P04.15		CS16.07
Körner Roman	CS26.04	Kuster Bernhard	CS09.05, CS19.07, CS22.03,
Kosters Miwako	P17.17		P04.03, <b>P04.12</b> , P06.24, P15.02
	P04.31	Kusunoki Shunta	P11.07
Kovalchuk Sergey	P01.23, P04.48, P06.63	Kuta Victoria	CS07.06
Kovary Kyle M	P13.04	Ku Xin	P04.44
Kowalewski Daniel J	CS08.07	Kuzma Marek	P06.65
	P02.15		P25.03
•	CS26.10		P05.04
,	P25.01		P16.02
	CS26.07		<b>CS09.01</b> , CS09.10
	P01.06		P01.22
	CS16.04	Kwon O. Jung	P07.19
	CS13.01		
	CS30.03, P06.04, P06.15,	L	
	<b>P06.26</b> , P09.13	Lagiala E	CS23.07, P07.38
	P04.05		CS23.07, F07.38
	P06.29		P06.02
	P07.14		CS07.06, CS27.06
	P09.24		P07.13
	P11.24		CS28.07
•	CS28.07	•	CS23.07
	CS09.09		CS23.07
•			P09.04
	P08.05	•	P15.12, P15.13, P15.15, P15.17
	P05.04		CS07.09
	P15.25	Lai Zon	CS01.04
	CS29.06, P23.05		CS27.08
Krulisova Pavla	P15.11	Lakota Jan	P07.14
Kruppa Gary	P07.39	Lambert Jean-Philippe	eCS10.08
Krutova Marcela	P09.30	Lam Ching Wan	P28.17
Kuan Chia-Wei	P27.01	Lam Henry	CS08.07, CS11.09
Ku Chung-Yu	P11.16	Lam Maggie	CS15.02
Kuharev Jörg	P16.04		P18.12
Kuhlmann Katja	P01.07, P15.25		CS27.10
Kuhlmann Laura	P06.72		P11.12
	CS29.06		P16.06
	P04.42		CS19.06
	P28.10		P06.47
	P09.02, P09.12		P02.09, P11.19
	P28.04		P19.03
	P17.13		P13.05, P19.01, <b>P19.13</b>
	CS16.08		CS07.07
	P09.18		
	CS14.07, P27.04		P18.01, P20.02, P20.03, P25.01
	P17.02, P27.03		CS05.07
	P28.03		P08.01
	P09.13		P11.01, <b>P11.02</b>
numar vipin	CS28.08	Larsen Diett	

	<b>27.07</b> , CS30.03, <b>P04.06</b> , P13.10P06.67, P15.20, P16.14,		CS05.08
	P19.04, P19.19, P28.07		
	<b>P16.14</b> , P19.04, P19.19		P06.36, P07.15
	P11.12		CS19.04
	P04.25		P22.07
	CS08.03		P17.13
	P09.14	-	P07.04
	P08.03		P09.23
	CS17.07, <b>CS25.06</b> ,	Levine Douglas	CS01.06
	P13.08, <b>P13.16</b>		CS12.04, P09.27
_averdure Jena-Philippe.	CS08.03	Lewis Michael T	P28.03
_avinder Jason	CS08.05, P27.05	Lewis Steve	CS17.08
_avoie Geneviève	P06.35	Lewitt Martin	P07.40, P07.41, P07.42
_avoie Jessie	P03.02	Lezan Emmanuelle	P15.23
_aw Eric	P28.17	Liang Kun	P11.14
Lazarev Vasilij	P01.23	Liang Tao	CS25.08
_azaris Anthoula	CS04.03	Liang Xiao	CS26.07
_azarus Stephen C	P07.04	Liang Ying	P06.60
Learned Katrina	P28.10	Liao Hanqing	P04.34
	CS30.06		P02.08
_eblanc Andre	P19.25	Liao Pao-Chi	P06.27
Le Cao Kim-Anh	CS07.03, P28.13, P28.15	Li Bo	CS18.05
Lechman Eric R	CS13.03	Lichtenauer Anton M	CS16.04
Lee Bonghee	CS13.02	Lichtenstein Paul	P16.06
Lee Brian T	P28.10	Li Ding	P01.15
_ee Chan-Hyeong	P06.05	Li Dong	P19.06
_ee Cheolju	P07.32	Liebler Daniel C	CS07.10, P06.61
ee Chien-Wei	P06.11	Li Guang	P01.02
ee Chien-Yun	P19.23	Li Henghong	P28.01
ee Chi-Ying	P04.22	Li Hong	P16.23
Lee Dong I	CS15.06	Li Hong-Dong	P13.07
Lee Eun Young	P19.10	Li Jun	P04.29
_ee Hong Gu	P11.23	Li Li	CS19.04
ee Hyoung-Joo	P01.14, P01.22, P19.18	Li Lihua	CS19.07
Lee Hyun Kyoung	P01.22, P21.08	Lill Jennie R	CS05.06, P06.16, P19.08
	CS09.08	Lim John	CS02.05
Lee Jeong-Eun	P06.05		CS07.09
ee Jessica M	P11.13	Limonciel Alice	CS16.05
_ee Ji Eun	P07.32	Lim Xin Shan	P10.05
Lee Jiwon	CS08.05, P27.05	Lin Chi-Hung	P06.04
	CS11.07		ilia SCS08.07
	P01.22, P21.08		CS02.03
•	P23.01		CS16.03
	CS09.08		P02.05
	CS06.03	•	CS07.07
	P09.29		CS12.03
	P07.19		P08.06
	CS03.05		CS14.04
	P06.56		CS26.08
	CS16.09, CS25.04, P16.03		P11.17
	P04.01, P04.39, P17.19		<b>P11.16</b> , P11.17
	P05.03		12.03, CS12.08, <b>P25.02</b> , P25.09
	P28.02		CS12.06
	CS04.10		CS16.0
	CS08.03		CS07.09, <b>P10.05</b>
	CS13.05		P07.20
	P06.40		P19.23
	CS26.07, P22.01		CS18.03, CS27.07
_éon E	P11.12		P15.03
	CS28.09		P18.02
	P07.31		CS19.05
	P15.25	Li Qingqing	P02.12
	CS02.04, P17.06	Li Do	CS15.07

Lisitsa Andrev V	P01.06, P01.12, P01.13, P01.16	Lu Hao Jie	P04.04
	CS27.08		CS18.05
Lithgow Karen V	P09.31	Lu Jianan	P02.12
Liu Chia-Hsun	P06.10	Lu Kuan-Yi	P04.21
Liu Chien-Chun	P11.08	Lu Liang	P19.06
Liu Chin-Ching	P06.60	Lunardi Gianluigi	P07.05
Liu Fang	P06.37	Lundberg Emma	CS18.06, CS30.05, P24.02
Liu Feng	P06.69	Lund-Johansen Fritdjof	P18.04
	P19.23	Lundrigan Tricia	P09.24
Liu Guomin	CS18.04, P13.10, P13.11	Luo Xuemei	P18.08
Liu Hao-Ping	P06.49	Luo Yi	CS18.03
Liu Kate	CS04.04	Lutzke Jeanette	P09.26
	P25.07	Lu Wenyuan	P24.01, <b>P29.01</b>
	CS29.04	Lyu Ping-Chiang	CS26.08
Liu Pei-Jun	P06.11		
	P19.08	М	
	P13.23		
	CS01.07		P13.23
	P16.01		P15.11
	CS08.10, CS19.05, CS30.03, P24.03		CS29.06, P09.15, P23.05
	CS22.04, P06.38, P06.39		CS04.10
	P25.07	, ,	CS07.10
	CS06.07		P28.12
	P06.08, P06.69, P24.01, P29.01		P11.26
	P24.03		CS11.05, P19.22
	<b>CS19.04</b> , <b>CS30.03</b> , P13.24, P19.12		CS07.08
	CS05.04		P23.01
	P06.53, P28.01	_	P16.02
	CS06.03		P06.53
	P19.06		P09.14
	P02.12		P28.01
	CS15.09		CS28.05
Li Zhilu	CS24.04		P06.20
•	CS24.04		P06.64
Li Ziquan	P16.01	Magdeldin Sameh	CS19.08, P01.08, P01.18,
Li Ziquan Li Zongze	P16.01 P16.01	Magdeldin Sameh	
Li Ziquan Li Zongze Llinas Manuel	P16.01 P16.01 P09.27	Magdeldin Sameh Mahboob Sadia	
Li Ziquan Li Zongze Llinas Manuel Llombart Victor	P16.01 P16.01 P09.27 <b>CS04.07</b> , CS07.04	Magdeldin Sameh Mahboob Sadia Maher Christopher A	
Li Ziquan Li Zongze Llinas Manuel Llombart Victor L. Nielsen Michael	P16.01 P16.01 P09.27 CS04.07, CS07.04 P02.06	Magdeldin Sameh Mahboob Sadia Maher Christopher A Mahr Claudius	
Li Ziquan Li Zongze Llinas Manuel Llombart Victor L. Nielsen Michael Loessner Martin		Magdeldin Sameh Mahboob Sadia Maher Christopher A Mahr Claudius Maiolica Alessio	
Li Ziquan Li Zongze Llinas Manuel Llombart Victor L. Nielsen Michael Loessner Martin Lombaert Nathalie		Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b> P06.12, P06.58 CS07.10 CS15.04 P15.10 P09.15
Li Ziquan	P16.01 P16.01 P09.27 CS04.07, CS07.04 P02.06 CS21.07 P14.02 P16.16	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b> P06.12, P06.58 CS07.10 CS15.04 P15.10 P09.15 CS16.04
Li Ziquan	P16.01 P16.01 P09.27 CS04.07, CS07.04 P02.06 CS21.07 P14.02 P16.16 P02.17	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b> P06.12, P06.58 CS07.10 CS15.04 P15.10 P09.15 CS16.04 CS10.04
Li Ziquan		Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b> P06.12, P06.58  CS07.10  CS15.04  P15.10  P09.15  CS16.04  CS10.04  P10.02
Li Ziquan	P16.01 P16.01 P09.27  CS04.07, CS07.04 P02.06 CS21.07 P14.02 P16.16 P02.17 CS04.04 CS04.04 CS04.04	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b>
Li Ziquan	P16.01 P16.01 P09.27 P09.27  CS04.07, CS07.04 P02.06 CS21.07 P14.02 P16.16 P02.17 CS04.04 CS04.04 CS04.04 CS06.07, CS25.03,	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b> P06.12, P06.58 CS07.10 CS15.04 P15.10 P09.15 CS16.04 <b>CS10.04 P10.02</b> CS20.03
Li Ziquan	P16.01 P16.01 P09.27 P09.27  CS04.07, CS07.04 P02.06 CS21.07 P14.02 P16.16 P02.17 CS04.04 CS04.04 CS06.07, CS25.03, P17.20, P25.03	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b> P06.12, P06.58 CS07.10 CS15.04 P15.10 P09.15 CS16.04 CS10.04 P10.02 CS20.03 P07.31 P11.25, P11.28
Li Ziquan	P16.01 P16.01 P16.01 P09.27  C\$04.07, C\$07.04 P02.06 C\$21.07 P14.02 P16.16 P02.17 C\$04.04 C\$04.04 C\$06.07, C\$25.03, P17.20, P25.03 ia P06.25	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b> P06.12, P06.58  CS07.10  CS15.04  P15.10  P09.15  CS16.04 <b>CS10.04 P10.02</b> CS20.03  P07.31  P11.25, P11.25  P05.05
Li Ziquan	P16.01 P16.01 P16.01 P09.27  CS04.07, CS07.04 P02.06  CS21.07 P14.02 P16.16 P02.17  CS04.04 CS04.04 CS04.04 CS06.07, CS25.03, P17.20, P25.03 ia P06.25 P16.10, P17.16	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b> P06.12, P06.58  CS07.10  CS15.04  P15.10  P09.15  CS16.04 <b>CS10.04 P10.02</b> CS20.03  P07.31  P11.25, P11.28  P05.05  P06.07
Li Ziquan	P16.01 P16.01 P09.27 P09.27  CS04.07, CS07.04 P02.06  CS21.07 P14.02 P16.16 P02.17 CS04.04 CS04.04 CS06.07, CS25.03, P17.20, P25.03 P16.10, P17.16 P13.18	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b>
Li Ziquan	P16.01 P16.01 P16.01 P09.27 P09.27  CS04.07, CS07.04 P02.06  CS21.07 P14.02 P16.16 P02.17 CS04.04 CS04.04 CS04.04 CS06.07, CS25.03, P17.20, P25.03 ia P06.25 P15.18 P15.18 CS07.06, CS27.06	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b> P06.12, P06.58 CS07.10 CS15.04 P15.10 P09.15 CS16.04 CS10.04 P10.02 P70.02 P70.03 P71.28 P05.05 P13.24, P19.12 P04.17
Li Ziquan	P16.01 P16.01 P16.01 P09.27  CS04.07, CS07.04 P02.06 CS21.07 P14.02 P16.16 P02.17 CS04.04 CS04.04 CS04.04 CS06.07, CS25.03, P17.20, P25.03 ia P06.25 P16.10, P17.16 P13.18 CS07.06, CS27.06 P09.19	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b> P06.12, P06.58 CS07.10 CS15.04 P15.10 P09.15 CS16.04 P10.02 CS20.03 P07.31 P11.25, P11.28 P05.05 P06.07 P13.24, P19.12 P04.17 CS02.06
Li Ziquan	P16.01 P16.01 P16.01 P09.27  CS04.07, CS07.04 P02.06  CS21.07 P14.02 P16.16 P02.17  CS04.04 CS04.04 CS04.04 CS06.07, CS25.03, P17.20, P25.03  ia P06.25 P16.10, P17.16 P13.18 CS07.06, CS27.06 P09.19 P09.23	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b> P06.12, P06.58  CS07.10  CS15.04  P15.10  P09.15  CS16.04 <b>P10.02</b> CS20.03  P07.31  P11.25, P11.28  P05.05  P06.07  P13.24, P19.12  P04.17  CS02.06  CS10.04, P10.02
Li Ziquan	P16.01 P16.01 P16.01 P09.27  CS04.07, CS07.04 P02.06 CS21.07 P14.02 P16.16 P02.17 CS04.04 CS04.04 CS04.04 CS06.07, CS25.03, P17.20, P25.03 ia P06.25 P16.10, P17.16 P13.18 CS07.06, CS27.06 P09.19	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b> P06.12, P06.58 CS07.10 CS15.04 P15.10 P09.15 CS16.04 P10.02 CS20.03 P07.31 P11.25, P11.28 P05.05 P06.07 P13.24, P19.12 P04.17 CS02.06
Li Ziquan	P16.01 P16.01 P16.01 P09.27  C\$04.07, C\$07.04 P02.06  C\$21.07 P14.02 P16.16 P02.17  C\$04.04 C\$04.04  C\$04.04  C\$05.03, P17.20, P25.03 P16.10, P17.16 P13.18 C\$07.06, C\$27.06 P09.19 P09.23 C\$11.05 P13.14	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b> P06.12, P06.58  CS07.10  CS15.04  P15.10  P09.15  CS16.04 <b>CS10.04</b> P10.02  CS20.03  P07.31  P11.25, P11.28  P05.05  P06.07  P13.24, P19.12  P04.17  CS02.06  CS16.10, P13.14
Li Ziquan	P16.01 P16.01 P16.01 P09.27  C\$04.07, C\$07.04 P02.06  C\$21.07 P14.02 P16.16 P02.17  C\$04.04 C\$04.04 C\$06.07, C\$25.03, P17.20, P25.03  ia P06.25 P16.10, P17.16 P13.18 C\$07.06, C\$27.06 P09.19 P09.23 C\$11.05	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b> P06.12, P06.58  CS07.10  CS15.04  P15.10  P09.15  CS16.04 <b>P10.02</b> CS20.03  P07.31  P11.25, P11.28  P05.05  P06.07  P13.24, P19.12  P04.17  CS02.06  CS16.10, P13.14  P11.30  CS18.09
Li Ziquan	P16.01 P16.01 P16.01 P09.27  CS04.07, CS07.04 P02.06  CS21.07 P14.02 P16.16 P02.17 CS04.04 CS04.04 CS04.04 CS04.04 P06.25 P16.10, P17.16 P13.18 CS07.06, CS27.06 P09.19 P09.23 CS11.05 P13.14 CS30.06	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b> P06.12, P06.58  CS07.10  CS15.04  P15.10  P09.15  CS16.04 <b>P10.02</b> CS20.03  P07.31  P11.25, P11.28  P05.05  P06.07  P13.24, P19.12  P04.17  CS02.06  CS16.10, P13.14  P11.30  CS18.09  P11.21
Li Ziquan	P16.01 P16.01 P16.01 P16.01 P09.27  C\$04.07, C\$07.04 P02.06  C\$21.07 P14.02 P16.16 P02.17  C\$04.04 C\$04.04 C\$04.04 C\$05.07, C\$25.03, P17.20, P25.03 ia P06.25 P16.10, P17.16 P13.18 C\$07.6, C\$27.06 P09.19 P09.23 C\$11.05 P13.14 C\$30.06 C\$30.06	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, P04.07, P04.08  P06.12, P06.58  CS07.10  P15.10  P09.15  CS16.04  P10.02  CS20.03  P07.31  P11.25, P11.28  P05.05  P06.07  P13.24, P19.12  P04.17  CS02.06  CS16.10, P13.14  P11.30  CS18.09  P11.25  P11.25  P11.25  P11.25  P25.06
Li Ziquan	P16.01 P16.01 P16.01 P16.01 P09.27  C\$04.07, C\$07.04 P02.06  C\$21.07 P14.02 P16.16 P02.17  C\$04.04 C\$04.04 C\$04.04 C\$05.03 P17.20, P25.03 F17.20, P25.03 F18.18 C\$07.06, C\$27.06 P09.19 P09.23 C\$11.05 P13.14 C\$30.06 C\$30.06 C\$30.06 C\$30.06	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b> P06.12, P06.58  CS07.10  CS15.04  P15.10  P09.15  CS16.04 <b>P10.02</b> CS20.03  P07.31  P11.25, P11.28  P05.05  P06.07  P13.24, P19.12  P04.17  CCS02.06  CS16.10, P13.14  P11.30  CS18.09  P12.50  P12.50  CS18.09  P12.50  CS13.05
Li Ziquan	P16.01 P16.01 P16.01 P09.27  C\$04.07, C\$07.04 P02.06  C\$21.07 P14.02 P16.16 P02.17  C\$04.04 C\$04.04 C\$06.07, C\$25.03, P17.0, P25.03  P16.10, P17.16 P13.18 C\$07.06, C\$27.06 P09.19 P09.23 C\$11.05 P13.14 C\$30.06 C\$08.10, P06.69 P19.13	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, P04.07, P04.08  P06.12, P06.58  CS07.10  P15.10  P09.15  CS16.04  P10.02  CS20.03  P07.31  P11.25, P11.28  P05.05  P06.07  P13.24, P19.12  P04.17  CS02.06  CS16.10, P13.14  P11.30  CS18.09  P11.21  P25.06  CS13.05  P13.03  P13.03  P04.42  P13.03
Li Ziquan	P16.01 P16.01 P16.01 P09.27  C\$04.07, C\$07.04 P02.06  C\$21.07 P14.02 P16.16 P02.17  C\$04.04 C\$04.04 C\$04.04  C\$05.03 P17.20, P25.03 P17.20, P25.03 P18.18 C\$05.07, C\$27.06 P09.19 P09.23 C\$11.05 P13.14 C\$30.06 C\$30.06 P19.13 P13.14 C\$30.06 C\$08.10, P06.69 P19.13 P25.08 C\$01.09, C\$08.06	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, <b>P04.07</b> , <b>P04.08</b> P06.12, P06.58  CS07.10  CS15.04  P15.10  P09.15  CS16.04 <b>P10.02</b> CS20.03  P07.31  P11.25, P11.28  P05.05  P06.07  P13.24, P19.12  P04.17  CS02.06  CS16.10, P13.14  P11.30  CS18.09  P11.21  P25.06  CS13.05  P13.05  P13.05  P13.05  P14.21
Li Ziquan	P16.01 P16.01 P16.01 P16.01 P16.01 P09.27  C\$04.07, C\$07.04 P02.06 C\$21.07 P14.02 P16.16 P02.17 C\$04.04 C\$04.04 C\$06.07, C\$25.03, P17.20, P25.03 ia P06.25 P16.10, P17.16 P13.18 C\$05.06, C\$27.06 P09.19 P09.23 C\$11.05 P13.14 C\$30.06 C\$30.06 C\$08.10, P06.69 P19.13 P25.08 C\$08.06 C\$08.06 C\$08.06 C\$08.06	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, P04.07, P04.08  P06.12, P06.58  CS07.10  P15.10  P09.15  CS16.04  P10.02  CS20.03  P07.31  P11.25, P11.28  P05.05  P06.07  P13.24, P19.12  P04.17  CS02.06  CS16.10, P13.14  P11.30  CS18.09  P11.21  P25.06  CS13.05  P13.03  P13.03  P04.42  P13.03
Li Ziquan	P16.01 P16.01 P16.01 P16.01 P09.27  C\$04.07, C\$07.04 P02.06	Magdeldin Sameh	CS19.08, P01.08, P01.18, P01.26, P04.07, P04.08  P06.12, P06.58  CS07.10  P15.10  P09.15  CS16.04  P10.02  CS20.03  P07.31  P11.25, P11.28  P05.05  P06.07  P13.24, P19.12  P04.17  CS02.06  CS16.10, P13.14  P11.30  CS18.09  P13.24  P13.03  P25.06  CS13.05  P13.03  CS19.03, CS22.07, P02.07,

Man Petr	Mcclatchy Daniel B
Mao JiaweiCS20.05	Mcclatchy Daniel B
Marana RiccardoP07.30	Mcdermott Jason
Marcellin Marlène	Mcdonald PaulP19.13
Marcilla Miguel	Mcintosh LauraCS28.04
Marcinkiewicz Martin MCS04.03	Mckay Matthew JP06.26
Marcotte EdwardCS08.05, P13.02, P27.05	Mclaughlin TraceyP28.04
Marcus KatrinCS02.09, P15.25	Mclean LynnP09.04
Margulies Kenneth BHPP03.03	Mcleish KennethP17.21
Marino FabioP27.02	Mcleod JenniferP11.27
Marino Giada CS27.05, <b>P11.27</b>	Mcmanus Bruce MCS15.09, P07.04, P23.06, P28.15
Marin Philippe	Mcmanus FrancisCS27.10
Marissen RobP09.02	Mcmaster W. RobertP09.09
Marko-Varga GyörgyCS04.09, CS09.10,	Mcmullen Patrick DP28.01
P06.07, P18.05	Méant AntoineP06.35
Marquet PierreP07.16	Médard GuillaumeCS09.05, CS22.03
Marra GiancarloP06.02	Meding StephanP04.28
Marr Alexandra KP09.09	Megger Dominik AP07.36
Marshall Natalie C	Meier-Schellersheim MartinP13.03
Martens John W	Meiring Hugo DP27.02
Martens Lennart CS17.10, P11.11	Melamed Dganit
Martínez-Bartolomé Salvador	Melathopoulos AndonyP17.14
Martinez-Rodriguez Carmen	Melchers Micol
Martin FlorianCS23.09, P18.11	Melm Chris
Martin Leroy B	Melnik Andre
Martin Roy	Melo FernandaP06.31
Martins-De-Souza Daniel	Melo MatildeP13.14
Marziali MeganP09.26	Mendes Vera
Masignani VegaCS21.06	Mendoza LuisCS11.09
Masselot Alexandre	Menendez PabloP03.02
Massiot JulienCS26.08	Meng ChenCS22.03, P15.02
Mastali MitraP18.10	Meng Tzu-ChingP19.26
Masucci JohnP16.13	Menon RajasreeP01.27, P13.07
Masuda MariP23.04	Mentzer RobertP18.07
Masuishi YusukeP07.37	Merchant MichaelP17.21
Matafora VittoriaCS11.01	Mercuri Nicola BP16.16
Matejkova JanaP09.30	Merino-Jiménez Candelaria
Mathias Rommel AP06.28	Mertens IngeP06.20, <b>P07.16</b>
Mathis Andrew DP10.06	Mesri MehdiCS11.05
Matlock Andrea	Messana Irene
Matondo Mariette	Messuti NicolaCS21.06
Matsuda Atsushi	Metaxas Athanasios
Matsumoto Kazumasa	Metello Carlos
Matsumoto Masaki	Meterissian Sarkis
Matta AjayCS27.02	Metz Bernard
Matthews DavidP09.25	Mever Helmut EP01.07. P06.29. P07.36. P16.07
Matthews IanCS27.05	Meyer Kevin
Mattman Andre	Meyer Michael KCS20.08
Mattsson Cecilia	Meyer Tanja C
Maudsley StuartP17.02, P27.03	Michalak AgataP06.44
Mayboroda Oleg AP09.12	Michalik Stephan
May CarolineCS02.09	Michalski AnnetteP04.19
Maynskova MariaP01.01	Michaud Sarah CS06.06, P04.01
Ma YongchenP16.01	Middleton StefaniP04.21
Mayor ThibaultP10.03, P11.10, <b>P19.11</b>	Mi JiaP16.12
May Robert	Mikami ToshiyukiP17.05
Ma YuanhuiCS06.04	Mikolajczak JudithCS08.04
Mazzone MassimilianoP06.20	Mikus Maria <b>P07.12</b> , P16.09
Mcafee AlisonCS29.03	Milani PaoloP06.64
Mcarthur Steven JP09.01	Milardi DomenicoP07.30
Mccabe AntonyP13.15	Miliotis Tasso <b>CS05.02</b> , P01.05

Miller Christine	<b>P06.53</b> , P28.01	Mukai Yohei	P15 01
	P13.12	Mulder Jan	
	P05.04	Mulders Coen	
Minamida Satoru	P07.33	Mullen Christopher	P05.05
Min Chul Woo	P17.08, P17.09	Mulligan Joanne	CS06.03
Minden Mark D	CS13.03	Muñoz Amalia	CS30.04
Minic Zoran	CS02.06, P22.04	Muntel Jan	P07.02
Miot Hélio A	P17.22	Munthe Sune	
Mirza Shama	P06.53	Muradia Gauri	P03.02
Mitchell Amanda	CS13.03	Muralidharan Monita	P11.21
Mitra Gopa	P11.21	Murata Syota	P09.08
	P07.31	Muravieva Alisa	
Mitrofanov Sergey I	P07.07	Murphy James	
	P16.08	Murr Annette	
	CS04.05	Murray Christopher	
	P09.08	Murray Deirdre	
	P06.21	Mushtaq Shamim	
•	CS01.10	Muth-Pawlak Dorota	
	P07.02	Muzzi Alessandro	
	CS14.09, P06.12, P06.58	Myhr Kjell-Morten	
	P04.01, <b>P06.34</b> , <b>P11.18</b> , <b>P11.20</b>	Mykkänen J	
	P01.24	Myoba Shohei	P07.37
	P29.02	N	
	CS28.05	N	
	CS01.05	Maharata Marat	D07.70
	CS07.04	Naboulsi Wael	
	CS14.06	Nadler Wiebke	
	P18.01	Na Dokyun Naesens Maarten	
	CS30.03, P06.15		
	P06.04, P06.26, <b>P09.13</b>	Nagai-Okatani Chiaki Nagano Kazuya	
	<b>CS01.09</b>	Nagano Maiko Nagayama Megumi	
		Naicker Previn	
	P04.23	Nakagawa Tomomi	
	P16.05	Nakamuta Shinichi	
	P16.03	Nakano Miyako	
	P15.19	Nakayama Haruhiko	
	P11.12	Nalpas Nicolas	
	P13.18	Namperumalsamy Venkatesh Pra	
	P11.12	Nancarrow Derek	
	P17.14	Nanni Paolo	
	P19.03, P28.05	Narimatsu HisashiCS	
	P06.05	Narita Masako	
	CS04.07	Narita Masashi	
	CS23.06	Naryzhny Stanislav	
	CS25.06	Nassar Roy	
		Nasso Sara	
	CS30.03, P07.25	Nättinen Janika	CS28.10, <b>P11.05</b>
Moriya Yuki	P13.22	Nauck Matthias	CS23.04
Morns lan	P13.15	Naumann Michael	P22.03
Morrice Nick	CS06.05, P06.66	Naumov V. A	CS28.07
Morrison Charlotte J	P09.09	Navarrete Mario A	CS09.09
Moschioni Monica	CS21.06	Navarro Pedro	CS08.07, P13.24
	P06.38	Naylor Bradley C	
Moss Christopher L	P07.25	Nebuloni Manuela	P06.64
	P15.22	Nehmé Benjamin	
	CS13.07	Neiman Maja	
	CS07.06, CS27.06	Nemkov Travis	
	CS23.07	Neo Suat Peng	
	CS30.06	Nesvizhskii AlexeyCS1	
	P20.02		
	CS14.05	Neubert Hendrik	
Mueller Margareta M	P06.03	Ngai Sai Ming	P06.71, <b>P22.07</b>

	P18.14		P06.21
	P07.04, P23.06, P28.15		P13.22, P29.03
	CS23.07		CS26.05
	CS14.09, P01.19, P06.01, P06.58		P06.23
	CS14.09, P01.19, P00.01, P00.36		<b>CS22.01</b> , P15.04, P15.07, P15.09
	P06.66		
	P04.09		P06.16
	<b>P02.01</b> , P26.03		CS04.09
	P16.13		P16.08
	P28.11		
	CS28.07		P25.05
			P06.45
	CS28.07. <b>P07.07</b> . P16.17		CS26.10
Nikolaev Evgeny	P11.01, P11.02		P07.28
Nikolaev Yaroslav	CS26.05		CS19.09
Nilsson Carol L	CS13.07	Orfao Alberto	P01.17, P01.21, P18.04
Nilsson Peter	CS15.03, P04.14, P04.39, P06.50,	Ornelas Loren	CS13.05
P07	7.12, P07.29, P11.24, <b>P16.08</b> , P16.09,	Osbak Kara K	P09.06
	P17.19, P27.06	Osetrova Maria	P04.48
Ning Zhibin	P19.03	Oshita Fumihiro	P06.21
Nishi Mayuko	P06.21	Osinalde Nerea	CS13.04
Nishioka Tomoki	P15.21		CS16.03
Nita-Lazar Aleksandra	aP13.03		CS30.06
	P16.04		P21.06
	P29.04		P17.17, P17.18
	P17.05		P06.51
	P01.20, P06.23		CS02.04, CS17.10, P17.06
	P15.22	·	CS08.09, CS27.05, HPP03.04,
	P21.01		1.27, P13.05, P19.01, P19.13, P28.16
	P09.08		CS18.02, CS18.07, CS21.03
	P02.16		CS11.07
Noor-Ul-Huda Hafiza	P11.25, P11.28	Ozcan Servet	P06.51, P09.21
Noor-UI-Huda Hafiza Norais Nathalie	P11.25, P11.28	Ozcan Servet Özcengiz Erkan	<b>P06.51</b> , <b>P09.21</b>
Noor-Ul-Huda Hafiza Norais Nathalie Noro Erika	P11.25, P11.28 	Ozcan Servet Özcengiz Erkan Özcengiz Gülay	
Noor-Ul-Huda Hafiza Norais Nathalie Noro Erika Noronha Melissa	P11.25, P11.28 CS21.06 CS03.10, CS30.09 P18.02	Ozcan Servet Özcengiz Erkan Özcengiz Gülay	<b>P06.51</b> , <b>P09.21</b>
Noor-Ul-Huda Hafiza Norais Nathalie Noro Erika Noronha Melissa Novak Petr	P11.25, P11.28  CS21.06  CS03.10, CS30.09  P18.02  P06.65	Ozcan ServetÖzcengiz ErkanÖzcengiz GülayÖzcengiz GülayOzturk Ahmet R	
Noor-Ul-Huda Hafiza Norais Nathalie Noro Erika Noronha Melissa Novak Petr Novikova Swetlana	P11.25, P11.28	Ozcan Servet Özcengiz Erkan Özcengiz Gülay	
Noor-Ul-Huda Hafiza Norais Nathalie Noro Erika Noronha Melissa Novak Petr Novikova Swetlana Novoa-Herran Susana	P11.25, P11.28	Ozcan ServetÖzcengiz ErkanÖzcengiz GülayOzturk Ahmet R	P06.51, P09.21 P09.21 P09.21 P06.51
Noor-Ul-Huda Hafiza Norais Nathalie Noro Erika Noroha Melissa Novak Petr Novikova Swetlana Novoa-Herran Susana Núñez Galindo Antoni	P11.25, P11.28	Ozcan Servet Özcengiz Erkan Özcengiz Gülay Ozturk Ahmet R P Packer Nicolle H	P06.51, P09.21 P09.21 P09.21 P06.51 P06.51
Noor-Ul-Huda Hafiza Norais Nathalie Noro Erika Noronha Melissa Novak Petr Novikova Swetlana Novoa-Herran Susana Núñez Galindo Antoni Nury Catherine	P11.25, P11.28	Ozcan Servet Özcengiz Erkan Özcengiz Gülay Ozturk Ahmet R  P  Packer Nicolle H Padden Juliet	P06.51, P09.21
Noor-Ul-Huda Hafiza Norais Nathalie Noro Erika Noronha Melissa Novak Petr Novikova Swetlana Nova-Herran Susana Núñez Galindo Antoni Nury Catherine	P11.25, P11.28	Ozcan Servet Özcengiz Erkan Özcengiz Gülay Ozturk Ahmet R  P  Packer Nicolle H Padden Juliet Padurariu Simona	P06.51, P09.21 P09.21 P09.21 P06.51  CS03.06, P09.13, P09.14 P07.36 CS24.10
Noor-Ul-Huda Hafiza Norais Nathalie Noro Erika Noronha Melissa Novak Petr Novikova Swetlana Nova-Herran Susana Núñez Galindo Antoni Nury Catherine	P11.25, P11.28	Ozcan Servet	P06.51, P09.21 P09.21 P09.21 P09.21 P06.51  CS03.06, P09.13, P09.14 P07.36 CS24.10 P02.09
Noor-Ul-Huda Hafiza Norais Nathalie Noro Erika Noronha Melissa Novak Petr Novikova Swetlana Nova-Herran Susana Núñez Galindo Antoni Nury Catherine	P11.25, P11.28	Ozcan Servet	P06.51, P09.21 P09.21 P09.21 P06.51 P06.51
Noor-Ul-Huda Hafiza Norais Nathalie Noro Erika Noronha Melissa Novak Petr Novikova Swetlana Novoa-Herran Susana Núñez Galindo Antoni Nury Catherine Nyc Otakar Nykter Matti	P11.25, P11.28	Ozcan Servet Özcengiz Erkan Özcengiz Gülay Ozturk Ahmet R  P  Packer Nicolle H Padden Juliet Padurariu Simona Pagallies Felix Paik Young-Ki Pai Roopesh R	P06.51, P09.21 P09.21 P09.21 P06.51 P06.51  CS03.06, P09.13, P09.14 P07.36 CS24.10 P02.09 P01.11, P01.14, P01.22, P19.18 P01.24
Noor-Ul-Huda Hafiza Norais Nathalie Noro Erika Noronha Melissa Novak Petr Novikova Swetlana Novoa-Herran Susana Núñez Galindo Antoni Nury Catherine Nyc Otakar Nykter Matti	P11.25, P11.28	Ozcan Servet	
Noor-UI-Huda Hafiza Norais Nathalie Noron Erika Noronha Melissa Novak Petr Novikova Swetlana Novoa-Herran Susana Núñez Galindo Antoni Nury Catherine Nykter Matti  O  Oberbach Andreas	P11.25, P11.28	Ozcan Servet	P06.51, P09.21 P09.21 P09.21 P06.51 P06.51  CS03.06, P09.13, P09.14 P07.36 CS24.10 P02.09 P01.11, P01.14, P01.22, P19.18 P01.24
Noor-UI-Huda Hafiza Norais Nathalie Noron Erika Noronha Melissa Novak Petr Novikova Swetlana Novoa-Herran Susana Núñez Galindo Antoni Nury Catherine Nyc Otakar Nykter Matti	P11.25, P11.28	Ozcan Servet	
Noor-UI-Huda Hafiza Norais Nathalie Noronha Melissa Novak Petr Novikova Swetlana Novoa-Herran Susana Nűñez Galindo Antoni Nury Catherine Nyc Otakar Nykter Matti  O  Oberbach Andreas Oberhaus Andrea O'Byrne Paul	P11.25, P11.28	Ozcan Servet	
Noor-UI-Huda Hafiza Norais Nathalie Noronha Melissa Novak Petr Novikova Swetlana Novoa-Herran Susana Núñez Galindo Antoni Nury Catherine Nyc Otakar Nykter Matti  O  Oberbach Andreas Oberhaus Andrea O'Byrne Paul Ochiya Takahiro	P11.25, P11.28	Ozcan Servet	
Noor-UI-Huda Hafiza Norais Nathalie Noronha Melissa Novak Petr Novikova Swetlana Novae-Herran Susana Núñez Galindo Antoni Nury Catherine Nykter Matti  O  Oberbach Andreas Oberhaus Andrea O'Byrne Paul Ochiya Takahiro Ochoa Begona	P11.25, P11.28	Ozcan Servet	P06.51, P09.21 P09.21 P09.21 P09.21 P06.51  CS03.06, P09.13, P09.14 P07.36 CS24.10 P02.09 P01.11, P01.14, P01.22, P19.18 P09.30, P09.30 P06.31, P06.47 P04.09, P06.34, P07.06, P09.02 P19.04, P19.19 CS01.06, P06.22
Noor-UI-Huda Hafiza Norais Nathalie Noronha Melissa Novak Petr Novikova Swetlana Novoa-Herran Susana Nűnez Galindo Antoni Nury Catherine Nyc Otakar Nykter Matti  O  Oberbach Andreas Oberhaus Andrea O'Byrne Paul Ochoa Begona Odeberg Jacob Odriozola Leticia	P11.25, P11.28	Ozcan Servet	P06.51, P09.21 P09.21 P09.21 P09.21 P09.21 P06.51  CS03.06, P09.13, P09.14 P07.36 CS24.10 P02.09 P01.11, P01.14, P01.22, P19.18 P09.30, P09.30 P06.31, P06.47 P04.09, P06.34, P07.06, P09.02 P19.04, P19.19 CS01.06, P06.22 S. P01.24 CS24.03, CS25.05, P05.01, P07.39, P20.01
Noor-UI-Huda Hafiza Norais Nathalie Noronha Melissa Novak Petr Novikova Swetlana Novae-Herran Susana Nüñez Galindo Antoni Nury Catherine Nyc Otakar Nykter Matti  O  Oberbach Andreas Oberhaus Andrea O'Byrne Paul Ochoja Takahiro Ochoa Begona Odeberg Jacob. Odriozola Leticia Odwin-Dacosta Shelly	P11.25, P11.28	Ozcan Servet	P06.51, P09.21 P09.21 P09.21 P09.21 P09.21 P06.51  CS03.06, P09.13, P09.14 P07.36 CS24.10 P02.09 P01.11, P01.14, P01.22, P19.18 P09.30, P09.30 P06.31, P06.47 P04.09, P06.34, P07.06, P09.02 P19.04, P19.19 CS01.06, P06.22 S. P01.24 P07.39, P20.01 P07.39, P20.01
Noor-Ul-Huda Hafiza Norais Nathalie Noro Erika	P11.25, P11.28	Ozcan Servet	P06.51, P09.21 P09.21 P09.21 P09.21 P09.21 P06.51  CS03.06, P09.13, P09.14 P07.36 CS24.10 P02.09 P01.11, P01.14, P01.22, P19.18 P09.30, P09.30 P06.31, P06.47 P04.09, P06.34, P07.06, P09.02 P19.04, P19.19 CS01.06, P06.22 S. P01.24 CS24.03, CS25.05, P05.01, P07.39, P20.01 P22.01 CS01.03
Noor-UI-Huda Hafiza Norais Nathalie Noron Erika Noronha Melissa Novak Petr Novikova Swetlana Novak-Herran Susana Núñez Galindo Antoni Nury Catherine Nykter Matti  O  Oberbach Andreas Oberhaus Andrea O'Byrne Paul Ochiya Takahiro Ochoa Begona Odeberg Jacob Odriozola Leticia Odwin-Dacosta Shelly Oehler Martin K Ogata Kosuke	P11.25, P11.28	Ozcan Servet	P06.51, P09.21 P09.21 P09.21 P09.21 P09.21 P09.21 P06.51
Noor-UI-Huda Hafiza Norais Nathalie Noron Erika Noronha Melissa Novak Petr Novikova Swetlana Novoa-Herran Susana Núñez Galindo Antoni Nury Catherine Nyc Otakar Nykter Matti   O  Oberbach Andreas Oberhaus Andrea O'Byrne Paul Ochiya Takahiro Ochoa Begona Odeberg Jacob Odwin-Dacosta Shelly Oehler Martin K Ogata Kosuke O'Grady John P	P11.25, P11.28	Ozcan Servet	P06.51, P09.21 P09.21 P09.21 P09.21 P09.21 P09.21 P06.51  CS03.06, P09.13, P09.14 P07.36 CS24.10 P02.09 P01.11, P01.14, P01.22, P19.18 P01.24 P09.30, P09.30 P06.31, P06.47 P04.09, P06.34, P07.06, P09.02 P19.04, P19.19 CS01.06, P06.22 S. P01.24 CS24.03, CS25.05, P05.01, P07.39, P20.01 P22.01 CS01.03 P01.27 P06.41, P06.42
Noor-UI-Huda Hafiza Norais Nathalie Noronha Melissa Novak Petr Novikova Swetlana Novoa-Herran Susana Nűnez Galindo Antoni Nury Catherine Nyk ter Matti   O  Oberbach Andreas Oberhaus Andrea O'Byrne Paul Ochiya Takahiro Ochoa Begona Odeberg Jacob Odwin-Dacosta Shelly Oehler Martin K Ogata Kosuke O'Grady John P Ohana Dana	P11.25, P11.28	Ozcan Servet	P06.51, P09.21 P09.21 P09.21 P09.21 P09.21 P09.21 P06.51  CS03.06, P09.13, P09.14 P07.36 CS24.10 P02.09 P01.11, P01.14, P01.22, P19.18 P09.30, P09.30 P06.31, P06.47 P04.09, P06.34, P07.06, P09.02 P19.04, P19.19 CS01.06, P06.22 S. P01.24 CS24.03, CS25.05, P05.01, P07.39, P20.01 P22.01 CS01.03 P01.27 P06.41, P06.42 CS08.03
Noor-UI-Huda Hafiza Norais Nathalie Noronha Melissa Novak Petr Novikova Swetlana Novoa-Herran Susana Nűñez Galindo Antoni Nury Catherine Nyc Otakar Nykter Matti  O  Oberbach Andreas Oberhaus Andrea O'Byrne Paul Ochoa Begona Odeberg Jacob Odeberg Jacob Odeberg Jacob Odwin-Dacosta Shelly Oehler Martin K Ogata Kosuke O'Grady John P Ohana Dana Oh Kenneth	P11.25, P11.28	Ozcan Servet	P06.51, P09.21 P09.21 P09.21 P09.21 P09.21 P09.21 P06.51  CS03.06, P09.13, P09.14 P07.36 CS24.10 P02.09 P01.11, P01.14, P01.22, P19.18 P01.24 P09.30, P09.30 P06.31, P06.47 P04.09, P06.34, P07.06, P09.02 P19.04, P19.19 CS01.06, P06.22 S. P01.24 CS24.03, CS25.05, P05.01, P07.39, P20.01 P22.01 CS01.03 P01.27 P06.41, P06.42 CS08.03 P06.13
Noor-UI-Huda Hafiza Norais Nathalie Noro Erika	P11.25, P11.28	Ozcan Servet	P06.51, P09.21 P09.21 P09.21 P09.21 P09.21 P09.21 P06.51
Noor-UI-Huda Hafiza Norais Nathalie Norais Nathalie Noronha Melissa Novak Petr Novikova Swetlana Novoa-Herran Susana Núñez Galindo Antoni Nury Catherine Nykter Matti  O  Oberbach Andreas Oberhaus Andrea O'Byrne Paul Ochiya Takahiro Ochiya Takahiro Odeberg Jacob Odriozola Leticia Odwin-Dacosta Shelly Oehler Martin K Ogata Kosuke O'Grady John P Ohana Dana Oh Kenneth Ohtake Norihisa	P11.25, P11.28	Ozcan Servet	P06.51, P09.21 P09.21 P09.21 P09.21 P09.21 P09.21 P06.51
Noor-UI-Huda Hafiza Norais Nathalie Noro Erika Noronha Melissa Novak Petr Novikova Swetlana Novoa-Herran Susana Núñez Galindo Antoni Nury Catherine Nyc Otakar Nykter Matti  O  Oberbach Andreas Oberhaus Andrea Oberhaus Andrea Ochiya Takahiro Ochoa Begona Odeberg Jacob Odiozola Leticia Odwin-Dacosta Shelly Oehler Martin K Ogata Kosuke O'Grady John P Ohana Dana Oh Kenneth Ohl Frank Ohtsuki Sumio	P11.25, P11.28	Ozcan Servet	P06.51, P09.21 P09.21 P09.21 P09.21 P09.21 P09.21 P06.51  CS03.06, P09.13, P09.14 P07.36 CS24.10 P02.09 P01.11, P01.14, P01.22, P19.18 P01.24 P09.30, P09.30 P06.31, P06.47 P04.09, P06.34, P07.06, P09.02 P19.04, P19.19 CS01.06, P06.22 S. P01.24 CS24.03, CS25.05, P05.01, P07.39, P20.01 P22.01 CS01.03 P01.27 P06.41, P06.42 CS08.03 P06.13 P15.09 CS19.09, CS30.01, P01.17
Noor-UI-Huda Hafiza Norais Nathalie Noronha Melissa Novak Petr Novikova Swetlana Novae-Herran Susana Nűnez Galindo Antoni Nury Catherine Nyk ter Matti   O  Oberbach Andreas Oberhaus Andrea O'Byrne Paul Ochiya Takahiro Ochoa Begona Odeberg Jacob Odwin-Dacosta Shelly Oehler Martin K Ogata Kosuke O'Grady John P Ohana Dana Oh Kenneth Oh Kenneth Ohtake Norihisa Ohtsuki Sumio Oh Y. K	P11.25, P11.28	Ozcan Servet	P06.51, P09.21 P09.21 P09.21 P09.21 P09.21 P09.21 P06.51

Park Amber J	P11 26	Perlman David H	CS12 04 <b>P09.27</b>
Park B K		Pernal Stephen F	
Park Don-Ha	·	Perreault Claude	
Parker Robert		Perry Suzanne	
Parker Sarah J	HPP03.02	Perzanowska Anna	P06.44
Park Gun Wook	P01.22, P21.08	Peterman Scott	CS03.09, P06.55
Park Hye Yun	P07.19	Petrak Jiri	CS14.08
Park Ji Hyun	P07.32	Petre Brindusa-Alina	CS02.03
Park Jung Kap	CS25.07	Petrotchenko Evgeniy V	CS21.10, <b>CS26.02</b> , P10.01,
Park Jun H	P28.03		P10.02, P10.04, P10.07
Park Junho	P06.30, P07.10	Pettelkau Jens	P13.09
Park Kyu Hyung	P07.32	Petyuk Vladislav AC	<b>\$02.08</b> , CS22.04, CS25.07
Park Morag	CS07.06	Pferdehirt Rebecca	P19.08
Park Seong-Jun	P07.32	Pfeuffer Julianus	CS26.07, P11.22
Park Sung Kyu (Robin)	P01.22, P09.33	Pfister David	P06.29
Park Young Mok	P01.22, <b>P16.24</b>	Phanse Sadhna	CS02.06
Parodi Alessandro	CS14.06	Phillips Blaine	CS23.09
Parrado Antonio	P16.13	Phinney Brett S	HPP03.03
Pascal John M	P19.03	Phu Lilian	P22.06
Pascovici Dana	P06.26, P06.58, P09.13	Phung Qui	P06.16
Pasculescu Adrian	P13.11	Picard Guillaume	CS30.06
Pastushkova Liudmila	<b>P11.01</b> , P11.02	Picard Valerie	P06.56
Patel Bhavin	P06.45	Piccinini Renata	P09.22
Patel Purvi	CS16.08	Pich Andreas	CS05.05
Patriotis Christos	P06.39	Pichlo Magdalena	CS14.05
Patterson Heath	CS04.03	Pickford Russell	P19.05
Pattison Rebecca	CS16.06	Picotti Paola	CS26.05, P19.12
Pattison Rebecca A	P04.11	Piehowski Paul D	CS02.08, <b>CS25.07</b>
Paula Adriano	CS04.10	Pienimaeki Roemer Annika	P01.07
Paulovich Amanda	CS11.05	Piening Brian D	P28.04
Paulsen Birgitte S	P22.02, P22.05	Pierson Nicolas	CS02.03
Paulsen Ian T	P09.13	Pike lan	P07.31
Pauwels Patrick	P06.20	Pineau Charles	CS19.06
Pavlidis Paul	P13.01, P13.05, P19.01	Pin Elisa	<b>P06.50</b> , P17.19
Pavlou Maria	CS21.07	Ping Peipei	<b>CS15.02</b> , P11.13, P18.12
Pavlovich Polina	P04.48	Pinkse Martijn W.H	P27.03
Pavlukov Marat	P06.63	Pinto Antonio F.M	CS25.06
Pawłowski Krzysztof	P06.07	Pinto Jennifer	P11.21
Payne Samuel	CS11.07, CS22.04, CS25.07	Pinto Mariana	P06.31
Pecks Ulrich	CS28.06	Pionneau Cédric	
Pedersen Anna-Kathrine		Piras Cristian	<b>P09.19</b> , P09.20, P09.22,
Peitsch Manuel C	CS23.09, P18.11		
Pelaez-Garcia Alberto		Pirmoradian Mohammad	
Pelech Steven	CS22.06, P15.12, P15.13,	Pitteri Sharon	P06.31, P28.04
	P15.15, P15.17	Pittock Paula	CS27.08
Pelletier Laurence		Pizza Mariagrazia	CS21.06
Pelosi Paolo		Planatscher Hannes	
Penalba Anna		Plumb Robert S	
Pena Vlad		Plum Sarah	CS02.09
Pendse Salil		Pockley Alan G	
Penesyan Anahit		Poe Derrick	
Peng D. Q	P11.23	Poersch Aline	P06.47
Pengelley Stuart		Poetsch Ansgar	
Peng Hui		Poetz OliverCS05.0	<b>3</b> , <b>CS05.09</b> , P02.09, <b>P11.19</b>
Peng Lifeng		Pohl Kerstin	
Percy Andrew J		Poirier Guy G	
P(		Poirier Valerie	
Perez-Brandão Juliana D		Polson Jennifer S	
Perez De Andres Martin		Polverino De Laureto Patrizia.	
Perez Eva		Pomiès Christelle	
Perez-Riverol Yasset		Pompa Giuseppina	
Perheentupa Antti		Ponomarenko Elena A	
Perkins Simon		Ponten Frederik	
Perleman Dalia	P28.04	Pontes Leticia G	P17.22, <b>P17.23</b>

Poole Alex			P06.39
Poon Terence C.W		•	CS08.07
Popov I. A			HPP03.02
Popov Igor			P04.19
Popov Igor A Popp Robert			P17.07
Porter Michael			CS27.02
Posch Anton			CS08.07
Pötz Oliver			P01.24
Poulsen Ann Sofie R		•	P01.24
Poulsen Pi Camilla			CS08.07
outanen Matti		•	CS18.09
Poverennaya Ekaterina V			CS05.08
Powlesland Alex S			P02.14
Poyet Cedric			CS15.06
Prajna Lalitha			P28.10
Prakash Amol		Rao Samhita	
Prassas Ioannis			P16.13
Pribyl Thomas			P18.13
Price John C		•	CS28.06
Pritzker Ken P			P09.17
Proteored-Isciii Consortium		•	CS09.03
Prudova Anna			CS18.03, CS18.04, P13.26
Przybylski Michael			P13.16
Puard Vincent			P17.02
Puddipeddi Aviv		Ravasi Timothy	
Pudil Radek		Ray Kevin	
Pulicat Manogaran		Ray Sandipan	
Punyadeera Chamindie		Reales-Calderon Jose	
Purcell Anthony W		Redmond Diane	
Puri Neelu		Rees Robert	
Putluri Nagireddy			HPP03.04
Puybasset Louis		•	CS24.04
Puzone Roberto			CS15.08
Pynn Christopher		Rehulka Pavel	
J		Rehulkova Helena	
Q		Reid Jennifer	
_		Reim Dominik	
Qamar Saadia	CS26.07	Reimer Ulf	
Qian Pei-Yuan		Reinert Knut	
Qian Wei-Jun			CS09.03
Qian Xiaohong			P11.03
Qiao Huichao		Reisinger Florian	
Qiao Jie		Reis Leonardo	
Qiao Zhiwei		Reiter Lukas	
Qi Da		Rejtar Tomas	
Qin Hao		Remes Phil	
Qin Hongqiang		Rendon Alvaro	
Qin Jun		Ren Liangliang	
Qin Weijie		Rennard Stephen I	
Qin Zhaoyu		Renner Florian	
Qi Yingzi		Reny Jean-Luc	
Quanico Jusal		Reventós Jaume	
Quebbemann Neil R		Rezeli Melinda	
Queiroz Rayner ML		Rhee David	
Qu Hong		Ricart Carlos André O	
Quick Joslyn		Riccio Amanda A	
Qu Jun		Richardson Keith	
Qundos Ulrika		Richard Vincent R	
20000 011 110	1 17.19	Richter Erik	
₹		Richter Sandra	
•			CS02.09
Rabalski Adam J	C 227 UB		CS26.04

Rigatto Claudio	CS09.09
Rigor Robert R	HPP03.03
Rijkers Erikjan	P19.17
Riley Ryan	
Rinaldi Lara	
Rinner Oliver	
Rios Eddy	
Rising Lisa	
Risk Brian	
Ritchie Graham R.S	
Rivera Mariela	
Rivet Amelie	CS07.06
Rizzoli Silvio O	CS18.09
R. Jersie-Christensen Rosa	P02.06
Roach Robert C	
Roark Joseph C	P06.53
Rodchenkova Marina G	
Rodchenkov Grigory	
Rodenbrock Anja	
Rodet Franck	
Rodland Karin	
Rodland Karin D	
Rodríguez Griselda	
Rodriguez HenryCS07.0	
Rodriguez Jose Manuel	P01.04, P01.25
Rodriguez Juan	P01.25
Rodriguez Madeline	P16.10, P17.16
Rodriguez Rene	
Roehrl Michael H	
Roesli Christoph	
Rogalski Jason	
	DO2 O7 DO2 11 DO2 17
Rogers John	
-	P06.45, P21.02
Rogers Lindsay	P06.45, P21.02
Rogers Lindsay Rogowska-Wrzesinska Adelina	P06.45, P21.02 CS18.02 CS22.05
Rogers Lindsay Rogowska-Wrzesinska Adelina Roncada Paola	
Rogers Lindsay Rogowska-Wrzesinska Adelina Roncada Paola	
Rogers Lindsay Rogowska-Wrzesinska Adelina Roncada Paola	
Rogers Lindsay	
Rogers Lindsay Rogowska-Wrzesinska Adelina Roncada Paola	
Rogers Lindsay	P06.45, P21.02
Rogers Lindsay	
Rogers Lindsay	
Rogers Lindsay	P06.45, P21.02 CS18.02 CS22.05P05.02, P09.19, <b>P09.20</b> , 12, P09.23, <b>P09.32</b> , P16.16 P01.01 P16.15 P04.18 P09.09 P02.02 P13.24, <b>P19.12</b> P28.01 P28.01 P28.01 P06.34 CS05.07 <b>P13.24</b> , P19.12
Rogers Lindsay Rogowska-Wrzesinska Adelina Roncada Paola	P06.45, P21.02 CS18.02 CS22.05
Rogers Lindsay	P06.45, P21.02 CS18.02 CS22.05 P05.02, P09.19, P09.20, P2, P09.23, P09.32, P16.16 P01.01 P16.15 P04.18 P09.09 P02.02 P13.24, P19.12 P28.01 P28.10 P06.34 CS05.07 P13.24, P19.12 P03.02 CS27.07
Rogers Lindsay	
Rogers Lindsay	
Rogers Lindsay	P06.45, P21.02 CS18.02 CS22.05P05.02, P09.19, <b>P09.20</b> , 12, P09.23, <b>P09.32</b> , P16.16P01.01P16.15P04.18P09.09P02.02P13.24, <b>P19.12</b> P28.10P06.34CS05.07P13.24, P19.12P03.02CS27.07P28.02P09.07, P15.24
Rogers Lindsay Rogewska-Wrzesinska Adelina Roncada Paola	P06.45, P21.02 CS18.02 CS22.05
Rogers Lindsay Rogowska-Wrzesinska Adelina Roncada Paola	P06.45, P21.02 CS18.02 CS22.05
Rogers Lindsay Rogowska-Wrzesinska Adelina Roncada Paola	P06.45, P21.02 CS18.02 CS22.05P05.02, P09.19, <b>P09.20</b> , 12, P09.23, <b>P09.32</b> , P16.16P01.01P16.15P04.18P09.09P02.02P13.24, <b>P19.12</b> P28.01P28.10P06.34CS05.07P13.24, P19.12P03.02CS27.07P28.02P09.07, P15.24P06.52P06.52
Rogers Lindsay	P06.45, P21.02 CS18.02 CS22.05P05.02, P09.19, <b>P09.20</b> , 12, P09.23, <b>P09.32</b> , P16.16P01.01P16.15P04.18P09.09P02.02P13.24, <b>P19.12</b> P28.01P06.34CS05.07P13.24, P19.12P03.02CS27.07P28.02P09.07, P15.24P06.35P17.13P06.52CS01.07
Rogers Lindsay	P06.45, P21.02 CS18.02 CS22.05P05.02, P09.19, <b>P09.20</b> , 12, P09.23, <b>P09.32</b> , P16.16P16.15P04.18P09.09P02.02P13.24, <b>P19.12</b> P28.10P06.34CS05.07P13.24, P19.12P03.02CS27.07P28.02P06.35P06.35P17.13P06.35P06.35P17.13P06.35P17.13P06.52CS01.07P06.38
Rogers Lindsay Rogewska-Wrzesinska Adelina Roncada Paola	P06.45, P21.02 CS18.02 CS22.05
Rogers Lindsay Rogowska-Wrzesinska Adelina Roncada Paola	P06.45, P21.02 CS18.02 CS22.05 P05.02, P09.19, P09.20, P2, P09.23, P09.32, P16.16 P01.01 P16.15 P04.18 P09.09 P02.02 P13.24, P19.12 P28.01 P28.10 P06.34 CS05.07 P13.24, P19.12 P03.02 CS27.07 P28.02 P09.07, P15.24 P06.35 P17.13 P06.52 CS01.07 P06.38 P06.61 P02.17
Rogers Lindsay Rogowska-Wrzesinska Adelina Roncada Paola	P06.45, P21.02 CS18.02 CS22.05P05.02, P09.19, P09.20,2, P09.23, P09.32, P16.16
Rogers Lindsay	P06.45, P21.02 CS18.02 CS22.05P05.02, P09.19, P09.20, 12, P09.23, P09.32, P16.16P01.01P16.15P04.18P09.09P02.02P13.24, P19.12P28.10P06.34CS05.07P13.24, P19.12P03.02CS27.07P28.02P07.P15.24P06.35P17.13P06.52CS01.07P06.38P06.38P06.39P06.39P06.39P06.39P06.39P06.39P06.39P06.39P06.39P06.39P06.39P06.39P06.39P06.39
Rogers Lindsay Rogewska-Wrzesinska Adelina Roncada Paola	P06.45, P21.02 CS18.02 CS22.05P05.02, P09.19, P09.20, 12, P09.23, P09.32, P16.16P16.15P04.18P09.09P02.02P13.24, P19.12P28.01P28.10P06.34CS05.07P13.24, P19.12P03.02CS27.07P28.02P06.35P06.35P17.13P06.52CS01.07P06.38P06.38P06.39
Rogers Lindsay Rogers Lindsay Rogowska-Wrzesinska Adelina Roncada Paola P09,2 Ronzhina Natalia Ross Andreas Roosjen Mark Rosamont-Ursulet Maryvonne Roschitzki Bernd Rosenberger George Rosenberg Michael Rosenbloom Kate R Rosenbloom Kate R Rosendaal Frits R Rostami-Hodgegan Amin Röst Hannes Rosu-Myles Michael Rottapel Rob Roumeliotis Theodoros Roux-Dalvai Florence Roux Philippe P Rouzbahman Marjan Roy Swapan Roy Swapan Roy Swapan Roy Swapan Roy Swapa Berney Roulin Mark Rudnick Paul Ruelcke Jayde E Ruggles Kelly V Ruiz Cristina Ruprecht Benjamin Russcher Anne	P06.45, P21.02 CS18.02 CS22.05
Rogers Lindsay Rogewska-Wrzesinska Adelina Roncada Paola	P06.45, P21.02 CS18.02 CS22.05

Russell Kristi	P18.03
Russell Shannon	P09.31
Russ Manuela	CS28.06
Rutishauser Dorothea	P04.17
Rutten Julie	P04.09
Ryabokon Anna M	P07.07
Ryan Sheila	P04.47
Ryo Akihide	P06.21

### S

Saba Julian	. CS03.09, <b>P03.02</b> , P21.02
Sabala Lúcia	P13.14
Sabanayagam C	
Sabido Eduard	
Sachsenberg Timo	
Saenz-Vash Veronica	
Safaei Javad	
Sahabian Anais	
Saha Subhrajit	
Saichi Naomi	CS14.03, P21.05
Saido Takaomi C	CS03.03
Saito Kozue	
Saito Tatsuya	P07.33
Saito Tomoko	P09.08
Sajic Tatjana	P07.18
Salmi J	CS23.07
Saloniemi-Heinonen Taija	P07.38
Salovska Barbora	
Salpin J-Y	P11.12
Salvatore Francesco	CS14.06
Salvi Sandra	P07.05
Salzet Michel	CS04.06, P06.18
Samayoa Kim	P20.05
Samonig Martin	
Sanchez Aniel	P06.23
Sanchez Del Pino Manuel M	CS30.01, P01.17
Sanchez-Gomez Myriam	
Sanchez Jean Charles	
Sanchez Jean-Charles	P07.13, <b>P21.01</b>
Sanchez Paola	P17.11
Sanchez-Quiles Virginia	CS13.04
Sanda Akihiro	
Sandin Charlotta	
Sandoval Wendy	CS05.06, P19.08
Sandros Marinella G	P04.13, P08.02, P26.01
Sanjib Meitei Ningombam	
Sanjuan Miguel	CS14.07
Santoni Federico	CS19.04
Santos Lucilene D	<b>P17.22</b> , P17.23
Santos Marcia S	P19.09
Saoudi Abdelhadhi	CS08.04
Sap Karen A	CS18.10, P19.17
Saraon Punit	CS27.03
Sareen Dhruv	CS13.05
Sarinay Cenik Elif	CS23.03
Saris Wim H.M	CS16.07
Sarrafzadeh Asita	P07.13, P17.11
Sathe Gajanan	
Satkamp Laura	P09.24
Sato Ayako	P23.03
Sato Takashi	CS30.09
Sato Tomoo	CS14.03
Saunders Nicholas A	CS07.03

Saveleva Tatiana	DO 4 40	Callacina Fuada	CS01.10
Savino Silvana			P15.25
Savitski Mikhail M		,	P09.15
Saxena Satya			P08.05
S. Batth Tanveer			CS03.09
Scarborough Hannah			P09.11
Schaefer Ralf	P20.04	Senko Mike	P29.05
Schäfer Mathias	P13.09	Seo Jawon	P07.11, P07.26
Schaller Karl	P07.13		CS21.10, <b>P10.04</b>
Schätzle Sebastian			CS08.07
Schepmoes Athena			P16.03
Scherzer Clemens R			P18.11
Schiess Ralph			CS16.06
Schildermans Karin			CS07.03, P21.04
Schilling Birgit			CS01.06, CS14.07
Schilling Oliver			P07.28
Schirle Markus Schittenhelm Ralf B			
Schiza Christina			P28.13, <b>P28.13</b>
Schlaak Jörg F			CS26.06
Schlabach Tim			P16.21
Schlapbach Ralph			<b>CS26.06</b> , CS26.07
Schlichting Nadine			P18.02
Schlueter Hartmut			P04.46, P05.05
Schmainda Kathleen			CS11.05
Schmeck Bernd			CS07.10
Schmeisser Michael J	P16.04		P04.48, <b>P06.63</b>
Schmidt Alexander	<b>CS22.09</b> , P04.41, P15.23	Shen Huali	CS12.06, P16.23
Schmidt Daniel	P07.40, P07.41, P07.42	Shen Shichen	P04.29
Schmidt Frank	<b>CS21.04</b> , CS21.08	Shen Xiaomeng	P04.29
Schmit Pierre Olivier		Sherman Jamie	P04.24, P04.49
Schmitt Andrea		•	CS01.06
Schmitt Sebastian			CS14.04
Schmitz Gerd			P15.17
Schmutz Christoph			CS03.10
Schnatbaum Karsten			P02.18
Schneider Luke V			P15.25
Schneider Thomas			CS13.06
Scholey James W			P06.41, P06.42
Scholey James W Schoof Erwin M			CS03.08
Schroeder Tara		•	P06.61
Schroetter Andreas			CS10.05
Schulz Benjamin L.			P25.01
Schulz-Knappe Peter			P15.21
Schuppe-Koistinen Ina			P01.17
Schuster Hieko			CS28.03
Schwämmle Veit	<b>P12.02</b> , P19.19	Shteynberg David	CS11.09
Schwartz Jae	CS25.03	Shulman Joshua M	CS02.08, CS25.07
Schwarz Carmen		Sickmann Albert	CS16.05, CS17.10, CS26.09,
Schweiger-Hufnagel Ulrike			<b>P18.09</b> , P28.06
Schweinsberg Vincent			P14.01, <b>P16.18</b>
Schwenk Jochen M			P12.02
P06.50, P0			CS22.10
	P16.09, P17.19, P27.06		P15.09
Scigelova Michaela			P28.11
Scott Nichollas E Scruggs Sarah B			P21.07
		<u> </u>	CS04.10
Seeberger Peter H Segawa Syunsuke			CS04.10
Segura Victor			P23.01
Seid Michael			CS23.07
Seifert Jana			CS23.07
Selevsek Nathalie			P16.21
	··• · · · <del>-</del>		

Cimpon Doborah	DO 4 47	Caallani Alida	D16 16
	P04.47		P16.16
	P16.02		P18.06
	P00.28		CS06.03
			CS21.06
	P18.13		P06.72
•	CS19.03		P28.03
			P11.21
	P06.29, P07.36		CS08.03
	CS27.02	•	CS07.10
	P04.14		P11.21
Sjoelund Virginie H	P13.03	Srivastava Sanjeeva	CS01.05, P09.16
Sjöstedt Evelina	CS11.03	Srivastava Sudhir	P06.38, P06.39
Sjouerman Jessica	P09.05	Stagljar Igor	CS14.02
Skates Steven	P06.39	Staiano Teresa	P06.02
Skinner Owen S	P11.30	Starodubtseva Natalia L	CS28.07, P07.07
Skogs Marie	<b>CS18.06</b> , P24.02	Starr Amanda E	P13.05
Sköld C M	P07.03		P21.07
Sköld Karl	P15.16	Steen Hanno	P07.02
	P20.03		CS09.03
	CS11.09		CS28.08
	P06.13		CS02.09
	CS13.06		CS17.07
	P16.13		P28.02
	P19.25		P06.29
	CS04.06		CS21.06
	P09.06		CS15.04
	P22.03		CS07.05, <b>CS20.08</b> , CS24.10
	CS20.04, P19.07		CS21.04
	CS29.04		P07.09
	P09.18		CS08.07
Smith Gustav J	P18.05	Stodulkova Eva	PU6.65
Caraltha Diahamal	DOC 70	Ctaliaa Matthaii D	D27.01
	P06.38		P23.01
Smith Richard D	CS02.08, <b>CS06.02</b> , CS11.07,	Stoll Dieter	<b>P02.09</b> , <b>P06.03</b> , P11.19
Smith Richard D	CS02.08, <b>CS06.02</b> , CS11.07,CS2.04, CS25.07	Stoll DieterStoyanova Tanya	<b>P02.09</b> , <b>P06.03</b> , P11.19
Smith Richard D Smith Suzanne	CS02.08, <b>CS06.02</b> , CS11.07,	Stoll Dieter Stoyanova Tanya Stoychev Stoyan	
Smith Richard D	CS02.08, <b>CS06.02</b> , CS11.07,	Stoll Dieter Stoyanova Tanya Stoychev Stoyan Stoynov Nikolay	P02.09, P06.03, P11.19 ————————————————————————————————————
Smith Richard D.  Smith Suzanne Smith William Smits Arne	CS02.08, <b>CS06.02</b> , CS11.07, CS22.04, CS25.07 P06.45 	Stoll Dieter Stoyanova Tanya Stoychev Stoyan Stoynov Nikolay Straub Peter	P02.09, P06.03, P11.19
Smith Richard D	CS02.08, <b>CS06.02</b> , CS11.07, CS22.04, CS25.07 ————————————————————————————————————	Stoll Dieter	P02.09, P06.03, P11.19 P05.05  CS24.09
Smith Richard D	CS02.08, <b>CS06.02</b> , CS11.07, CS22.04, CS25.07 P06.45 P17.04 P04.18 P14.02 P02.11, <b>P02.13</b> , P21.02	Stoll Dieter	P02.09, P06.03, P11.19
Smith Richard D	CS02.08, <b>CS06.02</b> , CS11.07,CS22.04, CS25.07	Stoll Dieter	P02.09, P06.03, P11.19 P05.05  CS24.09
Smith Richard D		Stoll Dieter	P02.09, P06.03, P11.19
Smith Richard D	CS02.08, <b>CS06.02</b> , CS11.07,CS22.04, CS25.07	Stoll Dieter	P02.09, P06.03, P11.19
Smith Richard D	CS02.08, <b>CS06.02</b> , CS11.07, CS22.04, CS25.07 P06.45 P17.04 P <b>04.18</b> P14.02 P02.11, <b>P02.13</b> , P21.02 CS01.06, CS23.03, P28.04 CS04.10 CS12.08	Stoll Dieter	P02.09, P06.03, P11.19
Smith Richard D	CS02.08, <b>CS06.02</b> , CS11.07, CS22.04, CS25.07	Stoll Dieter	P02.09, P06.03, P11.19
Smith Richard D		Stoll Dieter	P02.09, P06.03, P11.19
Smith Richard D	CS02.08, <b>CS06.02</b> , CS11.07,CS22.04, CS25.07	Stoll Dieter	P02.09, P06.03, P11.19
Smith Richard D	CS02.08, CS06.02, CS11.07,	Stoll Dieter Stoyanova Tanya Stoychev Stoyan Stoynov Nikolay Straub Peter Streiger Femke Strouhal Michal Struenker Timo Studer Patrick Stuhlfauth Juergen Stulik Jiri Stupp Gregory Sturm Theo Su Andrew	P02.09, P06.03, P11.19
Smith Richard D		Stoll Dieter	P02.09, P06.03, P11.19
Smith Richard D		Stoll Dieter	P02.09, P06.03, P11.19
Smith Richard D		Stoll Dieter Stoyanova Tanya Stoychev Stoyan Stoynov Nikolay Straub Peter Streiger Femke Strouhal Michal Struenker Timo Studer Patrick Stulik Jiri Stupp Gregory Sturm Theo Su Andrew I Subedi Prabal Subhudi Andrew W Subramanian Krishnakumai	P02.09, P06.03, P11.19
Smith Richard D	CS02.08, CS06.02, CS11.07,	Stoll Dieter	P02.09, P06.03, P11.19
Smith Richard D	CS02.08, CS06.02, CS11.07,	Stoll Dieter	P02.09, P06.03, P11.19
Smith Richard D		Stoll Dieter	P02.09, P06.03, P11.19
Smith Richard D		Stoll Dieter Stoyanova Tanya Stoychev Stoyan Stoynov Nikolay Straub Peter Streiger Femke Strouhal Michal Struenker Timo Studer Patrick Stulik Jiri Stupp Gregory Sturm Theo Su Andrew I. Subedi Prabal Subdudi Andrew W. Subramanian Krishnakumai Sugihara Yutaka Sugiyama Naoyuki Suh Eui Jin Suh Kyung Suk Sukhikh G. T	P02.09, P06.03, P11.19
Smith Richard D		Stoll Dieter Stoyanova Tanya Stoychev Stoyan Stoynov Nikolay Straub Peter Streiger Femke Strouhal Michal Struenker Timo Studer Patrick. Stuhlfauth Juergen Stulik Jiri. Stupp Gregory Sturm Theo Su Andrew Su Andrew I Subedi Prabal Subhudi Andrew W Subramanian Krishnakumal Sugihara Yutaka Sugiyama Naoyuki Suh Eui Jin Suh Kyung Suk Sukhikh G. T Sulman Eric P	P02.09, P06.03, P11.19
Smith Richard D		Stoll Dieter	P02.09, P06.03, P11.19
Smith Richard D	CS02.08, CS06.02, CS11.07, CS22.04, CS25.07 P06.45 P17.04 P04.18 P14.02 P02.11, P02.13, P21.02 CS01.06, CS23.03, P28.04 CS04.10 CS12.08 P22.02, P22.05 P18.10 P02.04 P09.08 P05.02, P09.19, P09.20, P09.22, P09.23, P09.32 P07.40, P07.41, P07.42 CS01.06 P28.06 P06.64 CS08.09, P28.16 P04.46, P29.05 P18.08 P15.12, P15.13 CS01.07 P25.07	Stoll Dieter	P02.09, P06.03, P11.19
Smith Richard D		Stoll Dieter Stoyanova Tanya Stoychev Stoyan Stoynov Nikolay Straub Peter Streiger Femke Struchal Michal Struenker Timo Studer Patrick Stulik Jiri Stupp Gregory Sturm Theo Su Andrew I Subedi Prabal Subdi Andrew W Subramanian Krishnakumai Sugiyama Naoyuki Sugiyama Naoyuki Suh Eui Jin Suh Kyung Suk Sukhikh G. T Sulman Eric P Su Na Sun Bingyun Sundaramoorthy Nandakur	P02.09, P06.03, P11.19
Smith Richard D	CS02.08, CS06.02, CS11.07, CS22.04, CS25.07 P06.45 P17.04 P04.18 P14.02 P02.11, P02.13, P21.02 CS01.06, CS23.03, P28.04 CS04.10 CS12.08 P22.02, P22.05 P18.10 P09.08 P09.08 P05.02, P09.19, P09.20, P09.22, P09.23, P09.32 P07.40, P07.41, P07.42 CS01.06 P28.06 P06.64 CS08.09, P28.16 P04.46, P29.05 P18.08 P15.12, P15.13 CS01.07 P25.07 P25.07 P06.26 P06.26 P06.26	Stoll Dieter Stoyanova Tanya Stoychev Stoyan Stoynov Nikolay Straub Peter Streiger Femke Strouhal Michal Struenker Timo Studer Patrick Stulik Jiri Stupp Gregory Sturm Theo Su Andrew I Subedi Prabal Subedi Prabal Subhudi Andrew W Subramanian Krishnakumai Sugihara Yutaka Sugiyama Naoyuki Suh Eui Jin Suh Kyung Suk Sukhikh G. T Sulman Eric P Su Na Sundaramoorthy Nandakur Suni Veronika	P02.09, P06.03, P11.19
Smith Richard D		Stoll Dieter Stoyanova Tanya Stoychev Stoyan Stoynov Nikolay Straub Peter Streiger Femke Strouhal Michal Struenker Timo Studer Patrick Stuhlfauth Juergen Stulik Jiri Stupp Gregory Sturm Theo Su Andrew I Subedi Prabal Subedi Prabal Subhudi Andrew W Subramanian Krishnakumai Sugihara Yutaka Sugiyama Naoyuki Suh Eui Jin Suh Kyung Suk Sukhikh G. T Sulman Eric P Su Na Sun Bingyun Sundaramoorthy Nandakur Suni Veronika	P02.09, P06.03, P11.19
Smith Richard D	CS02.08, CS06.02, CS11.07, CS22.04, CS25.07 P06.45 P17.04 P04.18 P14.02 P02.11, P02.13, P21.02 CS01.06, CS23.03, P28.04 CS04.10 CS12.08 P22.02, P22.05 P18.10 P09.08 P09.08 P05.02, P09.19, P09.20, P09.22, P09.23, P09.32 P07.40, P07.41, P07.42 CS01.06 P28.06 P06.64 CS08.09, P28.16 P04.46, P29.05 P18.08 P15.12, P15.13 CS01.07 P25.07 P25.07 P06.26 P06.26 P06.26	Stoll Dieter Stoyanova Tanya Stoychev Stoyan Stoynov Nikolay Straub Peter Streiger Femke Strouhal Michal Struenker Timo Stulfauth Juergen Stulfauth Juergen Stulfauth Juergen Stulfauth Juergen Su Andrew Su Andrew Su Andrew I Subedi Prabal Subedi Prabal Subramanian Krishnakumai Sugihara Yutaka Sugiyama Naoyuki Suh Kyung Suk Suh Kyung Suk Sukhikh G. T Sulman Eric P Su Na Sun Bingyun Sundaramoorthy Nandakur Sun Jing Sun Mingwei	P02.09, P06.03, P11.19

	P06.37		CS08.07
	CS06.07		P23.06
	P06.37		<b>CS17.03</b> , P13.04
	CS21.08, P28.10		P13.24
	CS21.04		P01.24
	dP04.21		CS18.07
	P07.38		CS08.03, CS24.02,
•			CS27.10, P06.35
	CS13.05		CS04.03
-	P19.15		C304.03
	P04.28, P04.38, P08.07		CS01.06, CS30.03, <b>P06.59</b>
	P04.09		P06.31, P06.47
			CS14.07
	P04.21		P16.03
	P06.71		CS01.06
	P21.06		P07.13, P17.11
02.900.110.001	200		P05.03
T			P20.05
			P11.01
Tabata Tsuyoshi	P13.22, P29.03		P09.18
	P06.41		CS26.09
	CS14.04, P16.11		P22.03
Tai Jung-Hsiang	CS10.07	Titz Bjoern	CS23.09, P18.11
	P21.09	Tiys Evgeniy	P11.02
Takagi Shunsuke	P15.18	Tkach Johnny	CS18.03
Takai Yoko	P06.41, P06.42	Todd Matthew	P16.13
Takats Zoltan	P20.02	Tokuda Takaho	P06.09
Takemori Ayako	P02.16, P04.43	Tolmachev Aleksey V	CS06.02
Takemori Nobuaki	P02.16, P04.43	Tomczyk Nick	P04.03
Takimoto Hiroki	CS19.08	Tomei Sara	CS21.06
	P06.65		CS03.10
	CS16.09		P06.70, P23.02,
	P04.39, P17.19		P23.03, P26.02
·	P19.22		P04.04
	CS30.09		P06.64
	P25.05		CS23.07
	CS12.07		P06.51, P09.21
	P06.33		CS01.08, P06.25
	CS23.03		CS22.05
	P25.03		P28.04
	CS16.01		P09.25
			P21.06
	<b>CS03.03</b> , CS03.08		P20.02, P20.03
	CS16.06, P04.11	-	CS30.09
	<b>CS20.06</b>		P18.03
	P03.01		CS25.08, P07.24
	P03.01		P06.29
•	<b>CS03.07</b> , CS30.09, <b>P09.03</b>		CS04.07
	P04.17		CS27.09
•			P01.04, P01.25
	CS17.04, <b>P04.24</b> , <b>P04.25</b> , <b>P04.49</b>		
	CS29.06, <b>P23.05</b>		CS14.05
	P19.05		CS14.03
•	P08.06		CS20.07
•	CS26.03	•	P06.72
	P22.06		P07.17, P07.17
	P07.04, P07.35, P28.13, P28.15		P02.08
	P07.40, P07.41, P07.42		P06.22
	P16.04		P04.06, P13.10
	P13.10	•	P28.03
	P13.10, P25.05		P15.01
Ternent Tobias	CS29.08		

Ternent Tobias ......CS29.08

Tsutsumi YasuoP15.01	Van Julie A.D	P17.03
Tu ChengjianP04.29	Van Leeuwen Hans C	CS21.05, P09.12
Tucholska Monika ZCS10.08, CS17.04	Van Ostade Xaveer W.M	P09.06
Tulbah AsmaCS13.06	Van Raemdonck Geert A.A	P09.06
Turck NatachaP07.13, P17.11	Vanscheeuwijck Patrick	CS23.09
Turecki GustavoP11.04	Van Soest Remco	P04.33
Turk JimP20.05	Vantangoli Marguerite M	P28.01
Turner Jeffrey LP26.03	Van Veelen Peter	P09.02
Turvey StuartHPP03.04	Van Vlijmen Bart	P06.34
Tvardovskiy AndreyCS10.05	Varfolomeev Eugene	P06.54
Tyanova StefkaCS19.03, P16.21	Varfolomeev Sergey D	P07.07
Tyers MichaelCS24.02		CS17.05
Tzeng Shin-ChengCS30.03	Varming Kim	P22.02, P22.05
	Vassallo José	CS04.10
U	Vaudel Marc	CS01.10, <b>CS17.10</b>
	Vaz Catarina	P15.19
Ueda Koji	Vázguez Jesús	P01.09, P01.25
Ueda TetsuyaP21.09		CS26.04
Ueffing MariusP28.09		CS13.07
Uhlen MathiasCS11.03, CS15.03, CS16.03, CS19.07,	•	P07.38
<b>CS23.01</b> , CS30.05, P01.03, P04.10,		CS23.07
P04.14, P04.39, P06.50, P07.12, P07.29,		CS26.07, <b>P11.22</b>
P11.24, P16.08, P16.09, P17.19, P24.02		P01.20, P06.23
Ulbrich DanielaP15.22		P15.19
Umar Arzu		CS26.04
Unterwurzacher MarkusCS16.04		P09.13
Urbach SergeP16.03		HPP03.02, P18.12
Urbani AndreaP09.19, P09.20, P09.22,		CS11.08, P04.05
P09.23, <b>P16.16</b>		P17.02, P27.03
Urban NicoleP06.39		P04.18
Urlaub HenningCS18.09, CS26.06, CS26.07, P22.01		CS11.01
Uusitalo Hannu		CS18.10, P19.17
Uzbak SajedehCS24.06		CS16.09, CS25.04
Uzozie Anuli CP06.02		CS30.01
		P02.01
V		P17.22, P17.23
		P16.03
Vadakekolathu JayakumarP06.66		CS28.08
Vähä-Mäkilä MCS23.07		P07.30
Vahidi SiavashP11.30		CS10.09, HPP03.04, P02.11,
Vaiphei KP18.13		P02.13, P03.02, <b>P19.09</b>
Vakhrushev IgorP01.01		P27.03
Valencia AlfonsoP01.04, P01.25		P04.03, P04.26, P13.15,
Valencia JesusP01.04		<b>P18.01</b> , P25.01
Valero María LP01.17		P28.03
Valis KarelP06.65		CS14.08
Valkenborg Dirk		17.08, CS29.08, P13.13, P13.17
Valsesia Armand		CS02.06
Vance Stephen		CS23.04
Vandemheen Kathy LP07.04		P16.04
Vanden Abeele Fabien		CS21.04, CS21.08, P09.11
Van Den Berg Bart HJ		P02.06
Van Der Beek MarthaP09.02	· ·	CS23.04
Van Der Burgt Yuri	-	P09.18
Van Der Gugten GraceP11.09, P16.20		P01.03
Van Der Odgten Grace		CS05.08
Van Der Wal Lennart		P06.54
Van De Werken Harmen JCS29.04	0 ,	CS29.08
Van Drogen AudreyCS17.05		CS17.05
Van Eyk Jennifer		CS17.05
	v yeny in Andreas	
P18 07 P18 12 P19 16		

......P18.07, P18.12, P19.16 Van Eyk Jennifer E. .....P18.10 Van Hest Jan.....P04.18

### w Waas Matthew ......CS15.04 Wagner Anja.....CS16.04 Wagner Sarah ......P06.66 Wahlander Asa.....P06.02 Wahlström Jan......P04.17 Walfish Paul G......CS27.02 Walter Jasmin P02 02 Walters Jim J......CS30.01 Wang Chih-Liang.....P06.11 Wang Dian Er......P26.03 Wang Ding......P11.13 Wang Dongxue......CS19.07 Wang Hui ......P06.38 Wang Jian.....CS16.08, CS17.04, P04.35, P13.10 Wang Jiaxi.....P04.37 Wang Jing.....P06.61 Wang Lili......P10.05 Wang Qianghu......CS13.07 Wang Qingtao.....P06.33, P06.57 Wang Quanhui.......CS19.05 Wang Renxue......CS12.03 Wang Rui......CS17.08 Wang Xiaodong ......CS04.08, **P20.01** Wang Xiaojing......P24.03 Wang Xue ......P04.29 Wang Yan......P09.17 Wang Yang......CS03.07 Wang Yi ......CS12.06 Wang Yi-Ting......CS14.04, P16.11 Wang Y. Karen ......CS09.02, CS10.03 Wang Yue......CS01.06 Wang Yuh Lih (Ana).....P09.33 Wang Zhenxin......CS12.06 Wan Xiao-Qing......P06.69 Ward Malcolm ......P07.31 Washburn Michael......P19.15 Wasinger Valerie C. ......CS28.09 Watanabe Chihiro.....P23.03 Watanabe Kenichi......CS04.09 Watanabe Masaharu ......P09.08 Watanabe Ryosuke......P23.02, P23.03, P26.02 Webb Ian K.....CS06.02 Weber Darren M......HPP03.03 Weber Frank......P07.36 Wee Sheena......P15.06 Weisbrod Chad......CS25.03, P05.05 Weis Joachim......P16.15 Weisser Hendrik P11.22 Weiss Stephan ......CS23.04 Welinder Charlotte......CS09.10. P06.07 Wendt Chris H CS28 08 Wenschuh Holger.....P07.23 Wergeland Stig......P17.06 Werneck Isabela C......CS04.10 Werner Thilo......CS09.03 Wertz Ingrid......CS05.06 Westerwoudt Gavin L.T.....P27.03

	CS06.08
	P03.02
	P04.17, P07.03
	P18.06
Whiteaker Jeff	CS11.05
White Eric	CS13.08
Whiteley Gordon	P06.61
Whiteman David C	CS07.03
White Rick	P17.14
White Wendy	P27.04
	P17.04
	P06.07
	P18.08
	P07.22
	P04.03
	P06.06
	CS18.09
	CS09.05, CS19.07, CS22.03,
	P04.12, P06.24
	CS11.07
Wilkins John A	CS09.09
	CS17.06, CS29.07, P19.05
	P28.02
Willems Hanny	P07.16
Willfors Charlotte	P16.06
Williams Brad	P04.26
	CS23.08
	P28.14
	P08.04
	P04.32
	CS12.05, CS23.05, P17.07
	C312.03, C323.03, P17.07
	CS13.09
	P15.12. P15.13. P15.17
	P25.06
	CS04.06, P06.18
	P09.04
	CS24.04
	CS14.08
Wojtas Grzegorz	P06.44
Wolan Dennis	P09.33
Wolf Andrea	CS09.03
Wolf Eckhard	P17.18
Wolf Eric	P19.14
	CS21.07, P06.06
	CS28.06
	P06.04
	CS07.07
	P16.22
	P28.03
	P06.16
	P06.71
	CS12.07
	P07.04
	P07.32
	P07.40, P07.41, P07.42
	CS11.05
Wu Baolin	CS28.08
Wu Chaochao	P06.38, P06.39
Wu Chih-Chieh	P06.27
	P06.11, P06.17, P06.49,
	P06.60, P07.08, <b>P09.10</b>
	P28.03
	CS18.05
**u Daye	

	CS19.05		P06.4
	P21.07	-	CS11.0
	P06.27		P04.4
	P06.26		CS26.10
	CS18.03		P18.0
	P05.04		P04.07, P04.08
	<b>CS20.04</b> , P19.07		P15.0
	CS25.07	•	CS29.0
Wu Wei	P18.04		. CS17.07, CS25.06, P01.22, P04.07
Wu Weining	P09.25		P04.08, P09.33, P13.08, P13.1
Wu Yanli	P04.44	Yates John R	CS06.0
Wu Yibo	CS23.08	Yau Yunki Y	CS28.0
Wu Yi-Cheng	P06.11	Yazaki Tatsuya	P15.1
Wu Zhixiang	CS20.06	Yefremova Yelena	CS26.1
		Yeh Christine Y	P28.0
X		Ye Juanying	P02.1
		Ye Mingliang	CS20.0
Xavier Ramnik J	CS08.08	Ye Qiuping	P20.0
Xiao Hua	CS07.07	Yi Eugene C	CS10.10, P19.1
	CS30.01	-	P09.2
	P04.04		P06.0
	CS13.03		P04.3
	CS08.10		CS18.0
	P08.06		P06.3
	P04.02		P25.0
	P04.02		P09.2
•	P01.02, P28.12		P07.3
	P04.30, <b>P07.02</b>		P07.3
	CS19.08, P01.08, <b>P01.18</b> ,		P09.3
	P01.26, P04.07, P04.08		P01.22, P21.0
	P25.10	-	P07.1
	CS08.10		CS25.08, P07.2
		-	P11.3
	CS19.05, P24.03	•	P07.1
•	P04.44		P16.2
	P01.22	•	
	P24.03		CS30.0
	P24.03		P04.07, P04.0
Au fally	P06.37		P15.0
Υ			P06.4
1		•	P13.2
V	D20 01		P28.0
	P28.01		CS18.04, P13.2
•	P19.05		CS20.0
	P06.07		P04.1
	P23.04	•	P06.11, <b>P06.6</b>
	P01.08, P04.08		P27.0
	<b>CS19.08</b> , P01.08, P01.18,		P25.1
	P01.26, P04.07, P04.08,	Yu Jau-Song	P04.16, P06.11, P06.17, P06.60
	P04.10, P13.22		P07.08, <b>P07.20</b> , P09.10, P11.0
Yamano Yoshihisa	CS14.03	Yu Jian	P23.0
	P06.48	Yu Kebing	P06.54, P22.0
Yanez M	P11.12	Yu Lei	CS02.08, CS25.0
Yang Chenxi	P07.35	Yun Sung Ho	P09.2
	P19.26		P15.2
Yang Dong	P01.02, P28.12	Yusuf Zai Jawairia J	P11.2
	CS24.03, P01.05, P20.01		CS26.0
	P07.25	•	
	P07.03	Z	
	CS12.06, P06.08, P06.32,	-	
	P06.69, P16.23, P21.03,	Zahrouskov Vlad	P04.46, P05.0
			P13.12, P29.0
	P04.04		P16.1
	P19.01		CS16.05, CS17.10, CS26.09

Zahid Maria	P09.28
Zahra Meraj	P14.01
Zaman Uzma	CS26.07
Zandian Arash	P07.29
Zanella Matteo	P13.24
Zapico Ines	CS19.09
Zaw Thiri	P06.26
Zayed Amro	CS29.03, P28.05
Zecha Jana	CS22.03
Zeggini Eleftheria	P28.02
	P09.28
Zeidan Effat	P08.02
	ardoCS22.03
Zegui Stenio	CS04.10
	P07.23
	P16.06
Zgoda Victor	P01.01, P01.13, P04.48, P06.27
	CS10.03
	P15.14
	<b>P06.61</b> , P24.03
	CS04.05
•	CS04.03
	CS01.07
	P15.17
	CS01.06, CS14.07, CS30.03,
	P11.03
	CS18.04, P13.10, P13.11
/nand IIA	
Zhang Lihui	P04.02
Zhang LihuiZhang Lijun	P04.02
Zhang LihuiZhang LijunZhang Suping	P04.02 C\$18.05 C\$06.06, C\$25.05, P05.01
Zhang LijunZhang SupingZhang SupingZhang Xian-En	P04.02 C\$18.05 C\$06.06, C\$25.05, P05.01 P09.03
Zhang LihuiZhang LijunZhang SupingZhang Xian-EnZhang Xiangmin	P04.02 CS18.05 CS06.06, CS25.05, P05.01 P09.03 P04.37, P04.40
Zhang LihuiZhang LijunZhang SupingZhang Xian-EnZhang XiangminZhang XiangminZhang Xiangmin	P04.02 C\$18.05 C\$06.06, C\$25.05, P05.01 P09.03 P04.37, P04.40 P02.12
Zhang LihuiZhang LijunZhang SupingZhang Xiang XiangminZhang XiangminZhang Xumin	P04.02 CS18.05 CS06.06, CS25.05, P05.01 P09.03
Zhang LihuiZhang LijunZhang SupingZhang Xian-EnZhang XiangminZhang XiangminZhang YangZhang YanZhang YangZhang YangZhang YangZhang Yang	P04.02 CS18.05 CS06.06, CS25.05, P05.01 P04.37, P04.40 P02.12 CS30.09, P04.34 P02.12, P06.32, P24.01
Zhang LihuiZhang LijunZhang SupingZhang Xian-EnZhang XiangminZhang XiangminZhang XuminZhang YangZhang YangZhang YangZhang YangZhang Yangjun	P04.02  C\$18.05  C\$06.06, C\$25.05, P05.01  P09.03  P04.37, P04.40  P02.12  C\$30.09, P04.34  P02.12, P06.32, P24.01  P04.36, P15.14
Zhang Lihui	P04.02 C\$18.05 C\$06.06, C\$25.05, P05.01 P09.03 P04.37, P04.40 P02.12 C\$30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 C\$19.05
Zhang Lihui	P04.02 C\$18.05 C\$06.06, C\$25.05, P05.01 P09.03 P04.37, P04.40 P02.12 C\$30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 C\$19.05 P01.15
Zhang Lihui	P04.02 CS18.05 CS06.06, CS25.05, P05.01 P09.03 P04.37, P04.40 P02.12 CS30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 CS19.05 P01.15 CS02.03, CS19.08, P01.08,
Zhang Lihui	P04.02 CS18.05 CS06.06, CS25.05, P05.01 P09.03
Zhang Lihui	P04.02 C\$18.05 C\$06.06, C\$25.05, P05.01 P09.03 P04.37, P04.40 P02.12 C\$30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 C\$19.05 P01.15 C\$02.03, C\$19.08, P01.08, P01.18, P01.26, P04.07, P04.08 C\$18.05
Zhang Lihui	P04.02 C\$18.05 C\$06.06, C\$25.05, P05.01 P09.03 P04.37, P04.40 P02.12 C\$30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 C\$19.05 P01.15 C\$02.03, C\$19.08, P01.08, P01.18, P01.26, P04.07, P04.08 C\$18.05 C\$01.06, C\$30.07, P06.39, P06.59
Zhang Lihui	P04.02 C\$18.05 C\$06.06, C\$25.05, P05.01 P09.03 P04.37, P04.40 P02.12 C\$30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 C\$19.05 P01.15 C\$02.03, C\$19.08, P01.08, P01.18, P01.26, P04.07, P04.08 C\$18.05 C\$01.06, C\$30.07, P06.39, P06.59 P06.33, P06.57, P07.27
Zhang Lihui	P04.02 CS18.05 CS06.06, CS25.05, P05.01 P09.03 P04.37, P04.40 P02.12 CS30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 CS19.05 P01.15 CS02.03, CS19.08, P01.08, P01.18, P01.26, P04.07, P04.08 CS18.05 CS01.06, CS30.07, P06.39, P06.59 P06.33, P06.57, P07.27 CS26.04
Zhang Lihui	P04.02 CS18.05 CS06.06, CS25.05, P05.01 P09.03 P04.37, P04.40 P02.12 CS30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 CS19.05 P01.15 CS02.03, CS19.08, P01.08, P01.18, P01.26, P04.07, P04.08 CS18.05 CS01.06, CS30.07, P06.39, P06.59, P06.59 P06.33, P06.57, P07.27 CS26.04 P13.04
Zhang Lihui	P04.02 CS18.05 CS06.06, CS25.05, P05.01 P09.03 P04.37, P04.40 P02.12 CS30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 CS19.05 P01.15 CS02.03, CS19.08, P01.08, P01.18, P01.26, P04.07, P04.08 CS18.05 CS01.06, CS30.07, P06.39, P06.59 P06.33, P06.57, P07.27 CS26.04
Zhang Lihui	P04.02 CS18.05 CS06.06, CS25.05, P05.01 P09.03 P04.37, P04.40 P02.12 CS30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 CS19.05 P01.15 CS02.03, CS19.08, P01.08, P01.18, P01.26, P04.07, P04.08 CS18.05 CS01.06, CS30.07, P06.39, P06.59 P06.33, P06.57, P07.27 CS26.04 P13.04 CS18.05 P06.37
Zhang Lihui	P04.02 C\$18.05 C\$06.06, C\$25.05, P05.01 P09.03 P04.37, P04.40 P02.12 C\$30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 C\$19.05 P01.15 C\$02.03, C\$19.08, P01.08, P01.18, P01.26, P04.07, P04.08 C\$18.05 C\$01.06, C\$30.07, P06.39, P06.59 P06.33, P06.57, P07.27 C\$26.04 P13.04 C\$18.05
Zhang Lihui	P04.02 CS18.05 CS06.06, CS25.05, P05.01 P09.03 P04.37, P04.40 P02.12 CS30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 CS19.05 P01.15 CS02.03, CS19.08, P01.08, P01.18, P01.26, P04.07, P04.08 CS18.05 CS01.06, CS30.07, P06.39, P06.59 P06.33, P06.57, P07.27 CS26.04 P13.04 CS18.05 P06.37
Zhang Lihui	P04.02 C\$18.05 C\$06.06, C\$25.05, P05.01 P09.03 P04.37, P04.40 P02.12 C\$30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 C\$19.05 P01.15 C\$02.03, C\$19.08, P01.08, P01.18, P01.26, P04.07, P04.08 C\$18.05 C\$01.06, C\$30.07, P06.39, P06.59 P06.33, P06.57, P07.27 C\$26.04 P13.04 C\$18.05 P06.37 P04.36
Zhang Lihui	P04.02 CS18.05 CS06.06, CS25.05, P05.01 P09.03 P04.37, P04.40 P02.12 CS30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 CS19.05 P01.15 CS02.03, CS19.08, P01.08, P01.18, P01.26, P04.07, P04.08 CS18.05 CS01.06, CS30.07, P06.39, P06.59 P06.33, P06.57, P07.27 CS26.04 P13.04 CS18.05 P06.37 P04.36 CS20.06
Zhang Lihui	P04.02
Zhang Lihui	P04.02 C\$18.05 C\$06.06, C\$25.05, P05.01 P09.03 P04.37, P04.40 P02.12 C\$30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 C\$19.05 P01.15 C\$19.05 P01.16, P04.07, P04.08 C\$18.05 C\$19.05 P06.37, P06.39, P06.59 P06.33, P06.57, P07.27 C\$26.04 P13.04 C\$18.05 P06.37 P04.36 C\$20.06 C\$20.06 C\$20.06 C\$20.06
Zhang Lihui	P04.02 C\$18.05 C\$06.06, C\$25.05, P05.01 P09.03 P04.37, P04.40 P02.12 C\$30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 C\$19.05 P01.15 C\$02.03, C\$19.08, P01.08, P01.18, P01.26, P04.07, P04.08 C\$18.05 C\$01.06, C\$30.07, P06.39, P06.59 P06.33, P06.57, P07.27 C\$26.04 P13.04 P13.04 C\$18.05 P06.37 P04.36 C\$20.06 C\$20.06 P06.52 C\$24.06 P06.52 C\$24.06
Zhang Lihui	P04.02 C\$18.05 C\$06.06, C\$25.05, P05.01 P09.03 P04.37, P04.40 P02.12 C\$30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 C\$19.05 P01.18, P01.26, P04.07, P04.08 P01.18, P01.26, P04.07, P04.08 C\$18.05 C\$01.06, C\$30.07, P06.39, P06.59 P06.33, P06.57, P07.27 C\$26.04 P13.04 C\$18.05 P06.37 P04.36 C\$20.06 P06.52 C\$24.06 P06.08 C\$24.06 P06.08 C\$02.05
Zhang Lihui	P04.02 C\$18.05 C\$06.06, C\$25.05, P05.01 P09.03 P04.37, P04.40 P02.12 C\$30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 C\$19.05 P01.18, P01.26, P04.07, P04.08 P01.18, P01.26, P04.07, P04.08 C\$18.05 C\$01.06, C\$30.07, P06.39, P06.59 P06.33, P06.57, P07.27 C\$26.04 P13.04 C\$18.05 P06.37 P04.36 C\$20.06 P06.52 C\$24.06 P06.08 C\$24.06 P06.08 C\$02.05
Zhang Lihui	P04.02 C\$18.05 C\$06.06, C\$25.05, P05.01 P09.03 P04.37, P04.40 P02.12 C\$30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 C\$19.05 P01.15 C\$02.03, C\$19.08, P01.08, P01.18, P01.26, P04.07, P04.08 C\$18.05 C\$01.06, C\$30.07, P06.39, P06.59 P06.33, P06.57, P07.27 C\$26.04 P13.04 C\$18.05 P06.37 P04.36 C\$20.06 P06.52 C\$24.06 P06.08 C\$20.05
Zhang Lihui	P04.02 C\$18.05 C\$06.06, C\$25.05, P05.01 P09.03 P04.37, P04.40 P02.12 C\$30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 C\$19.05 P01.15 C\$02.03, C\$19.08, P01.08, P01.18, P01.26, P04.07, P04.08 C\$18.05 C\$01.06, C\$30.07, P06.39, P06.59 P06.37 P06.37 P04.36 C\$20.06 P06.37 P06.37 P04.36 C\$20.06 P06.52 C\$24.06 P06.52 C\$24.06 P06.08 C\$02.05 P06.08 C\$03.07 P06.08 C\$03.07 P06.08 P06.08 C\$03.07 P06.08 P06.08 C\$03.07 P06.08 P06.08 P06.08 P06.08 P06.08 P06.08 P06.08 P06.08 P06.09
Zhang Lihui	P04.02 C\$18.05 C\$06.06, C\$25.05, P05.01 P09.03 P04.37, P04.40 P02.12 C\$30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 C\$19.05 P01.15 C\$02.03, C\$19.08, P01.08, P01.18, P01.26, P04.07, P04.08 C\$18.05 C\$01.06, C\$30.07, P06.39, P06.59 P06.37 P04.36 C\$18.05 P06.37 P04.36 C\$20.06 P06.08 C\$24.06 P06.08 C\$24.06 P06.08 C\$20.05 P06.37 P06.37 P06.37
Zhang Lihui	P04.02 C\$18.05 C\$06.06, C\$25.05, P05.01 P09.03 P04.37, P04.40 P02.12 C\$30.09, P04.34 P02.12, P06.32, P24.01 P04.36, P15.14 C\$19.05 P01.15 C\$02.03, C\$19.08, P01.08, P01.18, P01.26, P04.07, P04.08 C\$18.05 C\$01.06, C\$30.07, P06.39, P06.59 P06.37 P06.37 P04.36 C\$20.06 P06.37 P06.37 P04.36 C\$20.06 P06.52 C\$24.06 P06.52 C\$24.06 P06.08 C\$02.05 P06.08 C\$03.07 P06.08 C\$03.07 P06.08 P06.08 C\$03.07 P06.08 P06.08 C\$03.07 P06.08 P06.08 P06.08 P06.08 P06.08 P06.08 P06.08 P06.08 P06.09

Zhou Shu-Min	CS03.07
Zhou Wei	P15.03
Zhou Wenyu	P28.04
Zhou Xiaobing	CS05.09
Zhu Jie	P04.31
Zhu Jun	CS20.05
Zhu Kan	
Zhu Lin	
Zhu Mang	
Zhu Yafeng	
Zhu Yinghui	
Zichi Dominic A	
Ziganshin Rustam	
Zi Jin	
Zoldoš Vlatka	
Zou Hanfa	
Zou Xia	
Zubarev Roman	
Zubarev Roman A	
Zuberi Arshma	·
Zubiri Irene	
Zuzow Nathan	
Zvereva Irina	
Zvereva Iriila	



15<sup>th</sup> Human Proteome Organization World Congress



Precision Proteomics

Precision Precision

for Precision

Biology and Medicine



www.hupo2016.org

**CONGRESS DATE:** 

**SEPTEMBER 18-22, 2016** 

CONGRESS VENUE:

TAIPEI INTERNATIONAL CONVENTION CENTER
TAIPEI WORLD TRADE CENTER





# More Proteins. More accurately. Faster than ever.

Biology is complex and understanding it is a big challenge. Identify and quantify more proteins and complexities such as PTMs faster and more accurately with our new portfolio of LC-MS instruments, sample prep solutions and software. HRAM solutions using Thermo Scientific  $^{\text{TM}}$  Orbitrap  $^{\text{TM}}$  MS quantifies all detectable proteins and peptides with high specificity and fewer false positives, while triple quadrupole MS delivers SRM sensitivity and speed to detect targeted proteins more quickly. Join us in meeting today's challenges. Together we'll transform proteomics.

### Quantitation transformed.

 Visit booth 301 to learn about our latest advances in MS thermoscientific.com/HUPO2015





# Thermo Scientific<sup>™</sup> Orbitrap Fusion<sup>™</sup> Lumos<sup>™</sup> Tribrid<sup>™</sup> MS

Allows systems biology researchers to test new limits of quantitation and protein characterization



### Thermo Scientific™ Q Exactive™ HF MS Screen and quantify known and unknown targets with HRAM Orbitrap technology



Thermo Scientific™ TSQ Quantiva™ MS
Leading SRM sensitivity and speed
in a triple quadrupole MS/MS